[go: up one dir, main page]

US20180243297A1 - Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors - Google Patents

Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Download PDF

Info

Publication number
US20180243297A1
US20180243297A1 US15/963,535 US201815963535A US2018243297A1 US 20180243297 A1 US20180243297 A1 US 20180243297A1 US 201815963535 A US201815963535 A US 201815963535A US 2018243297 A1 US2018243297 A1 US 2018243297A1
Authority
US
United States
Prior art keywords
alkyl
heterocyclyl
cycloalkyl
hydroxy
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/963,535
Inventor
Benjamin Richard Bellenie
Graham Charles Bloomfield
Ian Bruce
Andrew James Culshaw
Edward Charles Hall
Gregory John Hollingworth
James Neef
Matthew SPENDIFF
Simon James Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to US15/963,535 priority Critical patent/US20180243297A1/en
Publication of US20180243297A1 publication Critical patent/US20180243297A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel amino pyrazine derivatives which are PI 3-kinase gamma isoform selective inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by the activation of PI 3-kinase gamma isoform, particularly asthma.
  • Phosphatidylinositol 3-kinases a family of enzymes which catalyse the phosphorylation of the 3′-OH of the inositol ring, play a central role in regulating a wide range of cellular processes including metabolism, survival, motility and cell activation (Vanhaesebroeck, B. et al., Annu. Rev. Biochem. 2001, 70, 535). These lipid kinases are divided into 3 major classes, I, II & III, according to their structure and in vitro substrate specificity (Wymann, M. et al.; Biochem. Biophys. Acta, 1998, 1436, 127).
  • class I family is further subdivided into subclasses IA and IB.
  • Class IA PI 3-kinases consist of an 85 kDa regulatory/adapter protein and three 110 kDa catalytic subunits (p110 ⁇ , p110 ⁇ and p110 ⁇ ) which are activated in the tyrosine kinase system whilst class IB consists of a single p110 ⁇ isoform (PI 3-kinase gamma isoform) which is activated by G protein-coupled receptors.
  • the three members of class II PI 3-kinases (C2 ⁇ , C2 ⁇ and C2 ⁇ ) and single member of class III PI 3 kinases (Vps34) are less well understood.
  • PI 4-kinases and several PI 3-kinase related protein kinases (termed PIKK's or class IV) including DNA-PK, mTOR, ATM and ATR, all of which have a similar catalytic domain (Abraham R. T. et al.; DNA repair 2004, 3(8-9), 883).
  • WO2009/115517 describes amino pyrazine and pyridine derivatives as PI 3-kinase inhibitors.
  • WO2009/013348 describes amino pyrimidine derivatives as PI 3-kinase inhibitors.
  • WO2003/093297 describes protein kinase modulators and methods of use of such modulators.
  • the invention relates to a compound of formula (I)
  • E is selected from N and CR E ;
  • R 1 , R 2 and R E are independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl and C 3-7 cycloalkyl;
  • R 3 is selected from (i) C 1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, CN, —(C 0-3 alkyl)-NR 3a R 3b , C 3-7 cycloalkyl and C 3-7 heterocyclyl, and wherein the C 3-7 cycloalkyl or C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituent
  • the invention relates to pharmaceutical compositions and combinations comprising compounds of the first aspect, and to the use of such compounds of the first aspect in the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform.
  • E is selected from N and CR E ;
  • R 1 , R 2 and R E are independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl and C 3-7 cycloalkyl;
  • R 3 is selected from (i) C 1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, CN, —(C 0-3 alkyl)-NR 3a R 3b , C 3-7 cycloalkyl and C 3-7 heterocyclyl, and wherein the C 3-7 cycloalkyl or C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituent
  • E is selected from N and CR E ;
  • R 1 , R 2 and R E are independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy and C 3-6 cycloalkyl;
  • R 3 is selected from (i) C 1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, —NR 3a R 3b and C 3-6 cycloalkyl, and wherein the C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy and C 1-4 haloalkyl; (ii) C 1-4 alkoxy which
  • Halo or “halogen”, as used herein, may be fluoro, chloro, bromo or iodo.
  • C 1-4 alkyl denotes straight chain or branched alkyl having 1-4 carbon atoms. If a different number of carbon atoms is specified, such as C 6 or C 3 , then the definition is to be amended accordingly, such as “C 1 -C 4 alkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
  • C 1-4 alkoxy refers to an —O—C 1-4 alkyl group wherein C 1-4 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like. As for alkyl unless a particular structure is specified the terms propoxy, butoxy etc include all straight and branched chain forms having the appropriate number of carbon atoms e.g. propoxy includes n-propoxy and isopropoxy.
  • C 1-4 haloalkoxy refers to an —O—C 1-4 alkyl group wherein C 1-4 alkyl is as defined herein and substituted with one or more halogen groups, e.g. —O—CF 3 .
  • C 1-4 haloalkyl denotes straight chain or branched alkyl having 1-4 carbon atoms with at least one hydrogen substituted with a halogen. If a different number of carbon atoms is specified, such as C 6 or C 3 , then the definition is to be amended accordingly, such as “C 1 -C 4 -Haloalkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with halogen, such as where the halogen is fluorine: CF 3 CF 2 —, (CF 3 ) 2 CH—, CH 3 —CF 2 —, CF 3 CF 2 —, CF 3 , CF 2 H—, CF 3 CF 2 CHCF 3 or CF 3 CF 2 CF 2 CF 2 —.
  • C 3-7 cycloalkyl refers to a saturated monocyclic hydrocarbon ring of 3 to 7 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. If a different number of carbon atoms is specified, then the definition is to be amended accordingly.
  • hydroxy or “hydroxyl” refers to —OH.
  • C 1-4 hydroxyalkyl denotes a straight chain or branched alkyl having 1-4 carbon atoms with at least one hydrogen substituted with a hydroxy group. If a different number of carbon atoms is specified, such as C 6 or C 3 , then the definition is to be amended accordingly, such as “C 1 -C 4 hydroxyalkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with hydroxy.
  • C 3-7 heterocyclyl ring refers to a 3 to 7 membered saturated or partially unsaturated aliphatic ring system which contains 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such ring systems include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, thienyl or oxazolinyl.
  • 5-6 membered heteroaryl refers to a 5-6 membered aromatic ring system which contains 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur.
  • 5-membered heteroaryl rings in this instance include furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, isothiazolyl, isoxazolyl, thiophenyl, or pyrazolyl.
  • 6-membered heteroaryl rings include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
  • Oxo refers to ⁇ O.
  • treatment refers to both to symptomatic and prophylactic treatment, particularly symptomatic.
  • any one of embodiments 1 to 5 refers not only to embodiments indicated by the integers such as 1 and 2 but also to embodiments indicated by numbers with a decimal component such as 1.1, 1.2 or 2.1, 2.2, 2.3.
  • “according to any one of embodiments 1 to 3” means according to any one of embodiments 1, 1.1, 2, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7. The same applies when referring to exemplified compounds.
  • R 1 is independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl and C 3-7 cycloalkyl
  • R 2 is selected from H, halogen, CF 3 and methyl
  • R 3 is selected from (i) C 1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, CN, —(C 0-3 alkyl)-NR 3a R 3b , C 3-7 cycloalkyl and C 3-7 heterocyclyl, and wherein the C 3-7 cycloalkyl or C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently
  • R E is selected from N and CR E ;
  • R 1 , R 2 and R E are independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy and C 3-6 cycloalkyl;
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, —NR 3a R 3b and C 3-6 cycloalkyl, and wherein the C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy and C 1-4 haloalkyl; (ii) C 1-4 alkoxy which is substituted with 1 to
  • R 1 is independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl and C 3-7 cycloalkyl
  • R 2 is selected from H, halogen, CF 3 and methyl
  • R 3 is selected from (i) C 1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, CN, —(C 0-3 alkyl)-NR 3a R 3b , C 3-7 cycloalkyl and C 3-7 heterocyclyl, and wherein the C 3-7 cycloalkyl or C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently
  • R 1 is selected from H and C 1-4 alkyl
  • R 2 is selected from H, halogen, C 1-4 haloalkyl and methyl
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, halogen, —NR 3a R 3b , C 1-4 alkyl, C 3-7 cycloalkyl and C 3-7 heterocyclyl; (ii) C 1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, halogen, —NR 3a R 3b , C 1-4 alkyl, C 3-7 cycloalkyl and C 3-7 heterocyclyl; (iii) —O—(C 0-3 alkyl)-C 3-7 heterocyclyl, and wherein said C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substitu
  • Y is selected from the group consisting of
  • Y is selected from the group consisting of
  • Y is selected from the group consisting of
  • Y is selected from the group consisting of
  • R 2 is selected from H, fluoro, chloro and methyl, particularly H and fluoro, more particularly H.
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (ii) C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (iii) —O—(C 0-3 alkyl)-C 3-7 heterocyclyl wherein the C 3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4 alkyl, hydroxy, C 1-4 hydroxyalkyl, halogen, oxo and C 1-4 haloalkyl; (iv) —O—(C 0-3 alkyl)-C 3-7 cycloalkyl wherein the C 3-7 cycloalkyl is unsubstituted or substitute
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (ii) C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (iii) —O—(C 0-3 alkyl)-C 3-7 heterocyclyl wherein the C 3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4 alkyl, hydroxy, C 1-4 hydroxyalkyl, halogen, oxo and C 1-4 haloalkyl; (iv) —O—(C 0-3 alkyl)-C 3-7 cycloalkyl wherein the C 3-7 cycloalkyl is unsubstituted or substitute
  • R 3 is C 1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 alkyl, oxo, —NR 3a R 3b and C 3-6 cycloalkyl, and wherein the C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy and C 1-4 haloalkyl.
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (ii) C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (iii) —O—(C 0-3 alkyl)-C 3-7 heterocyclyl wherein the C 3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C 3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4 alkyl, hydroxy, C 1-4 hydroxyalkyl, halogen and C 1-4 haloalkyl; (iv) —O—(C 0-3 alkyl)-C 3-7 cycloalkyl wherein the C 3-7 cycloalkyl is unsubstituted or substituted with 1 to 3
  • R 3 is selected from propyl, butyl and pentyl substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 alkyl, halogen, —NR 3a R 3b and oxo.
  • C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl;
  • C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl;
  • R 3 is selected from (i) C 1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C 1-4 alkyl; (ii) C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl and C 1-4 alkyl; or a pharmaceutically acceptable salt thereof.
  • R 3 is selected from
  • R 3 is C 1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl, C 1-4 alkyl, C 1-4 alkoxy, oxo, —NR 3a R 3b and C 3-6 cycloalkyl, and wherein the C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy and C 1-4 haloalkyl;
  • R 3 is selected from
  • R 3 is selected from
  • R 3 is C 3-6 cycloalkyl or —O—C 3-6 cycloalkyl wherein the C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy, C 1-4 haloalkyl and —(C 0-3 alkyl)-NR 3a R 3b .
  • R 3 is selected from
  • a compound or salt according to embodiment 16.1 wherein R 3 is selected from (C 0-3 alkyl)-cyclohexyl, —(C 0-3 alkyl)-cyclobutyl and —(C 0-3 alkyl)-cyclopropyl, and wherein the cyclohexyl, cyclobutyl and cyclopropyl are substituted with 1 or 2 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl and halogen.
  • R 3 is selected from
  • R 3 is selected from
  • R 3 and R 4 together with the nitrogen atom to which they are attached form a ring selected from
  • R 3 is —(C 0-3 alkyl)-C 3-6 cycloalkyl or —(O—C 0-3 alkyl)-C 3-6 cycloalkyl spiro fused to a second C 3-6 cycloalkyl or C 3-6 heterocyclyl by one single carbon atom, wherein the C 3-6 cycloalkyl or C 3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 alkoxy, C 1-4 haloalkyl and —(C 0-3 alkyl)-NR 3a R 3b .
  • a compound or salt according to embodiment 20.1 wherein R 3 is selected from spiro[3.3]heptan-2-yl, spiro[3.4]octan-6-yl, spiro[4.4]nonan-2-yl and spiro[3.4]undecan-3-yl, which is substituted with 1 to 3 substituents selected from hydroxy and halogen.
  • R 3 is —(C 0-3 alkyl)-C 3-6 heterocyclyl wherein the C 3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C 3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4 alkyl and C 1-4 hydroxyalkyl;
  • C 3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C 3-6 heterocyclyl is spiro fused to a second C 3-6 heterocyclyl or a C 3-6 cycloalkyl by one single carbon atom, and wherein the C 3-6 heterocyclyl or C 3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4 alkyl, C 1-4 alkoxy, hydroxy, C 1-4 hydroxyalkyl, halogen, C 1-4 haloalkyl and —(C 0-3 alkyl)-NR 3a R 3b .
  • R 3 is selected from a —(C 0-3 alkyl)-tetrahydrofuranyl, —(C 0-3 alkyl)-oxetanyl, —(C 0-3 alkyl)-pyrrolidinyl, and —(C 0-3 alkyl)-tetrahydropyranyl, each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, 4 alkyl and C 1-4 hydroxyalkyl.
  • E is selected from N and CR E ;
  • R 1 , R 2 and R E are independently selected from H, halogen, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 haloalkoxy, C 1-4 hydroxyalkyl and C 3-7 cycloalkyl;
  • Y is selected from the group consisting of
  • R 4 is H and R 3 is selected from the group consisting of
  • R 1 is H or C 1-4 alkyl, particularly C 1-4 alkyl, more particularly methyl; Y is selected from the group consisting of
  • R 3 is selected from the group consisting of
  • R 1 is H or C 1-4 alkyl, particularly C 1-4 alkyl, more particularly methyl; Y is selected from the group consisting of
  • R 3 is selected from the group consisting of
  • R 1 is H or C 1-4 alkyl, particularly C 1-4 alkyl, more particularly methyl; Y is selected from the group consisting of
  • R 3 is selected from the group consisting of
  • R 1 is H or C 1-4 alkyl, particularly C 1-4 alkyl, more particularly methyl; Y is selected from the group consisting of
  • R 3 is selected from the group consisting of
  • R 1 is H or C 1-4 alkyl, particularly C 1-4 alkyl, more particularly methyl; Y is selected from the group consisting of
  • R 3 is selected from the group consisting of
  • a compound or salt according to any one of embodiments 1-42 for use in the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • an embodiment 48 of the invention there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110- ⁇ ).
  • a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma.
  • a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof for the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110- ⁇ ).
  • a compound according to any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof for the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof for the treatment of respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma.
  • a method of treating a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110- ⁇ ), comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof.
  • a method of treating respiratory diseases particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising:
  • a pharmaceutical combination comprising:
  • a pharmaceutical combination according to embodiment 58 wherein the second active agent is selected from an anti-inflammatory, bronchodilatory or antihistamine drug substance.
  • X 1 is a halogen such as Br or I
  • Y, R 1 , R 2 , R 3 , R 4 and E are as defined in embodiment 1
  • X is a halogen such as I, Br or Cl.
  • the reaction between halopyrazine II and boronic acid or boronic ester III to form compounds of formula I as shown in Scheme 1 may be carried out using a suitable palladium catalyst, such as Pd(PPh 3 ) 2 Cl 2 , Pd-118 (PdCl 2 (dtbpf)), Pd(dppf)Cl 2 or its adduct with dichloromethane, in a suitable solvent or mixture of solvents, such as 1,2-dimethoxyethane (DME), DME/ethanol, acetonitrile, 1,4-dioxane or toluene/ethanol.
  • a suitable base such as aqueous sodium carbonate, aqueous potassium phosphate or in some cases potassium acetate and may be carried out at elevated temperatures, using conventional or microwave heating.
  • Compounds of formula II may be obtained from commercial suppliers, prepared as described in Schemes 2b, 3a, 6, 6a, 6b, 6c, 6d, 6e, 8 or 10 or by other methods known in the art.
  • Compounds of formula III may be obtained from commercial suppliers or prepared by borylation of an aryl halide of formula IV with a boron source such as bis(pinacolato)diboron at elevated temperature using conventional or microwave heating (Method A). This reaction is typically catalysed by a palladium catalyst such as Pd(dppf)Cl 2 .CH 2 Cl 2 , and utilises a suitable base such as potassium acetate in an appropriate solvent such as DME or dioxane.
  • a palladium catalyst such as Pd(dppf)Cl 2 .CH 2 Cl 2
  • a suitable base such as potassium acetate in an appropriate solvent such as DME or dioxane.
  • this borylation of IV to form III may be followed without isolation of III by the subsequent coupling with compound II in a ‘one-pot’ procedure to form compound I.
  • the ‘one-pot’ procedure can be carried out by borylation of II and subsequent coupling with IV.
  • Compounds of formula III may also be prepared by halogen-metal exchange, followed by reaction of the resulting organometallic with a boron source (Method B). Typically this reaction may be carried out by lithiation of a compound of formula IV using an appropriate organometallic species such as n-butyl lithium in an appropriate solvent such as THF, with cooling (for example to ⁇ 78° C.). The resulting species can then be reacted in situ with an appropriate boron source such as triisopropyl borate.
  • a boron source such as triisopropyl borate.
  • Y, R 1 , R 2 , R 3 , R 4 and E are as defined in embodiment 1, and X is a halogen such as I, Br or Cl.
  • Y, R 1 , R 2 , R 3 , R 4 and E are as defined in embodiment 1, and X is a halogen such as I, Br or Cl.
  • compounds of formula I may be prepared as shown in Scheme 2a via a reaction between compounds V and stannane Sn-VI (for example, optionally substituted 4-(tributylstannyl)thiazole).
  • stannane Sn-VI for example, optionally substituted 4-(tributylstannyl)thiazole.
  • This may be carried out using a suitable palladium catalyst, such as Pd-118, in a suitable solvent such as THF at elevated temperature, optionally in the presence of an appropriate additive such as copper (I) iodide.
  • a suitable palladium catalyst such as Pd-118
  • THF a suitable solvent
  • an appropriate additive such as copper (I) iodide.
  • Alternative conditions for Stille couplings such as this are known in the art.
  • Y is as defined in embodiment 1, X 1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • Compounds of formula II, where Y is attached to the pyrazine ring by a carbon-carbon bond may be prepared via a palladium mediated cross coupling reaction between a compound of formula VII, as shown in Scheme 2b.
  • Various conditions for this reaction are known in the art, for example bromination by use of a halogenating agent such as NBS, in an appropriate solvent such as acetonitrile at elevated temperature.
  • Compounds VII, such as 3-bromo-5-chloropyrazin-2-amine are commercially available, or may be formed by known methods.
  • R 1 , R 2 , R 3 , R 4 and E are selected from those in embodiment 1, X 1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • Y, R 1 , R 2 , R 3 , R 4 and E are as defined in embodiment 1, and where Y can be attached to the pyrazine ring by a nitrogen-carbon bond, and X is a halogen.
  • Compounds of formula I where Y can be attached to the pyrazine ring by a nitrogen-carbon bond may be prepared by a reaction of compound V with an appropriate heteroaryl Y containing an NH group, such as (optionally substituted) 1,2,4-triazole, imidazole or pyrazole.
  • This reaction is typically carried out in the presence of a suitable base (such as an amine, an alkali metal hydride or carbonate, e.g. sodium hydride or cesium carbonate), in a suitable solvent such as dimethyl acetamide (DMA), optionally in the presence of an appropriate catalyst system such as CuI and N,N-dimethylglycine, typically at an elevated temperature of up to 180° C. using, for example, microwave heating.
  • a suitable base such as an amine, an alkali metal hydride or carbonate, e.g. sodium hydride or cesium carbonate
  • DMA dimethyl acetamide
  • an appropriate catalyst system such as CuI and N,N
  • Y is as defined in embodiment 1, where Y can be attached to the pyridine ring by a nitrogen-carbon bond, X 1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • Compounds of formula II may be prepared via reaction between a compound of formula VII, such as 5-bromo-3-chloropyrazin-2-amine and an appropriate heteroaryl containing an NH group, such as (optionally substituted) 1,2,4-triazole, imidazole or pyrazole as shown in Scheme 3a.
  • Typical conditions include the use of catalyst systems as described in Scheme 3, or direct reaction of compound VII with an appropriate heteroaryl, for example by heating in an appropriate solvent such as DMF in the presence of a base such as cesium carbonate.
  • compound I can be prepared directly from aminopyrazine halides V and heterocycles, such as oxazole (to give I where Y is oxazol-5-yl or oxazol-2-yl), using a palladium catalysed C—H activation protocol as shown in Scheme 3b.
  • Suitable conditions are known in the art, such as the use of palladium acetate with an added ligand such as di(adamant-1-yl)-n-butyl phosphine, with a base such as potassium carbonate and an additive such as pivalic acid in a solvent such as dimethylacetamide, heating at elevated temperatures such as 110° C.
  • Compounds of formula I may be prepared by reacting sulfonyl chloride VIII with an amine IX in the presence of a suitable base such as pyridine, triethylamine or diisopropylethylamine, in a suitable solvent such as DCM, THF, pyridine or dimethylacetamide.
  • a suitable base such as pyridine, triethylamine or diisopropylethylamine
  • X 1 is a halogen such as Br or I
  • Y, R 1 , R 2 , R 3 , R 4 and E are as defined in embodiment 1.
  • J is a halogen such as Br or I, or
  • Scheme 5 may be prepared according to Scheme 5 by chlorosulfonation of a compound of formula X (method C), typically using chlorosulfonic acid in an appropriate solvent such as chloroform, at ambient temperature or with cooling such as to 0° C.
  • Sulfonyl chlorides VIII/VIII′ formed may be reacted directly with amines IX without isolation or purification as described in Schemes 4 and 4a to form compounds I/IV.
  • An alternative preparation of compound VIII is shown in Scheme 5 (method D), by a diazotisation/chlorosulfonation sequence (see, for example Meerwein, H. et al, Chem.
  • Example conditions include the reaction of compound NH 2 —X with sodium nitrite in the presence of acid (for example, mixture of acetic acid and conc. HCl) in water with cooling (typically 0° C.), then the resulting mixture added to a stirring solution of the green supernatant of a mixture prepared by bubbling sulfur dioxide gas into glacial acetic acid followed by the addition of CuCl 2 in water.
  • acid for example, mixture of acetic acid and conc. HCl
  • cooling typically 0° C.
  • Compounds of formula VIII′ are commercially available or may be prepared according to the same methods.
  • Compounds of formula X or NH 2 —X may be obtained from commercial suppliers or made by known methods.
  • R is an appropriate group chosen from the substitutents listed in the definition of Y in embodiment 1, X 1 is a halogen such as bromo, chloro or iodo, and X is a halogen or hydrogen.
  • R and X are as defined in Scheme 6, X 1 is bromo or iodo, Alk is an alkyl group such as methyl or ethyl.
  • step 4 to form compound II is typically catalysed by acid (such as aqueous HCl in AcOH) or by gold catalysis as described in Synlett, 2010, No. 5, pp 0777-0781.
  • acid such as aqueous HCl in AcOH
  • gold catalysis as described in Synlett, 2010, No. 5, pp 0777-0781.
  • Compounds of formula II* can also be formed from ketone XIII, for example by treatment with hydroxylamine-O-sulfonic acid, sodium bicarbonate and sodium hydrogen sulfide in an appropriate solvent mixture such as THF/water.
  • Ketone XIII can be formed from a dihaloaminopyrazine such as 3-bromo-5-chloropyrazin-2-amine using known methods as shown in Scheme 6a, for example by Sonogashira coupling with propargylic alcohol XIV, followed by oxidation using an oxidising agent such as manganese dioxide.
  • a dihaloaminopyrazine such as 3-bromo-5-chloropyrazin-2-amine
  • Scheme 6a for example by Sonogashira coupling with propargylic alcohol XIV, followed by oxidation using an oxidising agent such as manganese dioxide.
  • Suitable reagents for the condensation and dehydration are known in the art and include Ghosez′ reagent, T3P®, DCC and HOBt, or HATU in an appropriate solvent such as DCM, THF or toluene, in the presence of an appropriate base such as DIPEA.
  • compounds of formula II** are prepared by condensation and dehydration of compounds XVI and XVII using conditions known in the art. This can be carried out by a one or two step process, for example using an amide coupling reagent such as HATU or T3P in the presence of an appropriate base such as triethylamine, then dehydrative cyclisation using for example tosyl chloride in the presence of an appropriate base such as triethylamine, in a suitable solvent such as DCM.
  • Other dehydrating agents are known in the art, such as POCI 3 .
  • Compounds of formulae XV, XVI, Alk-XVI and XVII are commercially available or can be prepared by known methods.
  • R and X are as defined in Scheme 6, and R a is hydrogen or an appropriate group chosen from the substitutents listed in the definition of Y in embodiment 1.
  • the resulting triazole (where R ⁇ H) can be alkylated using an alkylating agent (such as iodomethane, iodoethane, 2,2,2-trifluoroethyl trifluoromethanesulfonate or other alkyl halides or sulfonates) in the presence of an appropriate base/additive (such as TBAF or metal carbonates such as caesium carbonate), in an suitable solvent such as acetonitrile or THF, to give compounds of formula II as mixtures of N1 and N2 alkylated products, which may be separable by known methods.
  • an alkylating agent such as iodomethane, iodoethane, 2,2,2-trifluoroethyl trifluoromethanesulfonate or other alkyl halides or sulfonates
  • an appropriate base/additive such as TBAF or metal carbonates such as caesium carbonate
  • suitable solvent
  • X is a halogen or hydrogen
  • R is an appropriate group chosen from the relevant list of substituents in embodiment 1.
  • Compounds of formula IX′ can be prepared from alcohols XVIII (obtained commercially or prepared by known methods) by treatment with N-hydroxyphthalamide under Mitsunobu-type conditions known in the art (for example using PS-triphenylphosphine and di-tert-butyl azodicarboxylate in a solvent such as THF), followed by deprotection of the phthalamide group using known consitions, typically by treatment with hydrazine.
  • Mitsunobu-type conditions known in the art (for example using PS-triphenylphosphine and di-tert-butyl azodicarboxylate in a solvent such as THF), followed by deprotection of the phthalamide group using known consitions, typically by treatment with hydrazine.
  • X is hydrogen or halogen
  • R, R a are as defined in embodiment 1
  • X 1 is halogen
  • Compound XXI can be prepared by halogenation of ketone XX by conditions known in the art, such as treatment with pyridinium tribromide (optionally on polymer support) and HBr in acetic acid at elevated temperature.
  • Ketone XX can be prepared from commercially available starting materials by formation of the Weinreb amide from acid XIX (obtained commercially or prepared by known methods), followed by addition of a Grignard reagent.
  • Certain compounds of formula IV may be prepared by a cross coupling reaction of compound XXIV with an appropriate boronic acid (such as methyl boronic acid), in the presence of a base (for example aqueous sodium carbonate), an appropriate catalyst (for example bis(triphenylphosphine) palladium dichloride) and in an appropriate solvent such as 1,4-dioxane under elevated temperature.
  • an appropriate boronic acid such as methyl boronic acid
  • a base for example aqueous sodium carbonate
  • an appropriate catalyst for example bis(triphenylphosphine) palladium dichloride
  • an iodide source such as trimethylsilyliodide (or trimethylsilyl chloride plus sodium iodide) in an appropriate solvent such as acetonitrile.
  • Compounds XXIII are commercially available or can be made by known methods.
  • Compounds of formula II may be prepared by reaction of amidoxime XXV with an acid chloride using known conditions, followed by dehydrative cyclisation. Conditions for this sort of cyclisation are known in the art, and include the use of hexachloroethane in acetic acid at elevated temperature.
  • Compound XXV can be formed by known methods, for example the reaction of commercially available 3-amino-6-bromopyrazine-2-carbonitrile with hydroxylamine hydrochloride, in the presence of a base (such as triethylamine) and in an appropriate solvent such as methanol.
  • Y is an appropriate group selected from the groups defined in embodiment 1, X 1 is halogen such as I, Br or Cl and X is H or halogen.
  • Compounds of formula II may be prepared by a decarboxylative cross-coupling of carboxylic acid XXVI (obtained from commercial suppliers or prepared by known methods) with compound VII.
  • the invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material.
  • protecting group a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention.
  • the protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J.
  • Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art.
  • salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
  • metal compounds such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid
  • organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbonates
  • Acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent.
  • Internal salts of compounds of the present invention containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
  • Salts can be converted into the free compounds in accordance with methods known to those skilled in the art.
  • Metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
  • diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
  • Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
  • 190° C. including, for example, from approximately ⁇ 80° C. to approximately 150° C., for example at from ⁇ 80 to ⁇ 60° C., at room temperature, at from ⁇ 20 to 40° C. or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or nitrogen atmosphere.
  • mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described under “Additional process steps”.
  • solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride,
  • the compounds of the present invention may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
  • the invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
  • an optical isomer or “a stereoisomer” refers to any of the various stereoisomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
  • the term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other.
  • a 1:1 mixture of a pair of enantiomers is a “racemic” mixture.
  • the term is used to designate a racemic mixture where appropriate.
  • “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
  • the absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R—S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
  • Resolved compounds whose absolute configuration is unknown can be designated (+) or ( ⁇ ) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
  • Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
  • the present invention is meant to include all such possible stereoisomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
  • Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
  • a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
  • Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • HPLC high pressure liquid chromatography
  • the compounds of the present invention can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
  • the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
  • solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules.
  • solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
  • hydrate refers to the complex where the solvent molecule is water.
  • the compounds of the present invention including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • salt refers to an acid addition or base addition salt of a compound of the present invention.
  • Salts include in particular “pharmaceutically acceptable salts”.
  • pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
  • the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
  • the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
  • Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
  • a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
  • Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds of the present invention.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 Cl, 125 I respectively.
  • the invention includes various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
  • isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F labeled compound of the present invention may be particularly desirable for PET or SPECT studies.
  • Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
  • Compounds of the present invention that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
  • These co-crystals may be prepared from compounds of the present invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the present invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
  • Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of the present invention.
  • the compounds of the present invention are potent inhibitors of the PI 3-kinase gamma isoform. This is shown in Table 4, assay E. Furthermore and importantly, the compounds of the present invention are selective for the PI 3-kinase gamma isoform over the other class 1 PI 3-kinase isoforms alpha, beta and delta, which is shown in Table 4, assays A, B and F, and over related lipid kinases Vps34 and PI 4-kinase beta, which is shown in Table 4, assays C and D, and also over the PI 3-kinase related protein kinases such as mTOR (Table 4, assay G).
  • Selectivity for PI 3-kinase gamma isoform is preferred in order to avoid possible unwanted side effects when treating patients. Particularly, selectivity for the PI 3-kinase gamma isoform over the PI 3-kinase alpha isoform is preferred as the PI 3-kinase alpha isoform is widely expressed in the body and has shown to be important in insulin receptor signalling.
  • the target enzyme of the compounds of the present invention i.e. PI 3-kinase gamma isoform
  • PI 3-kinase gamma isoform is an intracellular target.
  • compounds of the present invention which retain their activity in a cellular environment are preferred.
  • the compounds of the present invention have thus been tested in cellular assays (see Table 5, assays H1, H2, I1, I2, J1, J2, K1 and K2).
  • assays K1 and K2 the compounds were tested for their ability to inhibit the production of phosphorylated AKT (Protein Kinase B) generated in a PI 3-kinase gamma isoform-dependent process in a U937 human cell line.
  • AKT Protein Kinase B
  • Activity of a particular compound in a cellular assay depends on a variety of different factors such as potency of that compound at the target (see Table 4), solubility of the compound, Log P and permeability.
  • good cellular activity of compounds of the present invention results from the combination of structural features conveying a good overall balance of molecular properties.
  • preferred compounds of the present invention have high potency at the target (see Table 4) and show good activity in the cellular assays (Table 5).
  • a drug compound In order to effectively inhibit the PI 3-kinase gamma isoform target (present in leukocytes) in an in vivo system, a drug compound will preferably need to show sufficient activity in whole blood.
  • compounds of the present invention have been tested for their ability to inhibit neutrophil shape change in response to the chemotactic factor interleukin-8 (IL-8), which is a PI 3-kinase gamma isoform-dependent event, in human whole blood (Table 5, assay L).
  • IL-8 chemotactic factor interleukin-8
  • Activity in whole blood is dependent on additional factors such as plasma protein binding and plasma stability of a particular compound.
  • Preferred compounds of the present invention thus have besides of potency at the PI 3-kinase gamma isoform target (Table 4) and sufficient cellular potency (Table 5) also sufficient activity in human whole blood as tested in assay L. More preferably, compounds of the present invention have IC50 values of in this human whole blood assay of ⁇ 1 ⁇ M.
  • the compounds of the present invention may be useful in the treatment of conditions which are mediated by the activation of PI 3-kinase gamma isoform, particularly inflammatory or allergic conditions.
  • Inflammatory or obstructive airways diseases are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodelling or disease progression.
  • Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection.
  • Treatment of asthma is also to be understood as embracing treatment of subjects, e.g.
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. corticosteroid) or bronchodilatory.
  • Prophylactic benefit in asthma may in particular be apparent in subjects prone to “morning dipping”. “Morning dipping” is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
  • inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy.
  • the invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • pneumoconiosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts
  • aluminosis anthracosis
  • asbestosis chalicosis
  • ptilosis ptilosis
  • siderosis silicosis
  • tabacosis tabacosis and byssinosis.
  • compounds of the present invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g.
  • eosinophilic infiltration of pulmonary tissues including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Löffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • Compounds of the present invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
  • Compounds of the present invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or aetiology, including autoimmune haematological disorders (e.g.
  • haemolytic anaemia haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia
  • systemic lupus erythematosus polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g.
  • ulcerative colitis and Crohn's disease endocrine opthalmopathy
  • Grave's disease sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, leishmaniasis, primary billiary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy).
  • diseases or conditions which may be treated with compounds of the present invention include thrombosis, hypertension, heart ischaemia and pancreatitis, (Nature review November 2006 Vol 5), treatment of anaemia including haemolytic anaemia, aplastic anaemia and pure red cell anaemia (WO 2006/040318), septic shock, rheumatoid arthritis, osteoarthritis, proliferative diseases such as cancer, atherosclerosis, allograft rejection following transplantation, stroke, obesity, restenosis, diabetes, e.g.
  • diabetes mellitus type I (juvenile diabetes) and diabetes mellitus type II, diarrheal diseases, ischemia/reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterised by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
  • retinopathy such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy
  • conditions characterised by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma such as glaucoma.
  • Agents of the present invention may be useful in the treatment or prevention of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction including impaired cardiac contractility, hypertrophic cardiomyopathy, diabetic cardiac myopathy and other types of detrimental cardiac dysfunction and remodelling.
  • heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction including impaired cardiac contractility, hypertrophic cardiomyopathy, diabetic cardiac myopathy and other types of detrimental cardiac dysfunction and remodelling.
  • the compounds of the present invention may also be useful in the treatment of visceral disorders, inflammatory bowel disease, inflammatory bowel disorder, cystitis, e.g. interstitial cystitis and urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity.
  • an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflammatory conditions, for example as described by Szarka et al, J. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis . (1993) 148:932-939; Tsuyuki et al., J. Clin. Invest . (1995) 96:2924-2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8.
  • the compounds of the present invention are also useful as co-therapeutic agents for use in combination with PI 3-Kinase delta inhibitors, for example in allergic asthma or in immune-mediated inflammatory diseases, such as rheumatoid arthritis or multiple sclerosis.
  • PI 3-Kinase delta inhibitors for example in allergic asthma or in immune-mediated inflammatory diseases, such as rheumatoid arthritis or multiple sclerosis.
  • Such an effect could be potentially achieved through co-administration of a selective inhibitor of PI 3-kinase gamma isoform with a selective inhibitor of PI 3-kinase delta isoform.
  • the compounds of the present invention are also useful as co-therapeutic agents for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosage or potential side effects of such drugs.
  • An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • the invention includes a combination of an agent of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory or antihistamine drug substance, said agent of the invention and said drug substance being in the same or different pharmaceutical composition.
  • Useful combinations of PI 3-kinase inhibitors with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists, such as Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D; Takeda antagonists, such as N-[[4-[[[[6,7-dihydro-2-(4-methyl-phenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-amin-ium chloride (TAK-770); and CCR-5 antagonists described in U.S. Pat. No. 6,166,037 (particularly claims 18
  • Suitable anti-inflammatory drugs include steroids, in particular, glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679 (especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and 101), WO 03/35668, WO 03/48181, WO 03/62259, WO 03/64445, WO 03/72592, WO 04/39827 and WO 04/66920; non-steroidal glucocorticoid receptor agonists, such as those described in DE 10261874, WO 00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO 03/86294, WO 03/104195, WO 03/1019
  • Suitable bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in EP 424021, U.S. Pat. No. 3,714,357, U.S. Pat. No. 5,171,744, WO 01/04118, WO 02/00652, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO 04/018422 and WO 04/05285.
  • anticholinergic or antimuscarinic agents in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in EP 424021, U.S. Pat. No. 3,714,357, U
  • Suitable dual anti-inflammatory and bronchodilatory drugs include dual beta-2 adrenoceptor agonist/muscarinic antagonists such as those disclosed in USP 2004/0167167, WO 04/74246 and WO 04/74812.
  • Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine, as well as those disclosed in JP 2004107299, WO 03/099807 and WO 04/026841
  • Pi3 kinase inhibitors may be combined with an angiotensin receptor blocker, e.g. valsartan (an angiotensin receptor blocker) and achieve greater therapeutic effect than the administration of valsartan alone.
  • angiotensin receptor blocker e.g. valsartan (an angiotensin receptor blocker)
  • the combination regimen also surprisingly reduces the rate of progression of cardiac, renal and cerebral end-organ damage.
  • the combination elicits enhanced antihypertensive effects (whether malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type of hypertension) and lessening of pulse pressure.
  • the combination is also effective in treating supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling.
  • the combination is beneficial in the treatment and prevention of myocardial infarction and its sequelae, and is useful in treating atherosclerosis, angina (whether stable or unstable), renal insufficiency (diabetic and non-diabetic), peripheral vascular disease, cognitive dysfunction, and stroke.
  • the improvement in endothelial function with the combination therapy provides benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes.
  • the combination may be used for the treatment or prevention of primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.
  • renal failure conditions such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.
  • Compounds of the present invention may also be useful in the treatment of diseases or disorders mediated by lymphocytes interactions, e.g. in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g.
  • rheumatoid arthritis systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, Graves ophthalmopathy, alopecia areata and others, inflammatory diseases optionally with underlying aberrant reactions, e.g.
  • inflammatory bowel disease Crohn's disease or ulcerative colitis
  • intrinsic asthma inflammatory lung injury
  • inflammatory liver injury inflammatory glomerular injury
  • atherosclerosis osteoarthritis and further eczematous dermatitises
  • seborrhoeic dermatitis cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, myocarditis or hepatitis, gut ischemia, traumatic shock, cancer, e.g. breast cancer, T cell lymphomas or T cell leukemias, infectious diseases, e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g.
  • AIDS viral hepatitis, chronic bacterial infection, or senile dementia.
  • cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
  • Compounds of the present invention may be administered in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders.
  • other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders.
  • the compounds of formula I may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g.
  • rapamycin 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, biolimus-7 or biolimus-9; an ascomycin having immuno-suppressive properties, e.g. ABT-281 or ASM981; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g.
  • a PKC inhibitor e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g.
  • a JAK3 kinase inhibitor e.g. N-benzyl-3,4-dihydroxy-benzylidene-cyanoacetamide-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide (Tyrphostin AG 490), prodigiosin 25-C(PNU156804), [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P131), [4-(3′-bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P154), [4-(3′,5′-dibromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] WHI-P97, KRX-211, 3- ⁇ (3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo
  • a S1P receptor agonist or modulator e.g. FTY720 optionally phosphorylated or an analog thereof, e.g.
  • a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists.
  • the compounds of the present invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
  • any appropriate route e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
  • a compound of the present invention for use in therapy.
  • the therapy is selected from a disease or disorder which is mediated by the activation of PI 3-kinase gamma isoform.
  • the therapy is selected from a disease which may be treated by inhibiting of PI 3-kinase gamma isoform.
  • the therapy is selected from a disease which may be treated by inhibiting of PI 3-kinase gamma isoform selectively over PI 3-kinase delta isoform.
  • a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by the activation of PI 3-kinase, particularly the gamma isoform, or (ii) associated with PI 3-kinase gamma isoform activity, or (iii) characterized by activity (normal or abnormal) of PI 3-kinase gamma isoform; or (2) reducing or inhibiting the activity of PI 3-kinase gamma isoform.
  • a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of PI 3-kinase gamma isoform.
  • the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • primates e.g., humans, male or female
  • the subject is a primate.
  • the subject is a human.
  • the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
  • “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
  • “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
  • “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • the compounds of the present invention may be useful as pharmaceuticals and are thus usually formulated in the form of a pharmaceutical composition.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
  • the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
  • the pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc.
  • the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with
  • diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
  • lubricants e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol
  • binders e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
  • disintegrants e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures
  • absorbents colorants, flavors and sweeteners.
  • Tablets may be either film coated or enteric coated according to methods known in the art.
  • suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
  • Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in a mixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
  • Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
  • compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
  • Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier.
  • Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
  • transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
  • topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
  • Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
  • the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, such as 10 to 100 ⁇ l, e.g. 25 to 50 ⁇ l, of the composition, i.e. a device known as a metered dose inhaler.
  • a metered dose such as 10 to 100 ⁇ l, e.g. 25 to 50 ⁇ l
  • Suitable such aerosol vials and procedures for containing within them aerosol compositions under pressure are well known to those skilled in the art of inhalation therapy.
  • an aerosol composition may be administered from a coated can, for example as described in EP-A-0642992.
  • the inhalation device may be a known nebulizer, for example a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion; or a hand-held nebulizer, sometimes referred to as a soft mist or soft spray inhaler, for example an electronically controlled device such as an AERx (Aradigm, US) or Aerodose (Aerogen), or a mechanical device such as a RESPIMAT (Boehringer Ingelheim) nebulizer which allows much smaller nebulized volumes, e.g.
  • a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion
  • a hand-held nebulizer sometimes
  • the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing a dry powder comprising a dosage unit of (A) and/or (B) or a multidose dry powder inhalation (MDPI) device adapted to deliver, for example, 3-25 mg of dry powder comprising a dosage unit of (A) and/or (B) per actuation.
  • the dry powder composition preferably contains a diluent or carrier, such as lactose, and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate.
  • Suitable such dry powder inhalation devices include devices disclosed in U.S. Pat. No. 3,991,761 (including the AEROLIZERTM device), WO 05/113042, WO 97/20589 (including the CERTIHALERTM device), WO 97/30743 (including the TWISTHALERTM device) and WO 05/37353 (including the GYROHALERTM device).
  • the invention also includes (A) an agent of the invention, or a pharmaceutically acceptable salt or solvate thereof, in inhalable form; (B) an inhalable medicament comprising a compound of the present invention in inhalable form together with a pharmaceutically acceptable carrier in inhalable form; (C) a pharmaceutical product comprising such a compound in inhalable form in association with an inhalation device; and (D) an inhalation device containing such a compound in inhalable form.
  • Dosages of compounds of the present invention employed in practicing the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration.
  • suitable daily dosages for administration by inhalation are of the order of 0.0001 to 30 mg/kg, typically 0.01 to 10 mg per patient, while for oral administration suitable daily doses are of the order of 0.01 to 100 mg/kg.
  • the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
  • An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
  • compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
  • agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • the compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
  • the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • a pharmaceutical combination comprising a compound of the present invention and at least one other therapeutic agent, for example for simultaneous, separate or sequential use in therapy.
  • the therapy is the treatment of a disease or disorder mediated by the activation of PI 3-kinase, particularly the gamma isoform.
  • Products provided as a pharmaceutical combination include a composition comprising the compound of the present invention and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of the present invention and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • the invention provides a pharmaceutical combination comprising a compound of the present invention and another therapeutic agent(s).
  • the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
  • kits comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the present invention.
  • the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a container, divided bottle, or divided foil packet An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • the kit may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit of the invention typically comprises directions for administration.
  • the pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.
  • the therapeutically effective dosage of a compound of the present invention, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
  • the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, intravenously, e.g., as a suspension or in aqueous solution.
  • the dosage in vitro may range between about 10 ⁇ 3 molar and 10 ⁇ 9 molar concentrations.
  • a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
  • PI 3-kinase antagonists such as the compounds of the present invention are also useful as co-therapeutic agents for use in combination with a second active agent such as for example an organic nitrate and NO-donors, such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhalational NO; compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine monophosphate (cAMP), such as inhibitors of phosphodiesterases (PDE) 1, 2, 3, 4 and/or 5, especially PDE 5 inhibitors such as sildenafil, vardenafil and tadalafil; NO-independent, but haem-dependent stimulators of guanylate cyclase, such as in particular the compounds described in WO 00/06568, WO 00/06569, WO 02/42301 and WO
  • a pharmaceutical combination comprising the compounds of the present invention and a second agent wherein the second agent is a PDE 5 inhibitor or neutral endopeptidase inhibitor.
  • the compounds of the present invention may be mixed with a second agent in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • the invention includes in a further aspect a combination of a PI 3-kinase inhibitor such a compound of the present invention with osmotic agents (hypertonic saline, dextran, mannitol, Xylitol), ENaC blockers, an anti-inflammatory, bronchodilatory, antihistamine, anti-tussive, antibiotic and/or DNase drug substance, wherein the TPH1 antagonist and the further drug substance may be in the same or different pharmaceutical composition.
  • osmotic agents hyperertonic saline, dextran, mannitol, Xylitol
  • ENaC blockers an anti-inflammatory, bronchodilatory, antihistamine, anti-tussive, antibiotic and/or DNase drug substance
  • the TPH1 antagonist and the further drug substance may be in the same or different pharmaceutical composition.
  • Suitable antibiotics include macrolide antibiotics, e.g., tobramycin (TOBITM).
  • TOBITM tobramycin
  • Suitable DNase drug substances include dornase alfa (PulmozymenTM), a highly-purified solution of recombinant human deoxyribonuclease I (rhDNase), which selectively cleaves DNA.
  • Dornase alfa is used to treat cystic fibrosis.
  • the invention includes as a further aspect a combination of PI 3-kinase inhibitors such the compounds of the present invention with second agents that are IP receptor agonist, particularly the compounds disclosed in WO2012/007539.
  • the invention includes as a further aspect a combination of PI 3-kinase inhibitors such the compounds of the present invention with second agents that are multi-kinase inhibitors, such as imatinib mysilate, Gleevec.
  • lmatinib functions as a specific inhibitor of a number of tyrosine kinase enzymes. It occupies the TK active site, leading to a decrease in activity.
  • TK enzymes in the body include the insulin receptor.
  • lmatinib is specific for the TK domain in the Abelson proto-oncogene, c-kit and PDGF-R (platelet-derived growth factor receptor).
  • a pharmaceutical combination comprising a compound of the present invention and a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors, endothelin antagonist, diuretic, aldosteron receptor blocker, and endothelin receptor blocker.
  • a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors, endothelin antagonist, diuretic, aldosteron receptor blocker, and endothelin receptor blocker.
  • a pharmaceutical combination comprising a compound of the present invention and a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors.
  • a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors.
  • the present invention is illustrated by the following examplified compounds.
  • Mass spectra were run on LCMS systems using electrospray ionization. These were either Agilent 1100 HPLC/Micromass Platform Mass Spectrometer combinations or Waters Acquity UPLC with SQD Mass Spectrometer. [M+H] + refers to mono-isotopic molecular weights.
  • NMR spectra were run on Bruker AVANCE 400 MHz or 500 MHz NMR spectrometers using ICON-NMR. Spectra were measured at 298K and were referenced using the solvent peak.
  • the various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Unless otherwise stated, all starting materials are obtained from commercial suppliers and used without further purification. Salts may be prepared from compounds by known salt-forming procedures.
  • organic compounds according to the preferred embodiments may exhibit the phenomenon of tautomerism.
  • chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embodiments encompasses any tautomeric form of the drawn structure.
  • the mixture was stirred at 100° C. for 20 min in a microwave.
  • the mixture was diluted with DCM then washed with brine.
  • the organic phase was separated, using a phase separator.
  • the solvent was removed under reduced pressure.
  • the crude product was purified by flash column chromatography, eluting in a 0% to 100% i-hex:EtOAc gradient on a 4 g silica cartridge to give the titled compound;
  • Racemic 3-[5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide was prepared from 3-bromo-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide (Intermediate A8) and 5-bromo-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7) under analogous conditions to those of Example 6.
  • the title compound was prepared from 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) and 3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole under analogous conditions to those of Example 11 (using DME as solvent instead of MeCN).
  • the title compound was prepared from trans-3-(5-amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide (Intermediate D1) and 2-Methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-thiazole under analogous conditions to those of Example 11.
  • the reaction was heated in the microwave at 100° C. for 30 minutes. A further 0.05 equivalent of catalyst was added and the reaction heated in the microwave at 100° C. for a further 1 hour. More catalyst (5.52 mg, 7.87 ⁇ mol) was added and the reaction heated in the microwave at 100° C. for a further 2 hours. The reaction was diluted with ethyl acetate, washed with water and the organic layer dried (MgSO 4 ), filtered and concentrated. The product was purified by flash chromatography on silica gel (12 g) eluting with TBME/MeOH gradient (0-10%) to give the title compound;
  • the reaction was heated in a biotage initiator microwave at 120° C. for 2 hours.
  • the reactions were combined, extracted into ethyl acetate, washed with water, brine, the organic layer separated, dried over MgSO 4 , filtered and the solvent removed under reduced pressure.
  • the crude product was loaded onto silica and purified by flash column chromatography, elution with TBME:methanol (0-10%) on a 12 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a brown oil. The residue was taken up in hot ethanol and recrystallised to yield the title compound as a light brown solid;
  • Racemic 3-[5-amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide was prepared from 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and 3-bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) under analogous conditions to those of Example 6. Stereoisomers were separated using chiral SFC.
  • the reaction was heated in a microwave oven at 120° C. for 30 mins.
  • the reaction was added to water (50 ml), and the product extracted into EtOAc (2 ⁇ 60 ml).
  • the organic phase was washed with brine, dried over MgSO 4 and Si-TMT to remove Pd.
  • the mixture was swirled occasionally over 1 hour.
  • the solids were removed by filtration, washed with EtOAc and concentrated under vacuo.
  • the crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH 3 in MeOH) in DCM on a 12 g Si-column, loading with DCM to give a solid which was recrystalised from hot EtOAc ( ⁇ 3 ml). Upon cooling the product crystallised as a yellow solid;
  • the crude material was then suspended in DCM (2 ml) and TFA (0.15 ml, 1.97 mmol) added and the mixture shaken at room temperature for 3 hrs. The solvent was then removed under reduced pressure. The crude material was then purified via preparative HPLC using acetonitrile and water as the eluents with 0.1% TFA as a modifier, to give the title compound as an off white solid;
  • the title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and 2,2-difluoroethanamine using conditions analogous to those of Example 32.
  • purification was carried out using preparative HPLC with an acetonitrile/0.1% aqueous TFA solvent gradient.
  • the title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and (3-aminomethyl-oxetan-3-yl)-methanol using conditions analogous to those of Example 32. In this case, purification was carried out using preparative HPLC with acetonitrile/0.1% aqueous TFA solvent gradient.
  • the title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and 1-amino-3,3-dimethyl-butan-2-one using conditions analogous to those of Example 32. In this case, purification was carried out using preparative HPLC with acetonitrile/0.1% aqueous TFA solvent gradient.
  • the chlorosulfonylation reagent was prepared by bubbling 74 g of sulfur dioxide gas into 740 mL of glacial acetic acid followed by the addition of 30 g of CuCl 2 in 35-40 mL of water. This mixture was allowed to settle and the green supernatant is used for the reaction.
  • step 1 To a stirred solution of 3-bromo-4-chlorobenzene-1-sulfonyl chloride (step 1) (500 mg, 1.72 mmol) and triethylamine (0.385 mL, 2.76 mmol) in dry THF (10 mL) at room temp was added a solution of 4-amino-2-methylbutan-2-ol (231 mg, 2.6 mmol) in dry THF (5 mL). The mixture was stirred at room temp for 1 hour. The mixture was quenched by the addition of 50% aq. ammonium chloride (20 mL) and extracted with EtOAc (3 ⁇ 20 mL). The EtOAc extracts were combined and washed with sat. brine (20 mL), dried (MgSO 4 ), filtered and evaporated to give the title compound as a colourless solid. This material was used in the next step without further purification;
  • Step 3 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • Example 37 The title compound was prepared using analogous conditions to those used for the synthesis of Example 37.
  • the flask was diluted with a further 200 ml of DMF and was warmed to 40° C. and was left overnight. Further triethylamine (50 mL, 0.4 equiv), 0,N-dimethylhydroxylamine hydrochloride (10 g, 0.5 equiv) and T3P® (80 g, 0.5 equiv) were added and the reaction mixture was warmed to 40° C. and was allowed to stir for 2-3 hours. The mixture was allowed to cool to RT and then stirred for three days. The mixture was worked up by the addition of 2M HCl (100 mL) and was diluted with ethyl acetate (1 L) and water (500 mL). The biphasic mixture was separated.
  • the aqueous layer was basified with 2M NaOH ( ⁇ 150 mL), organic extract was added back and the biphasic mixture was shaken. The organic was extracted, washed with brine, dried over MgSO 4 , filtered and dried under vacuum to give a yellow oil.
  • the crude yellow oil was loaded directly onto a 750 g column (in DCM ⁇ 20 mL) and was eluted with iso-Hex/EtOAc (0-70% gradient). The fractions containing pure product were combined and evaporated to give a yellow oil. Diethyl ether (50 mL) was added and this was evaporated under vacuum to give a pale yellow solid;
  • step 1 3-amino-6-bromo-N-methoxy-N-methylpyrazine-2-carboxamide (step 1) (4 g, 15.32 mmol) in dry THF (50 ml), cooled on an ice bath under nitrogen, was added dropwise 1M ethylmagnesium bromide in THF (46.0 ml, 46.0 mmol). The mixture was slowly warmed to room temperature. The reaction was cooled on an ice bath and quenched by dropwise addition of water. The reaction was diluted with ethyl acetate, washed with water and the aqueous back extracted with further ethyl acetate. The organics were combined, dried (MgSO 4 ), filtered and concentrated. The brown residue was triturated in diethyl ether, filtered under vacuum and dried.
  • Step 3 1-(3-Amino-6-bromopyrazin-2-yl)-2-bromopropan-1-one
  • step 2 To a solution of 1-(3-amino-6-bromopyrazin-2-yl)propan-1-one (step 2) (3.04 g, 13.2 mmol) in glacial acetic acid (75 mL) at room temp was added polymer supported pyridinium tribromide (14.2 g of loading 2 mmol/g, 28.4 mmol) followed by 33% HBr in acetic acid (4.35 mL, 26.4 mmol). The mixture was heated at 70° C. for 1 hour. LCMS showed approx 4:1 product to starting material. Heating was continued at 70° C. for a further 30 min. Once cooled, the volatiles (including AcOH) were removed under reduced pressure.
  • step 3 A stirred mixture of 1-(3-amino-6-bromopyrazin-2-yl)-2-bromopropan-1-one (step 3) (782 mg, 2.53 mmol) and thioacetamide (399 mg, 5.32 mmol) in EtOH (25 mL) was heated at 50° C. for 30 mins. The mixture was cooled to RT and allowed to stir overnight. The volatiles were removed under reduced pressure. The residue was partitioned between EtOAc (30 mL) and water (30 mL) and extracted with further EtOAc (3 ⁇ 30 mL). The EtOAc extracts were combined, washed with sat brine (50 mL), dried (MgSO 4 ), filtered and evaporated to give a brown oil.
  • Step 5 3-(5-Amino-6-(2,5-dimethylthiazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • the reaction mixture was heated in a microwave reactor for 90 minutes at 120° C.
  • the reaction mixture was added to water (50 ml) and extracted with EtOAc (50 ml).
  • the organic phase was washed with brine (50 ml) and dried over MgSO 4 .
  • the solid was filtered off, washed with EtOAc and the solvent was concentrated under reduced pressure.
  • the residue was purified by flash column chromatography, eluting with a gradient of 0-10% MeOH in DCM using a 4 g silica column, loading with DCM.
  • the resulting oil was triturated with Et 2 O to give a solid, which was filtered off, washed with Et 2 O and dried overnight in a vacuum oven at 50° C. to give the title compound as a beige solid;
  • the crude material was purified by flash column chromatography, eluting with a gradient of 0-10% MeOH in DCM on a 4 g silica column, loading with DCM and MeOH.
  • the resulting oil was triturated with Et 2 O to give a solid which was filtered off, washed with Et 2 O and dried in a vacuum oven at 50° C. overnight to give the title compound as a beige solid;
  • the resulting mixture was diluted with 10% methanol in DCM and filtered through 1 g Celite® washing with further 10% methanol in DCM.
  • the crude product was purified by flash column chromatography (12 g silica, radient 0-20% methanol in TBME). The product fractions were evaporated under reduced pressure and dried in a vacuum oven to give the title compound as a brown-orange solid;
  • the title compound was prepared by an analogous method to that used for the preparation of Example 46 starting from 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
  • Step 4 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide
  • the title compound was prepared by an analogous method to that used for the preparation of Example 11, using 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 3-(5-amino-6-chloropyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide (prepared analogously to Intermediate D1);
  • the title compound was prepared by an analogous method to that used for the preparation of Example 11, using 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole and 3-(5-amino-6-chloropyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide (prepared analogously to Intermediate D1);

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.
Figure US20180243297A1-20180830-C00001

Description

    TECHNICAL FIELD
  • The present invention relates to novel amino pyrazine derivatives which are PI 3-kinase gamma isoform selective inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by the activation of PI 3-kinase gamma isoform, particularly asthma.
    • BACKGROUND
  • Phosphatidylinositol 3-kinases (PI 3-kinases), a family of enzymes which catalyse the phosphorylation of the 3′-OH of the inositol ring, play a central role in regulating a wide range of cellular processes including metabolism, survival, motility and cell activation (Vanhaesebroeck, B. et al., Annu. Rev. Biochem. 2001, 70, 535). These lipid kinases are divided into 3 major classes, I, II & III, according to their structure and in vitro substrate specificity (Wymann, M. et al.; Biochem. Biophys. Acta, 1998, 1436, 127). The most widely understood class I family is further subdivided into subclasses IA and IB. Class IA PI 3-kinases consist of an 85 kDa regulatory/adapter protein and three 110 kDa catalytic subunits (p110α, p110β and p110δ) which are activated in the tyrosine kinase system whilst class IB consists of a single p110γ isoform (PI 3-kinase gamma isoform) which is activated by G protein-coupled receptors. The three members of class II PI 3-kinases (C2α, C2β and C2γ) and single member of class III PI 3 kinases (Vps34) are less well understood. In addition there are also four PI 4-kinases and several PI 3-kinase related protein kinases (termed PIKK's or class IV) including DNA-PK, mTOR, ATM and ATR, all of which have a similar catalytic domain (Abraham R. T. et al.; DNA repair 2004, 3(8-9), 883).
  • A key role for PI 3-kinase gamma isoform in processes such as leukocyte activation, leukocyte chemotaxis and mast cell degranulation has been shown, thereby generating interest in this target for the treatment of autoimmune and inflammatory disorders (Ghigo et al., Bioessays, 2010, 32, p 185-196; Reif et al., J. Immunol., 2004, 173, p 2236-2240; Laffargue et al., Immunity, 2002, 16, p 441-451; Rommel et al, Nature Rev. Immunology, 2007, 7, p 191; Cushing et al J. Med. Chem., 2012, 55, p 8559; Bergamini et al, Nature Chem. Biol., 2012, 8, p 576). Specifically, numerous publications suggest the potential utility of PI3 Kinase gamma isoform inhibitors for the treatment of asthma (e.g. Thomas et al, Immunology, 2008, 126, p 413; Jiang et al, J. Pharm. Exp. Ther., 2012, 342, p 305; Takeda et al, Int. Arch. Allergy Immunol. 2010, 152 (suppl 1), p 90-95). There are also reports linking inhibition of the PI 3-kinase gamma isoform as having potential therapeutic value in numerous other indications such as cancer (Beagle and Fruman, Cancer Cell, 2011, 19, p 693; Schmid et al, Cancer Cell, 2011, 19, p 715; Xie et al, Biochem. Pharm., 2013, 85, p 1454; Subramaniam et al, Cancer Cell, 2012, 21, p 459), diabetes (Kobayashi et al, Proc. Nat. Acad. Sci, 2011, 108, p 5753; Azzi et al, Diabetes, 2012, 61, p 1509), cardiovascular disease (Fougerat et al, Clin. Sci., 2009, 116, p 791; Fougerat et al, Circulation, 2008, 117, p 1310; Chang et al, Proc. Nat. Acad. Sci., 2007, 104, p 8077; Fougerat et al, Br. J. Pharm., 2012, 166, p 1643), obesity (Becattini et al, Proc. Nat. Acad. Sci., 2011, 108, pE854), Alzheimer's disease (Passos et al, Brain, Behaviour and Immunity, 2010, 24, 493) and pancreatitis (Lupia et al, Am. J. Path, 2004, 165, p 2003). A recent review of PI 3-Kinase isoforms as drug targets is given in Blajecka et al, Current Drug Targets, 2011, 12, p 1056-1081.
  • WO2009/115517 (Novartis) describes amino pyrazine and pyridine derivatives as PI 3-kinase inhibitors.
  • WO2009/013348 (Novartis) describes amino pyrimidine derivatives as PI 3-kinase inhibitors.
  • WO2003/093297 (Exelixis) describes protein kinase modulators and methods of use of such modulators.
  • Leahy et al., J. Med. Chem., 2012, 55 (11), pp 5467-5482, describe PI 3-kinase gamma isoform inhibitors.
  • Hence, there is a need for potent, selective inhibitors of PI 3-kinase gamma isoform.
    • SUMMARY OF THE INVENTION
  • In a first aspect, the invention relates to a compound of formula (I)
  • Figure US20180243297A1-20180830-C00002
  • wherein
    E is selected from N and CRE;
    R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
    R3 is selected from
    (i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iii) —C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vii) H;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
    Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-N′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl;
    R′ and R″ are independently selected from H and C1-4 alkyl;
    or a pharmaceutically acceptable salt thereof.
  • In other aspects, the invention relates to pharmaceutical compositions and combinations comprising compounds of the first aspect, and to the use of such compounds of the first aspect in the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform.
    • DESCRIPTION OF THE EMBODIMENTS
  • In an embodiment 1 of the invention, there is provided a compound of formula (I)
  • Figure US20180243297A1-20180830-C00003
  • wherein
    E is selected from N and CRE;
    R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
    R3 is selected from
    (i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iii) —C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vii) H;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl; Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-N′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl; R′ and R″ are independently selected from H and C1-4 alkyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 1.1 of the invention, there is provided a compound of formula (I)
  • Figure US20180243297A1-20180830-C00004
  • wherein
    E is selected from N and CRE;
    R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy and C3-6 cycloalkyl;
    R3 is selected from
    (i) C1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkoxy, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    (iii) —C3-6 cycloalkyl or —O—C3-6 cycloalkyl wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (iv) —(C0-3 alkyl)-C3-6 cycloalkyl or —(O—C0-3 alkyl)-C3-6 cycloalkyl spiro fused to a second C3-6 cycloalkyl or C3-6 heterocyclyl by one single carbon atom, wherein the C3-6 cycloalkyl or C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (v) (C0-3 alkyl)-C3-6 heterocyclyl or —(O—C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (vi) —(C0-3 alkyl)-C3-6 heterocyclyl or —(O—C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is spiro fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and wherein the C3-6 heterocyclyl or C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-6 heterocyclyl, which C3-6 heterocyclyl is optionally spiro fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and which C3-6 heterocyclyl and C3-6 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, —(C0-3 alkyl)-NR3aR3b, —(C0-3 alkyl)-C3-6 cycloalkyl and —(C0-3 alkyl)-C3-6 heterocyclyl;
    or a pharmaceutically acceptable salt thereof.
    • DEFINITIONS
  • “Halo” or “halogen”, as used herein, may be fluoro, chloro, bromo or iodo.
  • “C1-4 alkyl”, as used herein, denotes straight chain or branched alkyl having 1-4 carbon atoms. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as “C1-C4 alkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.
  • “C1-4 alkoxy”, as used herein, refers to an —O—C1-4 alkyl group wherein C1-4 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like. As for alkyl unless a particular structure is specified the terms propoxy, butoxy etc include all straight and branched chain forms having the appropriate number of carbon atoms e.g. propoxy includes n-propoxy and isopropoxy.
  • “C1-4 haloalkoxy” as used herein refers to an —O—C1-4 alkyl group wherein C1-4 alkyl is as defined herein and substituted with one or more halogen groups, e.g. —O—CF3.
  • “C1-4 haloalkyl”, as used herein, denotes straight chain or branched alkyl having 1-4 carbon atoms with at least one hydrogen substituted with a halogen. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as “C1-C4-Haloalkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with halogen, such as where the halogen is fluorine: CF3CF2—, (CF3)2CH—, CH3—CF2—, CF3CF2—, CF3, CF2H—, CF3CF2CHCF3 or CF3CF2CF2CF2—.
  • “C3-7 cycloalkyl” as used herein refers to a saturated monocyclic hydrocarbon ring of 3 to 7 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. If a different number of carbon atoms is specified, then the definition is to be amended accordingly.
  • The term “hydroxy” or “hydroxyl” refers to —OH.
  • “C1-4 hydroxyalkyl”, as used herein, denotes a straight chain or branched alkyl having 1-4 carbon atoms with at least one hydrogen substituted with a hydroxy group. If a different number of carbon atoms is specified, such as C6 or C3, then the definition is to be amended accordingly, such as “C1-C4 hydroxyalkyl” will represent methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl that have at least one hydrogen substituted with hydroxy.
  • “C3-7 heterocyclyl ring” refers to a 3 to 7 membered saturated or partially unsaturated aliphatic ring system which contains 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur. Suitable examples of such ring systems include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolinyl, thienyl or oxazolinyl.
  • “5-6 membered heteroaryl” refers to a 5-6 membered aromatic ring system which contains 1 to 3 heteroatoms selected from oxygen, nitrogen or sulfur. Examples of 5-membered heteroaryl rings in this instance include furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, isothiazolyl, isoxazolyl, thiophenyl, or pyrazolyl. Examples of 6-membered heteroaryl rings include pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or triazinyl.
  • “Oxo” refers to ═O.
  • The term “a,” “an,” “the” and similar terms used in the context of the present invention (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
  • The term “treatment” as used herein refers to both to symptomatic and prophylactic treatment, particularly symptomatic.
  • As used herein, when one embodiment refers to several other embodiments by using the term “according to any one of”, for example “according to any one of embodiments 1 to 5”, then said embodiment refers not only to embodiments indicated by the integers such as 1 and 2 but also to embodiments indicated by numbers with a decimal component such as 1.1, 1.2 or 2.1, 2.2, 2.3. For example, “according to any one of embodiments 1 to 3” means according to any one of embodiments 1, 1.1, 2, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7. The same applies when referring to exemplified compounds.
  • Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments.
  • In an embodiment 2 of the invention, there is provided a compound of formula (Ia)
  • Figure US20180243297A1-20180830-C00005
  • wherein
    R1 is independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
    R2 is selected from H, halogen, CF3 and methyl;
    R3 is selected from
    (i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iii) C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vii) H;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
    Y is selected from the group consisting of
      • thiazolyl,
      • thiadiazolyl,
      • isothiazolyl,
      • pyrazolyl,
      • pyridyl,
      • triazolyl,
      • imidazolyl,
      • oxadiazolyl,
      • isoxazolyl,
      • oxazolyl,
      • pyrrolyl,
      • thienyl, and
      • furanyl;
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-N′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl;
        R′ and R″ are independently selected from H and C1-4 alkyl;
        or a pharmaceutically acceptable salt thereof.
  • In an embodiment 2.1 of the invention, there is provided a compound according to embodiment 1.1, wherein
  • E is selected from N and CRE;
    R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy and C3-6 cycloalkyl;
    R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    (ii) C1-4 alkoxy which is substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkoxy, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    (iii) C3-6 cycloalkyl or —O—C3-6 cycloalkyl wherein the C3-6 cycloalkyl is substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (iv) a —(C0-3 alkyl)-C3-6 cycloalkyl or —(O—C0-3 alkyl)-C3-6 cycloalkyl spiro fused to a second C3-6 cycloalkyl or C3-6 heterocyclyl by one single carbon atom, wherein the second C3-6 cycloalkyl or C3-6 heterocyclyl is substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (v) a —(C0-3 alkyl)-C3-6 heterocyclyl or —(O—C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    (vi) a —(C0-3 alkyl)-C3-6 heterocyclyl or —(O—C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and wherein said second C3-6 heterocyclyl or C3-6 cycloalkyl is substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-6 heterocyclyl, which C3-6 heterocyclyl is optionally spiro fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and which C3-6 heterocyclyl and C3-6 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
    Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, —(C0-3 alkyl)-NR3aR3b, —(C0-3 alkyl)-C3-6 cycloalkyl and —(C0-3 alkyl)-C3-6 heterocyclyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 2.2 of the invention, there is provided a compound of formula (Ia)
  • Figure US20180243297A1-20180830-C00006
  • wherein
    R1 is independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
    R2 is selected from H, halogen, CF3 and methyl;
    R3 is selected from
    (i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iii) —C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    (vii) H;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
    Y is selected from the group consisting of
      • thiazolyl,
      • thiadiazolyl,
      • isothiazolyl,
      • pyrazolyl,
      • pyridyl,
      • triazolyl,
      • imidazolyl,
      • oxadiazolyl,
      • isoxazolyl,
      • oxazolyl,
      • pyrrolyl,
      • pyrimidinyl,
      • thienyl, and
      • furanyl;
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-N′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl;
        R′ and R″ are independently selected from H and C1-4 alkyl;
        or a pharmaceutically acceptable salt thereof.
  • In an embodiment 3 of the invention, there is provided a compound according to embodiment 1 or 2, wherein
  • R1 is selected from H and C1-4 alkyl;
    R2 is selected from H, halogen, C1-4 haloalkyl and methyl;
    R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, halogen, —NR3aR3b, C1-4 alkyl, C3-7 cycloalkyl and C3-7 heterocyclyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, halogen, —NR3aR3b, C1-4 alkyl, C3-7 cycloalkyl and C3-7 heterocyclyl;
    (iii) —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (iv) —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (v) —(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (vi) (C0-3 alkyl)-C3-7 heterocyclyl, wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (vii) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    R4 is selected from H and C1-4 alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
    R3a and R3b are independently selected from H and C1-4 alkyl;
    Y is selected from the group consisting of
      • thiazolyl,
      • thiadiazolyl,
      • isothiazolyl,
      • pyrazolyl,
      • pyridyl,
      • triazolyl,
      • imidazolyl,
      • oxadiazolyl,
      • isoxazolyl,
      • oxazolyl;
      • pyrrolyl,
      • thienyl, and
      • furanyl;
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4hydroxyalkyl, —(C0-3 alkyl)-C3-7 cycloalkyl, —(C═O)—C3-7 heterocyclyl, —(C0-3 alkyl)-N′R″, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-pyridyl;
        R′ and R″ are independently selected from H and C1-4 alkyl;
        or a pharmaceutically acceptable salt thereof.
  • In an embodiment 3.1 of the invention, there is provided a compound or salt according to embodiment 1.1 or 2.1 wherein E is CRE and RE is H.
  • In an embodiment 4 of the invention, there is provided a compound according to any one of embodiments 1 to 3, wherein
  • Y is selected from the group consisting of
      • oxazol-2-yl,
      • oxazol-5-yl,
      • oxazol-4-yl,
      • thiazol-5-yl,
      • thiazol-4-yl,
      • 1,3,4-thiadiazol-2-yl,
      • isothiazol-5-yl,
      • pyrazol-4-yl,
      • pyrazol-3-yl,
      • pyrazol-1-yl,
      • pyrid-4-yl,
      • pyrid-3-yl,
      • pyrid-2-yl,
      • 1,2,4-triazol-1-yl,
      • 1,2,3-triazol-4-yl,
      • imidazol-1-yl,
      • 1,2,4-oxadiazol-5-yl,
      • 1,3,4-oxadiazol-2-yl,
      • 1,2,4-oxadiazol-3-yl,
      • isoxazol-5-yl,
      • isoxazol-3-yl,
      • isoxazol-4-yl,
      • pyrrol-3-yl,
      • thien-2-yl,
      • thien-3-yl, and
      • furan-3-yl,
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4hydroxyalkyl, —(C0-3 alkyl)-C3-7 cycloalkyl, —(C═O)—C3-7 heterocyclyl, —(C0-3 alkyl)-N′R″, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-pyridyl;
        R′ and R″ are independently selected from H and C1-4 alkyl;
        or a pharmaceutically acceptable salt thereof.
  • In an embodiment 4.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 3 wherein R1 is selected from C1-4 alkyl and H.
  • In an embodiment 5 of the invention, there is provided a compound according to any one of embodiments 1 to 4, wherein
  • Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00007
    Figure US20180243297A1-20180830-C00008
    Figure US20180243297A1-20180830-C00009
    Figure US20180243297A1-20180830-C00010
    Figure US20180243297A1-20180830-C00011
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 5.1 of the invention, there is provided a compound or salt according to embodiment 4.1, wherein R1 is selected from methyl and H, particularly methyl.
  • In an embodiment 6 of the invention, there is provided a compound according to any one of embodiments 1 to 4, wherein
  • Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00012
    Figure US20180243297A1-20180830-C00013
    Figure US20180243297A1-20180830-C00014
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 6.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 5, wherein R2 is selected from H, C1-4 alkyl and halogen.
  • In an embodiment 7 of the invention, there is provided a compound according to any one of embodiments 1 to 4, wherein
  • Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00015
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 7.1 of the invention, there is provided a compound or salt according to embodiment 6.1, wherein R2 is selected from H, fluoro, chloro and methyl, particularly H and fluoro, more particularly H.
  • In an embodiment 8 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (iii) —O—(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (iv) —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (v) —(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (vi) —(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, oxo, halogen and C1-4 haloalkyl;
    (vii) a —(C0-3 alkyl)-C3-7 cycloalkyl or —(O—C0-3 alkyl)-C3-7 cycloalkyl where the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (viii) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 8.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is selected from
  • (i) C1-4 alkyl substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 alkyl, halogen, oxo, and —NR3aR3b;
    (ii) C1-4 alkoxy substituted with 1 to 3 substituents independently selected from hydroxy, halogen and C1-4 alkyl;
    (iii) —(C0-3 alkyl)-C3-6 cycloalkyl wherein the C3-6 cycloalkyl is substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl and halogen;
    (iv) —(C0-3 alkyl)-C3-6 cycloalkyl spiro fused to a second C3-6 cycloalkyl by one single carbon atom, wherein the second C3-6 cycloalkyl is substituted with 1 to 3 substituents independently selected from hydroxy and halogen; and
    (v) —(C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 alkyl and C1-4 hydroxyalkyl;
    (vi) a —(C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is spiro fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and wherein the C3-6 heterocyclyl or C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy and C1-4 hydroxyalkyl;
    R3a and R3b are independently selected from H and C1-4 alkyl;
    R4 is selected from H and C1-4alkyl; or
    R3 and R4 together with the nitrogen atom to which they are attached form a C3-6 heterocyclyl, which C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl and C1-4 alkyl.
  • In an embodiment 9 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (iii) —O—(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (iv) —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (v) —(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, oxo and C1-4 haloalkyl;
    (vi) —(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, oxo, halogen and C1-4 haloalkyl;
    (vii) a —(C0-3 alkyl)-C3-7 cycloalkyl or —(O—C0-3 alkyl)-C3-7 cycloalkyl spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, oxo, halogen and C1-4 haloalkyl; or a pharmaceutically acceptable salt thereof.
  • In an embodiment 9.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is C1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl.
  • In an embodiment 10 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (iii) —O—(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen and C1-4 haloalkyl;
    (iv) —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen and C1-4 haloalkyl;
    (v) (C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen and C1-4 haloalkyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 10.1 of the invention, there is provided a compound or salt according to embodiment 9.1, wherein R3 is selected from propyl, butyl and pentyl substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 alkyl, halogen, —NR3aR3b and oxo.
  • In an embodiment 11 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein R3 is selected from
  • (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (iii) —O—(C0-3 alkyl)-C3-7 heterocyclyl wherein the C3-7 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen and C1-4 haloalkyl;
    (iv) —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen and C1-4 haloalkyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 11.1 of the invention, there is provided a compound or salt according to embodiment 9.1, wherein R3 is selected from
    • 3-hydroxypropyl-;
    • 3-hydroxy-2,2-dimethylpropyl-;
    • 3-hydroxy-3-methylbutyl-;
    • 2-hydroxy-2-methylpropyl-;
    • 4,4,4-trifluoro-3-hydroxybutyl-;
    • 2,2-difluoroethyl-;
    • 3,3-dimethyl-2-oxo-butyl; and
    • 3,3,3-trifluoro-2-hydroxy-2-methylpropyl-.
  • In an embodiment 12 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
    (i) C1-4 alkyl which is substituted with 1 to 3 substituents independently selected from hydroxyl, halogen and C1-4 alkyl;
    (ii) C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxyl and C1-4 alkyl;
    or a pharmaceutically acceptable salt thereof.
  • In an embodiment 12.1 of the invention, there is provided a compound or salt according to embodiment 11.1, wherein R3 is selected from
    • 3-hydroxypropyl-;
    • 3-hydroxy-2,2-dimethylpropyl-;
    • 2-hydroxy-2-methylpropyl; and
    • 3-hydroxy-3-methylbutyl-.
  • In an embodiment 13 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00016
    Figure US20180243297A1-20180830-C00017
    Figure US20180243297A1-20180830-C00018
    Figure US20180243297A1-20180830-C00019
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 13.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is C1-4 alkoxy which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkyl, C1-4 alkoxy, oxo, —NR3aR3b and C3-6 cycloalkyl, and wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl;
  • In an embodiment 14 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00020
    Figure US20180243297A1-20180830-C00021
    Figure US20180243297A1-20180830-C00022
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 14.1 of the invention, there is provided a compound or salt according to any one of embodiment 13.1, wherein R3 is selected from propoxy, butoxy and pentoxy substituted with 1 to 3 substituents selected from hydroxy, C1-4 alkyl and halogen.
  • In an embodiment 15 of the invention, there is provided a compound according to an one of embodiments 1 to 7, wherein R3 is selected from
  • Figure US20180243297A1-20180830-C00023
    Figure US20180243297A1-20180830-C00024
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 15.1 of the invention, there is provided a compound or salt according to any one of embodiment 14.1, wherein R3 is 2-hydroxy-2-methylpropoxy-.
  • In an embodiment 16 of the invention, there is provided a compound according to an one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00025
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 16.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is C3-6 cycloalkyl or —O—C3-6 cycloalkyl wherein the C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b.
  • In an embodiment 17 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00026
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 17.1 of the invention, there is provided a compound or salt according to embodiment 16.1, wherein R3 is selected from (C0-3 alkyl)-cyclohexyl, —(C0-3 alkyl)-cyclobutyl and —(C0-3 alkyl)-cyclopropyl, and wherein the cyclohexyl, cyclobutyl and cyclopropyl are substituted with 1 or 2 substituents independently selected from hydroxy, C1-4 hydroxyalkyl and halogen.
  • In an embodiment 18 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00027
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 18.1 of the invention, there is provided a compound or salt according to embodiment 17.1, wherein R3 is selected from
    • 4-hydroxycyclohexyl-;
    • 3-hydroxycyclobutyl-methyl-;
    • 1-hydroxycyclobutyl-methyl-;
    • 1-(hydroxymethyl)cyclopropyl; and
    • 1-hydroxycyclopropyl-methyl-.
  • In an embodiment 19 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 is selected from
  • Figure US20180243297A1-20180830-C00028
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 19.1 of the invention, there is provided a compound or salt according to embodiment 17.1, wherein R3 is selected from 4-hydroxycyclohexyl-.
  • In an embodiment 20 of the invention, there is provided a compound according to any one of embodiments 1 to 7, wherein
  • R3 and R4 together with the nitrogen atom to which they are attached form a ring selected from
  • Figure US20180243297A1-20180830-C00029
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 20.1 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is —(C0-3 alkyl)-C3-6 cycloalkyl or —(O—C0-3 alkyl)-C3-6 cycloalkyl spiro fused to a second C3-6 cycloalkyl or C3-6 heterocyclyl by one single carbon atom, wherein the C3-6 cycloalkyl or C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b.
  • In an embodiment 21 of the invention, there is provided a compound or salt according to embodiment 20.1, wherein R3 is selected from spiro[3.3]heptan-2-yl, spiro[3.4]octan-6-yl, spiro[4.4]nonan-2-yl and spiro[3.4]undecan-3-yl, which is substituted with 1 to 3 substituents selected from hydroxy and halogen.
  • In an embodiment 22 of the invention, there is provided a compound or salt according to embodiment 21, wherein R3 is 6-hydroxyspiro[3.3]heptan-2-yl.
  • In an embodiment 23 of the invention, there is provided a compound or salt according to any one of embodiments 1 to 7, wherein R3 is —(C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 alkyl and C1-4 hydroxyalkyl;
  • or —(C0-3 alkyl)-C3-6 heterocyclyl or —(O—C0-3 alkyl)-C3-6 heterocyclyl wherein the C3-6 heterocyclyl contains at least one heteroatom selected from O and N, and wherein said C3-6 heterocyclyl is spiro fused to a second C3-6 heterocyclyl or a C3-6 cycloalkyl by one single carbon atom, and wherein the C3-6 heterocyclyl or C3-6 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 alkoxy, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl and —(C0-3 alkyl)-NR3aR3b.
  • In an embodiment 24 of the invention, there is provided a compound or salt according to embodiment 23, wherein R3 is selected from a —(C0-3 alkyl)-tetrahydrofuranyl, —(C0-3 alkyl)-oxetanyl, —(C0-3 alkyl)-pyrrolidinyl, and —(C0-3 alkyl)-tetrahydropyranyl, each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, 4 alkyl and C1-4 hydroxyalkyl.
  • In an embodiment 25 of the invention, there is provided a compound or salt according to embodiment 24, wherein R3 is selected from
      • (1-ethylpyrrolidin-2-yl)methyl,
      • (tetrahydro-2H-pyran-4-yl,
      • (3-hydroxyoxetan-3-yl)methyl,
      • (3-methyloxetan-3-yl)methyl,
      • (4-hydroxy-tetrahydropyran)methyl,
      • (3-hydroxymethyl-oxetan-3-yl)methyl, and
      • (tetrahydrofuran-3-yl)methyl.
  • In an embodiment 26 of the invention, there is provided a compound or salt according to any one of embodiment 1 to 25, wherein R4 is H or methyl.
  • In an embodiment 27 of the invention, there is provided a compound or salt according to any one of embodiment 1 to 7, wherein R3 and R4 together with the nitrogen atom to which they are attached form a C3-6 heterocyclyl, which heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkoxy and C1-4 haloalkyl.
  • In an embodiment 28 of the invention, there is provided a compound or salt according to embodiment 27, wherein R3 and R4 together with the nitrogen atom to which they are attached form a piperazinyl, piperidinyl, or azetidinyl, which are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl and C1-4 alkyl.
  • In an embodiment 29 of the invention, there is provided a compound or salt according to embodiment 28, wherein R3 and R4 together with the nitrogen atom to which they are attached form a
      • 3-(trifluoromethyl)piperazin-1-yl,
      • 3,3-difluoropiperidin-1-yl, or
      • 1-(hydroxymethyl)azetidin-3-yl.
  • In an embodiment 30 of the invention, there is provided a compound or salt according to any one of embodiment 1 to 29, wherein Y is selected from
      • thiazolyl,
      • pyrazolyl,
      • pyridyl,
      • triazolyl,
      • imidazolyl,
      • oxadiazolyl,
      • pyrimidinyl,
      • isoxazolyl,
      • oxazolyl, and
      • thienyl;
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, —NR3aR3b, —(C0-3 alkyl)-C3-6 cycloalkyl and —(C0-3 alkyl)-C3-6 heterocyclyl.
  • In an embodiment 31 of the invention, there is provided a compound or salt according to embodiment 30, wherein Y is selected from
      • thiazol-5-yl,
      • pyrazol-4-yl,
      • pyrazol-5-yl,
      • pyrazol-1-yl,
      • pyrid-4-yl,
      • pyrid-3-yl,
      • 1,2,4-triazol-1-yl,
      • 1,2,3-triazol-4-yl,
      • imidazol-1-yl,
      • 1,2,4-oxadiazol-5-yl,
      • 1,3,4-oxadiazol-2-yl,
      • isoxazol-5-yl,
      • pyrimidin-5-yl,
      • thien-3-yl,
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy and —(C0-3 alkyl)-C3-6 cycloalkyl.
  • In an embodiment 32 of the invention, there is provided a compound or salt according to embodiment 31, wherein Y is selected from
      • thiazol-5-yl,
      • pyrazol-4-yl,
      • pyrazol-5-yl,
      • pyrazol-1-yl,
      • pyrid-4-yl,
      • pyrid-3-yl,
      • 1,2,4-triazol-1-yl,
      • 1,2,3-triazol-4-yl,
      • imidazol-1-yl,
      • 1,2,4-oxadiazol-5-yl,
      • isoxazol-5-yl,
      • pyrimidin-5-yl,
      • thien-3-yl,
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, CF3, hydroxyethyl, methoxyethyl and methoxy.
  • In an embodiment 33 of the invention, there is provided a compound or salt according to embodiment 30, wherein Y is selected from
      • 5-morpholin-4-ylmethyl-thien-3-yl,
      • 3-cyclopropyl-[1,2,4]triazol-1-yl,
      • 2-cyclopropyl-thiazol-5-yl,
      • 2,5-dimethyl-2H-[1,2,3]triazol-4-yl,
      • 2-methylthiazol-5-yl,
      • 1,3-dimethyl-1H-pyrazol-4-yl,
      • 1,2,4-triazol-1-yl,
      • 3-isopropyl-1,2,4-oxadiazol-5-yl,
      • 1-methyl-1H-pyrazol-4-yl,
      • 1H-pyrazol-1-yl,
      • 3-ethyl-1,2,4-oxadiazol-5-yl,
      • 2-methyl-2H-1,2,3-triazol-4-yl,
      • 1H-pyrazol-4-yl,
      • 3-methylisoxazol-5-yl,
      • 2-methylpyridin-4-yl)pyrazin-2-yl,
      • 1H-1,2,4-triazol-1-yl,
      • 3-propyl-1,2,4-oxadiazol-5-yl,
      • pyrimidin-5-yl,
      • 3-methyl-1H-1,2,4-triazol-1-yl,
      • 5-methyl-1,3,4-oxadiazol-2-yl,
      • 1-methyl-1H-pyrazol-5-yl,
      • pyrid-3-yl,
      • pyrid-4-yl,
      • 2-methyl-pyrid-4-yl,
      • 3-methyl-1,2,4-oxadiazol-5-yl,
      • 2-methylthiazol-4-yl,
      • 4-methyl-1H-imidazol-1-yl,
      • 1-ethyl-1H-pyrazol-4-yl,
      • 3,5-dimethyl-1H-pyrazol-1-yl,
      • 3-cyclopropyl-1,2,4-oxadiazol-5-yl,
      • 3-methylisoxazol-5-yl,
      • 1-isopropyl-1H-pyrazol-4-yl,
      • 1H-1,2,4-triazol-1-yl,
      • 1-propyl-1H-pyrazol-4-yl,
      • 4-methoxypyridin-3-yl,
      • pyrazol-3-yl,
      • 3-methylisoxazol-5-yl, and
      • 1-(2-methoxyethyl)-1H-pyrazol-4-yl.
  • In an embodiment 34 of the invention, there is provided a compound or salt according to any one of embodiment 1 to 29, wherein Y is selected from
      • thiazolyl,
      • pyrazolyl,
      • pyridyl, and
      • triazolyl,
        each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, —(C0-3 alkyl)-C3-6 cycloalkyl and (C0-3 alkyl)-C3-6 heterocyclyl.
  • In an embodiment 35 of the invention, there is provided a compound or salt according to embodiment 34, wherein Y is selected from
      • thiazol-5-yl,
      • pyrazol-4-yl,
      • pyrazol-5-yl,
      • pyrazol-1-yl,
      • pyrid-4-yl,
      • pyrid-3-yl,
      • 1,2,4-triazol-1-yl,
      • 1,2,3-triazol-4-yl,
        each of which is unsubstituted or substituted with 1 or 2 substituents independently selected from methyl, ethyl, propyl and isopropyl.
  • In an particular embodiment 36 of the invention, there is provided a compound of formula (I)
  • Figure US20180243297A1-20180830-C00030
  • wherein
    E is selected from N and CRE;
    R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00031
    Figure US20180243297A1-20180830-C00032
    Figure US20180243297A1-20180830-C00033
  • R4 is H and R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00034
    Figure US20180243297A1-20180830-C00035
  • or R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl selected from the group consisting of
  • Figure US20180243297A1-20180830-C00036
  • or a pharmaceutically acceptable salt thereof.
  • In a further particular embodiment 37 of the invention, there is provided a compound of formula (Ib)
  • Figure US20180243297A1-20180830-C00037
  • wherein
    R1 is H or C1-4 alkyl, particularly C1-4 alkyl, more particularly methyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00038
    Figure US20180243297A1-20180830-C00039
  • R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00040
  • or a pharmaceutically acceptable salt thereof.
  • In a further particular embodiment 38 of the invention, there is provided a compound of formula (Ib)
  • Figure US20180243297A1-20180830-C00041
  • wherein
    R1 is H or C1-4 alkyl, particularly C1-4 alkyl, more particularly methyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00042
    Figure US20180243297A1-20180830-C00043
  • R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00044
  • or a pharmaceutically acceptable salt thereof.
  • In another particular embodiment 39 of the invention, there is provided a compound of formula (Ib)
  • Figure US20180243297A1-20180830-C00045
  • wherein
    R1 is H or C1-4 alkyl, particularly C1-4 alkyl, more particularly methyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00046
    Figure US20180243297A1-20180830-C00047
  • R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00048
  • or a pharmaceutically acceptable salt thereof.
  • In another particular embodiment 40 of the invention, there is provided a compound of formula (Ib)
  • Figure US20180243297A1-20180830-C00049
  • wherein
    R1 is H or C1-4 alkyl, particularly C1-4 alkyl, more particularly methyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00050
    Figure US20180243297A1-20180830-C00051
  • R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00052
  • or a pharmaceutically acceptable salt thereof.
  • In another particular embodiment 41 of the invention, there is provided a compound of formula (Ib)
  • Figure US20180243297A1-20180830-C00053
  • wherein
    R1 is H or C1-4 alkyl, particularly C1-4 alkyl, more particularly methyl;
    Y is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00054
    Figure US20180243297A1-20180830-C00055
  • R3 is selected from the group consisting of
  • Figure US20180243297A1-20180830-C00056
  • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 42 of the invention, there is provided a compound according to embodiment 1 selected from
    • 3-[5-Amino-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-isoxazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-2,2-dimethyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(pyridin-4-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N—[(R)-1-(tetrahydrofuran-3-yl)methyl]-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2,5-dimethyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2-cyclopropyl-thiazol-5-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-pyridin-3-yl-pyrazin-2-yl)-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide;
    • 3-[5-Amino-6-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-cyclopropyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N—((R)-1-ethyl-pyrrolidin-2-ylmethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(1-hydroxy-cyclopropylmethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-[5-Amino-6-(5-morpholin-4-ylmethyl-thiophen-3-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propoxy)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(4-hydroxy-tetrahydropyran-4-ylmethyl)-4-methylbenzenesulfonamide;
    • N-(2-Amino-ethyl)-3-(5-amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2,2-difluoro-ethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3-hydroxymethyl-oxetan-3-ylmethyl)-4-methyl-benzenesulfonamide; and
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3,3-dimethyl-2-oxo-butyl)-4-methyl-benzenesulfonamide;
      or a pharmaceutically acceptable salt thereof.
  • In an embodiment 42.1 of the invention, there is provided a compound according to embodiment 1 selected from
    • 3-[5-Amino-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-methyl-isoxazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-2,2-dimethyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(pyridin-4-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N—[(R)-1-(tetrahydrofuran-3-yl)methyl]-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2,5-dimethyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(2-cyclopropyl-thiazol-5-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-pyridin-3-yl-pyrazin-2-yl)-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide;
    • 3-[5-Amino-6-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide;
    • 3-[5-Amino-6-(3-methyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(3-cyclopropyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N—((R)-1-ethyl-pyrrolidin-2-ylmethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(1-hydroxy-cyclopropylmethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide;
    • 3-[5-Amino-6-(5-morpholin-4-ylmethyl-thiophen-3-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propoxy)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(4-hydroxy-tetrahydropyran-4-ylmethyl)-4-methylbenzenesulfonamide;
    • N-(2-Amino-ethyl)-3-(5-amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2,2-difluoro-ethyl)-4-methyl-benzenesulfonamide;
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3-hydroxymethyl-oxetan-3-ylmethyl)-4-methyl-benzenesulfonamide; and
    • 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3,3-dimethyl-2-oxo-butyl)-4-methyl-benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(3-hydroxy-3-methylbutyl)benzenesulfonamide;
    • 3-(5-amino-6-(furan-3-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2,5-dimethylthiazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((3-(hydroxymethyl)oxetan-3-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxyethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(oxetan-3-ylmethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide;
    • (1-(3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)azetidin-3-yl)methanol;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((3-hydroxyoxetan-3-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,5-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2,4-dimethylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3,4-dimethyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methyl propyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3,5-dimethyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(2,4-dimethyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide;
    • 5-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(pyrimidin-5-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-fluoropyridin-4-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-pyrazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-isopropyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,3r)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,3s)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methylthiazol-2-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-ethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-ethyl-1H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-(2,2,2-trifluoroethyl)-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methyl-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-methylisoxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-methylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methyl propyl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(3-methyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-di methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methyl propyl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(3-methyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-M1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-isopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(1-(hydroxymethyl)cyclopropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 2-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)-2-azaspiro[3.3]heptan-6-ol;
    • 3-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(5-(3-methoxy-3-methylazetidin-1-ylsulfonyl)-2-methylphenyl)pyrazin-2-amine;
    • 3-(5-amino-6-(1H-pyrazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-2-ylmethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-cyclopropylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(thiazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-cyclopropyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methyl benzenesulfonamide;
    • 3-(5-amino-6-(2-methoxythiazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-ethoxy-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-tert-butoxy-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-(dimethylamino)ethoxy)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-isopropoxy-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-isobutoxy-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yloxy)benzenesulfonamide;
    • 5-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 5-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 5-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 5-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 5-(2-methyl-5-(3-(trifluoromethyl)piperazin-1-ylsulfonyl)phenyl)-3-(2-methylthiazol-5-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-fluoropyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methoxypyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methoxypyridin-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methoxypyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(pyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-chloropyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-methylpyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-chloro-2-fluoropyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-chloro-4-methylpyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-fluoropyridin-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-fluoropyridin-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-isopropoxypyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-ethoxypyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
    • 3-(5-amino-6-(6-methoxy-2-methylpyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methyl butyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(furan-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-(pyrrolidin-1-yl)pyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-fluoropyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,5-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(pyrimidin-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-morpholinopyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-(piperidin-1-yl)pyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(6-(tetrahydro-2H-pyran-4-yloxy)pyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-propyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-isopentyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(pyridin-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-isopropyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-isobutyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-ethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-(hydroxymethyl)thiophen-2-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-(pyridin-2-ylmethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-(pyridin-4-ylmethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methyloxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-(2-morpholinoethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-pyrazol-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(4-methylthiophen-2-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-methylthiophen-2-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(thiophen-2-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methyl butyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-cyclopropylthiophen-2-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((3-methyloxetan-3-yl)methyl)benzenesulfonamide;
    • 5-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-2,4-di methylbenzenesulfonamide;
    • 5-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-fluoro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide;
    • 5-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-chloro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropoxy)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methyloxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide;
    • 5-(5-(3,3-difluoropiperidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 5-(5-(3-fluoropyrrolidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 5-(5-(3,3-difluoropyrrolidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 5-(5-(3,3-difluoroazetidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 5-(5-(3-fluoroazetidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(4-(hydroxymethyl)cyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3,3-difluorocyclobutyl)-4-methylbenzenesulfonamide;
    • 5-(2-methyl-5-(3,3,4,4-tetrafluoropyrrolidin-1-ylsulfonyl)phenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(5-hydroxypentyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-methoxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-hydroxycyclohexyl)methyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxypropyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((1-methylpyrrolidin-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-3-yl)methyl)benzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)benzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-(hydroxymethyl)cyclopentyl)methyl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-fluoroethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-fluoropropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(2-oxotetrahydrofuran-3-yl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(3,3,3-trifluoropropyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(2-methyl-2-morpholinopropyl)benzenesulfonamide;
    • 5-(5-(4,4-difluoropiperidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 5-(5-(4-fluoropiperidin-1-ylsulfonyl)-2-methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-hydroxycyclopentyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-(1-hydroxycyclopentyl)ethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-(1-hydroxycyclohexyl)ethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-(hydroxymethyl)cyclopropyl)methyl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((5,5-dimethyltetrahydrofuran-2-yl)methyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((5,5-dimethyltetrahydrofuran-2-yl)methyl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(1-hydroxypropan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(1-hydroxypropan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2,2-difluoropropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(3-methylbutan-2-yl)benzenesulfonamide;
    • (1-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)azetidin-3-yl)methanol;
    • 1-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)-3-methylazetidin-3-ol;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((3-hydroxyoxetan-3-yl)methyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(1-cyano-2-hydroxyethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-(hydroxymethyl)cyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(2-oxotetrahydrothiophen-3-yl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1-(hydroxymethyl)cyclohexyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-cyclopropyl-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-cyclobutyl-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-cyclopentyl-4-methylbenzenesulfonamide;
    • 1-((3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonamido)methyl)cyclopropanecarboxamide;
    • (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-3-ylmethyl)benzenesulfonamide;
    • (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-3-ylmethyl)benzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((3R,4R)-4-hydroxypyrrolidin-3-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((3-(hydroxymethyl)oxetan-3-yl)methyl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methyl morpholin-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((2-methyltetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-2-yl)methyl)benzenesulfonamide;
    • (R)-3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-3-ylmethyl)benzenesulfonamide;
    • (S)-3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-3-ylmethyl)benzenesulfonamide;
    • 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-2-ylmethyl)benzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(4-(hydroxymethyl)cyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(3,3-difluorocyclobutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(5-hydroxypentyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1-hydroxycyclohexyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(1-hydroxybutan-2-yl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(1-hydroxybutan-2-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(1-hydroxy-2-methylpropan-2-yl)-4-methylbenzenesulfonamide;
    • (S)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-hydroxypropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(3-methoxypropyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-methoxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(1-isopropylpiperidin-4-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(1-methylpiperidin-4-yl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(3-(diethylamino)propyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(3-(dimethylamino)-2,2-dimethylpropyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-(dimethylamino)ethyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-(pyrrolidin-1-yl)ethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-morpholinoethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-methyl-2-morpholinopropyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-((1-methylpyrrolidin-3-yl)methyl)benzenesulfonamide;
    • 4-((3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methylphenylsulfonamido)methyl)tetrahydro-2H-pyran-4-carboxamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((3-hydroxyoxetan-3-yl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-(methylamino)ethyl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-aminoethyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-3-ylmethyl)benzenesulfonamide;
    • (S)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-3-ylmethyl)benzenesulfonamide;
    • 5-(5-(2,6-diazaspiro[3.3]heptan-2-ylsulfonyl)-2-methylphenyl)-3-(2-methylpyridin-4-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1S,2S)-2-aminocyclopentyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1R,2R)-2-aminocyclopentyl)-4-methylbenzenesulfonamide;
    • (R)-5-(5-(3-aminopyrrolidin-1-ylsulfonyl)-2-methylphenyl)-3-(2-methylpyridin-4-yl)pyrazin-2-amine;
    • 5-(5-(4-aminopiperidin-1-ylsulfonyl)-2-methylphenyl)-3-(2-methylpyridin-4-yl)pyrazin-2-amine;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(((1S,3R)-3-(aminomethyl)cyclohexyl)methyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1r,4r)-4-aminocyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(oxetan-3-ylmethyl)benzenesulfonamide;
    • 3-(5-amino-6-(1-benzyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 2-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonamido)acetamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-oxopiperidin-4-yl)benzenesulfonamide;
    • 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(azetidin-3-yl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(5-ethyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • 3-(5-amino-6-(3-propyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide;
    • (1-(3-(5-amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)piperidin-4-yl)methanol;
    • cis-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide;
    • trans-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide;
    • (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide;
    • (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide;
    • (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide;
    • 3-(5-Amino-6-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide;
    • 3-(5-Amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide;
    • or a pharmaceutically acceptable salt thereof.
  • In an embodiment 43 of the invention, there is provided a compound or salt according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, for use in medicine.
  • In an embodiment 44 of the invention, there is provided a compound or salt according to any one of embodiments 1-42 for use in the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110-γ).
  • In an embodiment 45 of the invention, there is provided a compound or salt according to any one of embodiments 1-42 for use in the treatment of inflammatory, obstructive or allergic conditions.
  • In an embodiment 46 of the invention, there is provided a compound or salt according to any one of embodiments 1-42 for use in the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • In an embodiment 47 of the invention, there is provided a compound or salt according to any one of embodiments 1-42 for use in the treatment of respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma.
  • In an embodiment 48 of the invention, there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110-γ).
  • In an embodiment 49 of the invention, there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • In an embodiment 50 of the invention, there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma.
  • In an embodiment 51 of the invention, there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, for the treatment of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110-γ).
  • In an embodiment 52 of the invention, there is provided the use of a compound according to any one of embodiments 1-43, or a pharmaceutically acceptable salt thereof, for the treatment of respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis.
  • In an embodiment 53 of the invention, there is provided the use of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, for the treatment of respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma.
  • In an embodiment 54 of the invention, there is provided a method of treating a disorder or disease mediated by the activation of PI 3-kinase gamma isoform (p110-γ), comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof.
  • In an embodiment 55 of the invention, there is provided a method of treating respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis, comprising
  • administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-36, or a pharmaceutically acceptable salt thereof.
  • In an embodiment 56 of the invention, there is provided a method of treating respiratory diseases, particularly asthma, COPD, COAD, COLD, chronic bronchitis, dyspnea or emphysema, more particularly asthma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof.
  • In an embodiment 57 of the invention, there is provided a pharmaceutical composition comprising:
  • a therapeutically effective amount of the compound according to any one of embodiments 1-42, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
  • In an embodiment 58 of the invention, there is provided a pharmaceutical combination, comprising:
  • a therapeutically effective amount of the compound according to any one of embodiments 1 to 42, or a pharmaceutically acceptable salt thereof, and a second active agent.
  • In an embodiment 59 of the invention, there is provided a pharmaceutical combination according to embodiment 58, wherein the second active agent is selected from an anti-inflammatory, bronchodilatory or antihistamine drug substance.
  • In another embodiment, individual compounds according to the invention are those listed in the Examples section below.
  • The term “compounds of the present invention” or “a compound of the present invention” refers to a compound as defined in any one of embodiments 1-42.
  • The compounds as defined in embodiments 1-42 may be synthesized by the general synthetic routes below, specific examples of which are described in more detail in the Examples.
  • Figure US20180243297A1-20180830-C00057
  • wherein X1 is a halogen such as Br or I, Y, R1, R2, R3, R4 and E are as defined in embodiment 1, and X is a halogen such as I, Br or Cl.
  • The reaction between halopyrazine II and boronic acid or boronic ester III to form compounds of formula I as shown in Scheme 1 may be carried out using a suitable palladium catalyst, such as Pd(PPh3)2Cl2, Pd-118 (PdCl2(dtbpf)), Pd(dppf)Cl2 or its adduct with dichloromethane, in a suitable solvent or mixture of solvents, such as 1,2-dimethoxyethane (DME), DME/ethanol, acetonitrile, 1,4-dioxane or toluene/ethanol. The reaction typically requires a base, such as aqueous sodium carbonate, aqueous potassium phosphate or in some cases potassium acetate and may be carried out at elevated temperatures, using conventional or microwave heating.
  • Compounds of formula II may be obtained from commercial suppliers, prepared as described in Schemes 2b, 3a, 6, 6a, 6b, 6c, 6d, 6e, 8 or 10 or by other methods known in the art. Compounds of formula III may be obtained from commercial suppliers or prepared by borylation of an aryl halide of formula IV with a boron source such as bis(pinacolato)diboron at elevated temperature using conventional or microwave heating (Method A). This reaction is typically catalysed by a palladium catalyst such as Pd(dppf)Cl2.CH2Cl2, and utilises a suitable base such as potassium acetate in an appropriate solvent such as DME or dioxane. In a variation of scheme 1, this borylation of IV to form III may be followed without isolation of III by the subsequent coupling with compound II in a ‘one-pot’ procedure to form compound I. In a further variation of scheme 1, the ‘one-pot’ procedure can be carried out by borylation of II and subsequent coupling with IV.
  • Compounds of formula III may also be prepared by halogen-metal exchange, followed by reaction of the resulting organometallic with a boron source (Method B). Typically this reaction may be carried out by lithiation of a compound of formula IV using an appropriate organometallic species such as n-butyl lithium in an appropriate solvent such as THF, with cooling (for example to −78° C.). The resulting species can then be reacted in situ with an appropriate boron source such as triisopropyl borate.
  • Compounds of formula IV may be obtained from commercial suppliers, prepared as described in Schemes 4a and 9, or by other methods known in the art.
  • Figure US20180243297A1-20180830-C00058
  • wherein Y, R1, R2, R3, R4 and E are as defined in embodiment 1, and X is a halogen such as I, Br or Cl.
  • Where Y is attached to the pyrazine ring by a carbon-carbon bond, compounds of formula I may be prepared as shown in Scheme 2 via a reaction between compounds V and a boronic acid or ester VI. Appropriate conditions for Suzuki couplings such as this are known in the art and include those described in Scheme 1.
  • Figure US20180243297A1-20180830-C00059
  • wherein Y, R1, R2, R3, R4 and E are as defined in embodiment 1, and X is a halogen such as I, Br or Cl.
  • Where Y is attached to the pyrazine ring by a carbon-carbon bond, compounds of formula I may be prepared as shown in Scheme 2a via a reaction between compounds V and stannane Sn-VI (for example, optionally substituted 4-(tributylstannyl)thiazole). This may be carried out using a suitable palladium catalyst, such as Pd-118, in a suitable solvent such as THF at elevated temperature, optionally in the presence of an appropriate additive such as copper (I) iodide. Alternative conditions for Stille couplings such as this are known in the art.
  • Figure US20180243297A1-20180830-C00060
  • wherein Y is as defined in embodiment 1, X1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • Compounds of formula II, where Y is attached to the pyrazine ring by a carbon-carbon bond, may be prepared via a palladium mediated cross coupling reaction between a compound of formula VII, as shown in Scheme 2b. Appropriate conditions include those described in Scheme 1 or others known in the art. Where X═H, this can be converted to X=halogen by halogenation conditions. Various conditions for this reaction are known in the art, for example bromination by use of a halogenating agent such as NBS, in an appropriate solvent such as acetonitrile at elevated temperature. Compounds VII, such as 3-bromo-5-chloropyrazin-2-amine, are commercially available, or may be formed by known methods.
  • Figure US20180243297A1-20180830-C00061
  • wherein R1, R2, R3, R4 and E are selected from those in embodiment 1, X1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • The same general method can be used to prepare compounds of formula V, via a reaction between a boronic acid or ester of formula III and a compound of formula VII′ as shown in Scheme 2c. Where X═H, this can be converted to X=halogen by methods known in the art. Typically the halogenation could be carried out with a halogenating agent such as N-bromosuccinimide in an appropriate solvent such as DCM.
  • Compounds of formula VI, VII, VII′ are commercially available or may be prepared according to known methods.
  • Figure US20180243297A1-20180830-C00062
  • wherein Y, R1, R2, R3, R4 and E are as defined in embodiment 1, and where Y can be attached to the pyrazine ring by a nitrogen-carbon bond, and X is a halogen.
  • Compounds of formula I where Y can be attached to the pyrazine ring by a nitrogen-carbon bond may be prepared by a reaction of compound V with an appropriate heteroaryl Y containing an NH group, such as (optionally substituted) 1,2,4-triazole, imidazole or pyrazole. This reaction is typically carried out in the presence of a suitable base (such as an amine, an alkali metal hydride or carbonate, e.g. sodium hydride or cesium carbonate), in a suitable solvent such as dimethyl acetamide (DMA), optionally in the presence of an appropriate catalyst system such as CuI and N,N-dimethylglycine, typically at an elevated temperature of up to 180° C. using, for example, microwave heating. Heteroaryls used may be commercially available or prepared by known methods.
  • Figure US20180243297A1-20180830-C00063
  • wherein Y is as defined in embodiment 1, where Y can be attached to the pyridine ring by a nitrogen-carbon bond, X1 is a halogen such as I, Br or Cl, and X is hydrogen or a halogen.
  • Compounds of formula II may be prepared via reaction between a compound of formula VII, such as 5-bromo-3-chloropyrazin-2-amine and an appropriate heteroaryl containing an NH group, such as (optionally substituted) 1,2,4-triazole, imidazole or pyrazole as shown in Scheme 3a. Typical conditions include the use of catalyst systems as described in Scheme 3, or direct reaction of compound VII with an appropriate heteroaryl, for example by heating in an appropriate solvent such as DMF in the presence of a base such as cesium carbonate. Where X═H, this can be converted to X=halogen by halogenation conditions known in the art.
  • Figure US20180243297A1-20180830-C00064
  • wherein Y, R1, R2, R3, R4 and E are as defined in embodiment 1, and X is a halogen.
  • In certain cases compound I can be prepared directly from aminopyrazine halides V and heterocycles, such as oxazole (to give I where Y is oxazol-5-yl or oxazol-2-yl), using a palladium catalysed C—H activation protocol as shown in Scheme 3b. Suitable conditions are known in the art, such as the use of palladium acetate with an added ligand such as di(adamant-1-yl)-n-butyl phosphine, with a base such as potassium carbonate and an additive such as pivalic acid in a solvent such as dimethylacetamide, heating at elevated temperatures such as 110° C.
  • Figure US20180243297A1-20180830-C00065
  • wherein Y, R1, R2, R3, R4 and E are as defined in embodiment 1.
  • Compounds of formula I may be prepared by reacting sulfonyl chloride VIII with an amine IX in the presence of a suitable base such as pyridine, triethylamine or diisopropylethylamine, in a suitable solvent such as DCM, THF, pyridine or dimethylacetamide.
  • Figure US20180243297A1-20180830-C00066
  • wherein X1 is a halogen such as Br or I, Y, R1, R2, R3, R4 and E are as defined in embodiment 1.
  • The same method can be used to prepare compounds of formula IV from sulfonyl chlorides VIII* as shown in Scheme 4a. Compounds of formula IX are commercially available or may be prepared by known methods.
  • Figure US20180243297A1-20180830-C00067
  • wherein J is a halogen such as Br or I, or
  • Figure US20180243297A1-20180830-C00068
  • and wherein Y, R1, R2 and E are appropriate groups chosen from those in embodiment 1.
  • Compounds of formula VIII (J=
  • Figure US20180243297A1-20180830-C00069
  • may be prepared according to Scheme 5 by chlorosulfonation of a compound of formula X (method C), typically using chlorosulfonic acid in an appropriate solvent such as chloroform, at ambient temperature or with cooling such as to 0° C. Sulfonyl chlorides VIII/VIII′ formed may be reacted directly with amines IX without isolation or purification as described in Schemes 4 and 4a to form compounds I/IV. An alternative preparation of compound VIII is shown in Scheme 5 (method D), by a diazotisation/chlorosulfonation sequence (see, for example Meerwein, H. et al, Chem. Ber., 90: 841-852.) Example conditions include the reaction of compound NH2—X with sodium nitrite in the presence of acid (for example, mixture of acetic acid and conc. HCl) in water with cooling (typically 0° C.), then the resulting mixture added to a stirring solution of the green supernatant of a mixture prepared by bubbling sulfur dioxide gas into glacial acetic acid followed by the addition of CuCl2 in water. Compounds of formula VIII′ are commercially available or may be prepared according to the same methods. Compounds of formula X or NH2—X may be obtained from commercial suppliers or made by known methods.
  • Figure US20180243297A1-20180830-C00070
  • wherein R is an appropriate group chosen from the substitutents listed in the definition of Y in embodiment 1, X1 is a halogen such as bromo, chloro or iodo, and X is a halogen or hydrogen.
  • Compounds of formula II where Y is 3-substituted-isoxazol-5-yl can be prepared according to the route shown in Scheme 6 by the reaction of a compound of formula XI with an alkyne of formula XII. Typical conditions for this transformation use copper (II) sulfate, sodium ascorbate and sodium bicarbonate in appropriate solvent mixtures such as t-BuOH and water, under a nitrogen atmosphere at ambient temperature. Compounds of formula XI are commercially available, or can be prepared by known methods, or prepared in situ. For example compounds of formula XI can be prepared by halogenation of aldehyde oximes. By adding chloramine-T, copper powder and copper (II) sulfate to the mixture of an aldehyde, hydroxylamine hydrochloride, and base (e.g. sodium hydroxide) in appropriate solvent mixture (e.g. t-butanol water), followed by addition of alkyne XII and heating, compound II can be formed. Where X═H, this can be converted to X=halogen by halogenation conditions known in the art.
  • Compounds of formula XII are commercially available or can be prepared by known methods, for example using Sonogashira coupling with TMS-acetylene followed by deprotection.
  • Figure US20180243297A1-20180830-C00071
  • wherein R and X are as defined in Scheme 6, X1 is bromo or iodo, Alk is an alkyl group such as methyl or ethyl.
  • Compounds of formula II where Y is 3-substituted-isoxazol-5-yl can also be formed by cycloisomerization of acetylenic oximes as shown in scheme 6a.
  • Following oxime formation from ketone XIII by known methods, the cyclisation in step 4 to form compound II is typically catalysed by acid (such as aqueous HCl in AcOH) or by gold catalysis as described in Synlett, 2010, No. 5, pp 0777-0781. Compounds of formula II* (compounds of formula II where Y is 3-substituted-isothiazol-5-yl) can also be formed from ketone XIII, for example by treatment with hydroxylamine-O-sulfonic acid, sodium bicarbonate and sodium hydrogen sulfide in an appropriate solvent mixture such as THF/water. Ketone XIII can be formed from a dihaloaminopyrazine such as 3-bromo-5-chloropyrazin-2-amine using known methods as shown in Scheme 6a, for example by Sonogashira coupling with propargylic alcohol XIV, followed by oxidation using an oxidising agent such as manganese dioxide.
  • A further alternative preparation of compound II where Y is 3-substituted-isoxazol-5-yl is shown in Scheme 6a, and utilises the reaction of ester Alk-XVI with the dianion of an oxime, (typically formed by treatment of oxime (such as acetone oxime) with 2 eq. of n-butyllithium in dry solvent such as THF with cooling), followed by dehydrative cyclisation (using, for example sulfuric acid) to give compound II. Where X═H, this can be converted to X=halogen by halogenation conditions known in the art.
  • Compounds of formula XIV are commercially available or can be prepared by known methods.
  • Figure US20180243297A1-20180830-C00072
  • wherein R and X are as defined in Scheme 6.
  • Compounds of formula II where Y is 3-substituted-[1,2,4]oxadiazol-5-yl may be prepared by condensation and dehydration of amidoxime XV and acid XVI as shown in Scheme 6b. Where X═H, this can be converted to X=halogen by halogenation conditions known in the art. Suitable reagents for the condensation and dehydration are known in the art and include Ghosez′ reagent, T3P®, DCC and HOBt, or HATU in an appropriate solvent such as DCM, THF or toluene, in the presence of an appropriate base such as DIPEA.
  • Figure US20180243297A1-20180830-C00073
  • wherein R and X are as defined in Scheme 6.
  • In a related reaction shown in Scheme 6c, compounds of formula II** (compounds of formula II where Y=5-substituted-1,3,4-oxadiazol-2-yl) are prepared by condensation and dehydration of compounds XVI and XVII using conditions known in the art. This can be carried out by a one or two step process, for example using an amide coupling reagent such as HATU or T3P in the presence of an appropriate base such as triethylamine, then dehydrative cyclisation using for example tosyl chloride in the presence of an appropriate base such as triethylamine, in a suitable solvent such as DCM. Other dehydrating agents are known in the art, such as POCI3. Similarly, following amide formation/condensation, the resulting N-acylhydrazide may be treated with Lawesson's reagent to prepare compounds of formula II*** (compounds of formula II where Y=5-substituted-1,3,4-thiadiazol-2-yl). Where X═H, compounds II** and II*** can be converted to X=halogen by halogenation conditions known in the art. Compounds of formulae XV, XVI, Alk-XVI and XVII are commercially available or can be prepared by known methods.
  • Figure US20180243297A1-20180830-C00074
  • wherein R and X are as defined in Scheme 6, and Ra is hydrogen or an appropriate group chosen from the substitutents listed in the definition of Y in embodiment 1.
  • Compounds of formula II (where Y is 1,2,3-triazol-4-yl optionally substituted in the Sand 1 or 2 positions) are prepared by reaction of alkyne XII′ with trimethylsilyl azide, followed by optional alkylation if 1 or 2 position substitution is required, as shown in Scheme 6d. Typical conditions for the first step of this transformation use copper (II) sulfate, sodium ascorbate and sodium bicarbonate in appropriate solvent mixtures such as t-BuOH and water, at elevated temperature such as 90° C. The resulting triazole (where R═H) can be alkylated using an alkylating agent (such as iodomethane, iodoethane, 2,2,2-trifluoroethyl trifluoromethanesulfonate or other alkyl halides or sulfonates) in the presence of an appropriate base/additive (such as TBAF or metal carbonates such as caesium carbonate), in an suitable solvent such as acetonitrile or THF, to give compounds of formula II as mixtures of N1 and N2 alkylated products, which may be separable by known methods. Where X═H, these can be converted to X=halogen by halogenation conditions known in the art. Compounds XII′ may be obtained from commercial suppliers or prepared by methods known in the art, for example Sonogashira coupling.
  • Figure US20180243297A1-20180830-C00075
  • wherein X is a halogen or hydrogen.
  • Compounds of formula II (where Y=oxazol-2-yl) can be prepared from acid XVI by formation of a propargyl amide using known conditions, followed by cyclisation, for example using gold (III) chloride in a solvent such as DCM. Where X═H, this can be converted to X=halogen by halogenation conditions known in the art.
  • Figure US20180243297A1-20180830-C00076
  • wherein R is an appropriate group chosen from the relevant list of substituents in embodiment 1.
  • Compounds of formula IX′ can be prepared from alcohols XVIII (obtained commercially or prepared by known methods) by treatment with N-hydroxyphthalamide under Mitsunobu-type conditions known in the art (for example using PS-triphenylphosphine and di-tert-butyl azodicarboxylate in a solvent such as THF), followed by deprotection of the phthalamide group using known consitions, typically by treatment with hydrazine.
  • Figure US20180243297A1-20180830-C00077
  • wherein X is hydrogen or halogen, R, Ra are as defined in embodiment 1, X1 is halogen.
  • Compounds of formula IIa (compounds of formula II where Y=2 or 2,5-substituted-thiazol-4-yl) can be prepared according to Scheme 8 from alpha-halo ketone XXI by reaction with a thioamide in a suitable solvent such as ethanol at elevated temperature such as 50-70° C. Similarly, compounds of formula IIb (compounds of formula II where Y=5 or 4,5-substituted-thiazol-2-yl) can be prepared from thioamide XXII and alpha-halo ketones (prepared by known methods or obtained commercially). Compound XXI can be prepared by halogenation of ketone XX by conditions known in the art, such as treatment with pyridinium tribromide (optionally on polymer support) and HBr in acetic acid at elevated temperature. Ketone XX can be prepared from commercially available starting materials by formation of the Weinreb amide from acid XIX (obtained commercially or prepared by known methods), followed by addition of a Grignard reagent. Thioamide XXII can be prepared by methods known in the art, such as treatment of the appropriate primary amide (obtained commercially or prepared by known methods), with Lawesson's reagent. Where X═H, IIa or IIb can be converted to the corresponding compound where X=halogen by halogenation conditions known in the art.
  • Figure US20180243297A1-20180830-C00078
  • wherein E, R1, R2, R3, R4 are as defined in embodiment 1.
  • Certain compounds of formula IV may be prepared by a cross coupling reaction of compound XXIV with an appropriate boronic acid (such as methyl boronic acid), in the presence of a base (for example aqueous sodium carbonate), an appropriate catalyst (for example bis(triphenylphosphine) palladium dichloride) and in an appropriate solvent such as 1,4-dioxane under elevated temperature. Compound XXIV (where E=N) can be prepared in two steps from compound XXIII by sulfonamide formation (for conditions, see Scheme 4) followed by iodination, which typically can be carried out by treatment with an iodide source such as trimethylsilyliodide (or trimethylsilyl chloride plus sodium iodide) in an appropriate solvent such as acetonitrile. Compounds XXIII are commercially available or can be made by known methods.
  • Figure US20180243297A1-20180830-C00079
  • wherein X=hydrogen or halogen, R is what
  • Compounds of formula II (where Y is 5-substituted-1,2,4-oxadiazol-3-yl) may be prepared by reaction of amidoxime XXV with an acid chloride using known conditions, followed by dehydrative cyclisation. Conditions for this sort of cyclisation are known in the art, and include the use of hexachloroethane in acetic acid at elevated temperature. Compound XXV can be formed by known methods, for example the reaction of commercially available 3-amino-6-bromopyrazine-2-carbonitrile with hydroxylamine hydrochloride, in the presence of a base (such as triethylamine) and in an appropriate solvent such as methanol.
  • Figure US20180243297A1-20180830-C00080
  • wherein Y is an appropriate group selected from the groups defined in embodiment 1, X1 is halogen such as I, Br or Cl and X is H or halogen.
  • Compounds of formula II may be prepared by a decarboxylative cross-coupling of carboxylic acid XXVI (obtained from commercial suppliers or prepared by known methods) with compound VII. Reagents for the coupling are known in the art and include a suitable palladium catalyst, such as Pd(PPh3)2Cl2 and a base (preferentially a silver salt such as silver carbonate) in an appropriate solvent such as NMP at elevated temperature. Where X═H, this can be converted to X=halogen by halogenation using known conditions.
  • The invention further includes any variant of the present processes, in which an intermediate product obtainable at any stage thereof is used as starting material and the remaining steps are carried out, or in which the starting materials are formed in situ under the reaction conditions, or in which the reaction components are used in the form of their salts or optically pure material.
  • Compounds of the present invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art.
  • Within the scope of this text, only a readily removable group that is not a constituent of the particular desired end product of the compounds of the present invention is designated a “protecting group”, unless the context indicates otherwise. The protection of functional groups by such protecting groups, the protecting groups themselves, and their cleavage reactions are described for example in standard reference works, such as J. F. W. McOmie, “Protective Groups in Organic Chemistry”, Plenum Press, London and New York 1973, in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis”, Third edition, Wiley, New York 1999, in “The Peptides”; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981, in “Methoden der organischen Chemie” (Methods of Organic Chemistry), Houben Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jeschkeit, “Aminosäuren, Peptide, Proteine” (Amino acids, Peptides, Proteins), Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, “Chemie der Kohlenhydrate: Monosaccharide und Derivate” (Chemistry of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974. A characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
  • Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art. For example, salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used. Acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent. Internal salts of compounds of the present invention containing acid and basic salt-forming groups, e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
  • Salts can be converted into the free compounds in accordance with methods known to those skilled in the art. Metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
  • Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g. medium pressure liquid chromatography over a reversed phase column, and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
  • Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
  • The following applies in general to all processes mentioned herein before and hereinafter. All the above-mentioned process steps can be carried out under reaction conditions that are known to those skilled in the art, including those mentioned specifically, in the absence or, customarily, in the presence of solvents or diluents, including, for example, solvents or diluents that are inert towards the reagents used and dissolve them, in the absence or presence of catalysts, condensation or neutralizing agents, for example ion exchangers, such as cation exchangers, e.g. in the H+ form, depending on the nature of the reaction and/or of the reactants at reduced, normal or elevated temperature, for example in a temperature range of from about −100° C. to about 190° C., including, for example, from approximately −80° C. to approximately 150° C., for example at from −80 to −60° C., at room temperature, at from −20 to 40° C. or at reflux temperature, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under an argon or nitrogen atmosphere.
  • At all stages of the reactions, mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers, for example analogously to the methods described under “Additional process steps”.
  • The solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2-propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic anhydride, cyclic, linear or branched hydrocarbons, such as cyclohexane, hexane or isopentane, methycyclohexane, or mixtures of those solvents, for example aqueous solutions, unless otherwise indicated in the description of the processes. Such solvent mixtures may also be used in working up, for example by chromatography or partitioning.
  • The compounds of the present invention, including their salts, may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
  • The invention relates also to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
  • All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents and catalysts utilized to synthesize the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 41h Ed. 1952, Methods of Organic Synthesis, Thieme, Volume 21).
  • The term “an optical isomer” or “a stereoisomer” refers to any of the various stereoisomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom. The term “chiral” refers to molecules which have the property of non-superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term is used to designate a racemic mixture where appropriate. “Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R—S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (−) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
  • Depending on the choice of the starting materials and procedures, the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms. The present invention is meant to include all such possible stereoisomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms. Optically active (R)- and (S)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
  • Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
  • Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
  • Furthermore, the compounds of the present invention, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms. The term “solvate” refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like. The term “hydrate” refers to the complex where the solvent molecule is water.
  • The compounds of the present invention, including salts, hydrates and solvates thereof, may inherently or by design form polymorphs.
  • As used herein, the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the present invention. “Salts” include in particular “pharmaceutically acceptable salts”. The term “pharmaceutically acceptable salts” refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable. In many cases, the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
  • Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
  • The pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable. Lists of additional suitable salts can be found, e.g., in “Remington's Pharmaceutical Sciences”, 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts: Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
  • Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds of the present invention. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35Cl, 125I respectively. The invention includes various isotopically labeled compounds of the present invention, for example those into which radioactive isotopes, such as 3H and 14C, or those into which non-radioactive isotopes, such as 2H and 13C are present. Such isotopically labelled compounds are useful in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F labeled compound of the present invention may be particularly desirable for PET or SPECT studies. Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • Further, substitution with heavier isotopes, particularly deuterium (i.e., 2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent of a compound of the present invention. The concentration of such a heavier isotope, specifically deuterium, may be defined by the isotopic enrichment factor. The term “isotopic enrichment factor” as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO.
  • Compounds of the present invention that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers. These co-crystals may be prepared from compounds of the present invention by known co-crystal forming procedures. Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of the present invention with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed. Suitable co-crystal formers include those described in WO 2004/078163. Hence the invention further provides co-crystals comprising a compound of the present invention.
  • The compounds of the present invention are potent inhibitors of the PI 3-kinase gamma isoform. This is shown in Table 4, assay E. Furthermore and importantly, the compounds of the present invention are selective for the PI 3-kinase gamma isoform over the other class 1 PI 3-kinase isoforms alpha, beta and delta, which is shown in Table 4, assays A, B and F, and over related lipid kinases Vps34 and PI 4-kinase beta, which is shown in Table 4, assays C and D, and also over the PI 3-kinase related protein kinases such as mTOR (Table 4, assay G). Selectivity for PI 3-kinase gamma isoform is preferred in order to avoid possible unwanted side effects when treating patients. Particularly, selectivity for the PI 3-kinase gamma isoform over the PI 3-kinase alpha isoform is preferred as the PI 3-kinase alpha isoform is widely expressed in the body and has shown to be important in insulin receptor signalling.
  • The target enzyme of the compounds of the present invention, i.e. PI 3-kinase gamma isoform, is an intracellular target. Thus, compounds of the present invention which retain their activity in a cellular environment are preferred. The compounds of the present invention have thus been tested in cellular assays (see Table 5, assays H1, H2, I1, I2, J1, J2, K1 and K2). In assays K1 and K2, the compounds were tested for their ability to inhibit the production of phosphorylated AKT (Protein Kinase B) generated in a PI 3-kinase gamma isoform-dependent process in a U937 human cell line. Activity of a particular compound in a cellular assay depends on a variety of different factors such as potency of that compound at the target (see Table 4), solubility of the compound, Log P and permeability. Thus, good cellular activity of compounds of the present invention results from the combination of structural features conveying a good overall balance of molecular properties. Generally, preferred compounds of the present invention have high potency at the target (see Table 4) and show good activity in the cellular assays (Table 5).
  • In order to effectively inhibit the PI 3-kinase gamma isoform target (present in leukocytes) in an in vivo system, a drug compound will preferably need to show sufficient activity in whole blood. Hence, compounds of the present invention have been tested for their ability to inhibit neutrophil shape change in response to the chemotactic factor interleukin-8 (IL-8), which is a PI 3-kinase gamma isoform-dependent event, in human whole blood (Table 5, assay L). Activity in whole blood is dependent on additional factors such as plasma protein binding and plasma stability of a particular compound. Preferred compounds of the present invention thus have besides of potency at the PI 3-kinase gamma isoform target (Table 4) and sufficient cellular potency (Table 5) also sufficient activity in human whole blood as tested in assay L. More preferably, compounds of the present invention have IC50 values of in this human whole blood assay of <1 μM.
  • Additionally to the on-target potency (Table 4, assay E)), selectivity (Table 4, assays A, B, C, D, F and G), activity in cellular assays (Table 5, assays H1, H2, I1, I2, J1, J2, K1 and K2) and human whole blood assay (Table 5, assay L), the maintenance of sufficient drug concentration in vivo after oral administration to inhibit the target is required. Such pharmacokinetic properties are dependent on a variety of factors such as Log P, permeability, aqueous solubility and stability against oxidative metabolism. Compounds of the present invention have been tested for stability against oxidative metabolism using an in vitro microsomal stability assay (Table 5, assay M). Preferred compounds of the present invention show sufficient stability in this liver microsomal assay. Furthermore, preferred compounds of the present invention also have sufficient aqueous solubility.
  • Thus, the compounds of the present invention may be useful in the treatment of conditions which are mediated by the activation of PI 3-kinase gamma isoform, particularly inflammatory or allergic conditions.
  • Compounds of the present invention are useful in the treatment of inflammatory or obstructive airways diseases, resulting, for example, in reduction of tissue damage, airways inflammation, bronchial hyperreactivity, remodelling or disease progression. Inflammatory or obstructive airways diseases to which the present invention is applicable include asthma of whatever type or genesis including both intrinsic (non-allergic) asthma and extrinsic (allergic) asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise-induced asthma, occupational asthma and asthma induced following bacterial infection. Treatment of asthma is also to be understood as embracing treatment of subjects, e.g. of less than 4 or 5 years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as “wheezy infants”, an established patient category of major medical concern and now often identified as incipient or early-phase asthmatics. (For convenience this particular asthmatic condition is referred to as “wheezy-infant syndrome”)
  • Prophylactic efficacy in the treatment of asthma will be evidenced by reduced frequency or severity of symptomatic attack, e.g. of acute asthmatic or bronchoconstrictor attack, improvement in lung function or improved airways hyperreactivity. It may further be evidenced by reduced requirement for other, symptomatic therapy, i.e. therapy for or intended to restrict or abort symptomatic attack when it occurs, for example anti-inflammatory (e.g. corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may in particular be apparent in subjects prone to “morning dipping”. “Morning dipping” is a recognised asthmatic syndrome, common to a substantial percentage of asthmatics and characterised by asthma attack, e.g. between the hours of about 4 to 6 am, i.e. at a time normally substantially distant form any previously administered symptomatic asthma therapy.
  • Other inflammatory or obstructive airways diseases and conditions to which the present invention is applicable include acute lung injury (ALI), adult/acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD, COAD or COLD), including chronic bronchitis or dyspnea associated therewith, emphysema, as well as exacerbation of airways hyperreactivity consequent to other drug therapy, in particular other inhaled drug therapy. The invention is also applicable to the treatment of bronchitis of whatever type or genesis including, e.g., acute, arachidic, catarrhal, croupus, chronic or phthinoid bronchitis. Further inflammatory or obstructive airways diseases to which the present invention is applicable include pneumoconiosis (an inflammatory, commonly occupational, disease of the lungs, frequently accompanied by airways obstruction, whether chronic or acute, and occasioned by repeated inhalation of dusts) of whatever type or genesis, including, for example, aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.
  • Having regard to their anti-inflammatory activity, in particular in relation to inhibition of eosinophil activation, compounds of the present invention are also useful in the treatment of eosinophil related disorders, e.g. eosinophilia, in particular eosinophil related disorders of the airways (e.g. involving morbid eosinophilic infiltration of pulmonary tissues) including hypereosinophilia as it effects the airways and/or lungs as well as, for example, eosinophil-related disorders of the airways consequential or concomitant to Löffler's syndrome, eosinophilic pneumonia, parasitic (in particular metazoan) infestation (including tropical eosinophilia), bronchopulmonary aspergillosis, polyarteritis nodosa (including Churg-Strauss syndrome), eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug-reaction.
  • Compounds of the present invention are also useful in the treatment of inflammatory or allergic conditions of the skin, for example psoriasis, contact dermatitis, atopic dermatitis, alopecia areata, erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis bullosa acquisita, and other inflammatory or allergic conditions of the skin.
  • Compounds of the present invention may also be used for the treatment of other diseases or conditions, in particular diseases or conditions having an inflammatory component, for example, treatment of diseases and conditions of the eye such as conjunctivitis, keratoconjunctivitis sicca, and vernal conjunctivitis, diseases affecting the nose including allergic rhinitis, and inflammatory disease in which autoimmune reactions are implicated or having an autoimmune component or aetiology, including autoimmune haematological disorders (e.g. haemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulamatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), endocrine opthalmopathy, Grave's disease, sarcoidosis, alveolitis, chronic hypersensitivity pneumonitis, multiple sclerosis, leishmaniasis, primary billiary cirrhosis, uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephrotic syndrome or minal change nephropathy).
  • Other diseases or conditions which may be treated with compounds of the present invention include thrombosis, hypertension, heart ischaemia and pancreatitis, (Nature review November 2006 Vol 5), treatment of anaemia including haemolytic anaemia, aplastic anaemia and pure red cell anaemia (WO 2006/040318), septic shock, rheumatoid arthritis, osteoarthritis, proliferative diseases such as cancer, atherosclerosis, allograft rejection following transplantation, stroke, obesity, restenosis, diabetes, e.g. diabetes mellitus type I (juvenile diabetes) and diabetes mellitus type II, diarrheal diseases, ischemia/reperfusion injuries, retinopathy, such as diabetic retinopathy or hyperbaric oxygen-induced retinopathy, and conditions characterised by elevated intraocular pressure or secretion of ocular aqueous humor, such as glaucoma.
  • Agents of the present invention may be useful in the treatment or prevention of heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction including impaired cardiac contractility, hypertrophic cardiomyopathy, diabetic cardiac myopathy and other types of detrimental cardiac dysfunction and remodelling.
  • The compounds of the present invention may also be useful in the treatment of visceral disorders, inflammatory bowel disease, inflammatory bowel disorder, cystitis, e.g. interstitial cystitis and urinary incontinence including bladder detrusor hyper-reflexia and bladder hypersensitivity.
  • The effectiveness of an agent of the invention in inhibiting inflammatory conditions, for example in inflammatory airways diseases, may be demonstrated in an animal model, e.g. a mouse or rat model, of airways inflammation or other inflammatory conditions, for example as described by Szarka et al, J. Immunol. Methods (1997) 202:49-57; Renzi et al, Am. Rev. Respir. Dis. (1993) 148:932-939; Tsuyuki et al., J. Clin. Invest. (1995) 96:2924-2931; and Cernadas et al (1999) Am. J. Respir. Cell Mol. Biol. 20:1-8.
  • The compounds of the present invention are also useful as co-therapeutic agents for use in combination with PI 3-Kinase delta inhibitors, for example in allergic asthma or in immune-mediated inflammatory diseases, such as rheumatoid arthritis or multiple sclerosis. Such an effect could be potentially achieved through co-administration of a selective inhibitor of PI 3-kinase gamma isoform with a selective inhibitor of PI 3-kinase delta isoform.
  • The compounds of the present invention are also useful as co-therapeutic agents for use in combination with other drug substances such as anti-inflammatory, bronchodilatory or antihistamine drug substances, particularly in the treatment of obstructive or inflammatory airways diseases such as those mentioned hereinbefore, for example as potentiators of therapeutic activity of such drugs or as a means of reducing required dosage or potential side effects of such drugs. An agent of the invention may be mixed with the other drug substance in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance. Accordingly the invention includes a combination of an agent of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory or antihistamine drug substance, said agent of the invention and said drug substance being in the same or different pharmaceutical composition.
  • Useful combinations of PI 3-kinase inhibitors with anti-inflammatory drugs are those with antagonists of chemokine receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9 and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5 antagonists, such as Schering-Plough antagonists SC-351125, SCH-55700 and SCH-D; Takeda antagonists, such as N-[[4-[[[6,7-dihydro-2-(4-methyl-phenyl)-5H-benzo-cyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]tetrahydro-N,N-dimethyl-2H-pyran-4-amin-ium chloride (TAK-770); and CCR-5 antagonists described in U.S. Pat. No. 6,166,037 (particularly claims 18 and 19), WO 00/66558 (particularly claim 8), WO 00/66559 (particularly claim 9), WO 04/018425 and WO 04/026873.
  • Suitable anti-inflammatory drugs include steroids, in particular, glucocorticosteroids, such as budesonide, beclamethasone dipropionate, fluticasone propionate, ciclesonide or mometasone furoate, or steroids described in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679 (especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60, 67, 72, 73, 90, 99 and 101), WO 03/35668, WO 03/48181, WO 03/62259, WO 03/64445, WO 03/72592, WO 04/39827 and WO 04/66920; non-steroidal glucocorticoid receptor agonists, such as those described in DE 10261874, WO 00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO 03/86294, WO 03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO 04/19935 and WO 04/26248; LTD4 antagonists, such as montelukast and zafirlukast; PDE4 inhibitors, such as cilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline (Almirall Prodesfarma), PD189659/PD168787 (Parke-Davis), AWD-12-281 (Asta Medica), CDC-801 (Celgene), SeICID™ 00-10004 (Celgene), VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), and those disclosed in WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751, WO 98/18796, WO 99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO 03/39544, WO 04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO 04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944, WO 04/019945, WO 04/045607 and WO 04/037805; adenosine A2B receptor antagonists such as those described in WO 02/42298; and beta-2 adrenoceptor agonists, such as albuterol (salbutamol), metaproterenol, terbutaline, salmeterol fenoterol, procaterol, and especially, formoterol, carmoterol and pharmaceutically acceptable salts thereof, and compounds (in free or salt or solvate form) of formula (I) of WO 0075114, which document is incorporated herein by reference, preferably compounds of the Examples thereof, especially a compound of formula:
  • Figure US20180243297A1-20180830-C00081
  • corresponding to indacaterol and pharmaceutically acceptable salts thereof, as well as compounds (in free or salt or solvate form) of formula (I) of WO 04/16601, and also compounds of EP 1440966, JP 05025045, WO 93/18007, WO 99/64035, USP 2002/0055651, WO 01/42193, WO 01/83462, WO 02/66422, WO 02/70490, WO 02/76933, WO 03/24439, WO 03/42160, WO 03/42164, WO 03/72539, WO 03/91204, WO 03/99764, WO 04/16578, WO 04/22547, WO 04/32921, WO 04/33412, WO 04/37768, WO 04/37773, WO 04/37807, WO 04/39762, WO 04/39766, WO 04/45618, WO 04/46083, WO 04/80964, WO 04/108765 and WO 04/108676.
  • Suitable bronchodilatory drugs include anticholinergic or antimuscarinic agents, in particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but also those described in EP 424021, U.S. Pat. No. 3,714,357, U.S. Pat. No. 5,171,744, WO 01/04118, WO 02/00652, WO 02/51841, WO 02/53564, WO 03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO 04/018422 and WO 04/05285.
  • Suitable dual anti-inflammatory and bronchodilatory drugs include dual beta-2 adrenoceptor agonist/muscarinic antagonists such as those disclosed in USP 2004/0167167, WO 04/74246 and WO 04/74812.
  • Suitable antihistamine drug substances include cetirizine hydrochloride, acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine, diphenhydramine and fexofenadine hydrochloride, activastine, astemizole, azelastine, ebastine, epinastine, mizolastine and tefenadine, as well as those disclosed in JP 2004107299, WO 03/099807 and WO 04/026841
  • Pi3 kinase inhibitors, e.g. those compounds of the invention, may be combined with an angiotensin receptor blocker, e.g. valsartan (an angiotensin receptor blocker) and achieve greater therapeutic effect than the administration of valsartan alone. The combination regimen also surprisingly reduces the rate of progression of cardiac, renal and cerebral end-organ damage. The combination elicits enhanced antihypertensive effects (whether malignant, essential, reno-vascular, diabetic, isolated systolic, or other secondary type of hypertension) and lessening of pulse pressure. The combination is also effective in treating supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter or detrimental vascular remodeling. It can further be shown that the combination is beneficial in the treatment and prevention of myocardial infarction and its sequelae, and is useful in treating atherosclerosis, angina (whether stable or unstable), renal insufficiency (diabetic and non-diabetic), peripheral vascular disease, cognitive dysfunction, and stroke. Furthermore, the improvement in endothelial function with the combination therapy provides benefit in diseases in which normal endothelial function is disrupted such as heart failure, angina pectoris and diabetes. Furthermore, the combination may be used for the treatment or prevention of primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.
  • Compounds of the present invention may also be useful in the treatment of diseases or disorders mediated by lymphocytes interactions, e.g. in transplantation, such as acute or chronic rejection of cell, tissue or organ allo- or xenografts or delayed graft function, graft versus host disease, autoimmune diseases, e.g. rheumatoid arthritis, systemic lupus erythematosus, hashimoto's thyroidis, multiple sclerosis, myasthenia gravis, diabetes type I or II and the disorders associated therewith, vasculitis, pernicious anemia, Sjoegren syndrome, uveitis, Graves ophthalmopathy, alopecia areata and others, inflammatory diseases optionally with underlying aberrant reactions, e.g. inflammatory bowel disease, Crohn's disease or ulcerative colitis, intrinsic asthma, inflammatory lung injury, inflammatory liver injury, inflammatory glomerular injury, atherosclerosis, osteoarthritis and further eczematous dermatitises, seborrhoeic dermatitis, cutaneous manifestations of immunologically-mediated disorders, inflammatory eye disease, myocarditis or hepatitis, gut ischemia, traumatic shock, cancer, e.g. breast cancer, T cell lymphomas or T cell leukemias, infectious diseases, e.g. toxic shock (e.g. superantigen induced), septic shock, adult respiratory distress syndrome or viral infections, e.g. AIDS, viral hepatitis, chronic bacterial infection, or senile dementia. Examples of cell, tissue or solid organ transplants include e.g. pancreatic islets, stem cells, bone marrow, corneal tissue, neuronal tissue, heart, lung, combined heart-lung, kidney, liver, bowel, pancreas, trachea or oesophagus.
  • Compounds of the present invention may be administered in conjunction with, e.g. as an adjuvant to, other drugs e.g. immunosuppressive or immunomodulating agents or other anti-inflammatory agents, e.g. for the treatment or prevention of allo- or xenograft acute or chronic rejection or inflammatory or autoimmune disorders. For example, the compounds of formula I may be used in combination with a calcineurin inhibitor, e.g. cyclosporin A or FK 506; a mTOR inhibitor, e.g. rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, CCI779, ABT578, AP23573, biolimus-7 or biolimus-9; an ascomycin having immuno-suppressive properties, e.g. ABT-281 or ASM981; corticosteroids; cyclophosphamide; azathioprene; methotrexate; leflunomide; mizoribine; mycophenolic acid or salt; mycophenolate mofetil; 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof; a PKC inhibitor, e.g. as disclosed in WO 02/38561 or WO 03/82859, e.g. the compound of Example 56 or 70; a JAK3 kinase inhibitor, e.g. N-benzyl-3,4-dihydroxy-benzylidene-cyanoacetamide-cyano-(3,4-dihydroxy)-]N-benzylcinnamamide (Tyrphostin AG 490), prodigiosin 25-C(PNU156804), [4-(4′-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P131), [4-(3′-bromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] (WHI-P154), [4-(3′,5′-dibromo-4′-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline] WHI-P97, KRX-211, 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile, in free form or in a pharmaceutically acceptable salt form, e.g. mono-citrate (also called CP-690,550), or a compound as disclosed in WO 04/052359 or WO 05/066156; a S1P receptor agonist or modulator, e.g. FTY720 optionally phosphorylated or an analog thereof, e.g. 2-amino-2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol optionally phosphorylated or 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid or its pharmaceutically acceptable salts; immunosuppressive monoclonal antibodies, e.g., monoclonal antibodies to leukocyte receptors, e.g., MHC, CD2, CD3, CD4, CD7, CD8, CD25, CD28, CD40, CD45, CD52, CD58, CD80, CD86 or their ligands; other immunomodulatory compounds, e.g. a recombinant binding molecule having at least a portion of the extracellular domain of CTLA4 or a mutant thereof, e.g. an at least extracellular portion of CTLA4 or a mutant thereof joined to a non-CTLA4 protein sequence, e.g. CTLA4Ig (for ex. designated ATCC 68629) or a mutant thereof, e.g. LEA29Y; adhesion molecule inhibitors, e.g. LFA-1 antagonists, ICAM-1 or -3 antagonists, VCAM-4 antagonists or VLA-4 antagonists.
  • The compounds of the present invention may be administered by any appropriate route, e.g. orally, for example in the form of a tablet or capsule; parenterally, for example intravenously; by inhalation, for example in the treatment of inflammatory or obstructive airways disease; intranasally, for example in the treatment of allergic rhinitis; topically to the skin, for example in the treatment of atopic dermatitis; or rectally, for example in the treatment of inflammatory bowel disease.
  • Thus, in a further aspect, there is provided a compound of the present invention for use in therapy. In a further embodiment, the therapy is selected from a disease or disorder which is mediated by the activation of PI 3-kinase gamma isoform. In a further embodiment, the therapy is selected from a disease which may be treated by inhibiting of PI 3-kinase gamma isoform. In another embodiment, the therapy is selected from a disease which may be treated by inhibiting of PI 3-kinase gamma isoform selectively over PI 3-kinase delta isoform.
  • The term “a therapeutically effective amount” of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, alleviate conditions, slow or delay disease progression, or prevent a disease, etc. In one non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing and/or ameliorating a condition, or a disorder or a disease (i) mediated by the activation of PI 3-kinase, particularly the gamma isoform, or (ii) associated with PI 3-kinase gamma isoform activity, or (iii) characterized by activity (normal or abnormal) of PI 3-kinase gamma isoform; or (2) reducing or inhibiting the activity of PI 3-kinase gamma isoform. In another non-limiting embodiment, the term “a therapeutically effective amount” refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of PI 3-kinase gamma isoform.
  • As used herein, the term “subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
  • As used herein, the term “inhibit”, “inhibition” or “inhibiting” refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
  • As used herein, the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient. In yet another embodiment, “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
  • As used herein, a subject is “in need of” a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
  • All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed.
  • The compounds of the present invention may be useful as pharmaceuticals and are thus usually formulated in the form of a pharmaceutical composition.
  • Hence, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
  • As used herein, the term “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc. In addition, the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc.
  • Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with
  • a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine;
    b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also
    c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired
    d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or
    e) absorbents, colorants, flavors and sweeteners.
  • Tablets may be either film coated or enteric coated according to methods known in the art. Suitable compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in a mixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
  • Certain injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
  • Suitable compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier. Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
  • Suitable compositions for topical application, e.g., to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like. Such topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
  • As used herein a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
  • Where the inhalable form of the active ingredient is an aerosol composition, the inhalation device may be an aerosol vial provided with a valve adapted to deliver a metered dose, such as 10 to 100 μl, e.g. 25 to 50 μl, of the composition, i.e. a device known as a metered dose inhaler. Suitable such aerosol vials and procedures for containing within them aerosol compositions under pressure are well known to those skilled in the art of inhalation therapy. For example, an aerosol composition may be administered from a coated can, for example as described in EP-A-0642992. Where the inhalable form of the active ingredient is a nebulizable aqueous, organic or aqueous/organic dispersion, the inhalation device may be a known nebulizer, for example a conventional pneumatic nebulizer such as an airjet nebulizer, or an ultrasonic nebulizer, which may contain, for example, from 1 to 50 ml, commonly 1 to 10 ml, of the dispersion; or a hand-held nebulizer, sometimes referred to as a soft mist or soft spray inhaler, for example an electronically controlled device such as an AERx (Aradigm, US) or Aerodose (Aerogen), or a mechanical device such as a RESPIMAT (Boehringer Ingelheim) nebulizer which allows much smaller nebulized volumes, e.g. 10 to 100 μl, than conventional nebulizers. Where the inhalable form of the active ingredient is the finely divided particulate form, the inhalation device may be, for example, a dry powder inhalation device adapted to deliver dry powder from a capsule or blister containing a dry powder comprising a dosage unit of (A) and/or (B) or a multidose dry powder inhalation (MDPI) device adapted to deliver, for example, 3-25 mg of dry powder comprising a dosage unit of (A) and/or (B) per actuation. The dry powder composition preferably contains a diluent or carrier, such as lactose, and a compound that helps to protect against product performance deterioration due to moisture e.g. magnesium stearate. Suitable such dry powder inhalation devices include devices disclosed in U.S. Pat. No. 3,991,761 (including the AEROLIZER™ device), WO 05/113042, WO 97/20589 (including the CERTIHALER™ device), WO 97/30743 (including the TWISTHALER™ device) and WO 05/37353 (including the GYROHALER™ device).
  • Hence, the invention also includes (A) an agent of the invention, or a pharmaceutically acceptable salt or solvate thereof, in inhalable form; (B) an inhalable medicament comprising a compound of the present invention in inhalable form together with a pharmaceutically acceptable carrier in inhalable form; (C) a pharmaceutical product comprising such a compound in inhalable form in association with an inhalation device; and (D) an inhalation device containing such a compound in inhalable form.
  • Dosages of compounds of the present invention employed in practicing the present invention will of course vary depending, for example, on the particular condition to be treated, the effect desired and the mode of administration. In general, suitable daily dosages for administration by inhalation are of the order of 0.0001 to 30 mg/kg, typically 0.01 to 10 mg per patient, while for oral administration suitable daily doses are of the order of 0.01 to 100 mg/kg.
  • The present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
  • Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
  • The invention further provides pharmaceutical compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose. Such agents, which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
  • The compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent. The compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
  • In a further aspect, there is provided a pharmaceutical combination comprising a compound of the present invention and at least one other therapeutic agent, for example for simultaneous, separate or sequential use in therapy. In one embodiment, the therapy is the treatment of a disease or disorder mediated by the activation of PI 3-kinase, particularly the gamma isoform. Products provided as a pharmaceutical combination include a composition comprising the compound of the present invention and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of the present invention and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
  • In one embodiment, the invention provides a pharmaceutical combination comprising a compound of the present invention and another therapeutic agent(s). Optionally, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
  • In one embodiment, there is provided a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of the present invention. In one embodiment, the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
  • The kit may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit of the invention typically comprises directions for administration.
  • The pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients. The therapeutically effective dosage of a compound of the present invention, the pharmaceutical composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
  • The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10−3 molar and 10−9 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
  • PI 3-kinase antagonists such as the compounds of the present invention are also useful as co-therapeutic agents for use in combination with a second active agent such as for example an organic nitrate and NO-donors, such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhalational NO; compounds that inhibit the degradation of cyclic guanosine monophosphate (cGMP) and/or cyclic adenosine monophosphate (cAMP), such as inhibitors of phosphodiesterases (PDE) 1, 2, 3, 4 and/or 5, especially PDE 5 inhibitors such as sildenafil, vardenafil and tadalafil; NO-independent, but haem-dependent stimulators of guanylate cyclase, such as in particular the compounds described in WO 00/06568, WO 00/06569, WO 02/42301 and WO 03/095451; NO— and haem-independent activators of guanylate cyclase, such as in particular the compounds described in WO 01/19355, WO 01/19776, WO 01/19778, WO 01/19780, WO 02/070462 and WO 02/070510; compounds which inhibit human neutrophilic elastase, such as sivelestat or DX-890 (Reltran); compounds inhibiting the signal transduction cascade, such as tyrosine kinase and/or serine/threonine kinase inhibitors, in particular imatinib, gefitinib, erlotinib, sorafenib and sunitinib; compounds influencing the energy metabolism of the heart, for example and preferably etomoxir, dichloroacetate, ranolazine or trimetazidine; antithrombotic agents, for example and preferably from the group comprising platelet aggregation inhibitors, anticoagulants or profibrinolytic substances; active substances for lowering blood pressure, for example and preferably from the group comprising calcium antagonists, angiotensin II antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, aldosterone synthase inhibitors, alpha receptor blockers, beta receptor blockers, mineralocorticoid receptor antagonists, Rho-kinase inhibitors and diuretics; and/or active substances that modify lipid metabolism, for example and preferably from the group comprising thyroid receptor agonists, inhibitors of cholesterol synthesis, for example and preferably HMG-CoA-reductase inhibitors or inhibitors of squalene synthesis, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or PPAR-delta agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors and lipoprotein (a) antagonists, particularly in the treatment of PAH or diseases and disorders such as those mentioned hereinbefore, e.g., as potentiators of therapeutic activity of such drugs or as a means of reducing required dosaging or potential side effects of such drugs.
  • In a particular embodiment, there is provided a pharmaceutical combination comprising the compounds of the present invention and a second agent wherein the second agent is a PDE 5 inhibitor or neutral endopeptidase inhibitor.
  • The compounds of the present invention may be mixed with a second agent in a fixed pharmaceutical composition or it may be administered separately, before, simultaneously with or after the other drug substance.
  • Particularly, the invention includes in a further aspect a combination of a PI 3-kinase inhibitor such a compound of the present invention with osmotic agents (hypertonic saline, dextran, mannitol, Xylitol), ENaC blockers, an anti-inflammatory, bronchodilatory, antihistamine, anti-tussive, antibiotic and/or DNase drug substance, wherein the TPH1 antagonist and the further drug substance may be in the same or different pharmaceutical composition.
  • Suitable antibiotics include macrolide antibiotics, e.g., tobramycin (TOBI™).
  • Suitable DNase drug substances include dornase alfa (Pulmozymen™), a highly-purified solution of recombinant human deoxyribonuclease I (rhDNase), which selectively cleaves DNA. Dornase alfa is used to treat cystic fibrosis.
  • Accordingly, the invention includes as a further aspect a combination of PI 3-kinase inhibitors such the compounds of the present invention with second agents that are IP receptor agonist, particularly the compounds disclosed in WO2012/007539.
  • Accordingly, the invention includes as a further aspect a combination of PI 3-kinase inhibitors such the compounds of the present invention with second agents that are multi-kinase inhibitors, such as imatinib mysilate, Gleevec. lmatinib functions as a specific inhibitor of a number of tyrosine kinase enzymes. It occupies the TK active site, leading to a decrease in activity. TK enzymes in the body, include the insulin receptor. lmatinib is specific for the TK domain in the Abelson proto-oncogene, c-kit and PDGF-R (platelet-derived growth factor receptor).
  • In a particular embodiment, there is provided a pharmaceutical combination comprising a compound of the present invention and a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors, endothelin antagonist, diuretic, aldosteron receptor blocker, and endothelin receptor blocker.
  • In another embodiment, there is provided a pharmaceutical combination comprising a compound of the present invention and a second active agent selected from phosphodiesterase V inhibitors, neutral endopeptidase 1 inhibitors, ALK-5 inhibitors, rho-kinase inhibitors, TPH1 inhibitors, multi-kinase inhibitors.
  • Compounds according to any one of embodiments 1-42 where both R3 and R4 are H have been found to be metabolites of the compounds of the present invention.
    • EXPERIMENTAL
  • The present invention is illustrated by the following examplified compounds.
  • From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
    • General Conditions:
  • Mass spectra were run on LCMS systems using electrospray ionization. These were either Agilent 1100 HPLC/Micromass Platform Mass Spectrometer combinations or Waters Acquity UPLC with SQD Mass Spectrometer. [M+H]+ refers to mono-isotopic molecular weights. NMR spectra were run on Bruker AVANCE 400 MHz or 500 MHz NMR spectrometers using ICON-NMR. Spectra were measured at 298K and were referenced using the solvent peak.
  • As a person skilled in the art understands, when running a 1H NMR in deuterated DMSO for compounds according to any one of embodiments 1-42 with R1=methyl, the signal of said methyl protons is often obscured due to the DMSO solvent peak at δ of around 2.5 ppm.
  • The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 mm Hg and 30 mm Hg (=20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g., microanalysis and spectroscopic characteristics, e.g., MS, IR, NMR. Abbreviations used are those conventional in the art. If not defined, the terms have their generally accepted meanings.
    • Abbreviations:
    • AcOH acetic acid
    • ACN acetonitrile
    • aq. aqueous
    • br broad
    • BuOH butanol
    • conc. concentrated
    • doublet
    • dd double doublet
    • DCM dichloromethane
    • DCC N,N′-dicyclohexylcarbodiimide
    • DOE 1,2-dichloroethane
    • DEAD diethyl azodicarboxylate
    • DIPEA diisopropylethylamine
    • DMA dimethylacetamide
    • DME 1,2-dimethoxyethane
    • DMF N,N-dimethylformamide
    • DMSO dimethylsulfoxide
    • Et2O diethyl ether
    • EtOAc ethyl acetate
    • EtOH ethanol
    • h hour(s)
    • HATU 0-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate
    • Hex hexane
    • HOBt.H2O 1-Hydroxybenzotriazole hydrate
    • HPLC High Performance Liquid Chromatography
    • IPA iso-propyl alcohol
    • KOAc Potassium acetate
    • KOtBu Potassium tert-butoxide
    • LCMS liquid chromatography and mass spectrometry
    • MeOH methanol
    • MeCN acetonitrile
    • MS mass spectrometry
    • m multiplet
    • min minute
    • ml milliliter(s)
    • m/z mass to charge ratio
    • NBS N-bromosuccinimide
    • NMR nuclear magnetic resonance
    • NOESY nuclear Overhauser effect spectroscopy
    • Pd-118 Dichloro [1,1′ bis(di-tert-butylphosphino)]ferrocene palladium (II)
    • PdCl2(dppf).CH2Cl2 adduct [1,1-Bis(diphenylphosphino) ferrocene]dichloropalladium (II) dichloromethane adduct.
    • Pd(PPh3)2Cl2 Bis(triphenylphosphine)palladium(II) dichloride
    • ppm parts per million
    • PS polymer supported
    • PS-TBD 1,5,7-triazabicyclo[4.4.0]dec-5-ene polystyrene
    • Rt retention time
    • RT room temperature
    • singlet
    • sat. saturated
    • SCX-2 strong cation exchange (e.g. Isolute® SCX-2 columns from Biotage)
    • SFC supercritical fluid chromatography
    • Si-TMT Si-TMT is the silica bound equivalent of 2,4,6-trimercaptotriazine, commercially available e.g. from Biotage
    • t triplet
    • TBME methyl-tert-butyl ether
    • TEA triethylamine
    • TFA trifluoroacetic acid
    • THF tetrahydrofuran
    • TLC thin layer chromatography
    • T3P® propylphosphonic anhydride
  • Referring to the examples that follow, compounds of the preferred embodiments were synthesized using the methods described herein, or other methods, which are known in the art.
  • The various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified, where appropriate, using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Unless otherwise stated, all starting materials are obtained from commercial suppliers and used without further purification. Salts may be prepared from compounds by known salt-forming procedures.
  • It should be understood that the organic compounds according to the preferred embodiments may exhibit the phenomenon of tautomerism. As the chemical structures within this specification can only represent one of the possible tautomeric forms, it should be understood that the preferred embodiments encompasses any tautomeric form of the drawn structure.
  • Where microwave heating was employed, this was carried out using a Biotage Initiator Sixty microwave in dedicated reaction vials at the temperature shown and for the time indicated.
  • If not indicated otherwise, the analytical LCMS conditions are as follows:
    • Method A
    • Column: Cynergi 2.5 uMMax-RP100A (20×4.0) mm.
    • Mobile Phase: A: Water +0.1% Formic Acid B:Acetonitrile
    • Gradient 0.0-0.5 min 20% B, 2.5-4.5 mins 95% B, 5.0 min 20% B
      Method 2minLC_v003
    • Column Waters BEH C18 50×2.1 mm, 1.7 m
    • Column Temperature 50° C.
    • Eluents A: H2O, B: acetonitrile, both containing 0.1% TFA
    • Flow Rate 0.8 ml/min
    • Gradient 0.20 min 5% B; 5% to 95% B in 1.30 min, 0.25 min 95% B
      Method 2minLowpH
    • Column: Waters Acquity CSH 1.7 μm, 2.1×50 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.3 min 5-98% B, 1.3-1.55 min 98% B, 1.55-1.6 min 98-5% B
      Method 2minLowpHv01
    • Column: Waters Acquity CSH 1.7 μm, 2.1×50 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.55 min 5-98% B, 1.55-1.75 min 98% B, 1.75-1.8 min 98-5% B
      Method 2minLowpHv02
    • Column: Acquity CSH C18 50×2.1 mm
    • Temperature: 50° C.
    • Eluents A: Water B: Acetonitrile both with +0.1% TFA
    • Flow Rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.55 min 5-98% B, 1.55-1.75 min 98% B, 1.75-1.8 min 98-5% B
      Method 2minLowpHv03:
    • Column: Waters Acquity CSH 1.7 μm, 2.1×50 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.8 min 5-98% B, 1.8-2.1 min 98% B, 2.1-2.3 min 98% B
      Method 10minLowpH
    • Column: Waters Acquity CSH 1.7 μm, 2.1×100 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 0.7 mL/min
    • Gradient: 0.0 min 2% B, 0.58-8.0 min 2-98% B, 8.0-9.0 min 98% B, 9.0-9.1 min 98-2% B
      Method 10minLowpHv01:
    • Column: Waters Acquity CSH 1.7 μm, 2.1×100 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 0.7 mL/min
    • Gradient: 0.0 min 2% B, 0.5-8.0 min 2-98% B, 8.0-9.0 min 98% B, 9.0-9.1 min 98-2% B
    Method10minHighpH
    • Column: Waters Acquity CSH 1.7 μm, 2.1×100 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Ammonia B: Acetonitrile +0.1% Ammonia
    • Flow rate: 0.7 mL/min
    • Gradient: 0.0 min 2% B, 0.5-8.0 min 2-98% B, 8.0-9.0 min 98% B, 9.0-9.1 min 98-2% B
      Method 2minLowpH_TFA
    • Column: Waters Acquity CSH 1.7 μm, 2.1×50 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% TFA
    • Flow rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.3 min 5-98% B, 1.3-1.55 min 98% B, 1.55-1.6 min 98-5% B
      Method LowpH_v002
    • Column Phenomenex Gemini C18 50×4.6 mm, 3.0 μm
    • Column Temperature 50° C.
    • Eluents A: H2O, B: methanol, both containing 0.1% TFA
    • Flow Rate 1.0 mL/min
    • Gradient 5% to 95% B in 2.0 min, 0.2 min 95% B
      Method 8minLowpHv01:
    • Column: Waters Acquity CSH 1.7 μm, 2.1×100 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Formic Acid B: Acetonitrile +0.1% Formic Acid
    • Flow rate: 0.7 mL/min
    • Gradient: 0.0 min 2% B, 0.3-6.5 min 2-98% B, 6.5-7.5 min 98% B, 7.5-8.0 min 5-98% B
      Method 2minHighpHv03:
    • Column: Waters Acquity CSH 1.7 μm, 2.1×50 mm
    • Temperature: 50° C.
    • Mobile Phase: A: Water +0.1% Ammonia B: Acetonitrile +0.1% Ammonia
    • Flow rate: 1.0 mL/min
    • Gradient: 0.0 min 5% B, 0.2-1.8 min 5-98% B, 1.8-2.1 min 98% B, 2.1-2.3 min 98-5% B
  • Unless indicated otherwise, preparative HPLC was carried out using an appropriate column and a mobile phase of 0.1% TFA in acetonitrile and 0.1% aqueous TFA with an appropriate gradient.
    • Example 1 Trans-3-[5-Amino-6-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00082
  • A stirred mixture of trans-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) (0.15 g, 0.47 mmol), 5-bromo-3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-ylamine (Intermediate C1) (0.122 g, 0.47 mmol) and potassium acetate (0.14 g, 1.43 mmol) in dioxane (10 ml) was degassed by bubbling argon through the mixture for 10 mins. After adding bis(diphenylphosphinoferrocene) dichloropalladium (39 mg, 0.047 mmol) and further degassing with argon the mixture was heated to 110° C. for 5 h. Cool water (50 ml) was added and the mixture was extracted with ethyl acetate (2×50 ml). The organic extract was dried over sodium sulphate and concentrated under reduced pressure. Purification by preparative TLC using silicagel (GF 254) as stationary phase and 70% EtOAc in petroleum ether as the mobile phase afforded the title compound as a yellow coloured solid;
  • LC-MS: [M+H]+=445.2 Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.45 (1H, s), 7.83 (1H, s), 7.75 (1H, d), 7.70 (2H, m), 7.55 (1H, d), 4.50 (1H, m), 3.30 (1H, m), 2.90 (1H, m), 2.60 (3H, s), 2.42 (3H, s), 1.70 (2H, m), 1.58 (2H, m), 1.00-1.23 (4H, m). One proton not visible, may be obscured by DMSO and/or water peaks.
    • Example 2 Trans-3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00083
  • The title compound was prepared using 5-bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2a) and trans-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) under analogous conditions to those of Example 1.
  • LCMS: Rt 1.79 mins MS m/z 445 [M+H]+: Method A
  • 1H NMR (400 MHz, CDCl3) δ 8.49 (1H, s), 8.00 (1H, s), 7.83 (1H, d), 7.49 (1H, d), 6.5-7.5 (2H, br s), 4.36 (1H, m), 3.59 (1H, br mult), 3.22 (1H, br mult), 2.55 (6H, 2×s), 1.95 (4H, mult.) 1.2-1.4 (4H, mult). One proton not visible, may be broad or obscured by water peaks.
    • Example 3 3-[5-Amino-6-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00084
  • The title compound was prepared using 5-bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2a) and N-(3-Hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide-3-boronic acid (Intermediate B3a) under analogous conditions to those of Example 1
  • 1H NMR (400 MHz, DMSO-d6) δ 8.59 (1H, s), 7.88 (1H, s), 7.80 (2H, br s), 7.75 (1H, d), 7.59 (1H, d), 7.45 (1H, m), 4.25 (1H, s), 2.85 (2H, mult.), 2.52 (3H, s), 2.49 (3H, s), 1.54 (2H, mult.), 1.03 (6H, s).
    • Example 4 Trans-3-[5-Amino-6-(3-methyl-isoxazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00085
  • The title compound was prepared from trans-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) and 5-bromo-3-(3-methyl-isoxazol-5-yl)-pyrazin-2-ylamine (Intermediate C3) using analogous conditions to those of Example 5.
  • LCMS MS m/z 444.2 [M+H]+: Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.39 (1H, s), 7.90 (1H, s), 7.73 (1H, d), 7.60 (1H, d), 7.52 (1H, d), 6.95 (1H, s), 6.92 (2H, br s), 4.45 (1H, s), 3.31 (1H, m), 2.90 (1H, m), 2.48 (3H, s), 2.35 (3H, s), 1.55-1.75 (4H, m), 1.00-1.25 (4H, m).
    • Example 5 3-[5-Amino-6-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00086
  • To a solution of 4-methyl-N-((3-methyloxetan-3-yl)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B4) (116 mg, 0.303 mmol) and 5-bromo-3-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine (Intermediate C4) (70 mg, 0.275 mmol) in DME (2 ml) was added PdCl2(dppf)-CH2Cl2 adduct (11.25 mg, 0.014 mmol) and the vial was degassed with N2 several times before adding 2M aqueous Na2CO3 (0.413 ml, 0.826 mmol). The mixture was stirred at 100° C. for 20 min in a microwave. The mixture was diluted with DCM then washed with brine. The organic phase was separated, using a phase separator. The solvent was removed under reduced pressure. The crude product was purified by flash column chromatography, eluting in a 0% to 100% i-hex:EtOAc gradient on a 4 g silica cartridge to give the titled compound;
  • LCMS: RT 0.86 mins; MS m/z 429.3 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, CDCl3) δ 8.08 (1H, s), 8.04 (1H, s), 7.98 (2H, s), 7.80 (1H, d), 7.45 (1H, d), 4.98 (2H, br s), 4.83 (1H, t), 4.39 (4H, dd), 4.02 (3H, s), 3.18 (2H, dd), 2.53 (3H, s), 1.33 (3H, s).
    • Example 6 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00087
  • A mixture comprising of 3-bromo-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide (Intermediate A2) (164 mg, 0.509 mmol), KOAc (74.9 mg, 0.763 mmol), PdCl2(dppf).CH2Cl2 adduct (20.77 mg, 0.025 mmol) and bis(pinacolato)diboron (129 mg, 0.509 mmol) in DME (2543 μL) under N2 was heated at 90° C. for 3 hours. 5-Chloro-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C5)(100 mg, 0.509 mmol), 2M aqueous Na2CO3 (763 μl, 1.526 mmol) and PdCl2(dppf).CH2Cl2 adduct (20.77 mg, 0.025 mmol) were added and reaction mixture was heated using microwave irradiation at 120° C. for 40 mins. The resulting mixture was added to water (50 ml) and extracted with EtOAc (2×50 ml). The organic phases were washed with brine, dried over MgSO4 and treated with Si-TMT to remove Pd. This mixture was swirled occasionally over 1 hour. The solids were removed by filtration and the resulting organic mixture was concentrated under reduced pressure. Purification by chromatography on silica gel eluting with a gradient of 0-10% [2M NH3 in MeOH] in DCM afforded the title compound as a solid. The solid was recrystallised from hot EtOAc (˜1 ml)/Et2O and allowed to stand overnight at RT to afford the title compound;
  • LCMS: Rt=0.81 mins; MS m/z 404.3 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.41 (1H, s), 8.39 (1H, s), 7.92 (1H, d), 7.71 (1H, dd), 7.53 (1H, d), 7.48 (1H, t), 7.37 (2H, br s), 4.51 (1H, s), 2.61 (2H, d), 2.50 (3H, s), 1.05 (6H, s).
    • Example 7 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00088
  • The title compound was prepared using 3-bromo-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide (Intermediate A2) and 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) under analogous conditions to those of Example 6.
  • LCMS: Rt=0.87 mins; MS m/z 434.2 [M+H]+; Method 10minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.28 (1H, s), 8.22 (1H, s), 7.87 (1H, s), 7.70 (1H, d), 7.52 (1H, d), 7.45 (1H, t), 6.74 (2H, s), 4.40 (1H, s), 2.69 (3H, s), 2.65 (2H, d), 2.50 (3H, s), 1.07 (6H, s).
    • Example 8 3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-2,2-dimethyl-propyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00089
  • The title compound was prepared using 3-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide (Intermediate A9) and 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) under analogous conditions to those of Example 6
  • LCMS: R t 0.92 mins; MS m/z 448.2 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.28 (1H, s), 8.23 (1H, s), 7.86 (1H, d), 7.70 (1H, dd), 7.53 (1H, d), 7.38 (1H, t), 6.74 (2H, s), 4.44 (1H, t), 3.10 (2H, d), 2.49 (3H, s), 2.69 (3H, s), 2.59 (2H, d), 0.79 (6H, s).
    • Example 9a and Example 9b (R)- and (S)-3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00090
  • Racemic 3-[5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide was prepared from 3-bromo-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide (Intermediate A8) and 5-bromo-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7) under analogous conditions to those of Example 6.
  • The racemic mixture was separated by chiral separation to afford the individual isomers:
  • Column: 2× Chiralpak AD-H, 250×10 mm, 5 um @ 35 deg C.,
  • Mobile phase: 35% Isopropanol+0.1% v/v DEA/65% CO2,
  • Flow: 10 ml/min,
  • Detection: UV @ 220 nm,
  • Instrument: Berger Minigram SF01)
    • Example 9a First Eluting Compound SFC Retention Time=7.14 (R)-3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide or (S)-3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide
  • LCMS: Rt 0.87 mins; MS m/z 469.6 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.06 (1H, s), 7.82 (2H, m), 7.64 (1H, dd), 7.49 (1H, d), 6.28 (2H, s), 4.82 (1H, d), 3.84 (1H, m), 3.83 (3H, s), 3.50 (1H, m),2.47 (3H, s), 2.30 (3H, s), 2.20 (1H, m), 2.02 (2H, m), 1.89 (1H, m), 1.71 (4H, m).
    • Example 9b Second Eluting Compound SFC Retention Time=7.93 mins (R)-3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide or (S)-3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide
  • LCMS: Rt 0.87 mins; MS m/z 469.2 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.06 (1H, s), 7.84-7.79 (2H, m), 7.63 (1H, dd), 7.49 (1H, d), 6.28 (2H, s), 4.82 (1H, d), 3.84 (1H, m), 3.83 (3H, s), 3.50 (1H, m), 2.47 (3H, s), 2.30 (3H, s), 2.20 (1H, m), 2.02 (2H, m), 1.89 (1H, m), 1.70 (4H, m).
    • Example 10 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00091
  • To a solution of N-(3-hydroxypropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B1) (62.7 mg, 0.176 mmol) in MeCN (882 μL) was added 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) (40 mg, 0.176 mmol), bis(triphenylphosphine)palladium(II) chloride (6.19 mg, 8.82 μmol) and 2M Na2CO3 (265 μl, 0.529 mmol). The reaction mixture was heated using microwave radiation at 150° C. for 30 minutes. The resulting mixture was added to water (50 ml) and extracted with EtOAc (2×40 ml). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-10% [2M NH3 in MeOH] in DCM afforded a green solid which was sonicated in TBME (2 ml) and filtered to afford the title compound;
  • LCMS; Rt 0.82 mins; MS m/z 420.2 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.28 (1H, s), 8.22 (1H, s), 7.83 (1H, s), 7.69 (1H, d), 7.53 (1H, d), 7.49 (1H, t), 6.73 (2H, s), 4.41 (1H, t), 3.37 (2H, q), 2.81 (2H, q), 2.68 (3H, s), 2.48 (3H, s), 1.54 (2H, m).
    • Example 11 Trans-3-(5-Amino-6-(pyridin-4-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00092
  • To a solution of trans-3-(5-amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide (Intermediate D1) (40 mg, 0.101 mmol) was added 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (24.80 mg, 0.121 mmol), bis(triphenylphosphine)palladium(II) chloride (3.54 mg, 5.04 μmol) and 2M Na2CO3 aq. (151 μL, 0.302 mmol). The reaction was heated using microwave radiation at 150° C. for 30 minutes. The resulting mixture was added to sat. Na2CO3 (40 ml) and extracted with EtOAc (2×40 ml). The organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica gel eluting with 0-100% EtOAc in iso-hexane afforded the title compound as yellow solid;
  • LCMS: Rt=0.74 mins; MS m/z 440.0 [M+H]+; Method 2minLC_v003.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.71 (2H, d), 8.29 (1H, s), 7.89 (1H, d), 7.77 (2H, d), 7.71 (1H, dd), 7.59 (1H, d), 7.51 (1H, d), 6.67 (2H, s), 4.48 (1H, d), 3.34-3.25 (1H, m), 2.97-2.86 (1H, m), 2.49 (3H, s), 1.73-1.58 (4H, m), 1.23-1.02 (4H, m).
    • Example 12 3-(5-Amino-6-(1,3-di methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methyl butyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00093
  • The title compound was prepared from 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) and 3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole under analogous conditions to those of Example 11 (using DME/EtOH as solvent instead of MeCN).
  • LC-MS: Rt. 0.81 min; m/z 445.2 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s); 8.06 (1H, s); 7.84 (1H, d); 7.66 (1H, dd); 7.51 (1H, d); 7.39 (1H, t); 6.27 (2H, s); 4.26 (1H, s); 3.82 (3H, s); 2.82 (2H, m); 2.47 (3H, s, partially overlapping with solvent); 2.29 (3H, s); 1.49 (2H, m); 1.00 (6H, s).
    • Example 13 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00094
  • The title compound was prepared from 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) and 3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole under analogous conditions to those of Example 11 (using DME as solvent instead of MeCN).
  • LCMS: Rt 3.24 min; m/z 431.5 [M+H]+; Method 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s); 8.06 (1H, s); 7.87 (1H, d); 7.68 (1H, dd); 7.50 (1H, d); 7.44 (1H, t); 6.33 (2H, br); 3.82 (3H, s); 3.17 (1H, s); 2.62 (2H, d); 2.47 (3H, s, partially overlapping solvent peak); 2.30 (3H, s); 1.05 (6H, s).
    • Example 14 Trans-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00095
  • The title compound was prepared from trans-3-(5-amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide (Intermediate D1) and 2-Methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-thiazole under analogous conditions to those of Example 11.
  • LCMS: Rt 0.87 mins; MS m/z 460.2 [M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 8.28 (1H, s), 8.21 (1H, s), 7.87 (1H, d), 7.71 (1H, dd), 7.59 (1H, d), 7.51 (1H, d), 6.73 (2H, s), 4.48 (1H, d), 3.35-3.25 (1H, m), 2.98-2.87 (1H, m), 2.68 (3H, s), 2.48 (3H, s), 1.77-1.58 (4H, m), 1.24-1.03 (4H, m).
    • Example 15 Trans-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00096
  • A mixture comprising trans-3-(5-amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methyl benzenesulfonamide (Intermediate D1) (50 mg, 0.126 mmol), 1H-[1,2,4]triazole (52.2 mg, 0.756 mmol), N,N-dimethylglycine (1.299 mg, 0.013 mmol), Cs2CO3 (123 mg, 0.378 mmol) and CuI (2.399 mg, 0.013 mmol) in DMA (1260 μl) was heated using microwave radiation at 180° C. for 2 hours. The resulting mixture was added to saturated Na2CO3 (50 ml) and extracted with EtOAc (2×50 ml). The organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-10% [2M NH3 in MeOH] in DCM afforded an oil. To this oil was added Et2O (2 ml) and the mixture sonicated until a fine was precipitate was produced. The excess Et2O was removed and the solid was dried to afford the title compound;
  • LCMS: Rt 0.86 mins; MS m/z 430.3 [M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.94 (1H, d), 7.74 (1H, dd), 7.63 (1H, d), 7.53 (1H, d), 7.38 (2H, s), 4.47 (1H, d), 3.30 (1H, m), 2.92 (1H, m), 2.51 (3H, s overlapping DMSO peak), 1.68 (4H, m), 1.12 (4H, m).
    • Example 16 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N—[(R)-1-(tetrahydro-furan-3-yl)methyl]-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00097
  • To a solution of (R)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B7) (60 mg, 0.157 mmol) in EtOH/Toluene (1.5 ml; 1:2) was added 5-bromo-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7) (35.2 mg, 0.157 mmol) followed by Pd(PPh3)2Cl2 (5.52 mg, 7.87 μmol) and 2M Na2CO3 (0.236 ml, 0.472 mmol). The reaction was heated in the microwave at 100° C. for 30 minutes. A further 0.05 equivalent of catalyst was added and the reaction heated in the microwave at 100° C. for a further 1 hour. More catalyst (5.52 mg, 7.87 μmol) was added and the reaction heated in the microwave at 100° C. for a further 2 hours. The reaction was diluted with ethyl acetate, washed with water and the organic layer dried (MgSO4), filtered and concentrated. The product was purified by flash chromatography on silica gel (12 g) eluting with TBME/MeOH gradient (0-10%) to give the title compound;
  • LCMS Rt 0.86, 100%, MS m/z 443.5 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.09 (1H, s), 8.07 (1H, s), 7.85 (1H, s), 7.68 (2H, m), 7.52 (1H, d), 6.28 (2H, s), 3.82 (3H, s), 3.60 (3H, m), 3.32 (1H, m, partially obscured by water signal), 2.72 (2H, t), 2.48 (3H, s), 2.29 (3H, s), 2.27 (1H, m), 1.88 (1H, m), 1.48 (1H, m).
    • Example 17 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00098
  • To a solution of 4-Methyl-N-(3-methyl-oxetan-3-ylmethyl)-3-(4,4,5,5)tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzenesulfonamide (Intermediate B4) (511 mg, 1.341 mmol) and 5-chloro-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7) (200 mg, 0.894 mmol) in DME (8 ml) was added PdCl2(dppf) CH2Cl2 adduct (36.5 mg, 0.045 mmol) and the vial was degassed with N2 several times before adding 2N aqueous sodium carbonate (1.34 ml, 2.68 mmol). The mixture was stirred at 120° C. for 30 min in the microwave. The mixture was diluted with DCM then washed with brine. The organic layer was stirred with the Pd scavenger resin (polymer supported trimercaptotriazine). The organic phase was separated, using a phase separator. Solvent was removed under reduced pressure to give the crude product. Purification by flash column chromatography eluting in a 0% to 15%
  • TBME/MeOH gradient on a 12 g silica cartridge to afford the title compound;
  • LCMS: Rt 0.86, 100%, MS m/z 443.5 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 7.96 (1H, s), 7.78 (1H, d), 7.75 (1H, s), 7.45 (1H, d), 4.89 (2H, br s), 4.75 (1H, t), 4.37 (4H, dd), 3.93 (3H, s), 3.16 (2H, d), 2.52 (3H, s), 2.14 (3H, s), 1.30 (3H, s).
    • Example 18 3-[5-Amino-6-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00099
  • To 0.5-2 ml microwave vial was added N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (87 mg, 0.235 mmol), 5-bromo-3-(2-methyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8)(60 mg, 0.235 mmol), and PdCl2(dppf)-CH2Cl2 adduct (9.60 mg, 0.012 mmol) and 2M aqueous sodium carbonate (0.372 ml, 0.745 mmol) in DME (1.5 ml). The reaction was heated in a biotage initiator microwave at 120° C. for 2 hours. The reactions were combined, extracted into ethyl acetate, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was loaded onto silica and purified by flash column chromatography, elution with TBME:methanol (0-10%) on a 12 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a brown oil. The residue was taken up in hot ethanol and recrystallised to yield the title compound as a light brown solid;
  • LCMS Rt 0.98 mins m/z 418.1 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.32 (1H, s), 8.29 (1H, s), 7.90 (1H, d), 7.70 (1H, dd), 7.52 (1H, d), 7.47 (1H, t), 7.30 (2H, broad s), 4.40 (1H, s), 4.30 (3H, s), 2.62 (2H, d), 2.50 (3H, s), 1.06 (6H, s).
    • Example 19 3-[5-Amino-6-(2,5-dimethyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00100
  • A mixture of N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (240 mg, 0.650 mmol), 5-bromo-3-(2,5-dimethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C9) (175 mg, 0.325 mmol), and bis(triphenylphosphine)palladium(II) chloride (11.41 mg, 0.016 mmol) and 2M aqueous sodium carbonate (0.406 ml, 0.813 mmol) in DME (4 ml) was heated in the microwave at 120° C. for 90 mins. Further N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (120 mg, 0.325 mmol, 0.5 eq) was added and the reaction heated in the microwave at 120° C. for a further 2 hours. The reactions were combined, extracted into ethyl acetate, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was loaded onto silica and purified by flash column chromatography, elution with iso hexane:ethyl acetate (0-100%) on a 12 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a yellow oil. The residue was taken up in DMSO and purified by mass directed preparative chromatography. The required fractions were combined and the product extracted into DCM, washed with sat. NaHCO3 to remove all traces of TFA, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The product was recrystallised from the minimum of hot ethanol to afford the title compound; LCMS: Rt 1.01 mins MS m/z 432.2 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.25 (1H, s), 7.93 (1H, d), 7.70 (1H, dd), 7.52 (1H, d), 7.46 (1H, broad), 7.34 (2H, broad), 4.41 (1H, broad), 4.21 (3H, s), 2.62 (2H, broad), 2.56 (3H, s), 2.49 (3H, s), 1.05 (6H, s).
    • Example 20a cis-3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide and Example 20b trans-3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00101
  • Racemic 3-[5-amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide was prepared from 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and 3-bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) under analogous conditions to those of Example 6. Stereoisomers were separated using chiral SFC.
    • First Eluted Peak: Example 20a cis-3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide
  • LCMS: Rt 0.85 mins; MS m/z 446.3 [M+H]+; Method: 2minLowpH
  • 1H NMR (500 MHz, DMSO-d6) δ 8.28 (1H, s), 8.22 (1H, s), 7.83 (1H, d), 7.68 (1H, dd), 7.54 (2H, m), 6.73 (2H, br s), 4.89 (1H, d), 3.84 (1H, m), 2.74 (2H, t), 2.68 (3H, s), 2.48 (3H, s), 2.17 (2H, m), 1.75 (1H, m), 1.41 (2H, m).
    • Second Eluted Peak: Example 20b trans-3-[5-Amino-6-(2-methyl-thiazol-5-yl)-pyrazin-2-yl]-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide
  • LCMS: Rt 0.85 mins; MS m/z 446.3 [M+H]+; Method: 2minLowpH
  • 1H NMR (500 MHz, DMSO-d6) δ 8.28 (1H, s), 8.22 (1H, s), 7.83 (1H, d), 7.68 (1H, dd), 7.60 (1H, t), 7.52 (1H, d), 6.73 (2H, br s), 4.90 (1H, d), 4.09 (1H, m), 2.78 (2H, t), 2.68 (3H, s), 2.48 (3H, s), 2.12 (1H, m), 1.92 (2H, m), 1.82 (2H, m).
  • The assignment of compounds as cis or trans was carried out using 2D NMR experiments including NOESY.
    • Example 21 3-[5-Amino-6-(2-cyclopropyl-thiazol-5-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00102
  • The title compound was prepared using N-(2-Hydroxy-2-methyl-propyl)-4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-Chloro-3-(2-cyclopropyl-thiazol-5-yl)-pyrazin-2-ylamine (Intermediate C10) under analogous conditions to those of Example 25.
  • LCMS: Rt 1.03 mins; MS m/z 460.2 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.07 (1H, s), 8.06 (1H, s), 7.84 (1H, d), 7.68 (1H, t), 7.65 (1H, dd), 7.50 (1H, d), 6.27 (2H, br s), 3.81 (3H, s), 3.59 (3H, m), 3.34 (1H, m), 2.71 (1H, t), 2.46 (3H, s), 2.28 (3H, s), 2.25 (1H, m), 1.85 (1H, m), 1.47 (1H, m).
    • Example 22 Trans-3-(5-Amino-6-pyridin-3-yl-pyrazin-2-yl)-N-(4-hydroxy-cyclohexyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00103
  • The title compound was prepared from trans-3-(5-Amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzene sulfonamide (Intermediate D1) and 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine using analogous conditions to those of Example 11.
  • LCMS: Rt 0.74 mins; MS m/z 440.2 [M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 8.94 (1H, d); 8.65 (1H, dd); 8.25 (1H, s); 8.15 (1H, dt); 7.90 (1H, d); 7.70 (1H, dd); 7.60 (1H, d); 7.55-7.49 (2H, m); 6.60 (2H, s); 4.46 (1H, d); 3.28 (1H, br m); 2.90 (1H, br m); 2.49 (3H, s); 1.74-1.58 (4H, m); 1.23-1.00 (4H, m)
    • Example 23 3-[5-Amino-6-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide
  • Figure US20180243297A1-20180830-C00104
  • The title compound was prepared analogously to Example 2 using trans-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) and 5-bromo-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2b).
  • LCMS: Rt 1.94 mins; MS m/z 473 [M+H]+: Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.61 (1H, s), 7.94 (1H, s), 7.83 (2H, br s), 7.77 (1H, d), 7.65 (1H, d), 7.57 (1H, d), 4.48 (1H, s), 3.32 (1H, mult.) 3.20 (1H, m), 2.95 (1H, br s), 2.45 (3H, s), 1.68 (4H, mult.), 1.37 (6H, d), 1.15 (4H, mult).
    • Example 24 Trans-3-[5-Amino-6-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide 1
  • Figure US20180243297A1-20180830-C00105
  • The title compound was prepared analogously to Example 2 using trans-N-(4-hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) and 5-bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2c).
  • LCMS: Rt 1.94 mins; MS m/z 471.1 [M+H]+: Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.60 (1H, s), 7.90 (1H, s), 7.75 (1H, d), 7.65 (2H, br s), 7.55 (1H, d), 4.48 (1H, s), 3.32 (1H, m), 2.95 (1H, m), 2.49 (3H, s), 2.25 (1H, m), 1.93 (1H, s), 1.68 (4H, m), 1.1 (8H, m).
    • Example 25 3-[5-Amino-6-(3-methyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00106
  • To a solution of N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfonamide (Intermediate B2) (319 mg, 0.862 mmol) in DME (3920 μL) was added 5-bromo-3-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C12, 200 mg, 0.784 mmol), bis(triphenylphosphine)palladium(II) chloride (27.5 mg, 0.039 mmol) and Na2CO3 (aq. 2.0M) (1176 μL, 2.352 mmol). The reaction was heated in a microwave oven at 120° C. for 30 mins. The reaction was added to water (50 ml), and the product extracted into EtOAc (2×60 ml). The organic phase was washed with brine, dried over MgSO4 and Si-TMT to remove Pd. The mixture was swirled occasionally over 1 hour. The solids were removed by filtration, washed with EtOAc and concentrated under vacuo. The crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH3 in MeOH) in DCM on a 12 g Si-column, loading with DCM to give a solid which was recrystalised from hot EtOAc (˜3 ml). Upon cooling the product crystallised as a yellow solid;
  • LCMS: Rt 0.90 mins; MS m/z 418.6 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ9.19 (1H, s); 8.37 (1H, s); 7.93 (1H, s); 7.72 (1H, d); 7.53 (1H, d); 7.49 (1H, m); 7.42 (2H, s); 4.41 (1H, s); 2.63 (2H, d); 2.50 (3H, s), 2.45 (3H, s); 1.07 (6H, s)
    • Example 26 3-[5-Amino-6-(3-cyclopropyl-[1,2,4]triazol-1-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00107
  • A mixture of 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (Intermediate D3) (250 mg, 0.650 mmol), 3-cyclopropyl-1H-1,2,4-triazole (213 mg, 1.949 mmol), N,N-dimethylglycine (6.70 mg, 0.065 mmol), Cs2CO3 (635 mg, 1.949 mmol), and CuI (12.37 mg, 0.065 mmol) in DMA (3248 μL) was heated in a microwave at 150° C. for 2 hours. The reaction was added to saturated Na2CO3 (50 ml), and product extracted into EtOAc (2×40 ml). The organic phases were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was purified by automated flash chromatography using a 12 g silica column eluting with a gradient (0-10% of 2M methanolic NH3 in dichloromethane). The product was crystallised from EtOAc to give the title compound as an off-white solid;
  • LCMS: Rt 0.95 mins; MS m/z 458.5[M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ9.13 (1H, s); 8.35 (1H, s); 7.87 (1H, d); 7.71 (1H, dd); 7.55 (1H, d); 7.44 (1H, br); 7.41 (2H, s); 4.28 (1H, s); 2.83 (2H, br m); 2.50 (3H, s, partially obscured by DMSO), 2.18 (1H, m): 1.51 (2H, m); 1.03 (2H, m) overlapping with 1.02 (6H, s); 0.95 (2H, m).
    • Example 27 3-[5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-yl]-N—((R)-1-ethyl-pyrrolidin-2-ylmethyl)-4-methyl-benzenesulfonamide hydrochloride
  • Figure US20180243297A1-20180830-C00108
  • The title compound was prepared from N—((R)-1-Ethyl-pyrrolidin-2-ylmethyl)-4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzenesulfonamide (Intermediate B6) and 5-chloro-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7) using analogous conditions to those of Example 16. HCl salt formed using methanolic HCl.
  • LCMS: RT 0.64 mins; MS m/z 470.4 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) (HCl Salt) δ 10.1 (1H br s), 8.15 (2H, mult), 7.89 (1H, s), 7.72 (1H, d), 7.55 (1H, d), 6.55 (1H, br s), 3.82 (3H, s), 3.50 (2H, mult), 3.47 (1H, mult), 3.20 (1H, mult), 3.15 (3H, s), 3.12 (1H, mult), 3.05 (2H, mult), 2.49 (2H, s), 2.29 (3H, s), 2.12 (1H, mult), 1.95 (1H, mult), 1.85 (1H, mult), 1.78 (1H, mult), 1.23 (3H, t).
    • Example 28 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(1-hydroxy-cyclopropylmethyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00109
  • In a microwave vial, a mixture of 5-bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C11, 100 mg, 0.415 mmol), bis(pinacolato)diboron (116 mg, 0.456 mmol), PdCl2(dppf).CH2Cl2 adduct (33.9 mg, 0.041 mmol) and potassium acetate (61 mg, 0.622 mmol) in DME (1.5 ml) was heated at 120° C. for 60 mins. To the reaction was then added 2M Na2CO3 solution (0.519 ml, 1.037 mmol), PdCl2(dppf).CH2Cl2 adduct (17 mg, 0.02 mmol) and 3-bromo-N-(1-hydroxy-cyclopropylmethyl)-4-methyl-benzenesulfonamide (Intermediate A11, 133 mg, 0.415 mmol). The reaction was heated using microwave radiation at 90° C. for 60 mins, then at 100° C. for a further 60 mins. The reaction was diluted with ethyl acetate and the organic phase washed with water, then brine. The organic layer was dried over MgSO4, and the solvent removed under reduced pressure. The residue was purified by automated flash column chromatography eluting with a gradient of MeOH (0-10%) in TBME over 15 mins using a 12 g silica cartridge. The product was dried in a vacuum oven at 40° C. overnight to yield a yellow solid (51 mg) which was further purified using preparative LCMS to afford the title compound;
  • LCMS: Rt 0.90 mins; MS m/z 402.2 [M+H]+; Method LowpH_v002
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.34 (1H, s), 8.42 (1H, s), 8.40 (1H, s), 7.93 (1H, d,), 7.73-7.71 (1H, dd), 7.67-7.64 (1H, m), 7.54-7.52 (1H, d), 7.38 (2H, broad s), 5.32 (1H, s), 2.87-2.86 (2H, d), 2.50 (3H, s), 0.50 (2H, m), 0.46 (2H, m).
    • Example 29 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00110
  • To a solution of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1, 100 mg, 0.285 mmol) in THF (5 ml) was added DIPEA (100 μl, 0.57 mmol) and (3-methyl-oxetan-3-yl)-methylamine (29 mg, 0.285 mmol) and the reaction mixture stirred for 2 h. The reaction was diluted into DCM, then washed with citric acid, then brine. The organic layer was separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to provide the title compound as a solid which required no further purification;
  • LCMS: Rt 0.84 mins; MS m/z 416.2 [M+H]+: Method LowpH_v002
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.42 (2H, mult), 7.93 (1H, d), 7.83 (1H, mult), 7.74 (1H, dd), 7.56 (1H, d), 7.38 (2H, br), 4.31 (2H, d), 4.16 (2H, d), 2.92 (2H, d), 2.50 (3H, s), 1.20 (3H, s).
    • Example 30 3-[5-Amino-6-(5-morpholin-4-ylmethyl-thiophen-3-yl)-pyrazin-2-yl]-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00111
  • Prepared from 3-(5-Amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) and 4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl)methyl)morpholine using analogous conditions to those of Example 11.
  • LCMS: Rt 0.63 mins; MS m/z 532.3 [M+H]+: Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.15 (1H, s), 7.98 (1H, m), 7.83 (1H, m), 7.69 (1H, dd), 7.53 (1H, d), 7.47 (1H, s), 7.43 (1H, t), 6.47 (2H, br s), 4.27 (1H, s), 3.72 (2H, s), 3.59 (4H, m), 2.83 (2H, m), 2.48 (3H, s), 2.44 (4H, m), 1.51 (2H, m), 1.02 (6H, s).
    • Example 31 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propoxy)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00112
  • A mixture of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1, 200 mg, 0.570 mmol) and 1-(aminooxy)-2-methylpropan-2-ol (200 mg, 1.90 mmol) in DCM (5 ml) was stirred at room temperature for 3 days. Pyridine (1 mL) was added and the reaction mixture stirred for 2 hours. The mixture was then evaporated under reduced pressure and partitioned between ethyl acetate and 5% citric acid. The aqueous phase was extracted with further ethyl acetate, then DCM and the combined organic phases were dried by passing through a phase separator and then evaporated under reduced pressure. The product was crystallised from ethyl acetate and dried under vacuum to give 100 mg of an off white solid. Recrystallisation from ethanol afforded the title compound as an off-white solid;
  • LC-MS: Rt 0.92 min; MS m/z 420.3 [M+H]+: Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.44 (1H, s), 9.32 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.95 (1H, br s), 7.78 (1H, br d), 7.61 (1H, d), 7.40 (2H, s), 4.47 (1H, s), 3.73 (2H, s), 2.54 (3H, s), 1.04 (6H, s).
    • Example 32 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(4-hydroxy-tetrahydropyran-4-ylmethyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00113
  • 4-Aminomethyl-tetrahydro-pyran-4-ol (20 mg, 0.15 mmol) was dissolved in DMA (1 ml) and a solution of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1, 35 mg, 0.1 mmol) in DMA (2 ml) was added, followed by DIPEA (0.035 ml, 0.2 mmol). The reaction was shaken at room temperature for 2 hrs, then the solvent was removed under reduced pressure to yield the crude product as a brown solid. The crude material was then recrystallised from methanol to give the title compound as an off white solid;
  • LCMS: Rt 0.87 mins MS m/z 428 [M—OH]+: Method 2minLowpHv02
  • 1H NMR (400 MHz, DMSO-d6) δ 9.35 (1H, s), 8.40 (2H, d), 7.93 (1H, s), 7.72 (1H, m), 7.54 (2H, d), 7.40 (2H, br), 3.56 (2H, d), 2.66 (2H, d), 2.52 (3H, s), 1.54 (2H, m), 1.32 (2H, m)
    • Example 33 N-(2-Amino-ethyl)-3-(5-amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-4-methyl-benzenesulfonamide trifluoroacetic acid salt
  • Figure US20180243297A1-20180830-C00114
  • Tert-butyl (2-aminoethyl)carbamate (21 mg, 0.128 mmol) was dissolved in DMA (1 ml) and a solution of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1.30 mg, 0.086 mmol) in DMA (1.5 ml) was added, followed by DIPEA (0.030 ml, 0.171 mmol). The reaction was shaken at room temperature for 2 hrs, then the solvent was removed under reduced pressure to yield the crude product as a brown solid. The crude material was then suspended in DCM (2 ml) and TFA (0.15 ml, 1.97 mmol) added and the mixture shaken at room temperature for 3 hrs. The solvent was then removed under reduced pressure. The crude material was then purified via preparative HPLC using acetonitrile and water as the eluents with 0.1% TFA as a modifier, to give the title compound as an off white solid;
  • LCMS: Rt 0.60 mins MS m/z 375.2 [M+H]+: Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.35 (1H, s), 8.40 (2H, d), 7.90 (2H, m), 7.80 (2H, br), 7.74 (1H, d), 7.60 (1H, d), 7.40 (2H, br), 2.95 (2H, m), 2.87 (2H, m), 2.52 (3H, s)
    • Example 34 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(2,2-difluoro-ethyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00115
  • The title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and 2,2-difluoroethanamine using conditions analogous to those of Example 32. In this case, purification was carried out using preparative HPLC with an acetonitrile/0.1% aqueous TFA solvent gradient.
  • LCMS: Rt 1.0 mins MS m/z 396.0 [M+H]+: Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.30 (1H, s), 8.41 (2H, d), 8.22 (1H, m), 7.92 (1H, s), 7.75 (1H, m), 7.55 (1H, d), 7.40 (2H, br), 6.00 (1H, t), 3.23 (2H, t), 2.51 (3H, s).
    • Example 35 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3-hydroxymethyl-oxetan-3-ylmethyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00116
  • The title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and (3-aminomethyl-oxetan-3-yl)-methanol using conditions analogous to those of Example 32. In this case, purification was carried out using preparative HPLC with acetonitrile/0.1% aqueous TFA solvent gradient.
  • LCMS: Rt 0.83 mins MS m/z 432.2 [M+H]+: Method 2minLowpHv02
  • 1H NMR (400 MHz, DMSO-d6) δ 9.35 (1H, s), 8.40 (2H, d), 7.94 (1H, s), 7.80 (1H, m), 7.75 (1H, m), 7.57 (1H, d), 7.40 (2H, br), 4.30 (2H, d), 4.25 (2H, d), 3.52 (2H, m), 2.29 (2H, d), 2.51 (3H, s). One exchangable not clearly observed.
    • Example 36 3-(5-Amino-6-[1,2,4]triazol-1-yl-pyrazin-2-yl)-N-(3,3-dimethyl-2-oxo-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00117
  • The title compound was prepared from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and 1-amino-3,3-dimethyl-butan-2-one using conditions analogous to those of Example 32. In this case, purification was carried out using preparative HPLC with acetonitrile/0.1% aqueous TFA solvent gradient.
  • LCMS: Rt 1.06 mins MS m/z 430.2 [M+H]+: Method 2minLowpHv02
  • 1H NMR (400 MHz, DMSO-d6) δ 9.35 (1H, s), 8.40 (2H, dd), 7.92 (1H, s), 7.80 (1H, m), 7.73 (1H, d), 7.52 (1H, d), 7.40 (2H, br), 4.00 (2H, d), 2.52 (3H, s), 1.00 (9H, s).
    • Example 37 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00118
    • Step 1: 3-Bromo-4-chlorobenzene-1-sulfonyl chloride
  • The chlorosulfonylation reagent was prepared by bubbling 74 g of sulfur dioxide gas into 740 mL of glacial acetic acid followed by the addition of 30 g of CuCl2 in 35-40 mL of water. This mixture was allowed to settle and the green supernatant is used for the reaction.
    • Procedure:
  • To a stirred suspension of 3-bromo-4-chloroaniline (1 g, 4.84 mmol) in acetic acid (8 mL) and conc hydrochloric acid (8 mL) at 0° was added, dropwise, a cooled (0° C.) solution of sodium nitrite (368 mg, 5.33 mmol) in water (5 mL). The mixture was stirred at 0° C. for one hour and then added, dropwise while still cold, to a flask containing cooled (0° C.), stirred chlorosulfonylation reagent (40 mL). The mixture turned black/brown and was then allowed to warm to room temp and stirred at room temp overnight, by which time it had become a yellow/green solution. Crushed ice was added and when this had melted, the precipitate that was formed was recovered by filtration and dried at the pump. It was dissolved in EtOAc (50 mL), dried (MgSO4), filtered and evaporated to give the title compound as a colourless oil. This material was used in the next step without further purification;
  • 1H NMR (400 MHz, CDCl3) δH 8.32 (1H, d), 7.95 (1H, dd), 7.73 (1H, d).
    • Step 2: 3-Bromo-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • To a stirred solution of 3-bromo-4-chlorobenzene-1-sulfonyl chloride (step 1) (500 mg, 1.72 mmol) and triethylamine (0.385 mL, 2.76 mmol) in dry THF (10 mL) at room temp was added a solution of 4-amino-2-methylbutan-2-ol (231 mg, 2.6 mmol) in dry THF (5 mL). The mixture was stirred at room temp for 1 hour. The mixture was quenched by the addition of 50% aq. ammonium chloride (20 mL) and extracted with EtOAc (3×20 mL). The EtOAc extracts were combined and washed with sat. brine (20 mL), dried (MgSO4), filtered and evaporated to give the title compound as a colourless solid. This material was used in the next step without further purification;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.14 (1H, d), 7.86 (1H, d), 7.80 (1H, dd), 7.72 (1H, br s), 4.45 (1H, br s), 2.65 (2H, s), 1.05 (6H, s).
    • Step 3: 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • A mixture of 5-bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C11) (200 mg, 0.83 mmol), bis(pinacolato)diboron (263 mg, 1.04 mmol), potassium acetate (122 mg, 1.25 mmol) and PdCl2(dppf).CH2Cl2 adduct (34 mg, 0.041 mmol) was dissolved in DME (5 mL) and heated at 90° C. for 5 hours before addition of 3-bromo-4-chloro-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide (step 2) (284 mg, 0.83 mmol), 2M aq. sodium carbonate (1.25 mL, 2.5 mmol) and further PdCl2(dppf).CH2Cl2 adduct (34 mg, 0.041 mmol) and the mixture was stirred at 90° C. for 16 hours. The mixture was cooled to room temp, diluted with water (20 mL) and extracted with EtOAc (3×20 mL). The EtOAc extracts were combined, washed with brine (20 mL), dried (MgSO4), filtered and absorbed directly onto silica gel for dry loading onto a column. The mixture was purified by chromatography on silica gel (24 g column) eluting with 0-100% EtOAc in isohexane over 20 min, then maintaining 100% EtOAc for a further 3 min. The product fractions were combined and evaporated. Trituration with EtOAc and filtration gave the title compound as a pale yellow powder;
  • 1H NMR (400 MHz, DMSO-d6) δH 9.33 (1H, s), 8.57 (1H, s), 8.43 (1H, s), 8.11 (1H, m), 7.82 (2H, m), 7.71 (1H, br s), 7.49 (2H, br s), 4.45 (1H, br s), 2.67 (2H, s), 1.06 (6H, s).
  • LCMS: Rt 0.86 mins; MS m/z 424/426[M+H]+: Method 2minLowpH
    • Example 38 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-chloro-N-(3-hydroxy-3-methylbutyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00119
  • The title compound was prepared using analogous conditions to those used for the synthesis of Example 37.
  • 1H NMR (400 MHz, DMSO-d6) δ 9.31 (1H, s), 8.58 (1H, s), 8.43 (1H, s), 8.08 (1H, d), 7.85 (1H, d), 7.81 (1H, dd), 7.67 (1H, br s), 7.49 (2H, br s), 4.28 (1H, br s), 2.87 (2H, m), 1.52 (2H, m), 1.02 (6H, s).
  • LCMS: Rt 0.87 mins; MS m/z 438/440[M+H]+: Method 2minLowpH
    • Example 39 3-(5-Amino-6-(furan-3-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00120
  • To a stirred mixture of 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) (200 mg, 0.54 mmol), furan-3-ylboronic acid (78 mg, 0.7 mmol) and PdCl2(dppf).CH2Cl2 adduct (22 mg, 0.027 mmol) in DME (3 mL) was added sodium carbonate (0.81 mL of a 2M aq. solution, 1.62 mmol). The mixture was heated at 90° C. for 2 hours then cooled to room temp, diluted with 10% aq. potassium hydrogen phosphate (5 mL) and extracted with EtOAc (3×15 mL). The EtOAc extracts were combined, washed with sat. brine (10 mL), dried (MgSO4), filtered and absorbed directly onto silica gel prior to chromatography. The crude product was purified by chromatography on silica gel (24 g) eluting with 0-100% EtOAc in isohexane over 10 min as eluant. The product peak eluted at 100% EtOAc. The product fractions were combined and the solvent removed under reduced pressure to give the title compound as a pale yellow solid;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.40 (1H, m), 8.17 (1H, s), 7.89 (1H, d), 7.82 (1H, m), 7.69 (1H, dd), 7.52 (1H, d), 7.47 (1H, t), 7.04 (1H, m), 6.42 (2H, br s), 4.39 (1H, s), 2.63 (2H, d), 2.49 (3H, s, partially obscured by DMSO-d6 peak), 1.06 (6H, s).
  • LC-MS: Rt 0.98 mins; MS m/z 403.6 MH+; Method 2minLowpHv01
    • Example 40 3-(5-Amino-6-(2,5-dimethylthiazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00121
    • Step 1: 3-Amino-6-bromo-N-methoxy-N-methylpyrazine-2-carboxamide
  • To a stirred suspension of 3-amino-6-bromopyrazine-2-carboxylic acid (45 g, 206 mmol) and O,N-dimethylhydroxylamine hydrochloride (20.13 g, 206 mmol) in DMF (295 mL) at RT was added triethylamine (115 mL, 826 mmol) under N2 supply. The resulting mixture was cooled to 0° C. and to this yellow suspension T3P® (50% in EtOAc) (151 g, 237 mmol) was added dropwise over 5 min (keeping T below 10° C.—exotherm). The mixture was allowed to warm to RT and stirred for 2-3 hours. During the reaction the contents had set solid into a gel. The flask was diluted with a further 200 ml of DMF and was warmed to 40° C. and was left overnight. Further triethylamine (50 mL, 0.4 equiv), 0,N-dimethylhydroxylamine hydrochloride (10 g, 0.5 equiv) and T3P® (80 g, 0.5 equiv) were added and the reaction mixture was warmed to 40° C. and was allowed to stir for 2-3 hours. The mixture was allowed to cool to RT and then stirred for three days. The mixture was worked up by the addition of 2M HCl (100 mL) and was diluted with ethyl acetate (1 L) and water (500 mL). The biphasic mixture was separated. The aqueous layer was basified with 2M NaOH (˜150 mL), organic extract was added back and the biphasic mixture was shaken. The organic was extracted, washed with brine, dried over MgSO4, filtered and dried under vacuum to give a yellow oil. The crude yellow oil was loaded directly onto a 750 g column (in DCM ˜20 mL) and was eluted with iso-Hex/EtOAc (0-70% gradient). The fractions containing pure product were combined and evaporated to give a yellow oil. Diethyl ether (50 mL) was added and this was evaporated under vacuum to give a pale yellow solid;
  • LC-MS: Rt 0.88 mins; MS m/z 263.1 MH+; Method 2minLC_v003
    • Step 2: 1-(3-Amino-6-bromopyrazin-2-yl)propan-1-one
  • To a stirred solution of 3-amino-6-bromo-N-methoxy-N-methylpyrazine-2-carboxamide (step 1) (4 g, 15.32 mmol) in dry THF (50 ml), cooled on an ice bath under nitrogen, was added dropwise 1M ethylmagnesium bromide in THF (46.0 ml, 46.0 mmol). The mixture was slowly warmed to room temperature. The reaction was cooled on an ice bath and quenched by dropwise addition of water. The reaction was diluted with ethyl acetate, washed with water and the aqueous back extracted with further ethyl acetate. The organics were combined, dried (MgSO4), filtered and concentrated. The brown residue was triturated in diethyl ether, filtered under vacuum and dried.
  • LC-MS: Rt 1.06 mins; MS m/z 230.0/232.0 [M+H]+ Method 2minLowpHv01
    • Step 3: 1-(3-Amino-6-bromopyrazin-2-yl)-2-bromopropan-1-one
  • To a solution of 1-(3-amino-6-bromopyrazin-2-yl)propan-1-one (step 2) (3.04 g, 13.2 mmol) in glacial acetic acid (75 mL) at room temp was added polymer supported pyridinium tribromide (14.2 g of loading 2 mmol/g, 28.4 mmol) followed by 33% HBr in acetic acid (4.35 mL, 26.4 mmol). The mixture was heated at 70° C. for 1 hour. LCMS showed approx 4:1 product to starting material. Heating was continued at 70° C. for a further 30 min. Once cooled, the volatiles (including AcOH) were removed under reduced pressure. The dark brown syrup that remained was dissolved in EtOAc (ca. 150 mL) and washed with sat. sodium bicarbonate (150 mL). The EtOAc extracts were separated, washed with brine (100 mL), dried (MgSO4) filtered and evaporated to give a brown oil. The oil was triturated in Et2O (50 mL) and isohexane (200 mL) was added to give a brown solid which was recovered by filtration and dried.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.53 (1H, s), 8.05 (2H, br s), 5.86 (1H, q), 1.77 (3H, d); approx 90% purity.
    • Step 4: 5-Bromo-3-(2,5-dimethylthiazol-4-yl)pyrazin-2-amine
  • A stirred mixture of 1-(3-amino-6-bromopyrazin-2-yl)-2-bromopropan-1-one (step 3) (782 mg, 2.53 mmol) and thioacetamide (399 mg, 5.32 mmol) in EtOH (25 mL) was heated at 50° C. for 30 mins. The mixture was cooled to RT and allowed to stir overnight. The volatiles were removed under reduced pressure. The residue was partitioned between EtOAc (30 mL) and water (30 mL) and extracted with further EtOAc (3×30 mL). The EtOAc extracts were combined, washed with sat brine (50 mL), dried (MgSO4), filtered and evaporated to give a brown oil. The crude product was absorbed onto silica gel and purified by flash chromatography on silica gel using 40 g column and 0-100% EtOAc in isohexane as eluant. The desired compound was the first to elute at approx 35% EtOAc. Evaporation of product-containing fractions gave a pale yellow solid;
  • LC-MS: Rt 1.24 mins; MS m/z 285.4/287.4 [M+H]+; Method 2minLowpH_v01
  • 1H NMR (400 MHz, CDCl3) δ 7.97 (1H, s), 6.57 (2H, br s), 2.76 (3H, s), 2.68 (3H, s).
    • Step 5: 3-(5-Amino-6-(2,5-dimethylthiazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a mixture of N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (95 mg, 0.26 mmol), 5-bromo-3-(2,5-dimethylthiazol-4-yl)pyrazin-2-amine (step 4) (67 mg, 0.24 mmol) and PdCl2(dppf).CH2Cl2 adduct (19 mg, 0.023 mmol) in DME (2 mL) in a 5 mL tube equipped with stirrer bar was added sodium carbonate (352 μL of a 2M aq solution, 0.705 mmol). The mixture was heated at 90° C. for 2 hours. The mixture was cooled to room temp, diluted with EtOAc (10 mL) and water (10 mL) and extracted with further EtOAc (3×10 mL). The EtOAc extracts were combined, washed with sat. brine (20 mL), dried (MgSO4), filtered and evaporated to give a brown oil. The crude product was dissolved in the minimum amount of DCM and applied to a 4 g silica gel column and purified by chromatography eluting with 0-100% EtOAc in isohexane as eluent. The fractions containing desired product were combined and evaporated to give a pale yellow oil which was triturated using DCM:Et2O (1:10). The yellow powder obtained was recovered by filtration and dried to afford the title compound;
  • LC-MS: Rt 1.07 mins; MS m/z 448.3 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, CDCl3) δ 8.09 (1H, s), 7.99 (1H, d), 7.77 (1H, dd), 7.44 (1H, d), 6.73 (2H, br s), 5.01 (1H, t), 2.94 (2H, d), 2.78 (3H, s), 2.73 (3H, s), 2.53 (3H, s), 1.27 (6H, s). OH proton missing due to exchange.
    • Example 41 (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00122
  • Pd-118 (13.58 mg, 0.022 mmol) was added to a mixture of 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) (100 mg, 0.441 mmol), N—((R)-1-ethyl-pyrrolidin-2-ylmethyl)-4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzenesulfonamide (Intermediate B6) (198 mg, 0.485 mmol), potassium phosphate (187 mg, 0.882 mmol), 1,4-dioxane (1765 μl) and water (441 μl). The reaction mixture was heated in a microwave reactor for 90 minutes at 120° C. The reaction mixture was added to water (50 ml) and extracted with EtOAc (50 ml). The organic phase was washed with brine (50 ml) and dried over MgSO4. The solid was filtered off, washed with EtOAc and the solvent was concentrated under reduced pressure. The residue was purified by flash column chromatography, eluting with a gradient of 0-10% MeOH in DCM using a 4 g silica column, loading with DCM. The resulting oil was triturated with Et2O to give a solid, which was filtered off, washed with Et2O and dried overnight in a vacuum oven at 50° C. to give the title compound as a beige solid;
  • LCMS: Rt 0.74 mins; MS m/z 473.6 [M+H]+; Method 2minLowpHv03.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.27 (1H, s), 8.21 (1H, s), 7.85 (1H, s), 7.70 (1H, d), 7.52 (1H, d), 7.48 (1H, br s), 6.73 (2H, br s), 2.94 (1H, m), 2.84 (1H, m), 2.67 (3H, s), 2.61-2.57 (2H, m), 2.48 (3H, s), 2.39 (1H, m), 2.14 (1H, m), 2.05 (1H, m), 1.76 (1H, m), 1.59-1.54 (3H, m), 0.92 (3H, t).
    • Example 42 (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00123
  • The title compound was prepared using 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and (R)-4-methyl-N-((tetrahydrofuran-3-yl)methyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B7) under analogous conditions to those of Example 41;
  • LCMS: Rt 1.07 mins; MS m/z 446.5 [M+H]+; Method 2minLowpHv03.
    • Example 43 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00124
  • The title compound was prepared using 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and N-(3-hydroxycyclobutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (prepared analogously to Intermediate B1, starting from 3-aminocyclobutanol) under analogous conditions to those of Example 41;
  • LCMS: Rt 1.02 mins; MS m/z 432.3 [M+H]+; Method 2minLowpHv03.
    • Example 43a cis-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide and Example 43b: trans-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00125
  • The diastereomeric mixture of 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide (Example 43) was separated by chiral SFC under the following conditions:
    • Method Details:
  • Column: Phenomenex LUX A2 250×100 mm 5 um @ 35 deg C.
  • Mobile phase: 45% IPA+0.1% DEA/55% CO2
  • Flow rate: 10 ml/min
  • The two separated fractions were concentrated under reduced pressure. The residues were dissolved in MeOH and left to stand at room temperature and then dried in a vacuum oven at 50° C. over the weekend to afford the title compounds.
    • Example 43a cis-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • Peak 1:
  • SFC retention time=8.36 mins
  • LCMS: Rt=0.97 mins, MS m/z 432.2 [M+H]+; Method 2minLowpHv03.
    • Example 43b trans-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • Peak 2:
  • SFC retention time=10.73 mins
  • LCMS: Rt=0.97 mins, MS m/z 432.3 [M+H]+; Method 2minLowpHv03
  • 1H NMR—AV81762-(400 MHz, MeOD)—Is consistent with proposed structure.
  • The cis/trans assignments were confirmed by NMR analysis.
    • Example 44 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((3-(hydroxymethyl)oxetan-3-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00126
  • The title compound was prepared using 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and N-((3-(hydroxymethyl)oxetan-3-yl)methyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (prepared analogously to Intermediate B1 starting from (3-(aminomethyl)oxetan-3-yl)methanol) under analogous conditions to those of Example 41;
  • LCMS: Rt 1.00 mins; MS m/z 462.3 [M+H]+; Method 2minLowpHv03.
    • Example 45 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxyethyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00127
  • To a stirring solution of ethanolamine (11.89 μl, 0.197 mmol), DIPEA (57.3 μl, 0.328 mmol) in DMA (656 μl) was added 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E) (50 mg, 0.131 mmol). The reaction mixture was stirred overnight at RT and then added to water (50 ml) and extracted with EtOAc (50 ml). The organic phase was washed with brine (50 ml) and dried over MgSO4. The solid was filtered off, washed with EtOAc and the solvent was concentrated under reduced pressure. The crude material was purified by flash column chromatography, eluting with a gradient of 0-10% MeOH in DCM on a 4 g silica column, loading with DCM and MeOH. The resulting oil was triturated with Et2O to give a solid which was filtered off, washed with Et2O and dried in a vacuum oven at 50° C. overnight to give the title compound as a beige solid;
  • LCMS: Rt 0.99 mins; MS m/z 406.3 [M+H]+; Method 2minLowpHv03.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.27 (1H, s), 8.22 (1H, s), 7.85 (1H, d), 7.70 (1H, dd), 7.57 (1H, t), 7.53 (1H, d), 6.73 (2H, br s), 4.67 (1H, t), 3.38 (2H, q), 2.81 (2H, q), 2.68 (3H, s), 2.48 (3H, s).
  • The following examples were prepared in an analogous manner to Example 45 from 3-(5-amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E) and the appropriate commercially available amine:
    • Example 45.1 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(oxetan-3-ylmethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00128
  • LCMS: Rt 1.06 mins; MS m/z 432.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.2 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00129
  • LCMS: Rt 1.15 mins; MS m/z 460.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.3 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00130
  • LCMS: Rt 1.06 mins; MS m/z 446.2 [M+H]+; Method 2minLowpHv03.
    • Example 45.4 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydro-2H-pyran-2-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00131
  • LCMS: Rt 1.20 mins; MS m/z 460.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.5 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00132
  • LCMS: Rt 1.22 mins; MS m/z 444.8 [M+H]+; Method 2minLowpHv03.
    • Example 45.6 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00133
  • LCMS: Rt 1.14 mins; MS m/z 446.2 [M+H]+; Method 2minLowpHv03.
    • Examples 45.6a and 45.6b (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yOmethyl)benzenesulfonamide and (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00134
  • In this case, the racemic mixture was separated by chiral separation to afford the individual isomers:
  • Column: Chiralpak AS-H, 250×10 mm, 5 um @ 35 deg C.,
  • Mobile phase: 50% Isopropanol+0.1% v/v DEA/50% CO2,
  • Flow: 10 ml/min,
  • Detection: UV @ 220 nm,
  • Instrument: Berger Minigram SFC1
    • Example 45.6a First Eluting Compound SFC Retention Time=7.00 mins. (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide or (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide
  • LCMS: Rt 1.13 mins; MS m/z 446.1 [M+H]+; Method 2minLowpHv03.
    • Example 45.6b Second Eluting Compound SFC Retention Time=8.73 mins. (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide or (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-2-yl)methyl)benzenesulfonamide
  • LCMS: Rt 1.15 mins; MS m/z 446.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.7 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00135
  • LCMS: Rt 1.09 mins; MS m/z 432.2 [M+H]+; Method 2minLowpHv03.
    • Examples 45.7a and 45.7b (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide and (S)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00136
  • In this case, the racemic mixture was separated by chiral separation to afford the individual isomers:
  • Column: Chiralpak IC, 250×10 mm, 5 um @ 35 deg C.,
  • Mobile phase: 50% Methanol+0.1% v/v DEA/50% CO2,
  • Flow: 10 ml/min,
  • Detection: UV @ 220 nm,
  • Instrument: Berger Minigram SFC1
    • Example 45.7a First Eluting Compound SFC Retention Time=11.74 mins. (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide or (5)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide
  • LCMS: Rt 1.06 mins; MS m/z 432.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.7b Second Eluting Compound SFC Retention Time=13.42 mins. (R)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide or (5)-3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydrofuran-3-yl)benzenesulfonamide
  • LCMS: Rt 1.06 mins; MS m/z 432.2 [M+H]+; Method 2minLowpHv03.
    • Example 45.8 (1-((3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylphenyl)sulfonyl)azetidin-3-yl)methanol
  • Figure US20180243297A1-20180830-C00137
  • LCMS: Rt 1.00 mins; MS m/z 432.1 [M+H]+; Method 2minLowpHv03.
    • Example 45.9 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00138
  • LCMS: Rt 1.05 mins; MS m/z 490.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.10 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00139
  • LCMS: Rt 1.03 mins; MS m/z 476.3 [M+H]+; Method 2minLowpHv03.
    • Example 45.11 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((3-hydroxyoxetan-3-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00140
  • LCMS: Rt 1.00 mins; MS m/z 448.2 [M+H]+; Method 2minLowpHv03.
    • Example 45.12 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00141
  • LCMS: Rt 0.71 mins; MS m/z 475.2 [M+H]+; Method 2minLowpHv03.
    • Example 46 3-(5-Amino-6-(1,5-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00142
  • A mixture of 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) (60 mg, 0.162 mmol), 1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (40 mg, 0.180 mmol), bis(triphenylphosphine) palladium dichloride (5 mg, 7.12 μmol) in DME (0.75 ml) and 2M aqueous sodium carbonate (0.25 mL, 0.500 mmol) was heated in the microwave to 130° C. for 1 hour. The resulting mixture was diluted with 10% methanol in DCM and filtered through 1 g Celite® washing with further 10% methanol in DCM. The crude product was purified by flash column chromatography (12 g silica, radient 0-20% methanol in TBME). The product fractions were evaporated under reduced pressure and dried in a vacuum oven to give the title compound as a brown-orange solid;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s); 7.86 (1H, s); 7.72 (1H, s); 7.67 (1H, dd); 7.49 (1H, d); 7.44 (1H, br m); 6.23 (2H, s); 4.38 (1H, s); 3.80 (3H, s); 2.61 (2H, d); 2.46 (3H, s); 2.36 (3H, s); 1.05 (6H, s)
  • LCMS: Rt 0.89 min; MS m/z 431.2 [M+H]+; Method: 2minLowpHv01
    • Example 46.1 3-(5-Amino-6-(2,4-dimethylthiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00143
  • The title compound was prepared by an analogous method to that used for the preparation of Example 46 starting from 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole;
  • LCMS: Rt 0.91 min; MS m/z 448.0 [M+H]+; 446.2 [M−H]−; Method: 2minLowpHv01
    • Example 46.2 3-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00144
  • The title compound was prepared by an analogous method to that used for the preparation of Example 46 starting from 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
  • LCMS: Rt 0.87 min; MS m/z 417.3 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, MeOD-d4) δ 8.26 (1H, s); 8.07 (1H, s); 8.00 (1H, s); 7.93 (1H, d, J 2 Hz); 7.80 (1H, dd, J˜8 and 2 Hz); 7.53 (1H, d, J˜8 Hz); 4.01 (3H, s); 2.81 (2H, s); 2.51 (3H, s); 1.19 (6H, s)
    • Example 47 3-(5-Amino-6-(3,4-di methyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methyl propyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00145
  • The title compound was prepared from 3,4-dimethyl-1H-pyrazole and 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) by an analogous method to that used for the preparation of Example 15.
  • LCMS: Rt 1.16 min; MS m/z 431.2 [M+H]+; Method: 2minLowpHv01
    • Example 48 3-(5-Amino-6-(3,5-di methyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methyl propyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00146
  • The title compound was prepared from 3,5-dimethyl-1H-pyrazole and 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) by an analogous method to that used for the preparation of Example 15.
  • 1H NMR (400 MHz, MeOD-d4) δ 8.19 (1H, s); 7.94 (1H, d, J˜2 Hz); 7.78 (1H, dd, J˜8 and 2 Hz); 7.52 (1H, d, J˜8 Hz); 6.15 (1H, s); 2.81 (2H, s); 2.51 (3H, s); 2.46 (3H, s); 2.31 (3H, s); 1.18 (6H, s)
  • LCMS: Rt 1.06 min; MS m/z 431.3 [M+H]+; Method: 2minLowpHv01
    • Example 49 3-(5-Amino-6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00147
  • The title compound was prepared from 3,5-dimethyl-1H-1,2,4-triazole and 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) by an analogous method to that used for the preparation of Example 15.
  • LCMS: Rt 0.88 min; m/z 430.2 [M−H]−; Method: 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.38 (1H, s); 7.86 (1H, d, J˜2 Hz); 7.71 (1H, dd, J˜8 and 2 Hz); 7.53 (1H, d, J˜8 Hz); 7.47 (1H, t, J˜6.5 Hz); 6.98 (2H, br); 2.62 (2H, d, J 6.5 Hz); 2.47 (3H, s); 2.33 (3H, s); 1.05 (6H, s). OH not seen (under water peak/exchanged?) and one methyl group not seen (this is often hidden by solvent peak in related compounds) Non-identical methyl groups on triazole suggest product as drawn rather than attached through the N between the methyl groups.
    • Example 50 3-(5-Amino-6-(2,4-dimethyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00148
  • The title compound was prepared from 2,4-dimethyl-1H-imidazole and 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) by an analogous method to that used for the preparation of Example 15.
  • LCMS: Rt 0.64 min; MS m/z 431.3 [M+H]+; Method: 2minLowpHv01
    • Example 51 3-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00149
  • A mixture of 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (45 mg, 0.216 mmol), bis(triphenylphosphine)palladium dichloride (14 mg, 0.020 mmol), 3-(5-amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide (Intermediate D4) (85 mg, 0.200 mmol), 2M sodium carbonate (0.300 ml, 0.600 mmol), 1,2-dimethoxyethane (1 ml) was heated in the microwave to 120° C. for 1 hour, then partitioned between DCM and water and separated using a phase separator column. The organic phase was evaporated under reduced pressure to give a brown gum, which was redissolved in ethyl acetate and bound to silica, then purified by flash column chromatography (2 g silica, 0-10% methanol in TBME). Appropriate fractions were combined and evaporated to give an orange gum. This was crystallised from ethyl acetate/diethyl ether to give a reddish solid; 1H NMR (400 MHz, MeOD-d4) δ 8.21 (1H, s); 8.05 (1H, s); 8.03 (1H, s); 7.90 (1H, d); 7.78 (1H, dd); 7.53 (1H, d); 4.02 (1H, br m) overlapping with 4.00 (3H, s); 3.07 (2H, m); 2.51 (3H, s); 1.83 (1H, m); 1.68 (1H, m).
  • LC-MS: Rt 0.83 min; MS m/z 471.4 [M+H]+; Method: 2minLowpH
    • Example 52a (R)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide or (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00150
  • A mixture of 3-(5-amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide (single enantiomer of unknown configuration, Intermediate D4a) (45 mg, 0.106 mmol), 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (25 mg, 0.113 mmol) and bis(triphenylphosphine)palladium dichloride (4 mg, 5.70 μmol) in 1,2-dimethoxyethane (0.5 ml) and 2M sodium carbonate (150 μL, 0.300 mmol) was heated in the microwave to 130° C. for 1 hour. The resulting mixture was diluted with 10% methanol in DCM and filtered through 1 g Celite® washing with further 10% methanol in DCM, then purified by flash column chromatography (12 g silica, 0-20% methanol in TBME) to give 35 mg of orange glassy solid;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s); 8.06 (1H, s); 7.85 (1H, d, J-2 Hz); 7.67 (1H, dd, ˜2 and 8 Hz) overlapping with 7.72-7.59 (approx, 1H, v broad); 7.52 (1H, d, J-8 Hz); 6.28 (2H, s); 6.17 (1H, v broad); 3.99 (1H, broad m); 3.82 (3H, s); 2.90 (2H, m); 2.47 (3H, s); 2.29 (3H, s); 1.69 (1H, broad m); 1.57 (1H, broad m).
  • LCMS: Rt 0.98 min; MS m/z 485.5 [M+H]+; Method: 2minLowpHv01
  • Chiral SFC: Rt 5.51 min; 100% purity by DAD;
  • Method: Chiralpak AD-3, 150×2.1 mm 3 urn @ 400, 0.7 ml/min, UV @ 220 nm and 254 nm A=002, B=Methanol+0.1% v/v DEA; Gradient: 0-1.5 min 5% B; 1.5-6.0 min 5-50% B; 6.0-9.0 min 50% B
    • Example 52b (R)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide or (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00151
  • The title compound was prepared analogously to Example 52a from Intermediate D4b;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s); 8.06 (1H, s); 7.85 (1H, d, J-2 Hz); 7.69-7.60 (2H, m); 7.52 (1H, d, J-8 Hz); 6.28 (2H, s); 6.16 (1H, d, J-6.5 Hz); 3.98 (1H, m); 3.81 (3H, s); 2.89 (2H, m); 2.47 (3H, s); 2.29 (3H, s); 1.73-1.51 (2H, m).
  • LCMS: Rt 0.93 min; m/z 485.2 [M+H]+; Method: 2minLowpHv01
  • Chiral SFC: Rt 5.15 min; 97.4% purity by DAD (hence ˜95% ee);
  • Method: Chiralpak AD-3, 150×2.1 mm 3 urn @ 400, 0.7 ml/min, UV @ 220 nm and 254 nm A=002, B=Methanol+0.1% v/v DEA; Gradient: 0-1.5 min 5% B; 1.5-6.0 min 5-50% B; 6.0-9.0 min 50% B.
    • Example 53 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide
  • Figure US20180243297A1-20180830-C00152
    • Step 1: 5-Bromo-6-chloro-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide
  • To a solution of 1-amino-2-methylpropan-2-ol (0.306 g, 3.44 mmol) and DIPEA (0.62 mL, 3.55 mmol) in THF (6 mL) cooled in an ice bath was added dropwise a solution of 5-bromo-6-chloropyridine-3-sulfonyl chloride (1 g, 3.44 mmol) in THF (6 mL). The resulting mixture was stirred at room temperature overnight, then water (30 mL) was added, the mixture adjusted to pH 4-5 with 1M HCl/1M sodium bicarbonate as necessary and extracted with ethyl acetate (3×25 mL). The combined organic extracts were washed with brine (25 mL), dried over magnesium sulfate, filtered and evaporated under reduced pressure to give a pale yellow solid which was dried in the vacuum oven to give the title compound;
  • LCMS: Rt 1.03 min; MS m/z 345.0 and 343.0 (Br isotopes) [M+H]+; Method: 2minLowpHv03
    • Step 2: 5-Bromo-N-(2-hydroxy-2-methylpropyl)-6-iodopyridine-3-sulfonamide
  • To a solution of 5-bromo-6-chloro-N-(2-hydroxy-2-methylpropyl)pyridine-3-sulfonamide (from step 1) (500 mg, 1.455 mmol) in acetonitrile (40 mL) was added trimethylsilylchloride (375 μL, 2.93 mmol). After 15 mins, sodium iodide (1 g, 6.67 mmol) was added in two portions. The resulting orange cloudy mixture was stirred at room temperature for two days, then poured into ice water (˜50 g). Sodium hydroxide (1M solution, 5 mL), was added, the pH adjusted to pH7 using 1M HCl (reached pH 3) then 1M sodium bicarbonate, and the mixture extracted with dichloromethane. The organic phase was washed with water and brine, dried by passing through a hydrophobic membrane and evaporated under reduced pressure. Trituration with ethyl acetate/hexane gave an off-white solid;
  • LCMS: Rt 1.08 min; MS m/z 435.1 and 437.2 [M+H]+; Method: 2minLowpHv03
    • Step 3: 5-Bromo-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide
  • To a mixture of methylboronic acid (9 mg, 0.150 mmol), 5-bromo-N-(2-hydroxy-2-methylpropyl)-6-iodopyridine-3-sulfonamide (from Step 2) (60 mg, 0.138 mmol), bis(triphenylphosphine) palladium dichloride (5 mg, 7.12 μmol) in 1,4-dioxane (1.3 mL) was added sodium carbonate 2M (44 mg, 0.415 mmol) and the resulting mixture heated under a nitrogen atmosphere at 50° C. for 90 minutes, at 80° C. for 1 hour, then at 100° C. for 1 hour. Additional methylboronic acid (9 mg) was added and the mixture stirred at 100° C. overnight. Further methylboronic acid (9 mg) was added, and the resulting mixture stirred for a further 5.5 hours at 100° C., with an additional portion of methylboronic acid (20 mg) added after 3 hours. After cooling to room temperature, the reaction mixture was diluted with methanol and passed through a Isolute® Si-TMT column (1 g) washing with further methanol and DCM. Combined organics were evaporated under reduced pressure, bound to silica gel and purified by flash column chromatography (4 g silica, 0-100% ethyl acetate in isohexane) to give the title compound as a yellow gum;
  • LCMS: Rt 0.94 min; MSm/z 323.4 [M+H]+; Method: 2minLowpHv03
    • Step 4: 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide
  • A mixture of 5-bromo-N-(2-hydroxy-2-methylpropyl)-6-methylpyridine-3-sulfonamide (from step 3) (30 mg, 0.093 mmol), 5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid (see Step 1 from the preparation of Example 121) (20 mg, 0.097 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene] dichloropalladium(11) (3 mg, 4.60 μmol) and potassium phosphate (40 mg, 0.188 mmol) in 1,4-dioxane (1 mL) and Water (0.25 mL) was heated to reflux for 30 minutes then cooled to room temperature, diluted with methanol: DCM (˜1:2) and filtered through a 500 mg Isolute® Si-TMT column. The mixture was evaporated under reduced pressure and purified by flash column chromatography (4 g silica, 0-10% 7M methanolic ammonia in DCM). Product eluted at ˜7%, and was collected and evaporated under reduced pressure to give a pale beige solid;
  • LCMS: Rt 0.83 min; MS m/z 405.3 [M+H]+; Method: 2minLowpHv03
  • 1H NMR (400 MHz, DMSO-d6) δ 9.39 (1H, s), 8.83 (1H, s), 8.49 (1H, s), 8.44 (1H, s), 8.29 (1H, s), 7.73 (1H, br. s.), 7.50 (2H, br. s.), 4.45 (1H, br. s.), 2.74 (3H, s), 2.69 (2H, s), 1.07 (6H, s)
    • Example 54 3-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00153
  • The title compound was prepared by an analogous method to that used for the preparation of Example 11, using 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 3-(5-amino-6-chloropyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide (prepared analogously to Intermediate D1);
  • LC-MS: Rt 4.18 mins; MS m/z 463.3 [M+H]+; Method 10minLowpH
    • Example 55 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00154
  • The title compound was prepared by an analogous method to that used for the preparation of Example 11, using 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole and 3-(5-amino-6-chloropyrazin-2-yl)-N-(4,4-difluorocyclohexyl)-4-methylbenzenesulfonamide (prepared analogously to Intermediate D1);
  • LC-MS: Rt 4.65 mins; MS m/z 480.2 [M+H]+; Method 10minLowpH
    • Example 56 Trans-3-(5-Amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00155
  • The title compound was prepared analogously to Example 15 using 4-methyl-1H-imidazole.
  • LCMS: Rt 0.75 mins; MS m/z 443.3 [M+H]+; Method: 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 8.29 (1H, s), 8.03 (1H, s), 8.87 (1H, d), 7.71 (1H, dd), 7.60 (1H, d), 7.51 (1H, d), 7.34 (1H, s), 6.71 (2H, s), 4.46 (1H, d), 3.29 (1H, m), 2.90 (1H, m), 2.47 (3H, s), 2.20 (3H, s), 1.70 (2H, m), 1.61 (2H, m), 1.23-1.00 (4H, m).
    • Example 57 3-(5-Amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00156
  • Prepared by analogy to Example 15 using 4-methyl-1H-imidazole and 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide (prepared by analogy to Intermediate D1, using Intermediate B1).
  • LCMS: Rt 0.54 mins; MS m/z 403.2 [M+H]+; Method: 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 8.29 (1H, s), 8.02 (1H, s), 7.82 (1H, s), 7.68 (1H, dd), 7.53 (1H, s), 7.31 (1H, s), 7.34 (1H, s), 6.70 (2H, s), 4.40 (1H, s), 3.35 (2H, m), 2.78 (2H, t), 2.46 (3H, s), 2.19 (3H, s), 1.52 (2H, m).
    • Example 58 Trans-3-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00157
  • Prepared using analogous conditions to those of Example 22, using 1-methylpyrazole-4-boronic acid pinacol ester.
  • LCMS: Rt 0.81 mins; MS m/z 443.0 [M+H]+; Method: 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 8.32 (1H, s), 8.08 (1H, s), 8.00 (1H, s), 7.87 (1H, d), 7.69 (1H, dd), 7.60 (1H, d), 7.50 (1H, d), 6.32 (2H, s), 4.47 (1H, d), 3.92 (3H, s), 3.29 (1H, m), 2.91 (1H, m), 2.48 (3H, s), 1.71 (2H, m), 1.63 (2H, m), 1.24-1.01 (4H, m).
    • Example 59 Trans-3-(5-Amino-6-(pyrimidin-5-yl)pyrazin-2-yl)-N-(-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00158
  • Prepared using analogous conditions to those of Example 22, using pyrimidin-5-ylboronic acid.
  • LCMS: Rt 0.80 mins; MS m/z 441.3 [M+H]+; Method: 2minLC_v003
    • Example 60 Trans-3-(5-Amino-6-(2-fluoropyridin-4-yl)pyrazin-2-yl)-N-(-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00159
  • Prepared using analogous conditions to those of Example 22 using 2-fluoropyridine-4-boronic acid pinacol ester.
  • LCMS: Rt 0.90 mins; MS m/z 458.3 [M+H]+; Method: 2minLC_v003
    • Example 61 3-(5-Amino-6-(1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00160
  • Prepared using analogous conditions to those of Example 26, using 1H-imidazole.
  • LCMS: Rt 0.62 mins; MS rrilz 417.4 [M+H]+; Method: 2minLC_v003
    • Example 62 3-(5-Amino-6-(1H-pyrazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00161
  • Prepared using analogous conditions to those of Example 26, using 1H-pyrazole.
  • LCMS: Rt 0.97 mins; MS rrilz 417.2 [M+H]+; Method: 2minLowpH
    • Example 63 3-(5-Amino-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00162
  • Prepared using analogous conditions to those of Example 26, using 4-methyl-1H-imidazole.
  • LCMS: Rt 0.61 mins; MS rrilz 431.3 [M+H]+; Method: 2minLC_v003
    • Example 64 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00163
  • Prepared using analogous conditions to those of Example 26, using 1H-1,2,4-triazole.
  • LCMS: Rt 0.83 mins; MS rrilz 418.3 [M+H]+; Method: 2minLC_v003
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.42 (1H, s), 8.40 (1H, s), 7.89 (1H, d), 7.72 (1H, dd), 7.56 (1H, d), 7.45 (1H, t), 7.38 (2H, d), 4.27 (1H, s), 2.83 (2H, m), 2.51 (3H, sunder DMSO), 1.51 (2H, m), 1.02 (6H, s).
    • Example 65 3-(5-Amino-6-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methyl butyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00164
  • Prepared using analogous conditions to those of Example 26, using 3-methyl-1H-1,2,4-triazole.
  • LCMS: Rt 0.87 mins; MS rrilz 432.3 [M+H]+; Method: 2minLC_v003.
    • Example 66 3-(5-Amino-6-(3-isopropyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00165
  • Prepared using analogous conditions to those of Example 26, using 3-isopropyl-1H-1,2,4-triazole.
  • LCMS: Rt 0.99 mins; MS rrilz 460.3 [M+H]+; Method: 2minLC_v003
    • Example 67 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00166
  • Prepared using analogous conditions to those of Example 29, using 6-aminospiro[3.3]heptan-2-ol.HCl, which was prepared by deprotection of commercially available tert-butyl (6-hydroxyspiro[3.3]heptan-2-yl)carbamate using 1.25M HCl in MeOH.
  • LCMS: Rt 0.90 mins; MS m/z 442.3 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.88 (2H, m), 7.69 (1H, dd), 7.53 (1H, d), 7.38 (2H, d), 4.82 (1H, d), 3.85 (1H, m), 3.53 (1H, m), 2.51 (3H, s, under DMSO), 2.21 (1H, m), 2.03 (2H, m), 1.91 (1H, m), 1.76 (2H, m), 1.68 (2H, m).
    • Example 68 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00167
  • Prepared using analogous conditions to those of Example 29, using tetrahydro-2H-pyran-4-amine.
  • LCMS: Rt 0.92 mins; MS m/z 416.3 [M+H]+; Method: 2minLowpHv01
    • Example 69a 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(trans-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide and Example 69b: 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(cis-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00168
  • Prepared using analogous conditions to those of Example 29, using 4-amino-1-methylcyclohexanol. The resulting stereomeric mixture was separated by Chiral SFC.
    • Method Details:
  • Column: Chiralpak IC 250×10 mm, 5 um;
  • Mobile phase: 50% MeOH+0.1% v/v DEA/50% 002;
  • Flow: 10 ml/min; Detection: UV @ 220 nm; System: Berger Minigram SFC 2
    • Example 69a First eluting peak at RT 6.2 mins as 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.87 mins; MS m/z 444.5 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.42 (1H, s), 8.40 (1H, s), 7.95 (1H, d), 7.73 (1H, dd), 7.59 (1H, d), 7.53 (1H, d), 7.38 (2H, s), 4.11 (1H, s), 3.06 (1H, m), 2.51 (3H, s, under DMSO), 1.60 (2H, m), 1.50 (2H, m), 1.32-1.20 (4H, m), 1.06 (3H, s).
    • Example 69a Second eluting peak at RT 10.67 mins as 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,45)-4-hydroxy-4-methylcyclohexyl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.94 mins; MS m/z 426.5 (minus OH) [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.41, (1H, s), 8.39 (1H, s), 7.94 (1H, s), 7.73 (1H, d), 7.60 (1H, d), 7.53 (1H, d), 7.38 (2H, s), 3.98 (1H, s), 2.93 (1H, m), 2.51 (3H, s, under DMSO), 1.53 (2H, m), 1.40 (2H, m), 1.25-1.12 (4H, m), 1.01 (3H, s).
    • Cis/Trans Stereochemistry Confirmed by NOESY NMR Spectroscopy Example 70a (R)- or (S)-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide and Example 70b (R)- or (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00169
  • 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide (Example 67) was separated into its isomers by chiral SFC. METHOD DETAILS: Column: Chiralpak AD-H 250×10 mm, Sum @ 35 deg C.; Mobile phase: 40%; Isopropanol+0.1% v/v DEA/60% 002; Flow: 10 ml/min; Detection: UV @ 220 nm; Instrument: Berger Minigram SF01
    • Example 70a First Eluting Peak at 11.87 Mins (S)-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide or (R)-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.88 mins; MS m/z 442.5 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.90-7.85 (2H, m), 7.69 (1H, dd), 7.53 (1H, d), 7.39 (2H, s), 4.82 (1H, d), 3.84 (1H, m), 3.53 (1H, m) 2.51 (3H, s, under DMSO), 2.21 (1H, m), 2.03 (2H, m), 1.92 (1H, m), 1.76 (2H, m), 1.69 (2H, s).
    • Example 70b Second Eluting Peak at 14.41 Mins (S)-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide or (R)-3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.90 mins; MS m/z 442.3 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.91-7.86 (2H, m), 7.69 (1H, dd), 7.53 (1H, d), 7.38 (2H, s), 4.82 (1H, d), 3.85 (1H, m), 3.53 (1H, m) 2.51 (3H, s, under DMSO), 2.21 (1H, m), 2.03 (2H, m), 1.92 (1H, m), 1.76 (2H, m), 1.69 (2H, s)
    • Example 71a 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,3r)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide and Example 71b:3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,3s)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00170
  • Prepared using analogous conditions to those of Example 29, using 3-aminocyclobutanol. The mixture of stereoisomers was separated by chiral SFC.
  • METHOD DETAILS: Column: Chiralpak AD-H, 250×10 mm, 5 um @ 35 deg C.; Mobile phase: 50% Methanol+0.1% v/v DEA/50% 002; Flow: 10 ml/min; Detection: UV @ 220 nm; Instrument: Berger Minigram SFC1
    • Example 71a First Eluting Peak at RT 4.41 Mins 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,3r)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide or 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,35)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.83 mins; MS m/z 402.4 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.34 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.90 (1H, br s), 7.88 (1H, s), 7.69 (1H, d), 7.54 (1H, d), 7.39 (2H, s), 4.92 (1H, d), 4.14 (1H, m), 3.75 (1H, m), 2.51 (3H, s, under DMSO), 1.98 (2H, m), 1.89 (2H, m).
    • Example 71b Second Eluting Peak at RT 5.88 Mins 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1r,3r)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide or 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-((1s,3s)-3-hydroxycyclobutyl)-4-methylbenzenesulfonamide
  • LCMS: Rt 0.82 mins; MS m/z 402.5 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.34 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.89 (1H, s), 7.86 (1H, br s), 7.70 (1H, dd), 7.54 (1H, d), 7.39 (2H, s), 4.99 (1H, d), 3.66 (1H, m), 3.13 (1H, m), 2.51 (3H, s, under DMSO), 2.24 (2H, m), 1.60 (2H, m).
    • Cis/Trans Stereochemistry Confirmed by NOESY NMR Spectroscopy Example 72 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00171
  • Prepared using analogous conditions to those of Example 6 using cis-3-bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) and 5-Chloro-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C5).
  • LCMS: Rt 0.80 mins; MS m/z 416.3 [M+H]+; Method: 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 9.34 (1H, s), 8.42 (1H, s), 8.40 (1H, s), 7.89 (1H, s), 7.71 (1H, d), 7.60-7.52 (2H, m), 7.39 (2H, s), 4.89 (1H, s), 3.84 (1H, m), 2.74 (2H, t), 2.51 (3H, s, under DMSO), 2.17 (2H, m), 1.75 (1H, m), 1.41 (2H, m).
    • Example 73 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00172
  • Prepared using analogous conditions to those of Example 6 using 3-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide (Intermediate A9) and 5-chloro-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C5).
  • LCMS: Rt 0.86 mins; MS m/z 418.2 [M+H]+; Method: 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.91 (1H, s), 7.72 (1H, s), 7.55 (1H, d), 7.43-7.35 (3H, m), 4.45 (1H, t), 3.10 (2H, d), 2.57 (2H, d), 2.51 (3H, s, under DMSO), 0.77 (6H, s).
    • Example 74 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(6-hydroxyspiro[3.3]heptan-2-yl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00173
  • Prepared using analogous conditions to those of Example 6 using 3-Bromo-N-(6-hydroxy-spiro[3.3]hept-2-yl)-4-methyl-benzenesulfonamide (Intermediate A8) and 5-bromo-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine (Intermediate C7).
  • LCMS Rt 0.87 mins; MS m/z 469.2 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s), 8.05 (1H, s), 7.82 (1H, s), 7.80 (1H, s), 7.63 (1H, d), 7.48 (1H, d), 6.28 (2H, s), 4.82 (1H, d), 3.84 (1H, m), 3.82 (3H, s), 3.50 (1H, m), 2.46 (3H, s), 2.29 (3H, s), 2.18 (1H, m), 2.00 (2H, m), 1.88 (1H, m), 1.69 (4H, m).
    • Example 75 3-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00174
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-((cis)-4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B8) and 5-chloro-3-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine (prepared by analogy to Intermediate C6, starting from 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole).
  • LCMS: Rt 0.80 mins MS m/z 443.3 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.32 (1H, s), 8.07 (1H, s), 7.99 (1H, s), 7.99 (1H, s), 7.88 (1H, d, J=1.7 Hz), 7.70-7.68 (1H, dd, J=1.8, 8.0 Hz), 7.59-7.57 (1H, d, J=6.7 Hz), 7.50-7.48 (1H, d, J=8.0 Hz), 8.32 (2H, broad s), 3.91 (3H, s), 3.56 (1H, broad m), 2.97 (1H, broad m), 2.48 (3H, s), 1.58-1.49 (4H, m), 1.38-1.32 (4H, m).
    • Example 76 3-(5-Amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00175
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-((cis)-4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B8) and 5-chloro-3-(2-methylpyridin-4-yl)pyrazin-2-amine (prepared by analogy to Intermediate C6, starting from 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine);
  • LCMS: Rt 0.63 mins MS m/z 454.3 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.57-8.56 (1H, d, J=5.2 Hz), 8.26 (1H, s), 7.89 (1H, d, J=1.8 Hz), 7.72-7.69 (1H, dd, J=1.8, 8.0 Hz), 7.63 (1H, s), 7.59-7.55 (2H, m), 7.51-7.49 (1H, d, J=8.0 Hz), 6.64 (2H, s), 4.32 (1H, broad s), 3.55 (1H, m), 2.96 (1H, m), 2.55 (3H, s), 2.47 (3H, s), 1.55-1.50 (4H, m), 1.37-1.31 (4H, m).
    • Example 77 3-(5-Amino-6-(1-methyl-1H-pyrazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00176
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-(3-Hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B3) and 5-chloro-3-(1-methyl-1H-pyrazol-5-yl)pyrazin-2-amine), (prepared by analogy to Intermediate C6, starting from 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole)
  • LCMS: Rt 0.83 mins MS m/z 431.2 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.27 (1H, s), 7.84 (1H, d, J=2.0 Hz), 7.70-7.67 (1H, dd, J=2.0, 8.0 Hz), 7.57 (1H, d, J=2.0 Hz), 7.54-7.52 (1H, d, J=8.10 Hz), 7.44-7.41 (1H, m), 6.70 (1H, d), 6.50 (2H, s), 4.26 (1H, s), 3.91 (3H, s), 2.85-2.79 (2H, m), 2.48 (3H, s), 1.51-1.47 (2H, m), 1.00 (6H, s).
    • Example 78 3-(5-Amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00177
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-(3-Hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B3) and 5-chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine (Intermediate C13)
  • LCMS: Rt 0.98 mins MS m/z 458.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.37 (1H, s), 7.83 (1H, d), 7.71 (1H, dd), 7.55 (1H, d), 7.44 (1H, t), 6.91 (2H, br s), 6.81 (1H, s), 4.25 (1H, very broad s), 2.83 (2H, mult), 2.47 (3H, s), 2.09 (1H, mult), 1.51 (2H, mult), 1.06 (2H, mult), 1.02 (6H, s), 0.89 (2H, mult).
    • Example 79 3-(5-Amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00178
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-(2-hydroxy-2-methyl propyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine (Intermediate C)
  • LCMS: Rt 1.06 mins MS m/z 444.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.37 (1H, s), 7.86 (1H, d), 7.72 (1H, dd), 7.53 (1H, d), 7.47 (1H, t), 6.91 (2H, br s), 6.81 (1H, s), 4.39 (1H, s), 2.62 (2H, d), 2.46 (3H, s), 2.09 (1H, mult), 1.06 (6H, s), 1.05 (2H, mult), 0.90 (2H, mult).
    • Example 80 3-(5-Amino-6-(4-methylthiazol-2-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00179
    • Step 1: 3-Amino-6-bromopyrazine-2-carbothioamide
  • To a 100 ml flask was added 3-amino-6-bromopyrazine-2-carboxamide (1.5 g, 6.91 mmol) and Lawesson's Reagent (4.19 g, 10.37 mmol) in THF (30 ml). The reaction mixture was heated to 70° C. for 2 hours. The mixture was concentrated under reduced pressure and purified by flash column chromatography elution with Hex/EtOAc (0-40%) over 30 mins on a 24 g silica column. The required fractions were combined and concentrated under reduced pressure to yield a yellow solid; LCMS: Rt 0.88 mins MS m/z 233.2 [M+H]+; Method 2minLowpHv01.
    • Step 2: 5-Bromo-3-(4-methylthiazol-2-yl)pyrazin-2-amine
  • To a 10 ml flask was added 3-amino-6-bromopyrazine-2-carbothioamide (step 1) (300 mg, 1.287 mmol) and 1-chloropropan-2-one (0.154 ml, 1.931 mmol) in EtOH (7 ml) and stirred at 70° C. overnight. The reaction was extracted into EtOAc (10 ml), washed with sat. Na2CO3 (10 ml), brine (10 ml), dried over MgSO4 and concentrated under reduced pressure. The mixrure was purified by flash column chromatography, eluting with Hex/EtOAc (0-60%) over 15 mins on a 12 g silica cartridge. The required fractions were concentrated under reduced pressure to yield a yellow solid;
  • LCMS: Rt 1.23 mins MS m/z 273.2 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.27 (1H, s), 7.99 (2H, br s), 7.50 (1H, m), 2.48 (3H, s)
    • Step 3: 3-(5-Amino-6-(4-methylthiazol-2-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-bromo-3-(4-methylthiazol-2-yl)pyrazin-2-amine (Step 2)
  • LCMS: Rt 1.17 mins MS m/z 434.1 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, CDCl3), δ 8.24 (1H, s), 7.98 (1H, d), 7.81 (1H, dd), 7.49 (1H, d), 7.05 (1H, s), 4.90 (1H, t), 2.97 (2H, d), 2.59 (3H, s), 2.57 (3H, s), 1.29 (6H, s). Three exchangable protons not seen.
    • Example 81 3-(5-Amino-6-(1-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00180
    • Step 1: 5-Bromo-3-(1-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine
  • To a suspension of 5-bromo-3-(1H-1,2,3-triazol-4-yl)pyrazin-2-amine (see Intermediate C8 synthesis, step 3) (1 g, 4.15 mmol) and potassium carbonate (1.720 g, 12.45 mmol) in THF (20 ml) was added iodomethane (778 μl, 12.45 mmol) and the reaction stirred at room temperature for 1 hour. The resulting mixture was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude mixture was dissolved in DMSO (10 ml) and purified by mass directed preparative HPLC to afford the title compound;
  • LCMS: Rt 0.87 mins MS m/z 255.3 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.73 (1H, s), 8.12 (1H, s), 7.54 (2H, br s), 4.15 (3H, s).
    • Step 2: 3-(5-Amino-6-(1-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To 0.5-2 ml microwave vial was added N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (57.9 mg, 0.157 mmol), 5-bromo-3-(1-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine (from Step 1) (40 mg, 0.157 mmol), and bis(triphenylphosphine)palladium dichloride (5.50 mg, 7.84 μmol) and sodium carbonate (0.196 ml, 0.392 mmol) in DME (1.5 ml). The reaction was heated in the Biotage initiator microwave at 120° C. for 2 hours. The reaction was extracted into ethyl acetate, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was loaded onto silica and purified by flash column chromatography, elution with TBME:methanol (0-10%) on a 12 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a pale yellow solid;
  • LCMS: Rt 0.92 mins MS m/z 418.6 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.70 (1H, s), 8.22 (1H, s), 7.87 (1H, d), 7.69 (1H, dd), 7.52 (3H, mult), 7.45 (1H, broad), 4.40 (1H, s), 4.16 (3H, s), 2.62 (2H, s), 2.49 (3H, s), 1.06 (6H, s).
    • Example 82 3-(5-Amino-6-(2-ethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00181
  • Prepared by conditions analogous to those for the preparation of Example 81 starting from 5-bromo-3-(2-ethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8b) and N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2)
  • LCMS: Rt 1.05 mins MS m/z 432.6 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.34 (1H, s), 8.29 (1H, s), 7.90 (1H, d), 7.71 (1H, dd), 7.53 (1H, d), 7.47 (1H, broad), 7.31 (2H, broad), 4.59 (2H, q), 4.40 (1H, s), 2.63 (2H, broad), 2.51 (3H, s), 1.54 (3H, t), 1.07 (6H, s).
    • Example 83 3-(5-Amino-6-(1-ethyl-1H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00182
  • Prepared by conditions analogous to those for the preparation of Example 81 starting from 5-bromo-3-(1-ethyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8a) and N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2)
  • LCMS: Rt 0.98 mins MS m/z 432.6 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.76 (1H, s), 8.21 (1H, s), 7.86 (1H, d), 7.70 (1H, dd), 7.54 (3H, mult), 7.45 (1H, broad), 4.50 (2H, q), 4.40 (1H, s), 2.62 (2H, broad), 2.48 (3H, s), 1.50 (3H, t), 1.06 (6H, s).
    • Example 84 3-(5-Amino-6-(2-(2,2,2-trifluoroethyl)-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methyl benzenesulfonam ide
  • Figure US20180243297A1-20180830-C00183
  • Prepared by conditions analogous to those used for the preparation of Example 18 using N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-bromo-3-(2-(2,2,2-trifluoroethyl)-2H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8c);
  • LCMS: Rt 1.11 mins MS m/z 486.6 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.53 (1H, s), 8.35 (1H, s), 7.90 (1H, d), 7.71 (1H, dd), 7.53 (1H, d), 7.47 (1H, broad), 7.33 (2H, broad), 5.73 (2H, q), 4.40 (1H, s), 2.63 (2H, broad), 2.50 (3H, s), 1.06 (6H, s).
  • 19F NMR (400 MHz, DMSO-d6) δ−69.51 (CF3).
    • Example 85 3-(5-Amino-6-(2-methyl-2H-1,2,3-triazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00184
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-(3-hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B3) and 5-bromo-3-(2-methyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8);
  • LCMS: Rt 0.98 mins MS m/z 432.3 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.32 (1H, s), 8.28 (1H, s), 7.86 (1H, d), 7.70 (1H, dd), 7.54 (1H, d), 7.43 (1H, mult), 7.30 (2H, broad), 4.30 (3H, s), 4.27 (1H, s), 2.83 (2H, mult), 2.50 (3H, s), 1.51 (2H, mult), 1.02 (6H, s).
    • Example 87 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-N-((1s,4s)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00185
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-cis-4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B8) and 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6);
  • LCMS: Rt 0.88 mins MS m/z 460.2 [M+H]+; Method 2minLowpHv01.
    • Example 88 3-(5-Amino-6-(3-methylisoxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00186
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-bromo-3-(3-methyl-isoxazol-5-yl)-pyrazin-2-ylamine (Intermediate C3);
  • LCMS: Rt 0.98 mins MS m/z 418.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.39 (1H, s), 7.89 (1H, d), 7.72 (1H, dd), 7.53 (1H, d), 7.47 (1H, t), 6.96 (1H, s), 6.93 (2H, br s), 4.39 (1H, s), 2.63 (2H, d), 2.48 (3H, s), 2.33 (3H, s), 1.06 (6H, s).
    • Example 89 3-(5-Amino-6-(3-methylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00187
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-(3-Hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B3) and 5-bromo-3-(3-methyl-isoxazol-5-yl)-pyrazin-2-ylamine (Intermediate C3);
  • LCMS: Rt 1.00 mins MS m/z 432.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.39 (1H, s), 7.85 (1H, d), 7.71 (1H, dd), 7.55 (1H, d), 7.44 (1H, t), 6.96 (1H, s), 6.93 (2H, br s), 4.27 (1H, s), 2.84 (2H, mult), 2.49 (3H, s), 2.33 (3H, s), 1.51 (2H, mult), 1.02 (6H, s).
    • Example 90 3-(5-Amino-6-(5-methyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00188
  • Prepared by conditions analogous to those used for the preparation of Example 18, using N-(2-hydroxy-2-methyl propyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-bromo-3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-ylamine (Intermediate C1);
  • LCMS Rt 0.89 mins MS m/z 419.5 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.50 (1H, s), 7.86 (1H, m), 7.75 (1H, dd), 7.71 (2H, br s), 7.55 (1H, d), 7.48 (1H, t), 4.39 (1H, s), 2.63 (3H, s), 2.62 (2H, m), 2.46 (3H, s), 1.06 (6H, s). Three exchangable protons not observed.
    • Example 91 3-(5-Amino-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00189
    • Step 1: 3-Amino-6-bromo-N′-hydroxypyrazine-2-carboximidamide
  • To a 20 ml flask was added 3-amino-6-bromopyrazine-2-carbonitrile (600 mg, 3.01 mmol) in MeOH (12 ml) and cooled to 0° C. To the reaction mixture was added hydroxylamine hydrochloride (210 mg, 3.01 mmol) and triethylamine (0.420 ml, 3.01 mmol) and the mixture was allowed to warm to room temperature as a precipitate formed. The precipitate was filtered off and washed with MeOH. The filtrate was concentrated under reduced pressure and the resulting solid triturated in MeOH to give a second crop of product. The solid was triturated in MeOH again and sonicated for 15 mins until a suspension formed. The solid was filtered off and dried in a vacuum oven at 40° C. for 3 hours to afford the title compound;
  • 1H NMR (400 MHz, DMSO-d6), δ 10.38 (1H, s), 8.15 (1H, s), 7.64 (2H, br s), 5.88 (2H, s).
    • Step 2: 5-Bromo-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyrazin-2-amine
  • To a 10 ml flask was added 3-amino-6-bromo-N′-hydroxypyrazine-2-carboximidamide (from Step 1) (290 mg, 1.250 mmol) and triethylamine (0.192 ml, 1.375 mmol) in DCM (7 ml) and cooled to <5° C. To this stirring mixture was added cyclopropanecarbonyl chloride (0.113 ml, 1.250 mmol) dropwise. The reaction mixture was allowed to warm to room temperatureerature and stirred for 1 hour. To the mixture was added cyclopropanecarbonyl chloride (0.028 ml, 0.312 mmol) and continued at room temperature overnight. The resulting mixture was concentrated under reduced pressure to remove the solvent and the resulting residue was triturated in MeOH. The solid was collected by filtration, dried in a vacuum oven at 40° C. for 3 hours, then combined with hexachloroethane (483 mg, 2.039 mmol) in AcOH (6 ml) and heated to 100° C. for 1 hour in the biotage initiator microwave. To the reaction mixture was added hexachloroethane (241 mg, 1.020 mmol) and the reaction heated again in the microwave at 100° C. for 1 hour. The reaction was neutralised by addition of NaOH (1M) and extracted into EtOAc. The organic extracts were combined, washed with brine and dried over MgSO4 and concentrated under reduced pressure. The resulting pale orange solid was dried in a vacuum oven at 40° C. for 3 hours to afford the title compound;
  • LCMS: Rt 0.93 mins MS m/z 282.0 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.37 (1H, s), 7.34 (2H, br s), 2.46 (1H, m), 1.35 (2H, m), 1.25 (2H, m)
    • Step 3: 3-(5-Amino-6-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a 0.5-2 ml microwave vial was added N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (131 mg, 0.354 mmol), 5-bromo-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)pyrazin-2-amine (from step 2) (100 mg, 0.354 mmol), PdCl2(dppf)-CH2Cl2Adduct (14.47 mg, 0.018 mmol) and Na2CO3 (0.532 ml, 1.063 mmol) in DME (1.4 ml). The reaction mixture was heated at 120° C. for 45 mins in the Biotage initiator microwave. The reaction was combined with water (10 ml) and extracted into EtOAc (10 ml). The combined organic extracts were then washed with brine (10 ml) before being dried over magnesium sulfate and concentrated under reduced pressure. The reaction was purified by flash column chromatography elution with hexane/EtOAc (0-100%) over 15 mins on a 12 g silica cartridge. The required fractions were combined and concentrated under reduced pressure before being dried in a vacuum oven at 40° C. for 3 hours to afford the title compound;
  • LCMS: Rt 1.04 mins MS m/z 445.4[M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.46 (1H, s), 7.86 (1H, d), 7.73 (1H, dd), 7.54 (1H, d), 7.48 (1H, t), 7.30 (2H, s), 4.39 (1H, s), 2.63 (2H, d), 2.47 (1H, m), 2.45 (3H, s), 1.32 (2H, m), 1.25 (2H, m), 1.06 (6H, s).
    • Example 92 3-(5-Amino-6-(3-methyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00190
  • The title compound was prepared using 3-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide (Intermediate A9) and 5-bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2a) under analogous conditions to those of Example 28 LCMS: Rt 0.95 mins MS m/z 433.2[M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.61 (1H, s), 7.90 (1H, d), 7.81 (2H, br s), 7.74 (1H, dd), 7.56 (1H, d), 7.42 (1H, t), 4.44 (1H, t), 3.10 (2H, d), 2.58 (2H, d), 2.49 (3H, s), 0.77 (6H, s). One methyl group not observed; likely obscured by solvent peak.
    • Example 93 3-(5-Amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00191
  • The title compound was prepared using 3-bromo-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide (Intermediate A9) and 5-bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2c) under analogous conditions to those of Example 28.
  • LCMS: Rt 0.96 min; MS m/z=457.2 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6), δ 8.60 (1H, s), 7.89 (1H, d), 7.75 (1H, dd), 7.72 (2H, br s), 7.56 (1H, d), 7.41 (1H, t), 4.44 (1H, t), 3.10 (2H, d), 2.58 (2H, d), 2.48 (3H, s), 2.27 (1H, m), 1.14 (4H, m), 0.77 (6H, s).
    • Example 94 3-(5-Amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-W1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00192
  • The title compound was prepared using cis-3-bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) and 5-bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2c) under analogous conditions to those of Example 28;
  • LCMS: Rt 0.96 min; MS m/z=457.2 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6), δ 8.60 (1H, s), 7.87 (1H, d), 7.73 (1H, dd), 7.71 (2H, br s), 7.57 (1H, d), 4.89 (1H, d), 3.84 (1H, m), 2.74 (2H, m), 2.48 (3H, s), 2.26 (1H, m), 2.17 (2H, m), 1.74 (2H, m), 1.41 (2H, m), 1.13 (4H, m).
    • Example 95 3-(5-Amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00193
  • The title compound was prepared using N-(2-hydroxy-2-methyl-propyl)-4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzenesulfonamide (Intermediate A2) and 5-bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2c) under analogous conditions to those of Example 28;
  • LCMS: Rt 0.98 mins MS rniz 445.4[M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6), δ 8.60 (1H, s), 7.90 (1H, s), 7.75 (1H, d), 7.73 (2H, br, s), 7.55 (1H, d), 7.49 (1H, t), 4.39 (1H, s), 2.63 (2H, d), 2.48 (3H, s), 2.26 (1H, m), 1.14 (4H, m), 1.06 (6H, s).
    • Example 96 3-(5-Amino-6-(3-methyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00194
  • The title compound was prepared using cis-3-bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) and 5-bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2a) under analogous conditions to those of Example 28;
  • LCMS: Rt 0.97 mins MS m/z 431.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.62 (1H, s), 7.88 (1H, s), 7.81 (2H, br s), 7.73 (1H, dd), 7.58 (2H, m), 4.89 (1H, d), 3.84 (1H, m), 2.75 (2H, t), 2.49 (3H, s), 2.16 (2H, m), 1.75 (1H, m), 1.41 (2H, m). One methyl group not observed in NMR; likely under solvent peak.
    • Example 97 3-(5-Amino-6-(3-isopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00195
  • The title compound was prepared using N-(2-Hydroxy-2-methyl-propyl)-4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) and 5-bromo-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2b) under analogous conditions to those of Example 18;
  • LCMS: Rt 1.14 mins MS m/z 445.3[M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.62 (1H, s), 7.91 (1H, d), 7.82 (2H, br s), 7.75 (1H, dd), 7.56 (1H, d), 7.49 (1H, t), 4.40 (1H, s), 3.22 (1H, m), 2.64 (2H, d), 2.49 (3H, s), 1.37 (6H, d), 1.06 (6H, s).
    • Example 98 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(1-(hydroxymethyl)cyclopropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00196
  • The title compound was prepared using N-(1-(hydroxymethyl)cyclopropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (itself prepared in two steps by analogous conditions to those use for preparation of intermediate B1) and 5-bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C11) under analogous conditions to those of Example 18.
  • LCMS: Rt 0.88 mins MS m/z 424.1 [M+Na]+; Method LowpH_v002
  • 1H NMR (400 MHz, DMSO-d6) δ 9.34 (1H, s), 8.43 (1H, s), 8.39 (1H, s), 8.18 (1H, s), 7.91 (1H, d), 7.72-7.69 (1H, dd), 7.54-7.52 (1H, d), 7.41 (2H, broad s), 4.67-4.64 (1H, m), 3.30-3.28 (2H, d), 2.52 (3H, s), 0.60-0.57 (2H, m), 0.53-0.50 (2H, m).
    • Example 99 3-(5-Amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00197
  • The title compound was prepared using 3-Bromo-N-(3-hydroxy-2,2-dimethylpropyl)-4-methylbenzenesulfonamide (Intermediate A9) and 5-chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine (Intermediate C13) under analogous conditions to those of Example 28; LCMS: Rt 1.11 mins MS m/z 458.5 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.37 (1H, s), 7.85 (1H, d), 7.71 (1H, dd), 7.53 (1H, d), 7.38 (1H, t), 6.91 (2H, br s), 6.81 (1H, s), 4.44 (1H, mult), 3.09 (2H, d), 2.56 (2H, d), 2.46 (3H, s), 2.08 (1H, mult), 1.06 (2H, mult), 0.89 (2H, mult), 0.77 (6H, s).
    • Example 100 3-(5-Amino-6-(3-cyclopropylisoxazol-5-yl)pyrazin-2-yl)-N-(((1s,3s)-3-hydroxycyclobutyl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00198
  • The title compound was prepared using cis-3-Bromo-N-(3-hydroxy-cyclobutylmethyl)-4-methyl-benzenesulfonamide (Intermediate A10) and 5-chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine (Intermediate C13) under analogous conditions to those of Example 28
  • LCMS: Rt 0.94 mins MS m/z 456.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.37 (1H, s), 7.83 (1H, d), 7.70 (1H, dd), 7.57 (1H, t), 7.53 (1H, d), 6.91 (2H, br s), 6.81 (1H, s), 4.88 (1H, d), 3.84 (1H, mult), 2.74 (2H, t), 2.46 (3H, s), 2.16 (2H, mult), 2.09 (1H, mult), 1.74 (1H, mult), 1.40 (2H, mult), 1.06 (2H, mult), 0.89 (2H, mult).
    • Example 101 2-(3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl phenylsulfonyl)-2-azaspiro[3.3]heptan-6-ol
  • Figure US20180243297A1-20180830-C00199
    • Step 1: 2-Azaspiro[3.3]heptan-6-one
  • To a 25 mL round-bottomed flask was added tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate (600 mg, 2.84 mmol) and 4M HCl in dioxane (10 ml) to give a colorless solution. The reaction was stirred at room temperature for 1 hour. A thick white suspension formed. The crude reaction was filtered under reduced pressure to afford a white solid which was used without further purification;
    • Step 2: 2-(3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)-2-azaspiro[3.3]heptan-6-one
  • To a 50 mL round-bottomed flask was added 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) (200 mg, 0.570 mmol) and TEA (0.167 ml, 1.197 mmol) in DCM (15 ml) to give a yellow suspension. To the stirring solution was added 2-azaspiro[3.3]heptan-6-one (from Step 1) (84 mg, 0.570 mmol). The reaction mixture was stirred at room temperature for 30 mins after which time it became homogeneous. The reaction was diluted with DCM, washed with citric acid, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The product was purified by mass directed preparative chromatography. The product fractions were combined and extracted into DCM, washed with sat. sodium bicarbonate solution, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The resulting oil was diluted with the minimum volume of ethyl acetate and allowed to evaporate at RT overnight to yield the title compound as white solid;
  • LCMS: Rt 0.94 mins MS m/z 426.3 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 9.32 (1H, s), 8.45 (1H, s), 8.42 (1H, s), 7.85 (1H, d), 7.76 (1H, dd), 7.65 (1H, d), 7.40 (2H, br s), 3.94 (4H, s), 3.12 (4H, s), 2.55 (3H, s).
    • Step 3: 2-(3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)-2-azaspiro[3.3]heptan-6-ol
  • To a 10 mL round-bottomed flask was added 2-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonyl)-2-azaspiro[3.3]heptan-6-one (40 mg, 0.094 mmol) and sodium borohydride (5.34 mg, 0.141 mmol) in THF (2 ml) to give a white suspension. After 5 mins the mixture was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The resulting yellow residue was dissolved in DMSO and purified by mass-directed preparative chromatography.
  • The required fraction was extracted into ethyl acetate, washed with sodium bicarbonate solution, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue was dried in the oven at 40° C. overnight to yield a white solid;
  • LCMS: Rt 0.89 mins MS m/z 428.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 9.31 (1H, s), 8.44 (1H, s), 8.42 (1H, s), 7.83 (1H, d), 7.73 (1H, dd), 7.64 (1H, d), 7.40 (2H, br s), 4.97 (1H, d), 3.84 (1H, mult), 3.71 (2H, s), 3.66 (2H, s), 2.55 (3H, s), 2.14 (2H, mult), 1.76 (2H, mult).
    • Example 102 3-(1,3-Dimethyl-1H-pyrazol-4-yl)-5-(5-(3-methoxy-3-methylazetidin-1-ylsulfonyl)-2-methylphenyl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00200
  • To a solution of 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3) (165 mg, 0.437 mmol), and TEA (0.183 ml, 1.310 mmol) in DCM (5 ml) was added 3-methoxy-3-methylazetidine hydrochloride (60 mg, 0.437 mmol) and the mixture was stirred at room temperature for 30 mins. The resulting mixture was extracted with DCM, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was loaded onto silica and purified by flash column chromatography elution with TBME:methanol (0-10%) on a 12 g silica cartridge. The product fractions were combined and the solvent removed under reduced pressure to yield a yellow oil;
  • LCMS: Rt 0.95 mins MS m/z 443.5 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.12 (1H, s), 8.10 (1H, s), 7.84 (1H, d), 7.70 (1H, dd), 7.61 (1H, d), 6.31 (2H, br s), 3.82 (3H, s), 3.60 (2H, d), 3.55 (2H, d), 2.94 (3H, s), 2.53 (3H, s), 2.30 (3H, s).
    • Example 103 3-(5-Amino-6-(1H-pyrazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00201
  • The title compound was prepared analogously to Example 15 starting from pyrazole.
  • LCMS: Rt 0.92 mins; MS m/z 429.4 [M+H]+; Method: 2minLC_v003
    • Example 106 (R)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(pyrrolidin-2-ylmethyl)benzenesulfonamide hydrochloride
  • Figure US20180243297A1-20180830-C00202
  • The title compound was prepared analogously to Example 128 starting from 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3) and (R)-tert-butyl 2-(aminomethyl)pyrrolidine-1-carboxylate. The resulting product was stirred in DCM:TFA 3:1 v/v at room temperature for 4 hours to afford the title compound. Following purification the hydrochloride salt was prepared by treatment with 4N HCl in dioxane.
  • LCMS: Rt 0.65 mins; MS m/z 442.3 [M+H]+; Method: 2minLowpHv03
    • Example 107 3-(5-Amino-6-(2-cyclopropylthiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00203
  • A mixture of 5-bromo-2-cyclopropylthiazole (80 mg, 0.390 mmol), KOAc (57.4 mg, 0.585 mmol), PdCl2(dppf).CH2Cl2 adduct (15.91 mg, 0.019 mmol) and bis(pinicolato)diboron (109 mg, 0.429 mmol) in DME (1949 μL), under N2, was heated at 90° C. for 14 hours. 3-(5-Amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) (150 mg, 0.390 mmol) was added to the reaction mixture followed by Na2CO3 (585 μL, 1.169 mmol) and PdCl2(dppf).CH2Cl2 adduct (15.91 mg, 0.019 mmol). The resulting mixture was microwaved at 120° C. for 45 mins. The mixture was added to sat. Na2CO3 (50 ml) and the product extracted into EtOAc (2×50 ml). The organic extracts were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with a modified 0-10% gradient of (2M NH3 in MeOH) in DCM on a 12 g Si-column, followed by mass directed reverse phase prep chromatography to give the title compound;
  • LCMS: Rt 0.97 mins; MS m/z 472.3 [M−H]−; Method: 2minLowpH
    • Example 108 3-(5-Amino-6-(thiazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00204
  • To a solution of 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) (100 mg, 0.260 mmol) in THF (1299 μl) was added 4-(tributylstannyl)thiazole (146 mg, 0.390 mmol), CuI (2.474 mg, 0.013 mmol) and Pd-118 (8.47 mg, 0.013 mmol). The reaction mixture was heated in the microwave 1 hour at 100° C. Further 4-(tributylstannyl)thiazole (146 mg, 0.390 mmol), Pd-118 (8.47 mg, 0.013 mmol) and CuI (2.474 mg, 0.013 mmol) were added and reaction mixture microwaved at 150° C. for 3 hours. The resulting mixture was added to water (50 ml) and the product extracted into EtOAc (2×40 ml). The organic extracts were washed with brine, dried over MgSO4 and Isolute® Si-TMT resin to remove Pd. The solids were removed by filtration, washed with EtOAc and the filtrate concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH3 in MeOH) in DCM on a 12 g Si-column, followed by mass directed reverse phase prep chromatography to give the title compound as a white solid;
  • LCMS: Rt 1.04 mins; MS m/z 432.2[M−H]−; Method: 2minLowpHv01
    • Example 109 3-(5-Amino-6-(3-cyclopropyl-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methyl benzenesulfonam ide
  • Figure US20180243297A1-20180830-C00205
  • To a solution of N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (318 mg, 0.861 mmol) in DME (3913 μL) was added 5-bromo-3-(3-cyclopropyl-1H-1,2,4-triazol-1-yl)pyrazin-2-amine (prepared by analogy to intermediate C11 starting from 3-cyclopropyl-1H-1,2,4-triazole) (220 mg, 0.783 mmol), bis(triphenylphosphine)palladium(II) chloride (27.5 mg, 0.039 mmol) and Na2CO3 (aq. 2.0M) (1174 μL, 2.348 mmol). The reaction mixture was microwaved at 120° C. for 30 mins.
  • The mixture was added to water (50 ml) and the product extracted into EtOAc (2×60 ml). The organic extracts were washed with brine, dried over MgSO4 and Si-TMT resin to remove Pd. The solids were removed by filtration, washed with EtOAc and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH3 in MeOH) in DCM on a 12 g Si-column. The resulting solid was recrystallized from hot EtOAc (˜3 ml). TBME was added slowly while hot (˜3 ml). Upon cooling a yellow solid crystallized. This was collected by filtration and dried to give the title compound as a pale yellow solid;
  • LCMS: Rt 1.00 mins; MS m/z 444.6 [M+H]+; Method: 2minLowpHv01
    • Example 110 3-(5-Amino-6-(2-methoxythiazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00206
  • Prepared by analogy to Example 108 starting from 2-methoxy-4-(tributylstannyl)thiazole; LCMS: Rt 1.13 mins; MS m/z 464.5 [M+H]+; Method 2minLowpHv01
    • Example 111 3-(5-Amino-6-(4-methyl-1H-pyrazol-1-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00207
  • The title compound was prepared analogously to Example 15 starting from 4-methyl-1H-pyrazole.
  • LCMS: Rt 1.06 mins; MS m/z 443.3 [M+H]+; Method: 2minLC_v003
    • Example 112 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-ethoxy-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00208
  • A mixture of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) 100 mg, 0.285 mmol) and O-ethylhydroxylamine hydrochloride (83 mg, 0.855 mmol) in DCM (5 ml). Pyridine (1 ml, 12.36 mmol) was added to the reaction mixture and this was stirred at room temperature for lhr. The reaction mixture was washed with 1M HCl, brine and dried over MgSO4. The solvent was removed under reduced pressure. The crude product was dissolved in MeOH and water was added until the product precipitated out. This was filtered washing through with water and hexane to afford the title compound;
  • LCMS: Rt 3.96 min; MS m/z 376.4 [M+H]+; Method 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.36 (1H, s), 9.33 (1H, s), 8.43 (1H, s), 8.40 (1H, s), 7.93 (1H, m), 7.76 (1H, m), 7.59 (1H, m), 7.40 (2H, s), 3.92 (2H, q), 2.53 (3H, s), 1.10 (3H, t).
  • The following examples were prepared analogously to Example 112 from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and an appropriate amine (commercially available unless otherwise stated).
    • Example 112.1 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(tert-butoxy)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00209
  • LCMS: Rt 4.48 min; MS m/z 404.5 [M+H]+; Method 10minLowpHy01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.81 (1H, s), 9.32 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.92 (1H, m), 7.75 (1H, m), 7.57 (1H, m), 7.39 (2H, s), 2.53 (3H, s), 1.16 (9H, s).
    • Example 112.2 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-(dimethylamino)ethoxy)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00210
  • LCMS: Rt 2.24 min; MS m/z 419.7 [M+H]+; Method 10minLowpHy01
  • 1H NMR (400 MHz, MeOD-d4) δ ppm 9.35 (1H, s), 8.33 (2H, s), 8.02 (1H, d), 7.86 (1H, dd), 7.57 (1H, d), 4.14 (2H, t), 2.68 (2H, t), 2.58 (3H, s), 2.30 (6H, s).
    • Example 112.3 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-isopropoxy-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00211
  • LCMS: Rt 4.23 min; MS m/z 390.5 [M+H]+; Method 10minLowpHy01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.16 (1H, s), 9.32 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.92 (1H, d), 7.77 (1H, dd), 7.59 (1H, d), 7.40 (2H, s), 4.11 (1H, m), 2.53 (3H, s), 1.11 (6H, d).
    • Example 112.4 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-isobutoxy-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00212
  • LCMS: Rt 4.62 min; MS m/z 404.5 [M+H]+; Method 10minLowpHy01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.37 (1H, s), 9.32 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.93 (1H, d), 7.77 (1H, dd), 7.60 (1H, d), 7.40 (2H, s), 3.67 (2H, d), 2.53 (3H, m), 1.79-1.89 (1H, m), 0.83 (6H, d).
    • Example 112.5 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-((tetrahydrofuran-3-yl)oxy)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00213
  • Prepared using 0-(Tetrahydrofuran-3-yl)hydroxylamine (intermediate F)
  • LCMS: Rt 3.60 min; MS rniz 418.3 [M+H]+; Method 10minLowpHy01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.44 (1H, s), 9.32 (1H, s), 8.42 (1H, s), 8.39 (1H, s), 7.91 (1H, d), 7.77 (1H, dd), 7.60 (1H, d), 7.40 (2H, s), 4.68 (1H, m), 3.79 (1H, d), 3.63 (3H, m), 2.53 (3H, s), 1.97 (2H, m).
    • Example 113 5-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00214
  • Prepared from 5-(5-amino-6-chloropyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide (Intermediate D5) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-Athiazole by analogy to Example 11. The resulting solid was crystallized from EtOAc/Et2O (dissolving the compound in minimal hot EtOAc and diluting with Et2O. The resulting solution was left to cool and solid was collected by filtration, washed with a small amount of Et2O and dried to give the title compound as a yellow solid;
  • LCMS: Rt 0.83 mins; MS m/z 438.1 [M+H]+; Method: 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.27 (1H, s), 8.20 (1H, s), 7.81 (1H, br s), 7.78 (1H, d), 7.44 (1H, d), 6.72 (2H, s), 4.42 (1H, br m), 3.38 (2H, m), 2.93 (2H, m), 2.68 (3H, s), 2.47 (3H, s), 1.56 (2H, m).
    • Example 114 5-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00215
  • Prepared from 5-(5-amino-6-chloropyrazin-2-yl)-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide (Intermediate D5) and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole by analogy to Example 11. The resulting solid was crystallized from EtOAc/Et2O (dissolving the compound in minimal hot EtOAc and diluting with Et2O. The resulting solution was left to cool and solid was collected by filtration, washed with a small amount of Et2O and dried to give the title compound as a white solid;
  • LCMS: Rt 0.75 mins; MS m/z 421.2 [M+H]+; Method: 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.31 (1H, s), 8.06 (1H, s), 7.98 (1H, s), 7.80 (1H, br s), 7.77 (1H, d), 7.42 (1H, d), 6.31 (2H, s), 4.42 (1H, br s), 3.91 (3H, s), 3.38 (2H, t), 2.92 (2H, t), 2.46 (3H, s), 1.56 (2H, m).
    • Example 115 5-(5-Amino-6-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00216
  • Prepared by analogy to Example 11 from 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and 5-(5-amino-6-chloropyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (prepared in two steps by analogy to Intermediate D5) The resulting solid was crystallized from EtOAc/Et2O (dissolving the compound in minimal hot EtOAc and diluting with Et2O. The resulting solution was left to cool and solid was collected by filtration, washed with a small amount of Et2O and dried to give the title compound as a white solid;
  • LCMS; Rt 0.82 mins; MS m/z 449.2 [M+H]+; Method: 2minLowpH
    • Example 116 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00217
  • The title compound was prepared using 5-(5-amino-6-chloropyrazin-2-yl)-2-fluoro-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (prepared in two steps by analogy to Intermediate A12) and 5-chloro-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C5) under analogous conditions to those of Example 6. The resulting solid was crystallized from EtOAc/Et2O (dissolving the compound in minimal hot EtOAc and diluting with Et2O. The resulting solution was left to cool and solid was collected by filtration, washed with a small amount of Et2O and dried to give the title compound as a white solid;
  • LCMS: Rt 0.84 mins; MS m/z 436.3 [M+H]+; Method: 2minLC_v003
    • Example 117 3-(5-Amino-6-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yyl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide hydrochloride salt
  • Figure US20180243297A1-20180830-C00218
    • Step 1: N,N-Dimethyl-1-(1H-1,2,4-triazol-3-Amethanamine
  • To 3-(chloromethyl)-1H-1,2,4-triazole (400 mg, 2.60 mmol) was added dimethylamine (2.0M in THF) (51.900 ml, 10.38 mmol) and the reaction mixture was stirred for 24 hours at room temperature. The mixture was concentrated to dryness and crude product loaded onto 2×10 g Isolute® SCX-2 cartridges, flushed with MeOH (50 ml) and product eluted with 2.0M NH3 in MeOH (50 ml). Concentration of the ammonia in methanol gave the title compound;
  • 1H NMR (400 MHz, DMSO-d6) δ 3.51 (2H, s), 2.16 (6H, s).
    • Step 2: 5-Bromo-3-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yl)pyrazin-2-amine
  • A mixture of 5-bromo-3-chloropyrazin-2-amine (376 mg, 1.801 mmol), N,N-dimethyl-1-(1H-1,2,4-triazol-3-Amethanamine (from Step 1) (250 mg, 1.982 mmol), Cs2CO3 (1174 mg, 3.60 mmol) in DMF (9007 μl) was heated to 60° C. for 16 hours. The mixture was concentrated to dryness, added to water (50 ml) and product extracted into EtOAc (4×40 ml). The organic extracts were washed brine, dried over MgSO4 and concentrated under reduced pressure to give the title compound as a orange solid, which was taken onto the next step without further purification;
  • LCMS: Rt 0.84 mins; MS m/z 298.4 [M+H]+; Method: 2minLowpHv01
    • Step 3: 3-(5-Amino-6-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide hydrochloride salt
  • To a solution of N-(2-hydroxy-2-methylpropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B2) (235 mg, 0.636 mmol) in DME (2652 μl) was added 5-bromo-3-(3-((dimethylamino)methyl)-1H-1,2,4-triazol-1-yl)pyrazin-2-amine (from Step 2) (158 mg, 0.530 mmol), bis(triphenylphosphine)palladium(II) chloride (18.61 mg, 0.027 mmol) and Na2CO3 (aq. 2.0M) (795 μl, 1.591 mmol). The reaction mixture was microwaved at 120° C. for 60 mins. The mixture was added to water (50 ml) and product extracted into EtOAc (2×50 ml). The organic extracts were washed with brine, dried over MgSO4 and Si-TMT resin to remove Pd. The solids were removed by filtration, washed with EtOAc and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH3 in MeOH) in DCM on a 12 g Si-column. The resulting oil was dissolved in a small amount of MeOH (1 ml) and 4.0M HCl in dioxane was added (1 ml). The mixture was concentrated to dryness and the resulting solid recrystallized from hot EtOH (˜4 ml). Upon cooling a white solid crystallized. This was collected by filtration and dried to give the title compound as a pale yellow solid;
  • LCMS: Rt 0.66 mins; MS m/z 461.4 [M+H]+; Method: 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 10.76 (1H, br s), 9.42 (1H, s), 8.45 (1H, s), 7.93 (1H, s), 7.73 (1H, d), 7.58-7.49 (2H, m), 7.46 (2H, s), 4.58 (2H, s), 4.44 (1H, br s), 2.89 (6H, s), 2.62 (1H, d), 2.51 (3H, sunder DMSO), 1.07 (6H, s).
    • Example 118 5-(2-Methyl-5-(3-(trifluoromethyl)piperazin-1-ylsulfonyl)phenyl)-3-(2-methylthiazol-5-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00219
  • Prepared by analogy to Example 11 from 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiazole and 3-chloro-5-(2-methyl-5-((3-(trifluoromethyl)piperazin-1-1)sulfonyl)phenyl)pyrazin-2-amine (prepared in two steps by analogy to Intermediate D5 from 3-bromo-4-methylbenzene-1-sulfonyl chloride, 5-bromo-3-chloropyrazin-2-amine and 2-(trifluoromethyl)piperazine)
  • LCMS: Rt 0.99 mins; MS m/z 499.2 [M+H]+; Method 2minLowpH.
    • Example 119 3-(5-Amino-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00220
  • To 1-methyl-3-trifluoromethylpyrazole-5-boronic acid (18 mg, 0.094 mmol) was added Pd(PPh3)2Cl2 (2.74 mg, 3.9 μmol), sodium carbonate (2M aqueous solution, 0.117 mL, 0.234 mmol) and a solution of 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (Intermediate D3) (30 mg, 0.078 mmol) in acetonitrile (0.7 mL). The resulting mixture was heated in the microwave at 150° C. for 30 mins then filtered through a 500 mg IsoIte® Si-TMT cartridge, rinsing with acetonitrile (1 mL). After evaporation under reduced pressure, the residue was dissolved in DMSO and purified by HPLC (acetonitrile/water gradient, 0.1% TFA modifier). The product fractions were combined and evaporated to give the title compound;
  • LC-MS: Rt 1.00 mins; MS m/z 499.5 [M+H]+; Method 2minLowpH.
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 119 starting from 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (Intermediate D3) and the appropriate boronic acid or ester obtained from a commercial supplier. The reactions were carried out in an appropriate solvent e.g. acetonitrile or DME. Final compounds were purified by appropriate techniques known in the art, for example preparative HPLC as described for Example 119. Compounds were isolated as trifluoroacetic acid salt (from TFA modifier in preparative HPLC) or free base, except for 119.32 and 119.41 for which hydrochloride salts were formed after purification using standard conditions e.g. HCl/dioxane. For 119.42 to 119.46 (PdCl2(dppf)-CH2Cl2adduct) catalyst was used in place of Pd(PPh3)2Cl2.
  • Rt LCMS
    Ex Name (min) MS m/z Method
    119.1 3-(5-amino-6-(2-fluoropyridin-3- 0.87 446.3 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00221
    119.2 3-(5-amino-6-(4-methoxypyridin-3- 1.24 458.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00222
    119.3 3-(5-amino-6-(2-methoxypyridin-4- 1.23 458.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00223
    119.4 3-(5-amino-6-(2-methoxypyridin-3- 1.05 458.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00224
    119.5 3-(5-amino-6-(pyridin-3-yl)pyrazin-2-yl)- 0.99 428.5 2minLow
    N-(3-hydroxy-3-methylbutyl)-4- pH_TFA
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00225
    119.6 3-(5-amino-6-(2-chloropyridin-3- 1.21 462.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00226
    119.7 3-(5-amino-6-(5-methylpyridin-3- 1.21 no 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- ionisation pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00227
    119.8 3-(5-amino-6-(5-chloro-2-fluoropyridin-3- 1.26 no 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- ionisation pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00228
    119.9 3-(5-amino-6-(6-chloro-4-methylpyridin-3- 1.21 476.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00229
    119.10 3-(5-amino-6-(2-fluoropyridin-4- 1.18 no 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- ionisation pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00230
    119.11 3-(5-amino-6-(3-fluoropyridin-4- 1.08 no 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- ionisation pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00231
    Reference 3-(5-amino-6-(2-isopropoxypyridin-3- 1.22 486.7 2minLow
    example yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    119.12 methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00232
    119.13 3-(5-amino-6-(6-ethoxypyridin-3- 1.2 472.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00233
    119.14 3-(5-amino-6-(6-methoxy-2- 1.12 472.6 2minLow
    methylpyridin-3-yl)pyrazin-2-yl)-N-(3- pH_TFA
    hydroxy-3-methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00234
    119.15 3-(5-amino-6-(furan-3-yl)pyrazin-2-yl)-N- 1.09 417.5 2minLow
    (3-hydroxy-3-methylbutyl)-4- pH_TFA
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00235
    119.16 3-(5-amino-6-(1-methyl-1H-pyrazol-4- 0.81 431.4 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00236
    119.17 3-(5-amino-6-(6-(pyrrolidin-1-yl)pyridin-3- 1.00 497.7 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00237
    119.18 3-(5-amino-6-(6-fluoropyridin-3- 1.12 446.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00238
    119.19 3-(5-amino-6-(1,5-dimethyl-1H-pyrazol-4- 0.99 no 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- ionisation pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00239
    119.20 3-(5-amino-6-(pyrimidin-5-yl)pyrazin-2- 1.03 429.5 2minLow
    yl)-N-(3-hydroxy-3-methylbutyl)-4- pH_TFA
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00240
    119.21 3-(5-amino-6-(6-morpholinopyridin-3- 0.95 513.7 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00241
    119.22 3-(5-amino-6-(3-methyl-1H-pyrazol-4- 0.96 431.5 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00242
    119.23 3-(5-amino-6-(6-(piperidin-1-yl)pyridin-3- 1.02 511.8 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00243
    119.24 3-(5-amino-6-(6-(tetrahydro-2H-pyran-4- 1.17 528.6 2minLow
    yloxy)pyridin-3-yl)pyrazin-2-yl)-N-(3- pH_TFA
    hydroxy-3-methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00244
    119.25 3-(5-amino-6-(1-propyl-1H-pyrazol-4- 1.14 459.6 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00245
    119.26 3-(5-amino-6-(1-isopentyl-1H-pyrazol-4- 1.26 487.7 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH_TFA
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00246
    119.27 3-(5-amino-6-(pyridin-4-yl)pyrazin-2-yl)- 0.68 428.4 2minLow
    N-(3-hydroxy-3-methylbutyl)-4- pH
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00247
    119.28 3-(5-amino-6-(2-methylpyridin-4- 0.65 442.0 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00248
    119.29 3-(5-amino-6-(2-methylthiazol-5- 0.9 448.3 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00249
    119.30 3-(5-amino-6-(2-methylthiazol-4- 0.89 448.2 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00250
    119.31 3-(5-amino-6-(1-isopropyl-1H-pyrazol-4- 0.9 459.3 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00251
    119.32 3-(5-amino-6-(1-isobutyl-1H-pyrazol-4- 0.96 473.3 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    hydrochloride
    Figure US20180243297A1-20180830-C00252
    119.33 3-(5-amino-6-(1H-pyrazol-4-yl)pyrazin-2- 0.76 417.2 2minLow
    yl)-N-(3-hydroxy-3-methylbutyl)-4- pH
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00253
    119.34 3-(5-amino-6-(1-ethyl-1H-pyrazol-4- 0.86 445.3 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00254
    119.35 3-(5-amino-6-(5- 0.86 463.4 2minLow
    (hydroxymethyl)thiophen-2-yl)pyrazin-2- pH
    yl)-N-(3-hydroxy-3-methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00255
    119.36 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-5- 0.91 445.1 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pHv01
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00256
    119.37 3-(5-amino-6-(1-(pyridin-2-ylmethyl)-1H- 0.81 508.3 2minLow
    pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00257
    119.38 3-(5-amino-6-(1-(pyridin-3-ylmethyl)-1H- 0.71 508.7 2minLow
    pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00258
    119.39 3-(5-amino-6-(1-(pyridin-4-ylmethyl)-1H- 0.67 508.7 2minLow
    pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3- pH
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00259
    119.40 3-(5-amino-6-(2-methyloxazol-5- 0.89 432.5 2minLow
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- pHv01
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00260
    119.41 3-(5-amino-6-(1-(2-morpholinoethyl)-1H- 0.63 530.5 2minLow
    pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3- pHv01
    methylbutyl)-4-
    methylbenzenesulfonamide
    hydrochloride
    Figure US20180243297A1-20180830-C00261
    119.42 3-(5-amino-6-(1H-pyrazol-3-yl)pyrazin-2- 0.96 417.2 LowpH_v
    yl)-N-(3-hydroxy-3-methylbutyl)-4- 002
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00262
    119.43 3-(5-amino-6-(4-methylthiophen-2- 447.4 LowpH_v
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- 002
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00263
    119.44 3-(5-amino-6-(5-methylthiophen-2- 0.99 447.5 LowpH_v
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- 002
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00264
    119.45 3-(5-amino-6-(thiophen-2-yl)pyrazin-2-yl)- 0.95 433.5 LowpH_v
    N-(3-hydroxy-3-methylbutyl)-4- 002
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00265
    119.46 3-(5-amino-6-(5-cyclopropylthiophen-2- 1.18 473.3 LowpH_v
    yl)pyrazin-2-yl)-N-(3-hydroxy-3- 002
    methylbutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00266
    • Example 120 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methyl-N-((3-methyloxetan-3-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00267
  • The title compound was prepared using 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) and 4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-3-(4,4,5,5)tetramethyl-[1,3,2] dioxaborolan-2-yl)-benzenesulfonamide (Intermediate B4) under analogous conditions to those of Example 41;
  • LCMS: Rt 1.09 mins, MS m/z 446.2 [M+H]+; Method 2minLowpHv03.
    • Example 121 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-2,4-dimethylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00268
    • Step 1: 5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid
  • A mixture of bis(pinacolato)diboron (750 mg, 2.95 mmol), 5-bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C11), potassium acetate (435 mg, 4.43 mmol) and PdCl2(dppf).CH2Cl2 adduct (120 mg, 0.147 mmol) in 1,2-dimethoxyethane (14 mL) was heated in a microwave at 120° C. for 30 minutes. The resulting mixture was filtered through Celite®, washing with DCM and 5% methanol in DCM and the filtrate was evaporated under reduced pressure. The crude residue was dissolved in DCM (10 mL) and treated with pinacol (320 mg, 2.71 mmol) and stirred at room temperature. Hexane (20 mL) was added to the mixture and the resulting solid was collected by filtration, washed with water and dried in the vacuum oven to give the title compound as a grey solid;
  • LCMS: Rt 0.52 min; MS m/z 207.5 [M+H]+; Method: 2minLowpHv01
    • Step 2: 5-Bromo-N-(2-hydroxy-2-methylpropyl)-2,4-dimethylbenzenesulfonamide
  • To a stirring solution of 1-amino-2-methylpropan-2-ol (104 mg, 1.164 mmol) in DCM (5 mL), triethylamine (0.295 mL, 2.116 mmol) was added followed by 5-bromo-2,4-dimethylbenzene-1-sulfonyl chloride (300 mg, 1.058 mmol) and the reaction mixture was stirred for 30 minutes at room temperature. The resulting mixture was diluted in DCM and poured into a separating funnel. The solution was washed with 1M HCl and separated. The organic portion was washed with saturated brine, dried over MgSO4 and filtered. The solvent was removed under reduced pressure to give a white solid;
  • LCMS: Rt 1.12 min; MS m/z 337.4 [M+H]+; Method: 2minLowpHv01
    • Step 3: 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-2,4-dimethylbenzenesulfonamide
  • 5-Bromo-N-(2-hydroxy-2-methylpropyl)-2,4-dimethylbenzenesulfonamide (from step 2) (176 mg, 0.523 mmol), 5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid (from step 1) (108 mg, 0.523 mmol), potassium phosphate (222 mg, 1.047 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (17.06 mg, 0.026 mmol) were weighed out into the microwave vial. 1,4-Dioxane (2 ml) and water (0.500 ml) were added and the solution was placed in the microwave for 10 minutes at 100° C. The reaction mixture was diluted with water and ethyl acetate. The organic layer was extracted in a separating funnel by diluting with ethyl dried over magnesium sulphate and the solvent was removed under reduced pressure. The crude product was purified flash column chromatography, eluting in a 0% to 10% MeOH:DCM gradient, on a 12 g silica cartridge. The crude product was loaded on the column using DCM. The product fractions were combined and the solvent was removed to give a yellow solid.
  • LCMS: Rt 3.68 min; MS m/z 418.4 [M+H]+; Method: 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.32 (1H, s), 8.42 (1H, s), 8.38 (1H, s), 7.89 (1H, s), 7.53 (1H, s), 7.37 (1H, s), 7.34 (1H, s), 5.76 (1H, s), 4.39 (1H, s), 2.72 (2H, s), 2.59 (3H, s), 2.47 (3H, s), 1.05 (6H, s)
    • Example 122 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-fluoro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00269
    • Step 1: 5-bromo-2-fluoro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a stirring solution of 1-amino-2-methylpropan-2-ol (102 mg, 1.148 mmol) in DCM (10 ml), triethylamine (0.291 ml, 2.087 mmol) was added. 5-bromo-2-fluoro-4-methylbenzene-1-sulfonyl chloride (300 mg, 1.043 mmol) and stirring continued for 2 hrs. The reaction mixture was diluted with DCM and washed with 1M HCl and washed with saturated brine. The organic portion was dried over MgSO4 and filtered. The solvent was removed under reduced pressure to afford the title compound;
  • LCMS: Rt 1.03 min; MS m/z 341.2 [M+H]+; Method: 2minLowpHv01
    • Step 2: 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-fluoro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • 5-Bromo-2-fluoro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide (step 1) (100 mg, 0.294 mmol), 5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid (see Example 121 step 1) (60.5 mg, 0.294 mmol), potassium phosphate (125 mg, 0.588 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (9.58 mg, 0.015 mmol) were added to a microwave vial. 1,4-Dioxane (2 ml) and water (0.500 ml) were added and the reaction mixture was heated in the microwave at 100° C. for 10 minutes. The reaction mixture was diluted with ethyl acetate and washed with water and saturated brine. The organic portion was dried over MgSO4, filtered and vacuum evaporated under reduced pressure. The crude product was purified by flash column chromatography, eluting in a 0% to 100% iso-hexane:EtOAc gradient, on a 12 g silica cartridge. The product fractions were combined and the solvent was removed to give the title compound as a yellow solid;
  • LCMS: Rt 3.44 min; MS m/z 422.2 [M+H]+; Method: 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.32 (1H, s) 8.42 (1H, s) 8.38 (1H, s) 7.84 (1H, d) 7.72 (1H, s) 7.46 (1H, d) 7.37 (2H, s) 4.42 (1H, s) 2.80 (2H, s) 2.54 (3H, s), 1.07 (6H, s)
    • Example 123 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00270
    • Step 1: 3-Bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • A mixture comprising 3-bromobenzene-1-sulfonyl chloride (300 mg, 1.174 mmol), 1-amino-2-methylpropan-2-ol (115 mg, 1.292 mmol), triethylamine (0.327 ml, 2.348 mmol) and DCM (10 ml) was stirred at room temperature for 1 hour. The resulting mixture was diluted with DCM and washed with 1M HCl, sat. sodium bicarbonate solution and dried over MgSO4. The solution was then filtered and vacuum evaporated to remove the solvent. This gave the title compound as a yellow crystalline solid;
  • LCMS: Rt 0.92 min; MS m/z 308.1 [M+H]+; Method: 2minLowpHv01
    • Step 2: 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide
  • 3-Bromo-N-(2-hydroxy-2-methylpropyl)benzenesulfonamide (from step 1) (100 mg, 0.324 mmol), 5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid (see Example 121 step 1) (66.8 mg, 0.324 mmol), potassium phosphate (138 mg, 0.649 mmol) and [1,1′-bis(di-tert-butylphosphino) ferrocene]dichloropalladium(II) (10.57 mg, 0.016 mmol) was added to a microwave vial. 1,4-Dioxane (2 mL) and water (0.500 mL) were added and the mixture was heated using microwave radiation for 10 minutes. The reaction mixture was washed with ethyl acetate and water. The solution was washed with saturated brine and then separated. The solution was dried over MgSO4, filtered and vacuum evaporated on a rotary evaporator to give a brown oil. The crude product was purified by flash column chromatography, eluting in a 0% to 100% iso-hexane:EtOAc gradient, on a 4 g silica cartridge, crude product was dry loaded on the column. The relevant fractions were combined and the solvent was removed to give a light green solid;
  • LCMS: Rt 3.28 min; MS m/z 390.5 [M+H]+; Method: 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.56 (1H, s) 8.85 (1H, s) 8.48 (1H, s) 8.44 (1H, s) 8.34 (1H, d) 7.79 (1H, d) 7.68 (1H, t) 7.63 (1H, s) 7.46 (2H, s) 4.43 (1H, s) 2.65 (2H, s) 1.07 (6H, s)
    • Example 124 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-chloro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00271
    • Step 1: 5-Bromo-2-chloro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a round bottom flask was added 1-bromo-4-chloro-2-methylbenzene (300 mg, 1.460 mmol). At 0° C. was added chlorosulfonic acid (2.347 mL, 35.0 mmol) in CHCl3 (10 mL). The reaction mixture was warmed to RT and stirred for 2 hours. The reaction mixture was added to ice cold water and DCM and was stirred. The organic layer was separated and treated with 1-amino-2-methylpropan-2-ol (143 mg, 1.606 mmol) and triethylamine (0.407 mL, 2.92 mmol) and stirring continued RT for 1 hr. The reaction mixture was washed with 1M HCl and saturated bicarbonate solution. The organic layer was separated, dried over MgSO4 and filtered. The solvent was removed under reduced pressure to give a brown oil. The crude product was purified by flash column chromatography, eluting in a 0% to 40% iso-hexane:EtOAc gradient, on a 4 g silica cartridge, crude product was dry loaded on the column. The relevant fractions were combined and the solvent was removed to give a white solid;
  • LCMS: Rt 1.18 min; MS m/z 356.1 [M+H]+; Method: 2minLowpHv01
    • Step 2: 5-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-2-chloro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a microwave vial was added 5-bromo-2-chloro-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide (step 1) (60 mg, 0.168 mmol), 5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-ylboronic acid (see Example 121 step 1) (34.6 mg, 0.168 mmol), bis(triphenylphosphine)palladium dichloride (5.90 mg, 8.41 μmol), sodium carbonate (53.5 mg, 0.505 mmol) in DME (1 mL). The reaction mixture was placed in a microwave for 20 minutes at 70° C. and then 5 minutes at 100° C. The reaction mixture was washed with water and EtOAc. The organic layer was then separated, dried over MgSO4 and then filtered. The solvent was removed under reduced pressure to give a brown solid. The crude product was purified by flash coulmn chromatography, eluting in a 0% to 10% DCM:MeOH/NH3 gradient, on a 4 g silica cartridge, crude product was dry loaded on the column. The relevant fractions were combined and the solvent was removed to give a yellow solid;
  • LCMS: Rt 3.61 min; MS m/z 438.3 [M+H]+; Method: 10minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 9.33 (1H, s) 8.422 (1H, s) 8.419 (1H, s) 8.02 (1H, s) 7.67 (1H, s) 7.62 (1H, s) 7.42 (2H, s) 4.43 (1H, s) 2.50 (3H, s) 2.80 (2H, d) 1.07 (6H, s).
    • Example 125 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropoxy)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00272
  • To 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3) (338 mg, 0.895 mmol) in THF (6 mL) was added 1-(aminooxy)-2-methylpropan-2-ol (103 mg, 0.984 mmol) and pyridine (0.080 mL, 0.984 mmol). The reaction mixture was stirred at RT over the weekend. The solvent removed under reduced pressure to give a brown solid. The product was dissolved in 1 ml DMSO and purified by preparative HPLC. The product fractions were washed with saturated bicarbonate solution and dried over MgSO4, filtered and the solvent removed under reduced pressure to give an oil which was triturated with diethyl ether to give a pale yellow solid;
  • LCMS: Rt 3.45 min; MS m/z 447.2 [M+H]+; Method: 10minLowpHv01
  • 1H NMR (400 MHz, MeOD-d4) δ 8.03 (1H, s) 7.97 (1H, s) 7.96 (1H, d) 7.83 (1H, d) 7.54 (1H, d) 3.91 (3H, s) 3.85 (2H, s) 2.51 (3H, s) 2.36 (3H, s) 1.15 (6H, s)
    • Example 126 3-(5-Amino-6-(2-methyloxazol-5-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00273
  • To 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2) (140 mg, 0.378 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)oxazole (79 mg, 0.378 mmol), potassium phosphate (160 mg, 0.755 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (24.60 mg, 0.038 mmol) in 1,4-dioxane (2 mL), water (0.500 mL) was added. The reaction mixture was stirred at 120° C. for 20 mins in the microwave. The reaction mixture was poured into water and the product was extracted using EtOAc. The organic layer was separated and washed with water and brine then dried over MgSO4. Isolute® Si-TMT was added to the filtrate and this was stirred for 1 hr and filtered. The solvent was removed under reduced pressure. The crude product was purified by flash column chromatography, eluting in a 0% to 10% TBME:MeOH gradient, on a 12 g silica cartridge, the crude product was dry loaded on the column. The product fractions were combined and the solvent was removed under reduced pressure to afford the title compound;
  • LCMS: Rt 2.91 min; MS m/z 418.5 [M+H]+; Method: 8minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.24 (1H, s), 7.87-7.83 (1H, m), 7.74-7.65 (2H, m), 7.56-7.43 (2H, m), 6.73 (2H, s), 4.40 (1H, s), 2.62 (2H, br. s.), 2.54 (3H, s), 2.46 (3H, s), 1.06 (6H, s)
    • Example 127 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(2,2,2-trifluoroethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00274
  • To 2,2,2-trifluoroethanamine (15 mg, 0.15 mmol) was added DMA (1 ml) followed by DIPEA (0.035 ml, 0.200 mmol). The reaction mixture was shaken at RT for 30 mins and then treated with 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) (0.1 mmol) and DMA (1 ml). The resulting mixture was shaken at RT for 3 hrs and then concentrated under reduced pressure. The crude product was purified by HPLC (acetonitrile/water gradient, 0.1% TFA modifier) and the product fractions were combined and evaporated to give the title compound;
  • LCMS: Rt 0.82 min; MS m/z 414.1 [M+H]+; Method: 2minLowpHv01
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 127 starting from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and the appropriate commercially available amine. (Amines used in Examples 127.22 and 127.23 can be prepared according to the procedure described in patent application WO2011/113894 page 99). Final compounds were purified by appropriate techniques known in the art. Where trifluoroacetic acid salt formation is indicated, this was formed due to the presence of TFA as modifier in the reverse-phase purification and a basic centre in the molecule. LCMS Method 2minLowpHv01 used unless otherwise stated.
  • MS m/z
    (M + H)+
    unless
    Ex. Name Rt (min) stated
    127.1 5-(5-(3,3-difluoropiperidin-1-ylsulfonyl)-2- 1.12 436.2
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00275
    127.2 5-(5-(3-fluoropyrrolidin-1-ylsulfonyl)-2- 1.01 404.1
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00276
    127.3 5-(5-(3,3-difluoropyrrolidin-1-ylsulfonyl)-2- 1.08 422.1
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00277
    127.4 5-(5-(3,3-difluoroazetidin-1-ylsulfonyl)-2- 1.05 408.1
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00278
    127.5 5-(5-(3-fluoroazetidin-1-ylsulfonyl)-2-methylphenyl)- 0.99 390.1
    3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine
    Figure US20180243297A1-20180830-C00279
    127.6 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.93 444.2
    (4-(hydroxymethyl)cyclohexyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00280
    127.7 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.05 422.2
    (3,3-difluorocyclobutyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00281
    127.8 5-(2-methyl-5-(3,3,4,4-tetrafluoropyrrolidin-1- 1.16 458.1
    ylsulfonyl)phenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00282
    127.9 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.91 418.2
    (5-hydroxypentyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00283
    127.10 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.96 404.2
    (3-methoxypropyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00284
    127.11 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.04 426.2
    ((1-hydroxycyclohexyl)methyl)-4- (M − 17)
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00285
    127.12 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.76 443.2
    yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-
    methylbenzenesulfonamide trifluoroacetic acid salt
    Figure US20180243297A1-20180830-C00286
    127.13 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.87 390.1
    yl)-N-(2-hydroxypropyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00287
    127.14 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.97 416.1
    yl)-4-methyl-N-((tetrahydrofuran-2-
    yl)methyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00288
    127.16 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.95 416.1
    ((1-hydroxycyclobutyl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00289
    127.17 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 1.05 430.2
    methyl)-N-((tetrahydro-2H-pyran-2-
    yl)methyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00290
    127.18 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 0.74 429.2
    methyl-N-((1-methylpyrrolidin-3-
    yl)methyl)benzenesulfonamide trifluoroacetic acid
    salt
    Figure US20180243297A1-20180830-C00291
    127.19 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 0.99 430.2
    methyl-N-((tetrahydro-2H-pyran-3-
    yl)methyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00292
    127.20 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.91 402.1
    yl)-4-methyl-N-(tetrahydrofuran-3-
    yl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00293
    127.21 (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.91 402.1
    yl)-4-methyl-N-(tetrahydrofuran-3-
    yl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00294
    127.22 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 1.01 458.2
    yl)-4-methyl-N-(3,3,3-trifluoro-2-hydroxy-2-
    methylpropyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00295
    127.23 (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 1.01 458.2
    yl)-4-methyl-N-(3,3,3-trifluoro-2-hydroxy-2-
    methylpropyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00296
    127.24 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 1.02 472.2
    methyl-N-(4,4,4-trifluoro-3-hydroxy-3-
    methylbutyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00297
    127.25 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.91 444.2
    ((1-(hydroxymethyl)cyclopentyl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00298
    127.26 (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.79 416.1
    yl)-4-methyl-N-((tetrahydrofuran-3-
    yl)methyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00299
    127.27 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.79 416.1
    yl)-4-methyl-N-((tetrahydrofuran-3-
    yl)methyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00300
    127.28 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.75 378.2
    (2-fluoroethyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00301
    127.29 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.81 392.1
    (3-fluoropropyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00302
    127.30 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 0.90 416.1
    methyl-N-(2-oxotetrahydrofuran-3-
    yl)methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00303
    127.31 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 1.06 428.2
    methyl-N-(3,3,3-trifluoropropyl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00304
    127.32 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 0.73 473.3
    methyl-N-(2-methyl-2-
    morpholinopropyl)benzenesulfonamide
    trifluoroacetic acid salt
    Figure US20180243297A1-20180830-C00305
    127.33 5-(5-(4,4-difluoropiperidin-1-ylsulfonyl)-2- 1.11 436.2
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00306
    127.34 5-(5-(4-fluoropiperidin-1-ylsulfonyl)-2- 1.08 418.2
    methylphenyl)-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-
    amine
    Figure US20180243297A1-20180830-C00307
    127.35 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.99 412.2
    ((1-hydroxycyclopentyl)methyl)-4- (M − 17)
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00308
    127.36 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.02 426.2
    (2-(1-hydroxycyclopentyl)ethyl)-4- (M − 17)
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00309
    127.37 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.06 440.2
    (2-(1-hydroxycyclohexyl)ethyl)-4- (M − 17)
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00310
    127.38 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.92 398.1
    ((1-(hydroxymethyl)cyclopropyl)methyl)-4- (M − 17)
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00311
    127.39 (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 1.1 444.2
    yl)-N-((5,5-dimethyltetrahydrofuran-2-yl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00312
    127.40 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 1.07 444.2
    yl)-N-((5,5-dimethyltetrahydrofuran-2-yl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00313
    127.41 (S)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.87 390.1
    yl)-N-(1-hydroxypropan-2-yl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00314
    127.42 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.87 390.2
    (1-hydroxypropan-2-yl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00315
    127.43 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.02 410.2
    (2,2-difluoropropyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00316
    127.44 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 1.13 402.2
    methyl-N-(3-methylbutan-2-yl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00317
    127.45 (1-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.88 402.1
    yl)-4-methylphenylsulfonyl)azetidin-3-yl)methanol
    Figure US20180243297A1-20180830-C00318
    127.46 1-(3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)- 0.83 402.4
    4-methylphenylsulfonyl)-3-methylazetidin-3-ol
    Figure US20180243297A1-20180830-C00319
    127.47 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.81 418.5
    ((3-hydroxyoxetan-3-yl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00320
    127.48 (R)-3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.85 401.1
    yl)-N-(1-cyano-2-hydroxyethyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00321
    127.49 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.94 430.2
    ((1-(hydroxymethyl)cyclobutyl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00322
    127.50 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.88 460.2
    ((4-hydroxymethyl)tetrahydro-2H-pyran-4-
    yl)methyl)-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00323
    127.51 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4- 0.98 432.1
    methyl-N-(2-oxotetrahydrothiophen-3-
    yl)benzenesulfonamide
    Figure US20180243297A1-20180830-C00324
    127.52 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.08 458.3
    ((1-(hydroxymethyl)cyclohexyl)methyl)-4-
    methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00325
    127.53 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 0.97 372.7
    cyclopropyl-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00326
    127.54 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.03 386.2
    cyclobutyl-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00327
    127.55 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-N- 1.08 400.2
    cyclopentyl-4-methylbenzenesulfonamide
    Figure US20180243297A1-20180830-C00328
    127.56 1-((3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2- 0.88 429.2
    yl)-4-methyl phenylsulfonamido)methyl)
    cyclopropanecarboxamide
    Figure US20180243297A1-20180830-C00329
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 127 starting from 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) and an appropriate mono-boc protected amine. The boc protecting group was removed from the final compounds by shaking a solution of each compound in DCM (2 mL) containing TFA (0.15 mL) for 3 hours, prior to purification.
  • MS m/z
    Ex. Name Rt (min) (M + H)+
    127.57
    Figure US20180243297A1-20180830-C00330
         		0.72 415.2
    127.58
    Figure US20180243297A1-20180830-C00331
         		0.72 415.2
    127.60
    Figure US20180243297A1-20180830-C00332
         		1.01 417.2
    • Example 128 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((3-(hydroxymethyl)oxetan-3-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00333
  • 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3)(200 mg, 0.53 mmol) in DMA (2 ml) was added dropwise to a stirred solution of (3-(aminomethyl)oxetan-3-yl)methanol (68 mg, 0.58 mmol) and DIPEA (0.28 ml, 1.5 mmol) in DMA (2 ml) at 0° C. The reaction was allowed to warm to RT and stirred for 1 h when LCMS suggested a 1:1 mixture of product and sulfonic acid. The reaction mixture was diluted with EtOAc and washed with aq. NaHCO3. The organic extract was separated, dried over MgSO4, and the solvent removed to give a colourless oil. Chromatography on silica, eluting with EtOH, EtOH 1:1, gave the product as a white amorphous solid;
  • LCMS: Rt 0.84 mins; MS m/z 459.5 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (2H, s), 7.88 (1H, s), 7.75 (1H, br s), 7.70 (1H, d), 7.52 (1H, d), 6.29 (2H, s), 4.85 (1H br s), 4.28 (4H, m), 3.82 (3H, s), 3.52 (2H, s), 2.95 (2H, s), 2.45 (3H, s), 2.29 (3H, s).
  • The following compounds were prepared in an analogous manner to that used for the synthesis of Example 128, starting from 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3) and an appropriate amine.
    • Example 128.1 (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-((1-ethylpyrrolidin-2-yl)methyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00334
  • LCMS: Rt 0.6 mins; MS rrilz 470.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.05 (1H, s), 7.86 (1H, s), 7.67 (1H, d), 7.50 (1H, d), 7.46 (1H, br t), 6.29 (2H, s), 3.82 (3H, s), 2.95 (1H, m), 2.80 (1H, m), 2.60 (2H, m), 2.48 (3H, s), 2.38 (1H, m), 2.27 (3H, s), 2.13 (1H, m), 2.05 (1H, m), 1.74 (1H, m), 1.52 (3H, m), 0.92 (3H, t).
    • Example 128.2 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00335
  • LCMS: RT 0.67 mins; MS rrilz 472.4 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.07 (1H, s), 7.86 (1H, s), 7.58 (1H, d), 7.51 (2H, m), 6.28 (2H, s), 3.82 (3H, s), 3.62 (2H, m), 3.41 (1H, m), 3.19 (1H, m), 2.95 (1H, m), 2.69 (1H, m), 2.58 (1H, m), 2.45 (3H, s), 2.29 (3H, s), 2.11 (3H, s), 2.08 (2H, m).
    • Example 128.3a (R or S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide and Example 128.3b: (R or S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00336
  • Racemic 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide was purified by chiral SFC. Method details: (Chiralpak AS-H, 250×10 mm, 5 um @ 35 deg C.) eluting with 50% Isopropanol+0.1% v/v diethylamine/50% CO2 with a flow rate of 10 ml/min. (Detection: UV @ 220 nm, System: Berger Minigram SFC1). Two peaks were collected Peak 1 RT 3.13 mins, Peak 2 RT 4.86 mins.
    • Example 128.3a Peak 1 (First Eluted Peak)
  • SFC retention time=3.13 mins
    • (R)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide or (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide
  • LCMS: RT 0.94 mins; MS m/z 472.4 [M+H]+; Method 2minHighpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.07 (1H, s), 7.86 (1H, s), 7.58 (1H, d), 7.51 (2H, m), 6.28 (2H, s), 3.82 (3H, s), 3.62 (2H, m), 3.41 (1H, m), 3.19 (1H, m), 2.95 (1H, m), 2.69 (1H, m), 2.58 (1H, m), 2.45 (3H, s), 2.29 (3H, s), 2.11 (3H, s), 2.08 (2H, m).
    • Example 128.3b Peak 2 (Second Eluted Peak)
  • SFC retention time=4.86 mins
    • (R)-3-(5-Amino-6-(1,3-di methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholi n-3-yl)methyl)benzenesulfonamide or (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-3-yl)methyl)benzenesulfonamide
  • LCMS: RT 0.94 mins; MS rrilz 472.4 [M+H]+ Method 2minHighpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (1H, s), 8.07 (1H, s), 7.86 (1H, s), 7.58 (1H, d), 7.51 (2H, m), 6.28 (2H, s), 3.82 (3H, s), 3.62 (2H, m), 3.41 (1H, m), 3.19 (1H, m), 2.95 (1H, m), 2.69 (1H, m), 2.58 (1H, m), 2.45 (3H, s), 2.29 (3H, s), 2.11 (3H, s), 2.08 (2H, m).
    • Example 128.4 3-(5-Amino-6-(1,3-di methyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((2-methyltetrahydrofuran-2-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00337
  • LCMS: RT 0.97 min; MS rrilz 457.2 [M+H]+; Method 2minLowpH
    • Example 128.5 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-((4-methylmorpholin-2-yl)methyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00338
  • LCMS: RT 0.96 mins MS m/z 472.3 [M+H]+; Method 2minHighpH.
  • The following compounds were prepared in an analogous manner to that used for the synthesis of Example 128, starting from 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E3) and the appropriate amine protected with a Boc group. After sulfonamide formation, the Boc group was removed by treatment with DCM:TFA at room temperature prior to purification.
    • Example 128.6 (R)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-3-ylmethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00339
  • LCMS: Rt 0.60 mins; MS m/z 458.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.12 (2H, m), 7.89 (1H, s), 7.73 (1H, d), 7.60 (1H, br s), 7.50 (1H, d), 6.29 (2H, s), 3.82 (3H, s), 3.66 (1H, m), 3.58 (1H, m), 3.26 (2H, m), 2.99 (1H, m), 2.62 (5H, m), 2.45 (3H, s), 2.28 (3H, s).
    • Example 128.7 (S)-3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-3-ylmethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00340
  • LCMS: RT 0.60 mins; MS rrilz 458.3 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.09 (2H, m), 7.85 (1H, s), 7.65 (1H, d), 7.59 (1H, br s), 7.50 (1H, d), 6.29 (2H, s), 3.82 (3H, s), 3.65 (1H, d), 3.58 (1H, d), 3.28 (2H, m), 2.95 (1H, m), 2.60 (5H, m), 2.45 (3H, s), 2.28 (3H, s).
    • Example 128.8 3-(5-amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methyl-N-(morpholin-2-ylmethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00341
  • LCMS: Rt 0.84 mins; MS m/z 458.2 [M+H]+; Method 2minHighpHv03.
    • Example 129 (R)-3-(5-Amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-hydroxypropyl)-4-methyl benzene sulfonamide trifluoroacetic acid salt
  • Figure US20180243297A1-20180830-C00342
  • To a mixture of 2,4,6-trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methylbenzenesulfonate (Intermediate E4) (50 mg, 0.093 mmol), (2R)-1-aminopropan-2-ol (15 mg, 0.2 mmol), tetrabutylammonium chloride (41 mg, 1.6 eq) in acetonitrile (2 ml) was added triethylamine (100 μL, 7 eq). The reaction mixture was heated to 140° C. for 30 mins using microwave radiation. The solvent was evaporated under reduced pressure. The crude material was treated with DMSO (1 ml) and purified by HPLC (acetonitrile/water gradient, TFA modifier). The product fractions were combined and evaporated to give (R)-3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-(2-hydroxypropyl)-4-methylbenzenesulfonamide:trifluoroacetic acid (1:1)
  • LCMS: Rt 0.61 mins; MS m/z 412.2 [M−H]−; Method: 2minLowpH
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 129 starting from 2,4,6-trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methylbenzenesulfonate (Intermediate E4) and the appropriate amine. Amines used are commercially available except for amine used in synthesis of Example 129.20 which can be prepared according to the procedure described in patent application WO2011/113894 page 99. All compounds were obtained as trifluoroacetic acid salt except 129.17 to 127.19 which were obtained as free base. LCMS Method: 2minLowpH unless stated.
  • MS m/z
    [M + H]+
    Example Name unless stated Rt (min)
    129.1
    Figure US20180243297A1-20180830-C00343
         		468.3 0.67
    129.2
    Figure US20180243297A1-20180830-C00344
         		446.5 0.73
    129.3
    Figure US20180243297A1-20180830-C00345
         		442.4 0.65
    129.4
    Figure US20180243297A1-20180830-C00346
         		468.3 0.74
    129.5
    Figure US20180243297A1-20180830-C00347
         		438.3 [M − H]− 0.67
    129.6
    Figure US20180243297A1-20180830-C00348
         		426.4 [M − H]− 0.64
    129.7
    Figure US20180243297A1-20180830-C00349
         		428.5 0.64
    129.8
    Figure US20180243297A1-20180830-C00350
         		428.2 0.64
    129.9
    Figure US20180243297A1-20180830-C00351
         		414.2 0.61
    129.10
    Figure US20180243297A1-20180830-C00352
         		440.2 0.65
    129.11
    Figure US20180243297A1-20180830-C00353
         		426.3 [M − H]− 0.67
    129.12
    Figure US20180243297A1-20180830-C00354
         		438.3 [M − H]− 0.68
    129.13
    Figure US20180243297A1-20180830-C00355
         		496.3 0.72
    129.14
    Figure US20180243297A1-20180830-C00356
         		454.5 0.70
    129.15
    Figure US20180243297A1-20180830-C00357
         		442.3 0.71
    129.16
    Figure US20180243297A1-20180830-C00358
         		454.6 0.73
    129.17
    Figure US20180243297A1-20180830-C00359
         		440.2 0.67
    129.18
    Figure US20180243297A1-20180830-C00360
         		440.2 0.64
    129.19
    Figure US20180243297A1-20180830-C00361
         		468.2 0.68
    129.20
    Figure US20180243297A1-20180830-C00362
         		482.5 0.71
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 129 starting from 2,4,6-trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methylbenzenesulfonate (Intermediate E4) and the appropriate commercially available amine. Following HPLC and evaporation, an additional purification step using solid phase extraction (Isolute® PE-AX) was required to remove sulfonic acid impurity. The products 129.21 to 129.31 were hence obtained as acetic acid salts.
  • LCMS
    Method:
    2minLow
    MS m/z pH unless
    [M + H]+ stated
    Example Name unless stated Rt (min)
    129.21
    Figure US20180243297A1-20180830-C00363
         		481.3 0.51
    129.22
    Figure US20180243297A1-20180830-C00364
         		453.3 0.45
    129.23
    Figure US20180243297A1-20180830-C00365
         		469.3 0.52
    129.24
    Figure US20180243297A1-20180830-C00366
         		469.3 0.52
    129.25
    Figure US20180243297A1-20180830-C00367
         		467.3 0.51
    129.26
    Figure US20180243297A1-20180830-C00368
         		427.3 0.38
    129.27
    Figure US20180243297A1-20180830-C00369
         		453.3 0.49
    129.28
    Figure US20180243297A1-20180830-C00370
         		469.3 0.46
    129.29
    Figure US20180243297A1-20180830-C00371
         		497.3 0.51
    129.30
    Figure US20180243297A1-20180830-C00372
         		453.5 0.49
    129.31
    Figure US20180243297A1-20180830-C00373
         		497.5 0.60
  • The following examples were prepared by analogous conditions to those described for the preparation of Example 129 starting from 2,4,6-trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methylbenzenesulfonate (Intermediate E4) and the appropriate boc-protected amine. Prior to HPLC purification, 20% TFA in DCM (2 mL) was added to the crude residue and the mixtures were shaken at RT for 30 mins to remove the Boc group. Mixtures were evaporated and re-dissolved in DMSO (1 mL), then purified by HPLC as previously to give trifluoroacetic acid salts.
  • MS m/z
    [M + H]+
    unless
    Example Name Rt (min) stated
    129.32
    Figure US20180243297A1-20180830-C00374
         		0.59 442.3
    129.33
    Figure US20180243297A1-20180830-C00375
         		0.60 413.2
    129.34
    Figure US20180243297A1-20180830-C00376
         		0.60 399.2
    129.35
    Figure US20180243297A1-20180830-C00377
         		0.63 439.2
    129.36
    Figure US20180243297A1-20180830-C00378
         		0.63 439.3
    129.37
    Figure US20180243297A1-20180830-C00379
         		0.64 437.2
    129.38
    Figure US20180243297A1-20180830-C00380
         		0.63 439.3
    129.39
    Figure US20180243297A1-20180830-C00381
         		0.63 439.3
    129.40
    Figure US20180243297A1-20180830-C00382
         		0.63 425.2
    129.41
    Figure US20180243297A1-20180830-C00383
         		0.65 439.3
    129.42
    Figure US20180243297A1-20180830-C00384
         		0.71 481.3
    129.43
    Figure US20180243297A1-20180830-C00385
         		0.63 453.3
    • Example 130 3-(5-Amino-6-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00386
    • Step 1: 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole
  • Cesium carbonate (3.36 g, 10.31 mmol) was added to a stirred solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.0 g, 5.15 mmol) in dry DMF (12 ml). After stirring at RT for 10 min 2,2,2-trifluoroethyl trifluoromethanesulfonate (1.11 ml, 7.73 mmol) was added. The reaction was stirred for 2 days at RT then the solvent was removed and the residue was partitioned between diethyl ether and water. The organic extract was separated, dried over MgSO4 and the solvent removed to give an oil;
  • LCMS: Rt 1.00 mins; MS MS m/z 277.4 [M+H]+; Method 2minLCv003
    • Step 2: 3-(5-Amino-6-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • A mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole (step 1) (115 mg, 0.417 mmol), 3-(5-Amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) (150 mg, 0.390 mmol), bis(triphenylphosphine) palladium dichloride (14 mg, 0.020 mmol) in sodium carbonate 2M aqueous solution (0.6 mL, 1.200 mmol), Ethanol (1.2 ml) and DME (1.8 mL) was heated to 120° C. for 30 minutes in the microwave, then partitioned between DCM/water, separated using a phase separator and organics evaporated under reduced pressure. The crude product was purified by flash column chromatography (12 g silica, 0-5% methanol in TBME). The product fractions were combined and evaporated, triturated with a mixture of ethyl acetate/diethyl ether and solid collected by filtration, washed with cold dry diethyl ether and dried in the vacuum oven overnight to give pale yellow solid;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.49 (1H, s); 8.16 (1H, s); 8.13 (1H, s); 7.83 (1H, d, −2 Hz); 7.68 (1H, dd, ˜8 and 2 Hz); 7.53 (1H, d, −8 Hz); 7.42 (1H, t); 6.37 (2H, s); 5.21 (2H, q); 4.27 (1H, s); 2.83 (2H, m); 2.48 (3H, s, partially overlapping with solvent); 1.51 (2H, m); 1.01 (6H, s).
  • LC-MS: Rt 0.92 min; MS m/z 499.2 [M+H]+; Method: 2minLowpH
    • Example 131 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methyl-N-(oxetan-3-ylmethyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00387
  • To a stirring solution of 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) (80 mg, 0.228 mmol) and triethylamine (0.035 ml, 0.251 mmol) in DCM (5 ml) was added oxetane-3-ylmethanamine (22 mg, 0.251 mmol). The reaction mixture was stirred at room temp for 30 mins then extracted into DCM, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The yellow residue was dissolved in ethyl acetate and recrystallized overnight at room temperature to yield off white crystals;
  • LCMS: Rt 0.87 mins; MS m/z 402.3 [M+H]+; Method LowpH_v002
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.34 (1H, s), 8.43 (1H, s), 8.42 (1H, s), 7.91 (1H, d), 7.79 (1H, t), 7.73 (1H, dd), 7.56 (1H, d), 7.39 (2H, br s), 4.54 (2H, mult), 4.20 (2H, mult), 3.05 (2H, mult), 2.99 (1H, mult). Tolyl methyl group not seen, likely obscured by DMSO peak.
    • Example 132 3-(5-Amino-6-(1-benzyl-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide hydrochloride
  • Figure US20180243297A1-20180830-C00388
  • The title compound was prepared from 3-(5-amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide (Intermediate D3) and 1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole using analogous conditions to Example 11. Compound was treated with 1M hydrogen chloride in ether to form hydrochloride salt.
  • LC-MS: Rt 0.98 min; MS m/z 507.3 [M+H]+; Method: 2minLowpH
    • Example 133 2-(3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylphenylsulfonamido)acetamide
  • Figure US20180243297A1-20180830-C00389
  • To 3-(5-amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride (Intermediate E1) (50 mg, 0.143 mmol) in DCM (1.5 ml) was added 2-aminoacetamide hydrochloride (15.76 mg, 0.143 mmol) and TEA (0.040 ml, 0.285 mmol) and the resulting mixture stirred at room temperature. After 3 days, the mixture was diluted with sat. aq. NH4Cl and DCM. A white solid precipitated from the aqueous phase which was collected by filtration and triturated with diethyl ether to give a white solid.
  • LC-MS: Rt 2.84 mins; MS m/z 389.3 [M+H]+; Method 10minLowpHv01
    • Example 134 3-(5-Amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-oxopiperidin-4-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00390
    • Step 1: 3-Bromo-4-methyl-N-(2-oxopiperidin-4-yl)benzenesulfonamide
  • To a stirring solution of 3-bromo-4-methylbenzene-1-sulfonyl chloride (685 mg, 2.54 mmol) and DIPEA (0.532 ml, 3.05 mmol) in DCM (12.700 ml) under nitrogen was added 4-aminopiperidin-2-one (290 mg, 2.54 mmol). The reaction mixture was stirred overnight at room temperature then diluted with DCM (100 ml). The organic phase was washed with sat. Na2CO3 (80 ml), 1M HCl (80 ml), brine, dried over MgSO4, and concentrated to dryness. The crude product was purified by flash column chromatography (24 g silica, 0-100% ethyl acetate in hexane) to give an off-white solid;
  • LCMS: Rt 0.82 mins; MS m/z 349.1 [M+H]+; Method: 2minLowpH.
    • Step 2: 3-(5-Amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl-N-(2-oxopiperidin-4-yl)benzenesulfonamide
  • A mixture of 3-bromo-4-methyl-N-(2-oxopiperidin-4-yl)benzenesulfonamide (step 1) (100 mg, 0.288 mmol), potassium acetate (42.4 mg, 0.432 mmol), PdCl2(dppf).CH2Cl2 adduct (11.76 mg, 0.014 mmol) and bis(pinacolato)diboron (80 mg, 0.317 mmol) in DME (1440 μL), under nitrogen, was heated at 90° C. for 3 hours. To the mixture was added 5-chloro-3-(2-methylpyridin-4-yl)pyrazin-2-amine (prepared by analogy to Intermediate C6, starting from 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine and 3-bromo-5-chloropyrazin-2-amine) (63.5 mg, 0.288 mmol), followed by Na2CO3 (2.0M) (432 μL, 0.864 mmol), PdCl2(dppf).CH2Cl2 adduct (11.76 mg, 0.014 mmol) and reaction heated overnight at 90° C. The resulting mixture was added to sat. Na2CO3 (50 ml) and the product extracted into EtOAc (2×40 ml). The organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The crude product was purified first by flash column chromatography (12 g silica, 0-10% 2M methanolic ammonia in DCM) then further by preparative HPLC to give the title compound as a yellow solid;
  • LCMS: Rt 0.57 mins; MS m/z 453.3 [M+H]+; Method: 2minLowpH
    • Example 135 3-(5-Amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00391
  • The title compound was prepared by analogy to Example 25 from N-(trans-4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B5) and 5-chloro-3-(2-methylpyridin-4-yl)pyrazin-2-amine (itself prepared by analogy to intermediate C6, starting from 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine and 3-bromo-5-chloropyrazin-2-amine).
  • LCMS: Rt 0.66 mins; MS m/z 454.4 [M+H]+; Method2minLowpHv01
    • Example 136 3-(5-Amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00392
  • The title compound wasprepared using 5-bromo-3-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (Intermediate C2d) and N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide-3-boronic acid (Intermediate B3a) under analogous conditions to those of Example 1;
  • LC-MS: MS m/z 447.3 [M+H]+; Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.60 (1H, s), 7.91 (1H, s), 7.83 (1H, br s), 7.75 (1H, d), 7.57 (1H, d), 2.85 (4H, m), 2.50 (2H, m), 2.35 (3H, m), 1.00 (6H, s), OH, Me and NH2 not visible, may be obscured by DMSO and water peaks.
    • Example 137 3-(5-Amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(azetidin-3-yl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00393
  • The title compound was prepared using 5-bromo-3-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (Intermediate C2d) and tert-butyl 3-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylsulfonamido)azetidine-1-carboxylate (prepared by analogy to intermediate B1) under analogous conditions to those of Example 1, followed by removal of the Boc protecting group using TFA/DCM;
    • LCMS Method:
  • Column: Cynergi2.5 um Max-RP100A (20×4.0) mm Mobile Phase: A: 0.01M Ammonium acetate (Aq)B:ACN T % B: 0/20, 1.0/20, 2.5/85, 4.0/95, 4.5/20, 5.0/20
  • Flow: 1.0 mL/min, Diluent: ACN
  • LC-MS: MS m/z 416.2 [M+H]+
  • 1H NMR (400 MHz, DMSO-d6) δ 8.62 (1H, s), 7.90 (1H, s), 7.85 (1H, br s), 7.75 (1H, d), 7.57 (1H, d), 4.00 (1H, m), 3.25 (4H, m), 2.88 (2H, m), 1.75 (3H, s), 1.35 (2H, t). Two protons not visible, may be obscured by DMSO and/or water peaks.
    • Example 138 Trans-3-(5-Amino-6-(5-ethyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-N-((1r,4r)-4-hydroxycyclohexyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00394
  • The title compound prepared using 5-bromo-3-(5-ethyl-1,3,4-oxadiazol-2-yl)pyrazin-2-amine (Intermediate C1b) and Trans-N-(4-Hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (Intermediate B5a) under analogous conditions to those of Example 1;
  • LC-MS: MS m/z 459.3 [M+H]+;
  • 1H NMR (400 MHz, DMSO-d6) δ 8.50 (1H, s), 7.88 (1H, s), 7.75 (2H, m), 7.35 (1H, m), 4.45 (1H, br s), 3.30 (1H, br s), 3.00 (2H, m), 2.90 (1H, br s), 2.50 (1H, s), 2.48 (3H, s), 1.70 (4H, m), 1.32 (3H, m), 1.10 (4H, m). Two protons not visible, may be obscured by DMSO and/or water peaks.
    • Example 139 Trans-3-[5-Amino-6-(3-ethyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide
  • Figure US20180243297A1-20180830-C00395
  • The title compound prepared using 5-bromo-3-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (Intermediate C2d) and Trans-N-(4-Hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (intermediate B5a) under analogous conditions to those of Example 1;
  • LCMS: Rt 1.91 mins MS m/z 459.3 [M+H]+:
  • 1H NMR (400 MHz, DMSO-d6) δ 8.60 (1H, s), 7.92 (1H, s), 7.82 (1H, br s), 7.75 (1H, d), 7.65 (1H, d), 7.57 (1H, d), 4.45 (1H, s), 3.30 (1H, m), 2.90 (1H, m), 2.85 (2H, q), 1.78-1.60 (4H, m), 1.43 (3H, t), 1.22-1.00 (4H, m). One proton not visible, may be obscured by DMSO and/or water peaks.
    • Example 140 Trans-3-[5-Amino-6-(3-propyl-[1,2,4] oxadiazol-5-yl)-pyrazin-2-yl]-N-(4-hydroxy-cyclohexyl)-4-methyl-benzene sulfonamide
  • Figure US20180243297A1-20180830-C00396
  • The title compound prepared using 5-bromo-3-(3-propyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (Intermediate C2e) and trans-N-(4-Hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid (intermediate B5a) under analogous conditions to those of Example 1;
  • LCMS: Rt 2.03 mins MS m/z 473.3 [M+H]+
  • 1H NMR (400 MHz, DMSO-d6) δ 8.60 (1H, s), 7.92 (1H, s), 7.80 (2H, br s), 7.75 (1H, d), 7.65 (1H, d), 7.57 (1H, d), 4.45 (1H, s), 3.30 (1H, m), 2.90 (1H, m), 2.80 (2H, m), 2.47 (3H, s), 1.80 (2H, m), 1.60-1.78 (4H, m), 1.00-1.22 (4H, m), 0.95 (3H, t).
    • Example 141 (1-((3-(5-Amino-6-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-4-methylphenyl)sulfonyl) piperidin-4-yl)methanol
  • Figure US20180243297A1-20180830-C00397
  • The title compound prepared under analogous conditions to those of Example 1 using 5-bromo-3-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine (Intermediate C2d) and (5-((4-(hydroxymethyl)piperidin-1-yl)sulfonyl)-2-methylphenyl)boronic acid (prepared in two steps under analogous conditions to those of Intermediate B5a);
  • LC-MS: MS m/z 459.1 [M+H]+; Method A
  • 1H NMR (400 MHz, DMSO-d6) δ 8.63 (1H, s), 7.81 (1H, br s), 7.80 (1H, s), 7.70 (1H, m), 7.60 (1H, m), 4.44 (1H, br s), 3.33 (2H, d), 3.22 (2H, d), 2.87 (2H, m), 2.45 (3H, s), 2.14 (2H, m), 1.70 (2H, m), 1.33 (3H, m), 1.20 (3H, m). One proton not visible, may be obscured by DMSO and/or water peaks.
    • Example 142 3-(5-Amino-6-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00398
    • Step 1: 3-(5-Amino-6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • The title compound was prepared analogously to Example 13 from 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethanol (Syntech solutions commercially available) and 3-(5-amino-6-chloro-pyrazin-2-yl)-N-(2-hydroxy-2-methyl-propyl)-4-methyl-benzenesulfonamide (Intermediate D2);
  • LCMS: Rt=0.84 mins; MS m/z 447.3 [M+H]+; Method 2minLowpHv03
    • Step 2: 2-(4-(3-Amino-6-(5-(N-(2-hydroxy-2-methylpropyl)sulfamoyl)-2-methylphenyl)pyrazin-2-yl)-1H-pyrazol-1-yl)ethyl 4-methylbenzenesulfonate
  • Reference: Prepared according to Patent US 2002/0161004 (page. 44)
  • To a solution of 3-(5-amino-6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide (step 1) (190 mg, 0.426 mmol) in DCM (1064 μl) at 0° C., under an atmosphere of nitrogen, was added triethylamine (74.1 μl, 0.532 mmol). To this mixture was added a solution of p-toluenesulfonyl chloride (81 mg, 0.426 mmol) in DCM (1064 μl) dropwise over 5 minutes and the reaction mixture was stirred at 0° C. for 3.5 hours then allowed to warm to temperature overnight. Further portions of p-toluenesulfonyl chloride (81 mg, 0.426 mmol) and triethylamine (74.1 μl, 0.532 mmol) were added and stirring continued overnight. p-Toluenesulfonyl chloride (81 mg, 0.426 mmol) and triethylamine (74.1 μl, 0.532 mmol) were added and stirring continued overnight. The reaction mixture was added to water (50 ml) and the organic portion was separated, washed with 1M HCl (50 ml), saturated NaHCO3 solution (50 ml) and saturated brine (20 ml). The organics were dried over MgSO4, filtered and concentrated under reduced pressure to give a pale yellow oil. Purification by chromatography on silica eluting 0-10% MeOH in DCM afforded the title compound;
  • LCMS: Rt=1.15 mins; MS m/z 601.6 [M+H]+; Method 2minLowpHv03
    • Step 3: 3-(5-Amino-6-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)pyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • To a stirring solution of 2-(4-(3-amino-6-(5-(N-(2-hydroxy-2-methylpropyl)sulfamoyl)-2-methylphenyl)pyrazin-2-yl)-1H-pyrazol-1-yl)ethyl 4-methylbenzenesulfonate (step 2)(25 mg, 0.042 mmol) in THF (416 μl) under N2 was added DIPEA (14.54 μl, 0.083 mmol) and dimethylamine (2.0M in THF) (250 μl, 0.499 mmol). The reaction mixture was stirred for 16 hours at room temperature. A further portion of dimethylamine (2.0M in THF) (250 μl, 0.499 mmol) was added and stirring continued overnight. The resulting mixture was concentrated under reduced pressure. The crude product was purified by chromatography on silica eluting with 0-10% gradient of (2.0M NH3 in MeOH) in DCM. The resulting residue was further purified by loading onto a 1 g IsoluteeSCX-2 cartridge, flushing with MeOH and eluting the compound with 2.0M NH3 in MeOH to afford the title compound;
  • LCMS: Rt=0.65 mins; MS m/z 474.6 [M−H]+; Method 2minLowpHv03
    • Example 143 3-(5-Amino-6-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00399
  • The title compound was prepared by conditions analogous to those used for the preparation of Example 18 from N-(3-hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate B3) and 5-bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (Intermediate C2c);
  • LCMS: Rt 1.01 mins; MS m/z 359.2 [M+H]+; Method 2minLC_v003
    • PREPARATION OF INTERMEDIATES Bromides (A) Intermediate A1 3-Bromo-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00400
  • To a stirring solution of 3-bromo-4-methylbenzene-1-sulfonyl chloride (2 g, 7.42 mmol) in THF (37 mL) under N2 was added 3-amino-1-propanol (0.568 ml, 7.42 mmol) and the resulting mixture was stirred at RT for 24 hours. The solvent was removed under reduced pressure and the crude material was added to 0.1M HCl (100 ml). The mixture was extracted with EtOAc (150 ml) and the organic extract was washed with sat. Na2CO3 (60 ml), brine, dried over MgSO4 and concentrated under reduced pressure to afford the title compound;
  • LCMS: Rt 0.89 mins; MS m/z 310.1 [M+H]+; Method 2minLC_v003
    • Intermediate A2 3-Bromo-N-(2-hydroxy-2-methylpropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00401
  • To a stirring solution of 3-bromo-4-methylbenzene-1-sulfonyl chloride (3.02 g, 11.22 mmol) in pyridine (56.1 ml) under N2 was added 1-amino-2-methylpropan-2-ol (1.0 g, 11.22 mmol) and the mixture was stirred at RT for 72 hours. The solvent was removed under reduced pressure and the resulting crude material was added to 0.1M HCl (100 ml). The mixture was extracted with EtOAc (150 ml) and the organic extract was washed with sat. Na2CO3 (100 ml), brine, dried over MgSO4 and concentrated under reduced pressure to afford the title compound;
  • LCMS: Rt 1.01 mins; MS m/z 324.1 [M+H]+; Method 2minLC_v003
    • Intermediate A3 3-Bromo-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00402
  • Prepared from 3-bromo-4-methylbenzene-1-sulfonyl chloride and 4-amino-2-methylbutan-2-ol analogously to Intermediate A2
  • LCMS: Rt 1.04 mins; MS m/z does not ionise [M+H]+; Method 2minLC_v003
    • Intermediate A4 3-Bromo-4-methyl-N-(3-methyl-oxetan-3-ylmethyl)-benzenesulfonamide
  • Figure US20180243297A1-20180830-C00403
  • To a solution of (3-methyloxetan-3-yl)methanamine (2.026 g, 20.03 mmol) in DMA (50 ml) was added DIPEA (4.37 ml, 25.04 mmol). The mixture was stirred at RT for 30 min before adding 3-bromo-4-methylbenzene-1-sulfonyl chloride (4.5 g, 16.70 mmol). The mixture was stirred at RT for lhr. The solvent was removed under reduced pressure and the residue was dissolved in EtOAc and washed with saturated aq. NaHCO3 followed by 0.1M HCl then brine. The organic extract was dried over MgSO4 and the solvent removed to give the product as a pale yellow powder (5.19 g)
  • LCMS: Rt 1.10 mins; MS m/z 336.1 [M+H]+; Method 2minLowpHv01
  • The following tabulated intermediates were prepared using methods analogous to those for Intermediates A1 to A4 starting from 3-bromo-4-methylbenzene-1-sulfonyl chloride and the appropriate amines. The amines are either commercially available or may be prepared according to known methods.
  • TABLE 1
    Int. Structure Name [M + H]+/NMR
    A5
    Figure US20180243297A1-20180830-C00404
         		Trans-3- Bromo-N-(4- hydroxy-cyclohexyl)-4- methylbenzenesulfonamide LCMS: Rt 1.01 mins; MS m/z 348.1 [M + H]+; Method 2minLC_v003
    A6
    Figure US20180243297A1-20180830-C00405
         		3-Bromo-N-((R)-1-ethyl- pyrrolidin-2-ylmethyl)-4- methyl-benzenesulfonamide LCMS: RT 0.64 mins; MS m/z 363.5 [M + H]+; Method 2minLowpHv01
    A7
    Figure US20180243297A1-20180830-C00406
         		3-Bromo-4-methyl-N-[(R)-1- (tetrahydro- furan-3-yl)methyl]- benzenesulfonamide LCMS: RT 1.09 mins; MS m/z 336.4 [M + H]+; Method 2minLowpHv01
    A8
    Figure US20180243297A1-20180830-C00407
         		3-Bromo-N-(6-hydroxy- spiro[3.3]hept- 2-yl)-4-methyl- benzenesulfonamide LCMS: Rt 1.01 mins; MS m/z 360.3 [M + H]+; Method 2minLowpHv01
    A9
    Figure US20180243297A1-20180830-C00408
         		3-Bromo-N-(3-hydroxy-2,2- dimethylpropyl)-4- methylbenzenesulfonamide LCMS: Rt 0.98 mins; MS m/z 336.1 [M + H]+; Method 2minLC_v003
    A10
    Figure US20180243297A1-20180830-C00409
         		Cis-3-Bromo-N-(3-hydroxy- cyclobutylmethyl)-4-methyl- benzenesulfonamide (approx. 20% trans isomer) LCMS: RT 0.64 mins; MS m/z 363.5 [M + H]+; Method 2minLowpHv01
    A11
    Figure US20180243297A1-20180830-C00410
         		3-Bromo-N-(1-hydroxy- cyclopropylmethyl)-4-methyl- benzenesulfonamide 1H NMR (400 MHz, DMSO-d6) δ 7.97 (1H, d, J = 1.4 Hz), 7.77- 7.74 (1H, m, J = 6.0 Hz), 7.71-7.69 (1H, dd, J = 1.4, 8.0 Hz), 7.58-7.56 (1H, d, J = 8.0 Hz), 5.32 (1H, s), 2.86-2.85 (2H, d, J = 6.1 Hz), 2.42 (3H, s), 0.52-0.49 (2H, m), 0.46-0.43 (2H, m).
    • Intermediate A12 5-Bromo-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide
  • Figure US20180243297A1-20180830-C00411
  • The title compound was prepared from 5-bromo-2-fluoro-4-methylbenzene-1-sulfonyl chloride and 3-aminopropan-1-ol analogously to Intermediate A1.
  • LCMS: Rt 0.88 mins; MS m/z 328.1 [M+H]+; Method: 2minLC_v003
    • Boronic Esters (B) Intermediate B1 N-(3-Hydroxypropyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00412
  • A mixture comprising 3-bromo-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide (Intermediate A1) (2.25 g, 7.30 mmol), KOAc (1.075 g, 10.95 mmol), PdCl2(dppf).CH2Cl2 adduct (0.298 g, 0.365 mmol) and bis(pinicolato)diboron (2.039 g, 8.03 mmol) in DME (36.5 mL) under N2 was stirred at 90° C. for 5 hours. The resulting mixture was added to water (100 ml) and extracted with EtOAc (2×100 ml). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-100% gradient EtOAc in isohexane afforded the title compound;
  • LCMS: Rt 1.03 mins; MS m/z 356.5 [M+H]+; Method 2minLC_v003
  • The compounds of the following tabulated intermediates were prepared analogously to Intermediate B1 from the appropriate bromide starting compounds (see Intermediates A1-A11):
  • TABLE 2
    Int. Structure Name [M + H]+/NMR
    B2
    Figure US20180243297A1-20180830-C00413
         		N-(2-Hydroxy-2-methyl- propyl)-4-methyl-3- (4,4,5,5- tetramethyl[1,3,2] dioxaborolan-2-yl) benzenesulfonamide LCMS Rt 1.20 min. MS m/z 370.3 (M + H]+), Method: 2minLowpHv01
    B3
    Figure US20180243297A1-20180830-C00414
         		N-(3-Hydroxy-3- methylbutyl)-4-methyl-3- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2- yl)benzenesulfonamide LCMS: Rt 1.10 mins; MS m/z 384.5 [M + H]+; Method 2minLC_v003
    B4
    Figure US20180243297A1-20180830-C00415
         		4-Methyl-N-(3-methyl- oxetan-3-ylmethyl)-3- (4,4,5,5)tetramethyl- [1,3,2] dioxaborolan-2-yl)- benzenesulfonamide LCMS: Rt 1.22 mins MS m/z 382.6 [M + H]+; Method 2minLC_v003
    B5
    Figure US20180243297A1-20180830-C00416
         		N-(trans-4- Hydroxycyclohexyl)-4- methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)benzenesulfonamide LCMS: Rt 1.14 mins; MS m/z 396.3 [M + H]+; Method 2minLC_v003
    B6
    Figure US20180243297A1-20180830-C00417
         		N-((R)-1-Ethyl-pyrrolidine 2-ylmethyl)-4-rnethyl-3- (4,4,5,5- tetramethyl- [1,3,2]dioxaborolan-2-yl)- benzenesulfonamide LCMS: RT 0.97 mins; MS m/z 409.3 [M + H)+; Method 2minLowpHv02
    B7
    Figure US20180243297A1-20180830-C00418
         		4-Methyl-N-[(R)-1- (tetrahydro-furan- 3-yl)methyl]-3-(4,4,5,5- tetramethyl- [1,3,2]dioxaborolan-2-yl)- benzene sulfonamide LCMS Rt 1.28 mins; MS m/z 382.3 [M + H)+; Method 2minLowpHv01
    B8
    Figure US20180243297A1-20180830-C00419
         		N-((cis)-4- hydroxycyclohexyl)-4- methyl-3-(4,4,5,5- tetramethyl-1,3,2- dioxaborolan-2- yl)benzenesulfonamide 1H NMR (400 MHz, DMSO) δ 8.06 (1H, d, J = 2.1 Hz), 7.79-7.76 (1H, dd, J = 2.1, 8.0 Hz), 7.58- 7.56 (1H, d, J = 6.8 Hz), 7.38-7.40 (1H, d, J = 8.1 Hz), 4.32 (1H, d, J = 3.0 Hz), 3.58 (1H, broad m), 2.93 (1H, broad m), 2.53 (3H, s), 1.56-1.48 (4H, m), 1.38-1.28 (4H, m), 1.33 (12H, s).
    • Boronic Acids (B) Intermediate B3a N-(3-Hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide-3-boronic acid
  • Figure US20180243297A1-20180830-C00420
  • To a stirred solution of 3-bromo-N-(3-hydroxy-3-methyl-butyl)-4-methyl-benzenesulfonamide (Intermediate A3)(1.0 g, 2.97 mmol) in THF (20 ml) was added n-BuLi (5.9 ml, 14.85 mmol, 2.5 M) dropwise at −78° C. The reaction was maintained at this temperature for 30 min before dropwise addition of triisopropyl borate (8.9 g, 47.6 mmol). The reaction mixture was allowed to warm slowly to RT then stirred for an additional 15 h. The reaction was quenched with 3N HCl (50 ml) and extracted with ethyl acetate (3×100 ml). The organic extract was separated, dried over sodium sulphate and concentrated under reduced pressure to afford the crude compound. The product was dissolved in ethyl acetate (100 ml) and extracted with sodium carbonate solution (3×150 ml) (pH 9). The aqueous extract was brought to 2 by adding conc HCl, and the product was extracted with ethyl acetate (3×200 ml). The organic extract was dried over sodium sulphate and concentrated under vacuum to afford the title compound (0.29 g).
    • Intermediate B5a Trans-N-(4-Hydroxy-cyclohexyl)-4-methyl-benzenesulfonamide 3-boronic acid
  • Figure US20180243297A1-20180830-C00421
  • To a stirred solution of trans-3-bromo-N-(4-hydroxy-cyclohexyl)-4-methylbenzenesulfonamide (Intermediate A5) (2.0 g, 5.77 mmol) in THF (60 ml) was added n-BuLi (11.5 ml, 28.8 mmol, 2.5 M) dropwise at −78° C. The reaction was maintained at this temperature for 30 min before dropwise addition of triisopropyl borate (17.35 g, 92.32 mmol). The reaction mixture was allowed to warm slowly to RT then stirred for an additional 15 h. The reaction was quenched with 3N HCl (200 ml) and extracted with ethyl acetate (3×250 ml). The organic extract was separated, dried over sodium sulphate and concentrated under vacuum to afford the crude product. The product was dissolved in ethyl acetate (500 ml) and extracted with sodium carbonate solution (3×150 ml) (pH 9). The aqueous extract was brought to pH 2 by adding conc. HCl and the product was extracted with ethyl acetate (3×250 ml). The organic extract was dried over sodium sulphate and concentrated under vacuum to afford the title compound.
    • Intermediate C1 5-Bromo-3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00422
    • Step 1: 3-Amino-6-bromo-pyrazine-2-carboxylic acid N′-acetyl-hydrazide
  • HATU (3.4 g, 9.05 mmol) and triethylamine (1.2 g, 12.06 mmol) were added to a suspension of 2-Amino-5-bromopyrazine-3-carboxylic acid (1.40 g, 6.03 mmol) and acetohydrazide (0.44 g, 6.03 mmol) in DCM (100 ml) and the resultant solution was stirred at ambient temperature for 24 hr. The reaction was monitored by TLC. The reaction mixture was poured into water (200 ml) and the solid collected by filtration and dried under vacuum to afford 3-amino-6-bromo-pyrazine-2-carboxylic acid N′-acetyl-hydrazide;
  • LCMS: Rt 0.57 mins MS m/z 274.0 [M+H}+; Method 2minLowpHv01
    • Step 2: 5-Bromo-3-(5-methyl-[1,3,4]oxadiazol-2-yl)-pyrazin-2-ylamine
  • 3-Amino-6-bromo-pyrazine-2-carboxylic acid N′-acetyl-hydrazide (step 1) (0.86 g, 3.15 mmol) was dissolved in DCM (40 ml) and triethylamine (0.95 g, 9.45 mmol) was added dropwise at room temperature under nitrogen followed by p-toluenesulfonyl chloride (1.79 g, 9.45 mmol). The reaction was stirred at room temperature for 24 hr. DCM (20 ml) was added and the solid was removed by filtration and washed with DCM (30 ml). The organic filtrate was washed with water (2×30 ml) and concentrated under vacuum to afford required compound. The product was purified by flash-chromatography on silica eluting with EtOAc-hexane (9:1) to give the product as a yellow solid:
  • LCMS: Rt 0.86 mins MS m/z 256.0 [M+H]+; Method 2minLowpHv01
    • Intermediate C1b 5-Bromo-3-(5-ethyl-1,3,4-oxadiazol-2-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00423
  • The title compound was prepared analogously to Intermediate C1
    • Intermediate C2a 5-Bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00424
    • Step 1: 3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine
  • DCC (1.39 g, 6.75 mmol) and HOBt.H2O (1.03 g, 13.51 mmol) were added to a stirred suspension of N′-hydroxyacetimidamide (0.5 g, 10.12 mmol) and 3-amino pyrazine-2-carboxylic acid (0.94 g, 6.75 mmol) in DMF (15 ml). The reaction mixture was stirred at rt for 3 h followed by 100° C. for 2 h. When cool, the reaction mixture was poured in to water (100 ml) and diethyl ether (100 ml). The solid was removed by filtration and the filtrate was extracted with more diethyl ether (2×100 ml). The combined organic extracts was dried over Na2SO4 and concentrated under reduced pressure to afford the crude product. Purification by chromatography on silica, eluting with 10% EtOAc in hexane, gave the title compund as a white solid (0.35 g, 29%).
    • Step 2: 5-Bromo-3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine
  • A stirred solution of 3-(3-methyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine (step 1) (258 mg, 1.45 mmol) and NBS (259 mg, 1.45 mmol) in acetonitrile (10 ml) was heated at reflux for 5 h. The solvent was removed and the product was purified by chromatography on silica, eluting with 7% EtOAc in hexane, to give the product as a brown solid (240 mg, 64%).
    • Intermediate C2b 5-Bromo-3-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00425
  • The title compound was prepared analogously to Intermediate C2a starting from N′-hydroxyisobutyrimidamide
    • Intermediate C2c 5-Bromo-3-(3-cyclopropyl-[1,2,4]oxadiazol-5-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00426
  • The title compound was prepared analogously to Intermediate C2a starting from N′-hydroxycyclopropanecarboximidamide
    • Intermediate C2d 5-Bromo-3-(3-ethyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00427
  • The title compound was prepared analogously to Intermediate C2a, starting from N′-hydroxypropionimidamide
    • Intermediate C2e 5-Bromo-3-(3-propyl-1,2,4-oxadiazol-5-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00428
  • The title compound was prepared analogously to Intermediate C2a starting from N′-hydroxybutyrimidamide
    • Intermediate C3 5-Bromo-3-(3-methyl-isoxazol-5-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00429
    • Step 1: 3-(3-Methyl-isoxazol-5-yl)-pyrazin-2-ylamine
  • n-Butyllithium (7 ml, 9.8 mmol, 1.4 M in hexanes) was added to a solution of acetone oxime (0.36 g, 4.9 mmol) in dry THF (15 ml) under nitrogen at 0° C. The mixture was allowed to warm to RT and stirred for 30 min. A solution of 3-amino-pyrazine-2-carboxylic acid methyl ester (0.50 g, 3.26 mmol) in THF (5 ml) was added and the reaction was stirred at RT until the starting material was consumed. Sulfuric acid (2 ml) was added at 0° C. followed by stirring at room temperature for 1 h. The reaction mixture was basified with aq. Na2CO3 and the product was extracted with DCM (5×15 ml). The combined organic extracts were dried over Na2SO4 and the solvent removed. The residue was purified by chromatography on silica, eluting with EtOAc:hexane (2:8) to give the title compound.
    • Step 2: 5-Bromo-3-(3-methyl-isoxazol-5-yl)-pyrazin-2-ylamine
  • NBS (50 mg, 0.28 mmol) was added to a stirred solution of 3-(3-Methyl-isoxazol-5-yl)-pyrazin-2-ylamine (50 mg, 0.28 mmol) in chloroform and the reaction was stirred for 4 h at room temperature. The reaction was diluted with water and extracted with CHCl3. The organic extract was dried over Na2SO4 and purified by chromatography on silica, eluting with hexane: EtOAc (3:1) to give the title compound.
  • LCMS: Rt 0.98 mins MS m/z 255.0 [M+H]+; Method 2minLowpHv01
    • Intermediate C4 5-Bromo-3-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00430
    • Step 1: 3-(1-Methyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine
  • Sodium carbonate (17 ml of a 2M solution, 33 mmol) was added to a mixture of 3-chloropyrazin-2-amine (1.23 g, 9.47 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1H-pyrazole (1.97 g, 9.47 mmol) and PdCl2(dppf).CH2Cl2 (0.387 g, 0.473 mmol) in DME (60 ml). The mixture was de-gassed several times under nitrogen then heated at 85° C. for 3 h. The solvent was removed and the residue was diluted with water and extracted several times with EtOAc. The organic extract was separated, dried over MgSO4 and the solvent removed to give a dark oil. Chromatography on silica, eluting with EtOAc:MeOH (3:1), followed by trituration with EtOAc and diethyl ether gave the title compound as a grey powder (1.25 g)
  • LCMS: Rt 0.45 mins; MS m/z 176.4 [M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, CDCl3) 8.01 (2H, m), 7.93 (2H, s), 4.75 (2H, br s), 4.00 (3H, s)
    • Step 2: 5-Bromo-3-(1-methyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine
  • A stirred solution of 3-(1-methyl-1H-pyrazol-4-yl)pyrazin-2-amine (step 1) (1.3 g, 7.42 mmol) and NBS (1.45 g, 8.16 mmol) in acetonitrile (15 ml) was heated at reflux under nitrogen for 5 hrs. The solvent was removed under reduced pressure and the residue was diluted with aq. NaHCO3 and extracted several times with EtOAc. The organic extract was dried over MgSO4 and concentrated under reduced pressure to give a dark oil. Chromatography on silica, eluting with EtOAc, gave the title compound as a solid (0.523 g, 26%)
  • LCMS: Rt 0.75 mins MS m/z 254.3 [M+H]+; Method 2minLC_v003
  • 1H NMR (400 MHz, CDCl3) δ (ppm) 8.01 (2H, s), 7.96 (1H, s), 4.75 (2H, br s), 4.00 (3H, s).
    • Intermediate C5 5-Chloro-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00431
  • A mixture of 3-bromo-5-chloropyrazin-2-amine (5 g, 23.99 mmol), 1H-1,2,4-triazole (1.740 g, 25.2 mmol), N,N-dimethylglycine (0.247 g, 2.399 mmol), Cs2CO3 (23.45 g, 72.0 mmol) and CuI (0.457 g, 2.399 mmol) in dimethylaniline (120 ml) was heated at 150° C. for 4 hours. The resulting mixture was added to water (700 ml) and the product was extracted into EtOAc (2×500 ml). The combined organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with a gradient of 0-10% [2M NH3 in MeOH] in DCM afforded the title compound as a yellow solid; LCMS: Rt 0.74 mins; MS m/z 197.1 [M+H]+; Method 2minLowpH.
    • Intermediate C6 5-Chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00432
  • A mixture of 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-Athiazole (1 g, 4.44 mmol), 3-bromo-5-chloropyrazin-2-amine (0.926 g, 4.44 mmol), PdCl2(dppf).CH2Cl2 adduct (0.181 g, 0.222 mmol) and 2 M Na2CO3 (6.66 ml) in DME (22.21 ml) under N2 was heated using microwave radiation at 120° C. for 45 mins. The mixture was added to water (100 ml) and extracted with EtOAc (2×90 ml). The organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-10% [2.0M NH3 in MeOH] in TBME afforded the title compound as a brown solid;
  • LCMS: Rt 0.87 mins; MS m/z 227.1 [M+H]+; Method 2minLC_v003.
    • Intermediate C7 5-Chloro-3-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00433
  • To a solution of 3-bromo-5-chloropyrazin-2-amine (3.75 g, 18.01 mmol) in DME (90 mL) was added 1,3-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (4 g, 18.01 mmol), bis(triphenylphosphine)palladium(11) chloride (0.632 g, 0.901 mmol) and Na2CO3 (aq. 2.0M) (27.0 mL, 54.0 mmol). The reaction was heated to 90° C. overnight. The reaction was added to water (250 ml) and the product was extracted into EtOAc (2×230 ml). The organic phase was washed with brine, dried over MgSO4. The solids were removed by filtration, washed with EtOAc and the filtrate concentrated under vacuum. The crude product was purified by flash column chromatography, eluting with 0-10% gradient of (2M NH3 in MeOH) in DCM on a 80 g Si-column, loading with DCM to give the product (2.5 g)
  • LCMS: Rt 0.81 mins; MS m/z 224.0 [M+H]+; Method 2minLowpHv01
    • Intermediate C8 5-Bromo-3-(1H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00434
    • Step 1: 5-Bromo-3-trimethylsilanylethynyl-pyrazin-2-ylamine
  • To a 150 mL round-bottomed flask was added 3,5-dibromopyrazin-2-amine (3 g, 11.86 mmol) and triethylamine (16.53 ml, 119 mmol) in THF (60 ml) to give a yellow suspension. To the stirring solution was added bis(triphenylphosphine)palladium(11) chloride (833 mg, 1.186 mmol) and copper(I) iodide (452 mg, 2.373 mmol). Whilst maintaining the temperature below 10° C., ethynyltrimethylsilane (1.844 ml, 13.05 mmol) was added slowly and the reaction stirred at below 10° C. for 30 mins before warming to room temperature and stirring for a further 30 mins.
  • The reaction was concentrated under reduced pressure. After dilution with ethyl acetate the organics were washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue was loaded onto silica and purified by flash column chromatography, elution with iso hexane:ethyl acetate (0-30%) on an 80 g silica column. The required fractions were combined and the solvent removed under reduced pressure to yield the product as a light brown solid (2.5 g).
  • LCMS: Rt 1.26 mins MS m/z 272.3 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.12 (1H, s), 6.80 (2H, br s), 0.26 (9H, s).
    • Step 2: 5-Bromo-3-ethynyl-pyrazin-2-ylamine
  • To a 150 mL round-bottomed flask was added 5-bromo-3-((trimethylsilyl)ethynyl) pyrazin-2-amine (2.5 g, 9.25 mmol) and K2CO3 (1.279 g, 9.25 mmol) in MeOH (40 ml) to give a brown solution. The reaction was stirred at room temp for 30 mins. The reaction was extracted into DCM, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to yield the product as a brown solid (1.54 g).
  • LCMS; Rt 0.78 mins MS m/z 200.2. [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.12 (1H, s), 6.86 (2H, broad s), 4.81 (1H, s).
    • Step 3: 5-Bromo-3-(1H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • To a 100 mL round-bottomed flask was added 5-bromo-3-ethynylpyrazin-2-amine (800 mg, 4.04 mmol), Sodium ascorbate (0.404 ml, 0.404 mmol), and copper(II) sulfate pentahydrate (10.09 mg, 0.040 mmol) in tertiary butanol (10.00 ml) and water (20 ml) to give a brown suspension. To this was added trimethylsilyl azide (1.61 ml, 12.12 mmol) and the reaction heated at 90° C. for 4 hours. The reaction was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue was loaded onto silica and purified by flash column chromatography, elution with iso hexane:ethyl acetate (0-70%) on a 40 g silca cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield the product as a dark yellow solid (560 mg, 57%).
  • LCMS: Rt 0.82 mins MS m/z 243.2. [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ (ppm) 15.66 (1H br s), 8.52 (1H, br s), 8.14 (1H, s), 7.46 (2H, br s).
    • Step 4: 5-Bromo-3-(1H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • To a 25 mL round-bottomed flask was added 5-bromo-3-(1H-1,2,3-triazol-4-yl)pyrazin-2-amine (250 mg, 1.037 mmol), potassium carbonate (430 mg, 3.11 mmol), and iodomethane (0.195 ml, 3.11 mmol) in THF (10 ml) to give a yellow suspension. The reaction was stirred at room temp for 1 hour whereupon a 1:1 mixture of two regioisomers had formed. The reaction was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude mixture was taken up in DMSO and purified by mass directed preparative purification to give the title compound.
  • LCMS: Rt 0.95 mins MS m/z 255.2. [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6), δ 8.27 (1H, s), 8.18 (1H, s), 7.30 (2H, br s), 4.29 (3H, s).
    • Intermediate C8a 5-Bromo-3-(1-ethyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine and Intermediate C8b 5-Bromo-3-(2-ethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00435
  • To a 25 mL round-bottomed flask was added 5-bromo-3-(1H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8 step 3) (300 mg, 1.245 mmol), potassium carbonate (516 mg, 3.73 mmol) and iodoethane (0.302 mL, 3.73 mmol) in THF (10 mL) to give a yellow suspension. The reaction mixture was heated at 70° C. for 4 hours. A 4:6 ratio of two regioisomers formed. The reaction was extracted into ethyl acetate, washed with water, brine, the organic layer separated dried over MgSO4, filtered and the solvent removed under reduced pressure. The sample was dissolved in DMSO and purified by mass directed preparative chromatography. The required fractions were combined, extracted into DCM, washed with sat. sodium bicarbonate solution to remove all traces of TFA, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to afford the individual regioisomers:
    • First Eluted Peak: Intermediate C8a 5-Bromo-3-(1-ethyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine
  • LCMS: Rt 0.99 mins MS m/z 269.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.79 (1H, s), 8.12 (1H, s), 7.54 (2H, broad), 4.49 (2H, mult), 1.50 (3H, t).
    • Second Eluted Peak: Intermediate C8b 5-Bromo-3-(2-ethyl-2H-1,2,3-triazol-4-yl)pyrazin-2-amine
  • LCMS: Rt 1.07 mins MS m/z 269.3 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.29 (1H, s), 8.18 (1H, s), 7.30 (2H, broad), 4.57 (2H, mult), 1.52 (3H, t).
    • Intermediate C8c 5-Bromo-3-(2-(2,2,2-trifluoroethyl)-2H-1,2,3-triazol-4-yyl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00436
  • To a 25 mL round-bottomed flask was added 5-bromo-3-(1H-1,2,3-triazol-4-yl)pyrazin-2-amine (Intermediate C8 step 3) (300 mg, 1.245 mmol), cesium carbonate (1217 mg, 3.73 mmol), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (0.359 mL, 2.489 mmol) in acetonitrile (10 mL) to give a yellow suspension. The reaction mixture was stirred at room temperature for 1 hour. The mixture was extracted into ethyl acetate, washed with water, brine, the organic layer separated dried over MgSO4, filtered and the solvent removed under reduced pressure. The sample was dissolved in DMSO and purified by mass directed preparative chromatography.). The required fractions were combined, extracted into DCM, washed with sat. sodium bicarbonate to remove all traces of TFA, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to yield an off white solid;
  • LCMS: Rt 1.17 mins MS m/z 323.4 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.49 (1H, s), 8.24 (1H, s), 7.33 (2H, broad), 5.72 (2H, q).
    • Intermediate C9 5-Bromo-3-(2,5-dimethyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00437
    • Step 1: 5-Bromo-3-(prop-1-ynyl)pyrazin-2-amine
  • To a 100 mL round-bottomed flask was added 3,5-dibromopyrazin-2-amine (2 g, 7.91 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.278 g, 0.395 mmol) in toluene (30 ml) to give a yellow suspension. To the stirring solution was added tributyl(prop-1-ynyl)stannane (2.41 ml, 7.91 mmol) and the reaction heated at 60° C. for 1 hour. The crude reaction was loaded onto silica and the solvent removed under reduced pressure. The product was purified by flash column chromatography, elution with isohexane:ethyl acetate (0-50%) on an 40 g silica column. The required fractions were combined and the solvent removed under reduced pressure to yield the product as a light brown solid (1.3 g).
  • LCMS: Rt 0.87 mins MS m/z 212.0 [M+H]+; Method 2minLowpHv01
  • 1H NMR (400 MHz, DMSO-d6) δ 8.02 (1H, s), 6.80 (2H, br), 2.13 (3H, s).
    • Step 2: 5-Bromo-3-(5-methyl-1H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • To a 25 mL round-bottomed flask was added 5-bromo-3-(prop-1-ynyl)pyrazin-2-amine (1.1 g, 5.19 mmol) and TMS azide (2.066 ml, 15.56 mmol) in DMF (25 ml) to give a brown solution. The reaction was heated at 120° C. for 2 hours followed by 150° C. for a further 4 hours. The reaction was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The reddish brown residue was loaded onto silica and purified by flash column chromatography, elution with isohexane:ethyl acetate (0-50%) on a 40 g silca cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a dark yellow oil. DCM:isohexane (1:3) was added and the resulting yellow suspension filtered to yield a yellow solid (205 mg).
  • LCMS: Rt 0.95 mins; MS m/z 255.3 [M+H]+; Method 2minLowpHv01.
  • 1H NMR (400 MHz, DMSO-d6) δ 15.40 (1H, br s), 8.09 (1H, s), 7.51 (2H, br s), 2.58 (3H, s).
    • Step 3: 5-Bromo-3-(2,5-dimethyl-2H-[1,2,3]triazol-4-yl)-pyrazin-2-ylamine
  • To a 50 mL round-bottomed flask was added 5-bromo-3-(5-methyl-1H-1,2,3-triazol-4-yl)pyrazin-2-amine (205 mg, 0.804 mmol), potassium carbonate (333 mg, 2.411 mmol), and iodomethane (0.151 ml, 2.411 mmol) in THF (8 ml) to give a yellow suspension. The reaction was stirred at room temp for 1 hour then heated at 40° C. for 2 hours to give a 1:1 mixture of two regioisomers. The reaction was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was purified by flash column chromatography, elution with iso hexane:ethyl acetate (0-50%) on a 12 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield the product as a yellow solid (175 mg) containing an additional regioisomer.
  • LCMS: Rt 0.96 mins MS m/z 269.0 [M+H]+, 1.07 mins MS m/z 269.1 [M+H]+; Method 2minLowpHv01.
    • Intermediate C10 5-Chloro-3-(2-cyclopropyl-thiazol-5-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00438
  • The title compound was prepared from 2-Cyclopropyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-thiazole and 3-Bromo-5-chloro-pyrazin-2-ylamine analogously to Intermediate C7.
  • LCMS: Rt 1.06 mins; MS m/z 253.1 [M+H]+; Method: 2minLowpHv01
    • Intermediate C11 5-Bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00439
  • A mixture of 5-bromo-3-chloropyrazin-2-amine (1.3 g, 6.24 mmol), 1H-1,2,4-triazole (0.5 g, 7.24 mmol) and cesium carbonate (3.5 g, 10.74 mmol) in DMF (25 ml) was heated to 60° C. overnight. After cooling to room temperature, the mixture was partitioned between ethyl acetate (150 mL) and water (75 mL). The organic portion was separated and the aqueous was extracted with ethyl acetate (2×75 mL). The combined organic extracts were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and evaporated under reduced pressure. Purification of the crude product by chromatography on silica eluting with 10-25% ethyl acetate in iso-hexane afforded the title compound;
  • LCMS: Rt 2.86 min; m/z 241.1 and 243.3 [M+H]+ bromine isotopes; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 9.25 (1H, s), 8.40 (1H, s), 8.30 (1H, s), 7.34 (2H, s).
    • Intermediate C12 5-Bromo-3-(3-methyl-[1,2,4]triazol-1-yl)-pyrazin-2-ylamine
  • Figure US20180243297A1-20180830-C00440
  • Prepared using 5-bromo-3-chloropyrazin-2-amine and 3-methyl-1H-[1,2,4]triazole by analogy to Intermediate C11.
  • LCMS: Rt 0.87 mins; MS m/z 355.0 [M+H]+; Method 2minLowpHv01
    • Intermediate C13 5-Chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00441
    • Step 1: 5-Chloro-3-((trimethylsilyl)ethynyl)pyrazin-2-amine
  • To a 500 mL round-bottomed flask was added 3-bromo-5-chloropyrazin-2-amine (5 g, 23.99 mmol), ethynyltrimethylsilane (10.17 ml, 72.0 mmol), and triethylamine (33.4 ml, 240 mmol) in THF (100 ml) to give a brown solution. The reaction was degassed and purged with nitrogen. To the stirring solution was added bis(triphenylphosphine)palladium(II) chloride (1.684 g, 2.399 mmol) and copper(I) iodide (914 mg, 4.80 mmol). The reaction was stirred at room temperature for 30 mins. The reaction was extracted into ethyl acetate, washed with brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product loaded onto silica was purifiied by flash column chromatography elution with iso hexane:ethyl acetate (0-30%) using an 80 g silca cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a brown solid;
  • LCMS: Rt=1.29 mins MS m/z 226.2 [M+H]+; Method 2minLowpHv02.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.08 (1H, s), 6.82 (2H, broad s), 0.27 (9H, s).
    • Step 2: 5-Chloro-3-ethynylpyrazin-2-amine
  • To a 250 mL round-bottomed flask was added 5-chloro-3-((trimethylsilyl)ethynyl)pyrazin-2-amine (step 1) (3.64 g, 16.12 mmol) and K2CO3 (2.228 g, 16.12 mmol) in MeOH (75 ml) to give a brown solution. The reaction was stirred at room temperature for 30 mins. The reaction was extracted into DCM, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to yield a brown solid;
  • LCMS: Rt=0.80 mins MS m/z 154.1 [M+H]+; Method 2minLowpHv02.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.13 (1H, s), 6.92 (2H, broad s), 4.85 (1H, s).
    • Step 3: 5-Chloro-3-(3-cyclopropylisoxazol-5-yl)pyrazin-2-amine
  • To a 50 mL round-bottomed flask was added cyclopropanecarboxaldehyde (0.245 ml, 3.26 mmol), hydroxylamine hydrochloride (238 mg, 3.42 mmol) and NaOH (137 mg, 3.42 mmol) in t-BuOH (8 ml) and water (8 ml) to give a colorless solution. The reaction was stirred at room temperature for 30 mins. To the reaction was added chloramine-T (840 mg, 3.42 mmol), copper powder (9 mg, 0.140 mmol) and copper(I1)sulfate pentahydrate (24 mg, 0.098 mmol) and the mixture was stirred for 15 mins. To the greenish brown solution was added 5-chloro-3-ethynylpyrazin-2-amine (from step 2) (500 mg, 3.26 mmol) and the reaction stirred at 50° C. for 2 hours. The mixture was extracted into ethyl acetate, washed with ammonium hydroxide, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. The crude product was purified by flash column chromatography elution with iso-hexane:ethyl acetate (0-40%) on a 24 g silica cartridge. The required fractions were combined and the solvent removed under reduced pressure to yield a light brown solid. The solid was triturated in iso hexane:ethyl acetate (4:1) and the resulting suspension filterred to yield a yellow solid which was dissolved in DCM (20 mL) and PS-TBD (2896 mg, 3.19 mmol) added to give a yellow suspension. The reaction was stirred at room temperature for 2 hours. The suspension was filtered through Celitee cartridge to remove the polymer supported reagent. The filtrate was collected and the solvent removed under reduced pressure to yield a yellow solid;
  • LCMS: Rt=1.12 mins MS m/z 237.1 [M+H]+; Method 2minLowpHv02.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.24 (1H, s), 6.94 (2H, broad s), 6.82 (1H, s), 2.12-2.05 (1H, m), 1.08-1.04 (2H, m), 0.92-0.88 (2H, m).
    • Intermediate D1 Trans-3-(5-Amino-6-chloropyrazin-2-yl)-N-(4-hydroxycyclohexyl)-4-methylbenzene sulfonamide
  • Figure US20180243297A1-20180830-C00442
  • A mixture comprising trans-N-(4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate A5) (9.48 mg, 2.40 mmol), 5-bromo-3-chloropyrazin-2-amine (500 mg, 2.399 mmol), PdCl2(dppf).CH2Cl2 adduct (98 mg, 0.120 mmol) and Na2CO3 (6.00 ml, 11.99 mmol) in DME (11.400 ml) under N2 was heated using microwave irradiation at 120° C. for 45 mins. The mixture was added to water (100 ml) and extracted with EtOAc (2×100 ml). The organic extracts were washed with brine, dried over MgSO4 and concentrated under reduced pressure. Purification by chromatography on silica eluting with 0-100% EtOAc in iso-hexane followed by sonication of the resulting solid afforded the title compound as an off-white solid;
  • LCMS: Rt 0.88 mins; MS m/z 438.2 [M+H]+; Method 2minLC_v003
    • Intermediate D2 3-(5-amino-6-chloropyrazin-2-yl)-N-(2-hydroxy-2-methylpropyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00443
  • The title compound was prepared analogously to Intermediate D1 by replacing trans-N-(4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene sulfonamide (Intermediate A5) with N-(2-Hydroxy-2-methyl-propyl)-4-methyl-3-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzenesulfonamide (Intermediate A2);
  • LC-MS: RT 0.93 mins; MS m/z 371.2 [M+H]+; Method 2minLowpHv01
    • Intermediate D3 3-(5-Amino-6-chloropyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methyl benzenesulfonamide
  • Figure US20180243297A1-20180830-C00444
  • The title compound was prepared analogously to Intermediate D1 by replacing trans-N-(4-hydroxycyclohexyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzene sulfonamide (Intermediate A5) with N-(3-hydroxy-3-methylbutyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (Intermediate A3);
  • LCMS: Rt 0.88 mins; MS m/z 385.2 [M+H]+; 2minLC_v003
    • Intermediate D4 3-(5-Amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl) benzenesulfonamide
  • Figure US20180243297A1-20180830-C00445
  • To a solution of 4-amino-1,1,1-trifluorobutan-2-ol hydrochloride (275 mg, 1.531 mmol) and 3-bromo-4-methylbenzene-1-sulfonyl chloride (425 mg, 1.577 mmol) in THF (7 mL) was added DIPEA (0.55 mL, 3.15 mmol). The resulting mixture was stirred at room temperature overnight then diluted with DCM, washed with 10% citric acid, then dried by passing through a phase separator. The organic phase was evaporated under reduced pressure and purified by flash column chromatography (24 g silica, 0-50% ethyl acetate in isohexane). The resulting material [3-bromo-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide, 530 mg, estimated 80% purity] was dissolved in 1,2-dimethoxyethane (6 mL). Bis(pinacolato)diboron (340 mg, 1.339 mmol), bis(triphenylphosphine)palladium dichloride (40 mg, 0.057 mmol) and potassium acetate (175 mg, 1.783 mmol) were added and the reaction heated to reflux. After two hours further bis(pinacolato)diboron (100 mg) was added and the mixture refluxed again for three hours. 5Bromo-3-chloropyrazin-2-amine (260 mg, 1.247 mmol) and aq. 2M sodium carbonate (1.7 mL, 3.40 mmol) were added and the resulting mixture heated to 90° C. for 3 hours in the microwave. The resulting mixture was partitioned between DCM and water and separated using a phase separator cartridge. The organics were evaporated under reduced pressure, bound to silica and purified by flash column chromatography on 40 g silica, 10-70% ethyl acetate in isohexanes. The product fractions were combined and evaporated under reduced pressure to give title compound as a yellow oil;
  • LCMS: Rt 0.94 min; MS m/z 425.1 [M+H]+; Method Name: 2minLowpH
  • Chiral separation of 3-(5-amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl) benzenesulfonamide using Supercritical Fluid Chromatography afforded the individual enantiomers (Intermediate D4a and D4b).
    • Method Details:
  • Column: Phenomenex LUX C4 250×10 mm, 5 um @ 35 deg C.
  • Mobile phase: 20% Isopropanol+0.1c/ov/v DEA/80% CO2
  • System: Berger Minigram SF02
    • Intermediate D4a and Intermediate D4b (R) and (S)-3-(5-Amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide
  • Figure US20180243297A1-20180830-C00446
  • Chiral separation afforded two peaks which were analysed by analytical chiral SFC using the following method:
  • Column: Phenomenex LUX C4 250×10 mm, 5 um @ 35 deg C.
  • Mobile phase: 20% Isopropanol+0.1c/ov/v DEA/80% CO2
  • Flow: 10 ml/min; Run Time: 15.00 min
  • Detection: UV @ 220 nm
  • System: Berger Minigram SF02
    • Intermediate D4a
  • First eluted peak: SFC retention Time=10.5 min (S)-3-(5-amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide or (R)-3-(5-Amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide
    • Intermediate D4b
  • Second eluted peak: SFC retention Time=13.1 min (S)-3-(5-amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifluoro-3-hydroxybutyl)benzenesulfonamide or (R)-3-(5-Amino-6-chloropyrazin-2-yl)-4-methyl-N-(4,4,4-trifl uoro-3-hydroxybutyl)benzenesulfonamide
    • Intermediate D5 5-(5-Amino-6-chloropyrazin-2-yl)-2-fl uoro-N-(3-hydroxypropyl)-4-methyl benzene sulfonamide
  • Figure US20180243297A1-20180830-C00447
  • A mixture of 5-bromo-2-fluoro-N-(3-hydroxypropyl)-4-methylbenzenesulfonamide (Intermediate A12) (590 mg, 1.809 mmol), KOAc (266 mg, 2.71 mmol), PdCl2(dppf).CH2Cl2 adduct (73.9 mg, 0.090 mmol) and bis(pinicolato)diboron (505 mg, 1.990 mmol) in DME (9043 μL), under N2, was heated at 90° C. for 14 hours. 5-bromo-3-chloropyrazin-2-amine (377 mg, 1.809 mmol) was added to the reaction mixture, followed by Na2CO3 (2713 μL, 5.43 mmol) and PdCl2(dppf).CH2Cl2 adduct (73.9 mg, 0.090 mmol) and the reaction mixture was microwaved at 120° C. for 45 mins. To the mixture was added to sat. Na2CO3 (100 ml) and the product extracted into EtOAc (2×90 ml). The organic extracts were washed with brine, dried over MgSO4, and concentrated under reduced pressure. The crude product was purified by flash column chromatography, eluting with a 0-10% gradient of (2M NH3 in MeOH) in TBME on a 40 g Si-column to give the title compound as a pale yellow solid;
  • LCMS: Rt 0.81 mins; MS rrilz 375.1 [M+H]+; Method: 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) δ 8.19 (1H, s), 7.81 (1H, br s), 7.73 (1H, d), 7.42 (1H, d), 7.02 (2H, s), 4.41 (1H, br s), 3.37 (2H, t), 2.91 (2H, t), 2.42 (3H, s), 1.54 (2H, m).
    • Intermediate E1 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride Step 1: 5-o-Tolyl-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine
  • Figure US20180243297A1-20180830-C00448
  • To a 20 ml microwave vial was added o-tolylboronic acid (0.169 g, 1.245 mmol), 5-bromo-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (Intermediate C11, 0.3 g, 1.245 mmol), PdCl2(dppf)-CH2Cl2adduct (50.8 mg, 0.062 mmol) and 2M sodium carbonate (1.556 ml, 3.11 mmol) in DME (3.5 ml) to give an orange suspension. The reaction was heated in the biotage initiator microwave at 120° C. for 60 mins. The reaction was extracted into ethyl acetate, washed with water, brine, the organic layer separated, dried over MgSO4, filtered and the solvent removed under reduced pressure. Purified by flash column chromatography, elution with isohexane:ethyl acetate (0-100%) on a 12 g silica column. The required fractions were combined and the solvent removed under reduced pressure to yield the title compound as a brown solid (230 mg).
  • LCMS Rt 0.96 mins; MS m/z 253.2 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, DMSO-d6) 9.33 (1H, s), 8.41 (1H, s), 8.35 (1H, s), 7.52 (1H, mult), 7.32 (3H, mult), 7.27 (2H, br), 2.42 (3H, s).
    • Step 2: 3-(5-Amino-6-(1H-1,2,4-triazol-1-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride
  • Figure US20180243297A1-20180830-C00449
  • To a 50 ml round bottom flask cooled to <5° C. was added 5-o-tolyl-3-(1H-1,2,4-triazol-1-yl)pyrazin-2-amine (step 1, 780 mg, 3.09 mmol) and chlorosulfonic acid (4.97 ml, 74.2 mmol) in CHCl3 (15 ml) to give a brown solution. The solution became biphasic upon complete addition of the acid and was allowed to warm to room temperature with stirring overnight. The reaction was carefully added dropwise to a stirring solution of ice water and DCM (3:1). A suspension formed. The contents were transferred to a separating funnel, DCM added and the suspension shaken until it completely dissolved in the organic layer. The organics were separated, dried over MgSO4, filtered and the solvent removed under reduced pressure to yield the title compound as a pale yellow solid (900 mg).
  • 1H NMR (400 MHz, CHCl3) 9.21 (1H, s), 8.30 (1H, s), 8.22 (1H, s), 8.13 (1H, d), 8.01 (1H, dd), 7.59 (1H, d), 6.75 (2H, br), 2.61 (3H, s)
    • Intermediate E 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride
  • Figure US20180243297A1-20180830-C00450
    • Step 1: 3-(2-Methylthiazol-5-yl)-5-(o-tolyl)pyrazin-2-amine
  • Pd-118 (0.136 g, 0.221 mmol) was added to a mixture of 5-chloro-3-(2-methylthiazol-5-yl)pyrazin-2-amine (Intermediate C6) (1 g, 4.41 mmol), o-tolylboronic acid (0.660 g, 4.85 mmol), potassium phosphate (1.873 g, 8.82 mmol), 1,4-dioxane (17.65 ml) and water (4.41 ml). The reaction mixture was heated at 100° C. for 2.5 hours. The reaction mixture was added to water (100 ml) and extracted with EtOAc (2×100 ml). The organic phase was washed with brine (100 ml) and dried over MgSO4. The solid was filtered off, washed with EtOAc and the solvent was concentrated under reduced pressure to give a dark grey residue. The residue was triturated with Et2O to give a solid, which was filtered off, washed with Et2O and dried in a vacuum oven at 50° C. for 5 hours to give the title compound as a dark grey solid.
  • LCMS: Rt 1.24 mins, MS m/z 283.2 [M+H]+; Method 2minLowpHv03.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.26 (1H, s), 8.15 (1H, s), 7.44 (1H, m), 7.32-7.26 (3H, m), 6.57 (2H, br s), 2.67 (3H, s), 2.40 (3H, s).
    • Step 2: 3-(5-Amino-6-(2-methylthiazol-5-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride
  • Chlorosulfonic acid (4.50 mL, 67.1 mmol) was added dropwise to a stirring solution of 3-(2-methylthiazol-5-yl)-5-(o-tolyl)pyrazin-2-amine (step 1) (790 mg, 2.80 mmol) in CHCl3 (14 ml) at 0° C. Upon complete addition, the reaction mixture was allowed to warm up to RT and was stirred overnight at RT. The reaction mixture was added dropwise to stirring ice water and the resulting mixture was extracted with CHCl3 (125 ml). The organic phase was separated and washed with brine (100 ml) and dried over MgSO4. The solid was filtered off, washed with CHCl3 and the solvent was concentrated under reduced pressure to give a brown oil. The residue was triturated with Et2O to give a solid, which was filtered off, washed with Et2O and dried in a vacuum oven at 50° C. overnight to give the title compound as a brown solid which was used directly in the next step.
    • Intermediate E3 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride
  • Figure US20180243297A1-20180830-C00451
    • Step 1: 3-(1,3-Dimethyl-1H-pyrazol-4-yl)-5-(o-tolyl)pyrazin-2-amine
  • 5-Chloro-3-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-amine (Intermediate C7) (11.3 g, 50.5 mmol) and o-tolyl boronic acid (8.24 g, 60.6 mmol) were dissolved in dioxane (170 ml) with stirring and degassed with nitrogen. Potassium phosphate (21.45 g, 101 mmol) in water (45 ml) was added, followed by Pd-118 [PdCl2(dtbpf)] (1.646 g, 2.53 mmol). The dark red slurry gradually darkened with stirring. This was heated to 100° C. overnight, internal temp 85° C. under nitrogen.
  • The reaction mixture was partitioned in ethyl acetate/water (1:1, 500 ml). The layers were separated and the mainly organic layer filtered through Celite®. The aqueous layer was re-extracted with ethyl acetate (100 ml). The organic extracts were bulked, washed with saturated sodium bicarbonate (400 ml), water (300 ml), brine (300 ml), then dried over MgSO4 and charcoal. The desiccant was filtered off and the filtrate concentrated under reduced pressure to give a brown solid. This was slurried in diethyl ether (130 ml) and sonicated for 30 mins. The residual pale brown solid was removed by filtration and dried in vacuo to give the title compound;
  • LCMS: Rt 0.95 mins; MS m/z 280.3 & 281.4 [M+H]+; Method 2minLowpH.
  • 1H NMR (400 MHz, DMSO-d6) δ 8.1 (1H, s), 7.95 (1H, s), 7.4 (1H, m), 7.25 (3H, m), 6.1 (2H, br s), 3.8 (3H, s), 2.35 (3H, s), 2.25 (3H, s).
    • Step 2: 3-(5-Amino-6-(1,3-dimethyl-1H-pyrazol-4-yl)pyrazin-2-yl)-4-methylbenzene-1-sulfonyl chloride
  • Chlorosulfonic acid (5.75 ml, 86 mmol) was added dropwise to a stirred solution of 3-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(o-tolyl)pyrazin-2-amine (step 1) (1.0 g, 3.58 mmol) in chloroform (20 ml) at 0° C. When the addition was complete the reaction was allowed to warm to room temperature and stirred for 20 h. The reaction mixture was added dropwise to rapidly stirred ice water and the product precipitated as a pale yellow solid. When most of the ice had melted the mixture was filtered through a sinter funnel to collect the product which was washed with EtOAc and dried in a vacuum oven at RT to give the title compound;
  • LCMS: Rt 1.08 mins; MS m/z 378.3 [M+H]+; Method 2minLowpH
  • 1H NMR (400 MHz, CDCl3) δ 8.18 (1H, s), 7.98 (1H, s), 7.69 (1H, s), 7.55 (1H, d), 7.26 (1H, d), 3.35 (3H, s), 3.27 (3H, s), 2.27 (3H, s).
    • Intermediate E4 2,4,6-Trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl benzenesulfonate
  • Figure US20180243297A1-20180830-C00452
    • Step 1: 3-Chloro-5-o-tolylpyrazin-2-amine
  • A mixture comprising 5-bromo-3-chloropyrazin-2-amine (2 g, 9.59 mmol), o-tolylboronic acid (1.35 g, 9.93 mmol), PdCl2(dppf).CH2Cl2 adduct (0.25 g, 0.306 mmol) and Na2CO3 (5 g, 47.2 mmol) in DME (30 ml) and water (6.00 ml), under nitrogen was heated at reflux for 3 hours. The resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate. The combined organic extracts were dried over anhydrous magnesium sulfate, filtered and evaporated under reduced pressure. The resulting brown residue was bound to silica and purified by flash column chromatography (80 g silica, 0-25% ethyl acetate in iso-hexane) to give a pale yellow solid;
  • LCMS: Rt 1.00 min; MS m/z 220.1 [M+H]+; Method: 2minLowpH
    • Step 2: 3-(2-Methylpyridin-4-yl)-5-o-tolylpyrazin-2-amine
  • A mixture of Pd(PPh3)2Cl2 (0.125 g, 0.178 mmol), 3-chloro-5-o-tolylpyrazin-2-amine (step 1) (0.78 g, 3.55 mmol), 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.8 g, 3.65 mmol), sodium carbonate (1.1 g, 10.38 mmol) in DME (7.5 mL), EtOH (5.00 mL) and water (2.5 mL) was heated to 120° C. in the microwave for 2 hours. The resulting mixture was diluted with ethyl acetate and water, using sonication to ensure all material was transferred from the microwave vial and evaporated under reduced pressure to remove organics. The remaining aqueous was extracted with ethyl acetate (2×50 mL), washed with saturated sodium bicarbonate (50 mL) and brine (25 mL), dried over anhydrous magnesium sulfate and filtered. The resulting dark brown solution was evaporated and bound to silica, then purified by flash column chromatography (80 g silica, 70-100% ethyl acetate in iso-hexane, then 5-10% 2M methanolic ammonia in TBME). The product fractions were evaporated to give the title compound as a yellow solid;
  • LC-MS: Rt 0.69 min; m/z 277.6 [M+H]+; Method: 2minLowpH
    • Step 3: 2,4,6-Trichlorophenyl 3-(5-amino-6-(2-methylpyridin-4-yl)pyrazin-2-yl)-4-methyl benzenesulfonate
  • To a solution of 3-(2-methylpyridin-4-yl)-5-o-tolylpyrazin-2-amine (step 2) (600 mg, 2.171 mmol) in chloroform (10 mL) at 0° C. (ice bath) under nitrogen was added dropwise chlorosulfonic acid (3.5 mL, 52.3 mmol) over 10 minutes. The resulting red solution was stirred and allowed to warm slowly to room temperature and stirring continued overnight at room temperature. The resulting mixture was added dropwise to an ice-cooled stirring mixture of DCM (90 mL) and saturated sodium bicarbonate (150 mL). This mixture was passed through a phase separator directly into a stirring mixture of 2,4,6-trichlorophenol (450 mg, 2.280 mmol) and triethylamine (0.75 mL, 5.38 mmol) in DCM (5 mL). The aqueous and precipitate were re-extracted with DCM (50 mL) and passed through a phase separator directly into the same stirring mixture. After four hours stirring, the reaction mixture was evaporated under reduced pressure, then triturated with ethyl acetate and dried in vacuum oven overnight to give a yellow solid (465 mg, batch 1). The remaining aqueous and solid was extracted again with DCM (100 mL), washed with 2M sodium carbonate and passed through a phase separator directly into a stirring mixture of 2,4,6-trichlorophenol (200 mg) and triethylamine (0.3 mL). After stirring overnight, this was evaporated under reduced pressure and washed with ethyl acetate to give pale yellow solid (480 mg, batch 2). Estimated 80% purity, contains triethylamine/triethylamine hydrochloride but used without further purification.
  • LCMS: Rt 1.00 min; m/z 533.0, 535.1 [M−H]−; Method: 2minLowpH
    • Intermediate F O-(Tetrahydrofuran-3-yl)hydroxylamine
  • Figure US20180243297A1-20180830-C00453
    • Step 1: 2-((Tetrahydrofuran-3-yl)oxy)isoindoline-1,3-dione
  • To a stirring solution of N-hydroxyphthalimide (5 g, 30.7 mmol) in THF (200 ml) at 0° C., PS-triphenylphosphine (loading 1.88 mmol/g) (19.56 g, 36.8 mmol) was added followed by tetrahydrofuran-3-ol (2.477 ml, 30.7 mmol) and di-tert-butyl azodicarboxylate (7.06 g, 30.7 mmol). The mixture was stirred at 0° C. for 10 mins, then for 21 hours at RT. The mixture was filtered, and solvent removed under reduced pressure. The resulting yellow solid was triturated with ether and the solid collected by filtration, washing with more ether to give a pale yellow solid. The mother liquors were evaporated under reduced pressure and triturated again with ether to give a pale yellow solid;
  • LCMS: Rt 0.82 min; MS m/z 234.4[M+H]+; Method: 2minLowpHv01.
    • Step 2: O-(Tetrahydrofuran-3-yl)hydroxylamine
  • To a stirred solution of 2-((tetrahydrofuran-3-yl)oxy)isoindoline-1,3-dione (step 1) (3.07 g, 13.16 mmol) in MeOH (60 mL) was added hydrazine hydrate (1.097 mL, 14.48 mmol). The resulting mixture was stirred at RT for 16 hours overnight, yielding a yellow solution with a suspension of a white solid. The white solid was removed by filtration and the filtrate was evaporated under reduced pressure. This was triturated with DCM and the solid again removed by filtration. The filtrate was evaporated under reduced pressure to give a yellow oil, which was used without further purification in the subsequent step.
    • Pharmaceutical Use and Assay
  • The compounds of the present invention and their pharmaceutically acceptable salts may be useful as pharmaceuticals. In particular, the compounds are suitable PI 3-kinase gamma isoform selective inhibitors and may be tested in the following assays.
    • Abbreviations:
  • ADP: Adenosine diphosphate
    ATP: Adenosine triphosphate
    BSA: Bovine serum albumin
    DMEM: Dulbecco's modified Eagle's medium
    • DMSO: Dimethylsulfoxide DTT: Dithiothreitol
  • CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
    EDTA: Ethylenediaminetetraacetic acid
    EGTA: Ethylene glycol tetraacetic acid
    FACS: Fluorescence-activated cell sorting
    FBS: Fetal bovine serum
    • HBSS: Hank's Balanced Salt Solution
  • HEPES: 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid
    • HTRF: Homogeneous Time Resolved Fluorescence
  • MIP1α: Macrophage Inflammatory Protein form 1α (also known as CCL3)
    PBS: phosphate-buffered saline
    RPM I: Roswell Park Memorial Institute medium
    • TR-FRET: Time-Resolved Fluorescence Resonance Energy Transfer Kinase Glo Luminescent Kinase Assay (Kglo) for Pb 3-Kinase Alpha (A), Pb 3-Kinase Beta (B), Vps34 (C), Pb 4-Kinase Beta (D)
  • The luminescence-based ATP detection reagent KinaseGlo was obtained from Promega, (Cat. No. V6714, Lot No. 236161) through Catalys, Wallisellen, Switzerland. L-alpha-phosphatidylinositol (PI, liver, bovine) was obtained from Avanti Polar Lipid (Cat. No. 840042C, Lot#LPI-274), Phosphatidylinositol-4,5-bisphosphate (PIP(4,5)2) was also obtained from Avanti Polar Lipid (Cat. No. 840046X). L-a-Phosphatidylserine (PS) was obtained from Avanti Polar Lipid (Cat. No. 840032C), n-Octylglucoside from Avanti Polar Lipid (Cat. No. 10634425001). Luminescence is a well established readout to determine ATP concentrations and can thus be used to follow the activity of many kinases regardless of their substrate. The Kinase Glo Luminescent Kinase Assay (Promega, Madison/Wis., USA) is a homogeneous HTS method of measuring kinase activity by quantifying the amount of ATP remaining in solution following a kinase reaction.
  • 50 nL of compound dilutions were dispensed onto black 384-well low volume Non Binding Styrene (NBS) plates (Costar Cat. No. NBS#3676). L-α-phosphatidylinositol (PI), provided as 10 mg/ml solution in methanol, was transferred into a glass tube and dried under a nitrogen beam. It was then resuspended in 3% OctylGlucoside (1-0-n-octyl-beta-D-glucopyranoside) by vortexing and stored at 4° C. 5 μL of a mix of PI/OctylGlucoside with the PI 3-kinase alpha and PI 3-kinase beta subtypes, or Vps34 or PI 4-kinase beta were added. Kinase reactions were started by the addition of 5 μl of an ATP-mix containing in a final volume 10 μL 10 mM TRIS-HCl pH 7.5, 3 mM MgCl2, 50 mM NaCl, 0.05% CHAPS, 1 mM DTT and 1 μM ATP at room temperature. Reactions were stopped with 10 μl of KinaseGlo and plates were read 10 mins later in a Synergy2 reader using an integration time of 0.1 seconds per well. 2.5 μM of NVP-BGT226 (1-(3-(trifluoromethyl)-4-(piperazin-1-yOphenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one) was added to the assay plates to generate the 100% inhibition of the kinase reaction, and the 0% inhibition was given by the solvent vehicle (90% DMSO in water). (1-(3-(trifluoromethyl)-4-(piperazin-1-yOphenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one) was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
  • IC50 values of the percentage inhibition of each compound at 8 concentrations (10, 3.0, 1.0, 0.3, 0.1, 0.030, 0.010 and 0.003 μM) n=2 were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
    • TR-FRET Adapta Assay for PI 3-Kinase Gamma (E), PI 3-Kinase Delta (F)
  • The TR-FRET Adapta™ Universal Kinase Assay Kit was purchased from lnvitrogen Corporation (Carlsbad/CA, USA) (Cat. No. PV5099). The kit contains the following reagents: Adapta Eu-anti-ADP Antibody (Europium labeled anti-ADP antibody in HEPES buffered saline, Cat. No. PV5097), Alexa Fluor® 647-labeled ADP tracer (Alexa Fluor® 647-labeled ADP tracer in HEPES buffered saline, Cat. No. PV5098), TR-FRET dilution buffer pH 7.5 (Cat. No. PV3574).
  • PIK3CD substrate phosphatidylinositol (PI) was obtained from lnvitrogen (vesicules consisting of 2 mM phosphatidylinositol (PI) in 50 mM HEPES pH7.5; Cat. No. PV5371). PIK3CG substrate phosphatidylinositol-4,5-bisphosphate (PIP(4,5)2 was obtained from lnvitrogen (PIP2:PS large unilamellar vesicules consisting of 1 mM PIP2: 19 mM PS in 50 mM HEPES pH7.5, 3 mM MgCl2, 1 mM EGTA; Cat. No. PV5100).
  • Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) is a technology based on energy transfer between two adjacent dyes, from an excited electron in one dye (the donor) to an electron of an adjacent dye (the acceptor) through resonance, then released as a photon. This energy transfer is detected by an increase in the fluorescence emission of the acceptor, and a decrease in the fluorescence emission of the donor. TR-FRET assays for protein kinases use a long-lifetime lanthanide Terbium or Europium chelates as the donor species which overcome interference from compound autofluorescence or light scatter from precipitated compounds, by introducing a delay after excitation by a flashlamp excitation source. Results are often expressed as a ratio of the intensities of the acceptor and donor fluorophores. The ratiometric nature of such a value corrects for differences in assay volumes between wells, as well as corrects for quenching effects due to colored compounds. The Adapta™ assay can be divided into two phases: a kinase reaction phase and an ADP detection phase. In the kinase reaction phase, all kinase reaction components are added to the well and the reaction is allowed to incubate for a set period of time specific for each kinase. After the reaction, a detection solution of Eu-labeled anti-ADP antibody, Alexa Fluor® 647-labeled ADP tracer, and EDTA (to stop the kinase reaction) are added to the assay well. ADP formed by the kinase reaction will displace the Alexa Fluor® 647-labeled ADP tracer from the antibody, resulting in a decrease in TR-FRET signal. In the presence of an inhibitor, the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibodytracer interaction maintains a high TR-FRET signal. In the Adapta™ assay, the donor (Europium-anti-ADP antibody) is excited at 340 nm and will transfer its energy to the acceptor (Alexa Fluor® 647-labeled ADP tracer). The emission from the Alexa Fluor® 647 can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm.
  • 50 nL of compound dilutions were dispensed onto white 384-well small volume polystyrene plate. Then 5 μL of either PI 3-kinase gamma or PI 3-kinase delta and lipid substrate (PI or PIP2:PS) followed by 5 μL of ATP (final assay volume 10 μL) are incubated at RT. The standard reaction buffer for the Adapta™ TR-FRET assay contained 10 mM Tris-HCl pH 7.5, 3 mM MgCl2, 50 mM NaCl, 1 mM DTT, 0.05% CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate). Reactions were stopped with 5 μL of a mixture of EDTA containing the Eu-labeled anti-ADP antibody and the Alexa Fluor® 647-labeled ADP tracer in TR-FRET dilution buffer. Plates are read 15 to 60 mins later in a Synergy2 reader using an integration time of 0.4 seconds and a delay of 0.05 seconds. Control for the 100% inhibition of the kinase reaction was performed by replacing the PI 3-kinase by the standard reaction buffer. The control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H2O). The standard compound 1-(3-(trifluoromethyl)-4-(piperazin-1-yl)phenyl)-8-(6-methoxypyridin-3-yl)-3-methyl-1H-imidazo[4,5-c]quinolin-2(3H)-one (NVP-BGT226) was used as a reference compound and included in all assay plates in the form of 16 dilution points in duplicate.
  • Data are analyzed using Excel fit software or Graphpad Prism. IC50 values were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK). Determination of IC50 values of the percentage inhibition of each compound at 8 concentrations (usually 10, 3.0, 1.0, 0.3, 0.1, 0.030, 0.010 and 0.003 μM) n were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
  • Lanthascreen™ Kinase Binding Assay for mTOR (G)
  • Binding Assays are based on the binding and displacement of an Alexa Fluor® 647-labeled, ATP-competitive kinase inhibitors to the kinase of interest. lnvitrogen's “Kinase Tracers” have been developed to address a wide range of kinase targets and are based on ATP-competitive kinase inhibitors, making them suitable for detection of any compounds that bind to the ATP site or to an allosteric site altering the conformation of the ATP site. In the Lanthascreen™ kinase binding assay, the donor (Eu3+-anti-GST (glutathione 5-transferase) antibody) is excited at 340 nm and will transfer its energy to the acceptor (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor=Tracer-314). The emission from the Tracer-314 (Alexa Fluor® 647 inhibitor) can be monitored with a filter centered at 665 nm because it is located between the emission peaks of the donor, which is measured at 615/620 nm. The binding of both, the Tracer-314 and Eu3+-anti-GST antibody, to the kinase results in a high degree of FRET from the Eu3+-donor fluorophore to the Alexa-Fluor® 647-acceptor fluorophore on the Tracer-314. Binding of an inhibitor to the kinase competes for binding with the tracer, resulting in a loss of FRET.
  • 50 nL of compound dilutions were dispensed onto white 384-well small volume polystyrene plate. Then 5 μL of GST-mTOR and Europium-anti-GST antibody followed by 5 μL of tracer-314 (final assay volume 10 μL) are incubated at RT. The standard reaction buffer for the Lanthascreen™ kinase binding assay contained 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates are read 60 mins later in a Synergy2 reader using an integration time of 0.2 microseconds and a delay of 0.1 microseconds.
  • To calculate the emission ratio, the signal emitted at 665 nm from the acceptor (Alexa Fluor® 647-labeled Tracer-314) is divided by the signal emitted at 620 nm from the donor (Eu3+ anti-GST antibody).
  • Control for the 0% inhibition was given by the solvent vehicle of the compounds (90% DMSO in H2O). Control for the relative 100% inhibition was performed by adding 10 μM in the mix containing GST-mTOR and Europium anti-GST antibody. An additional control for the absolute 0% inhibition is given by Eu3+ anti-GST antibody without GST-mTOR. Standard compounds for the lipid kinase panel profiling were used as a reference and included in all assay plates in the form of 8 dilution points.
    • Cellular Assays for PI 3-Kinase Alpha (H1), Beta (I1) and Delta (J1): Surefire Format
  • AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay, ALPHA, Perkin Elmer) is a non-radioactive bead-based proximity assay technology to study biomolecular interactions in a homogenous microtiter plate format. The brand name SureFire denotes AlphaScreen assays that are adapted to quantify the phosphorylation of endogenous cellular proteins in cell lysates, by using matched antibody pairs, which consist of an anti-phospho-kinase and an anti-kinase antibody. The assay allows characterization of kinase signaling in cells as well as measurement of kinase inhibitor effects.
  • Rat-1 cell lines stably overexpressing activated PI 3-kinase class I isoforms Rat-1 pBABEpuro Myr-HA-hp110 delta clone 5 (Rat-1_PI3Kdelta) and Rat-1 pBABEpuro Myr-HA-hp110 alpha clone 6 (Rat-1_PI3Kalpha) and Rat-1 pBABEpuro Myr-HA-hp110 beta (Rat-1 PI3beta) were cultivated in complete growth medium (DMEM high glucose, 10% (v/v) fetal bovine serum, 1% (v/v) MEM NEAA, 10 mM HEPES, 2 mM L-glutamine, puromycin (10 μg/mL for Rat-1_PI3Kdelta and Rat-1_PI3Kalpha, 4 μg/mL for Rat-1_PI3beta), 1% (v/v) Pen/Strep) to 90% confluency at 37° C./5% CO2/90% humidity in a humidified CO2 incubator and were split twice a week.
  • The following materials were used for p-AKT(5473) detection in Rat-1 cell lysates: Dulbecco's modified Eagle's medium (DMEM) high glucose (Gibco lnvitrogen, Basel, Switzerland, Cat. No. 41965), heat inactivated fetal bovine serum, qualified (HI FBS; Gibco lnvitrogen, Basel, Switzerland, Lot. No. 16140), MEM non essential amino acids (NEAA; Gibco lnvitrogen, Basel, Switzerland, Cat. No. 11140), HEPES (Gibco lnvitrogen, Basel, Switzerland, Cat. No. 15630), penicillin/streptomycin (Pen/Strep, 100×; Gibco lnvitrogen, Basel, Switzerland, Cat. No. 15140-122), L-glutamine (Gibco lnvitrogen, Basel, Switzerland, Cat. No. 25030), puromycin (Sigma Aldrich, Buchs, Switzerland, Cat. No. P9620), DMSO (MERCK, Dietikon, Switzerland, Cat. No. 8.02912.2500), H2O, MilliQ-H2O unless otherwise stated (MILLIPORE QGARDOOR1, Millipore, Zug, Switzerland), bovine serum albumine (BSA; Sigma Aldrich, Buchs, Switzerland Cat. No. A8412), SureFire p-Akt ½ (Ser473) Assay Kit (PerkinElmer, Schwerzenbach, Switzerland, Cat. No. TGRAS50K).
  • The p-Akt (S473) SureFire assay measures the phosphorylation of endogenous cellular Akt ½ at Ser473 in cell lysates. Using Rat-1 cells stably expressing myr-HA-tagged versions of the human PI3Kdelta, PI3Kalpha, or PI3Kbeta p110 catalytic subunit isoforms, the assay was developed as a two-plate protocol in a 384-well format.
  • For compound testing, the cells were seeded at a density of 4000 (Rat-1_PI3Kdelta), 7500 (Rat-1_PI3Kalpha), or 6200 (Rat-1_PI3Kbeta) cells in 20 μl complete growth medium into cell culture treated 384-well plates and were grown at 37° C./5% CO2/90% humidity for 24 h. Shortly before compound transfer, the complete medium was removed, 30 μl assay buffer (DMEM high glucose, 1×MEM NEAA, 10 mM HEPES, 2 mM L-glutamine, 0.1% (w/v) BSA) was added and 10 μl of the compound predilutions were transferred to the cells. After treatment with compound for 1 h, the cells were lysed by the addition of 20 μl lysis buffer supplemented with 0.24% (w/v) BSA. Detection of p-AKT (Ser473) was performed with the SureFire p-Akt ½ (Ser473) Assay Kit according to the manufacturer's instructions using 5 μl of cell lysate in a total detection volume of 12 μl.
  • IC50 values of the percentage inhibition of each compound at 8 concentrations (usually 10, 3.0, 1.0, 0.3, 0.1, 0.030, 0.010 and 0.003 μM) n=2 were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over inhibitor concentration as described. All fits were performed with the program XLfit4 (ID Business Solutions, Guildford, UK).
    • Cellular Assays for PI 3-Kinase Alpha (H2), Beta (12) and Delta (J2): HTRF (Homogeneous Time Resolved Fluorescence) Format
  • The following materials were used for p-AKT(5473) detection in Rat-1 cell lysates: Dulbecco's modified Eagle's medium (DMEM), high Glucose, GlutaMAX™, Pyruvate (Gibco lnvitrogen, Basel, Switzerland, Cat. No. 31966), Dialyzed Fetal Bovine Serum (FBS) US origin (Gibco lnvitrogen, Basel, Switzerland, Cat. No. 36400, Lot. No. 776683), MEM non essential amino acids (NEAA; Gibco lnvitrogen, Basel, Switzerland, Cat. No. 11140), HEPES (Gibco Invitrogen, Basel, Switzerland, Cat. No. 15630), Penicillin/Streptomycin (Pen/Strep, 100×; Gibco lnvitrogen, Basel, Switzerland, Cat. No. 15140-122), Puromycin (Sigma Aldrich, Buchs, Switzerland, Cat. No. P9620), DMSO (MERCK, Dietikon, Switzerland, Cat. No. 8.02912.2500), H2O, MilliQ-H20 unless otherwise stated (MILLIPORE QGARDOOR1, Millipore, Zug, Switzerland), HTRF Phospho-AKT (Ser473) Assay Kit (Cisbio, Codolet, France, Cat. No. 64AKSPEH)
  • The Rat-1 cell lines stably overexpressing activated PI3K class I isoforms Rat-1 pBABEpuro Myr-HA-hp110 delta clone 6 (Rat-1_PI3Kdelta) and Rat-1 pBABEpuro Myr-HA-hp110 alpha clone 6 (Rat-1_PI3Kalpha) and Rat-1 pBABEpuro Myr-HA-hp110 beta clone 1-E8 (Rat-1_PI3Kbeta) were used. All cell lines were cultivated in complete growth medium (DMEM high glucose GlutaMAX™ Pyruvate, 10% (v/v) fetal bovine serum, 0.1 mM MEM NEAA, 25 mM HEPES, puromycin 10 μg/mL, 100 U/ml Penicillin, 100 μg/ml Streptomycin) to 90% confluency at 37° C./5% CO2/90% humidity in a humidified CO2 incubator and were split twice a week.
  • Semi-automated preparation of cell lysates: For low (inhibited) controls, 0.9 mM NVP-BGT226-AF-1 in 90% (v/v) DMSO was added to the compound master plate. For compound testing, the cells were seeded at a density of 4000 (Rat-1_PI3Kdelta), 8000 (Rat-1 PI3Kalpha), or 6500 (Rat-1_PI3Kbeta) cells in 30 μl complete growth medium into cell culture treated 384-well plates and were grown at 37° C./5% CO2/90% humidity for 24 h. 10 μl of the compound predilutions were transferred to the cells. After treatment with compound for 1 h, medium was removed and cells were lysed by the addition of 20 μl lysis buffer supplemented with blocking buffer. Detection of p-AKT(Ser473) was performed with the HTRF pAKT (Ser473) assay kit according to the manufacturer's instructions using 16 μl of cell lysate in a total detection volume of 20 μl.
    • Cellular U937 AKT Assay for PI 3-Kinase Gamma (K1)
  • The U937 monocyte cell line is maintained in a basal medium of RPMI 1640 supplemented with 10% heat inactivated FBS, 100 U/ml Penicillin, 100 ug/ml streptomycin and 2 mM L-glutamine (Invitrogen). U937 suspension culture is maintained by seeding cells at a density of 0.125×106 cells per ml in fresh medium every three or four days. Cells are incubated at 37° C., 5% CO2. Three or four days prior to assay, cells are seeded at a density of 0.25×106 cells per ml in a total volume of 40 ml in a T162 culture flask.
  • Before beginning the cell manipulations described below, the MSD (Meso Scale Discovery) assay plate is blocked by addition of 150 μl/well blocking buffer supplied and incubated with shaking for a minimum of one hour at room temperature. All steps of the assay must be performed quickly, with accurately timed incubation periods and observing temperature controls where indicated.
  • Cells seeded at 0.25×106/ml 3 or 4 days prior to the assay are aspirated, transferred to a 50 ml
  • falcon tube, counted and centrifuged for eight minutes at 300 g at room temperature. Supernatant is aspirated, the cell pellet resuspended and washed once in HBSS (Hank's Balanced Salt Solution) by centrifugation for eight minutes at 300 g at room temperature. The cell pellet is resuspended in HBSS to a concentration of 4×106 per ml, and 100 μL of cell suspension added to each well of a flat-bottomed 96-well tissue culture plate. Assay plates are incubated for 1.5 hours at 37° C., 5% CO2 to allow background AKT phosphorylation to reduce before the compound stimulation step.
  • A 5 mM stock concentration of compound is prepared in 100% DMSO; from this a 1 in 125 dilution is made in HBSS giving a top compound concentration of 40 μM, 0.8% DMSO. Compound titrations are prepared in a fresh flat-bottomed, 96-well plate, by 10-fold serial dilution of 40 μM into HBSS 0.8% DMSO; pipette tips are replaced after each dilution is made. Compound concentrations at this stage are 4-times the final concentration required in the assay plate. Cells are stimulated with compound or HBSS 0.8% DMSO by direct transfer of 50 μl/well from the compound dilution plate. The assay plate containing compound-treated cells is then incubated for 30 minutes at 37° C. A standard plate layout is used for all experiments.
  • Compound-treated cells, in addition to positive control wells (“max MIP1α”), are stimulated with 50 μL per well of 40 ng/ml MIP1α (R&D Systems catalogue number 270-LD, lyophilized stock reconstituted to 50 μg/ml with PBS 0.1% BSA). Negative control wells (“min HBSS”), are stimulated with 50 μl/well of HBSS in the absence of MIP1α. Final compound concentrations are now diluted 4-fold giving a top concentration of 10 μM; where added, the final concentration of MIP1α is 10 ng/ml. Cells are incubated with MIP1α for 3 minutes, at 37° C., 5% CO2. After the three minute stimulation period, the assay plate is kept ice cold at all times. Assay plates are centrifuged for 2 minutes at 300 g, 4° C. and supernatant is removed by gently inverting, and then blotting the plate on tissue. Cells are then washed by gentle addition of 150 μL/well of ice cold HBSS and centrifugation at 300 g, for 5 minutes at 4° C. Supernatant is
  • aspirated and the plate blotted as described above. The plate is placed on ice and cells are immediately treated with 35 μL per well of ice cold lysis buffer, prepared according to the kit instructions (per assay plate, to 5 ml of Tris lysis buffer add 100 μl of 50× protease inhibitor solution and 50 μl of each 100× phosphatase inhibitor solutions I and II). Plates are incubated on ice for 20 minutes before centrifugation at 841 g for 5 minutes, 4° C.
  • Block buffer is aspirated from the MSD plate, and the plate washed four times with 300 μl/well Tris wash buffer. 25 μL of cell lysate is then transferred from the assay plate to the washed MSD plate which is sealed and incubated at room temperature for one hour with shaking. The plate is washed four times with 300 μL per well of Tris wash buffer before addition of 25 μL per well of sulfo-tag anti-total AKT/pAKT detection antibody (60 μl of 50× antibody stock is diluted in lml block buffer mixed with 2 ml wash buffer) and incubated at room temperature for one hour with shaking. The plate is washed four times with 300 μl per well of Tris wash buffer and 150 μl per well of Read buffer is added, taking care to avoid the introduction of bubbles. The plate is immediately read using an MSD SECTOR Imager 6000. Results are exported in Excel and the percentage of phosphorylated AKT is calculated using the equation: % Phosphoprotein=((2*Phospho signal)/(Phospho signal+Total signal))*100. Compound-mediated inhibition of AKT phosphorylation is analysed using Prizm V Graphpad software.
    • Cellular U937 AKT Assay for PI 3-Kinase Gamma (K2)
  • Materials used: Bio-Rad TC10TM automated cell counter, Bio-RAD counting slides (#145-0011), Trypan blue solution 0.4% (#T8154 Sigma), diluted 1:2 in PBS), Bioconcept Multidrop combi, Versette automated liquid handler (Thermo scientific), HTRF Phospho-AKT (Ser473) 10′000 tests assay kit (cisbio #64AKSPEH), ProxiPlate-384 Plus, White, TC treated (Perkin Elmer #6008239)
  • 384-well tissue culture treated plate (BD Falcon #353289), RPMI+GlutaMAX (Life Technologies #61870-010), FBS dialyzed (Life Technologies #26400), Penicilin/Streptomycin (Life Technologies #15140), HBSS 1× (Life Technologies #14025-050), Wortmannin (Sigma-Aldrich # W1628), stock solution 10 mM in 90% DMSO, Recombinant Human CCL3/MIP1α (R&D Systems #270-LD) (stock solution 10 μg/ml), RUBYstar Microplate Reader (BMG Labtech #8)
  • U937 cells are split every 3-4 days: 5×106 cells/flask (175 cm2) in 40 ml. 3-4 days before the assay, cells should be seeded: 4-5 flasks with 107 cells in 40 ml.
  • Semi-automated preparation of cell lysates: Cells were resuspended in HBSS, seeded (200′000 cells/well/60 μl) into a 384-well plate and incubated in a humidified 37° C., 5% CO2 incubator for 1.5 hours. The compounds were diluted with HBSS and 40 μl were added to the starved cells (except for wells 24 I-P). 10 μM Wortmanin was added to the negative control (wells 24 I-P). The cells were then incubated for 30 minutes at 37° C. and 5% CO2. Stimulation occurred during 3 minutes by addition of 20 μl MIP1α (final 10 ng/ml, diluted in HBSS) in the incubator. Wells 24 A-H were only stimulated with HBSS.
  • The stimulation was then stopped by putting the cell plates on ice (filled with cold water). The cells were then centrifuged at 1200 rpm and 4° C. for 3 minutes.
  • 80 μl of supernatant was removed. The cells were again centrifuged at 1200 rpm and 4° C. for 3 minutes. The supernatant was then removed by turning plates upside down and 30 μl of lysis buffer were added. The plate was incubated at room temperature for 30 minutes under shaking. 16 μl were then transferred to a ProxiPlate Plus 384-well. 4 μl of the master mix (each conjugate diluted 1:20 with detection reagent) were added to each well and the plate was kept in the dark at room temperature for 4 hours. Fluorescence was measured at 665 nm and 620 nm with a RUBYstar Reader.
    • Whole Blood Neutrophil Shape Change Assay (L)
  • A flow cytometry based method used to measure the inhibition of IL-8 (interleukin-8)-induced neutrophil shape change in human whole blood.
    • Reagents, Material & Equipment
  • Sterile Distilled Water, Baxter # UKF117
  • 10× CelIFIX solution, BECTON DICKINSON Biosciences #340181
  • IL-8, R&D Systems #208-IL
  • DMSO, Hybri-Max, Sigma-Aldrich # D2650
  • Dulbecco's Phosphate Buffered Saline 1×HCaCL2, MgCL2, gibco by life technolgies #14040
  • Albumin Solution from Bovine Serum (30%), Sigma Aldrich # A9576-50 ml
  • Ammonium Chloride NH4CL, Sigma Aldrich # A0171
  • Potassium Bicarbonate KHCO3, Sigma Aldrich # P9144
  • K2 EDTA Vacutainers, Becton Dickinson Vacutainer®#367525
  • 96-well Polypropylene deep-well plates, VWR # PORV219009
  • 96 well Plates, V-bottom with lid, Costar #3894
  • 96 well Polypropylene Plates, Round Bottom, Greiner #650261 (for HIGH THROUGHPUT SAMPLER FACS)
  • 120 μl pre-sterilized Biohit Filter Tips, Biohit #790101F
  • 350 μl pre-sterilized Biohit Tips, Biohit #790350
  • 1200 μl pre-sterilized Biohit Tips, Biohit #791202
  • Biohit e1200 Electronic 8-channel Pipette
  • Biohit e120 Electronic 8-channel Pipette
  • Eppendorf Research Plus 100-1000 μl Pipette
  • Eppendorf Research Plus 20-200 μl Pipette
  • Becton Dickinson Biosciences FACS Canto 11 Flow Cytometer with HIGH THROUGHPUT SAMPLER
  • IL-8 was made up to 2 μM stocks in 0.1% bovine serum albumin/PBS and stored at −80° C. On the day IL-8 was diluted in PBS (phosphate buffered saline) 10 minutes before use. IL-8 was used at final concentration of 2 nM and a concentration range from 0.003 to 200 nM for the donor dose response curve.
  • Assay fixative solution was prepared fresh each day from 10× concentrated CellFlX™ solution diluted 1:10 in sterile distilled water and then 1:4 with PBS. Assay fixative solution was kept on ice prior to use.
  • A 10× lysis buffer was prepared in advance by dissolving 20.75 g NH4Cl and 2.5 g KHCO3 in 250 ml sterile H2O. This 10× lysis buffer was filtered under sterile conditions and stored for up to two weeks at 4° C. On the day a 1× lysis solution was prepared with sterile distilled H2O and kept on ice prior to use.
  • The test compounds were prepared as 10 mM stock solutions in 100% DMSO and were stored at 4° C. Once in use for an assay 10 mM stock compounds were thawed and stored at RT protected from light. Compound dilutions were prepared fresh on the day. The first series of dilutions in 100% DMSO were done first thing in the morning. Only once blood had been collected and arrived in laboratory was the next set of dilutions into PBS carried out (1:10 PBS, 10% DMSO). This limited the exposure of diluted compound to plastic and made sure the exposure timing was consistent between assays. Compounds were added to the deep 96 well plates at 10× the final desired concentration (with addition of blood final [DMSO]=1%).
  • Table 3 illustrates the compound dilution series used in human whole blood neutrophil shape change assay.
  • TABLE 3
    100% DMSO 10% DMSO 1% DMSO
    Serial Dil'n 1 in 4 1 in 10 PBS Assay Plate exampleWell ID*
    10000 μM 10000 μM 100 μM B2; CPD + IL-8
    2500 250 25 B3; CPD + IL-8
    625 62.5 6.25 B4; CPD + IL-8
    156.25 15.62 1.56 B5; CPD + IL-8
    39.0625 3.9 0.39 B6; CPD + IL-8
    9.765625 0.97 0.097 B7; CPD + IL-8
    2.441406 0.24 0.024 B8; CPD + IL-8
    0.610352 0.06 0.006 B9; CPD + IL-8
    100% DMSO 10% DMSO 1% DMSO B10; + IL-8
    100% DMSO 10% DMSO 1% DMSO B11; +PBS
  • On the day of running the assay, assay fixative buffer and 1× lysis solutions were prepared and stored on ice. Compound dilutions in 100% DMSO were prepared as described previously. Human whole blood was collected in K2 EDTA Vacutainers. Once blood was in the laboratory, compound dilutions into PBS were carried out as described previously and depicted in Table 1.
  • 10 μl of 10× final compound concentration was added to appropriate wells of a deep 96-well plate except controls where 10 μl of 10% DMSO was added in place of compound, as outlined in the dilution series in Table 1. The outer wells of the deep well assay plate were filled with 1200 μl of sterile distilled H2O in an effort to limit edge effects (rows A1-H1, A1-A12, A12-H12).
  • An IL-8 dose response was determined for each blood donor examined, to monitor the donor response to IL-8. At this step in assay preparation for the IL-8 dose response samples 10 μl of PBS was added to designated wells. In addition the assay window without DMSO was also assessed each day. For such samples at this step in assay preparation 10 μl of PBS was added in the place of 10% DMSO.
  • 80 μl of whole blood was added to compound/10% DMSO/PBS and mixed once gently upon addition. Lids were placed on the 96 well plates and samples were incubated for 15 minutes at 37° C. in a water-bath.
  • Following the compound pre-incubation 10× final IL-8 was added to appropriate wells (10 μl of 20 nM working stock IL-8, final IL-8 concentration in blood=2 nM) and 10 μl of PBS was added to the un-stimulated controls. 10× final dose response range IL-8 was also added to designated wells (final concentration range on assay plate was 200 nM to 0.0005 nM, 1:5 serial dilution in PBS). The IL-8 and PBS were added to appropriate wells across all assay plates in the same sequence as the blood to compound addition. Once added to all assay plates, samples were mixed quickly once to ensure even distribution of IL-8. Samples were incubated for 5 minutes at 37° C. in a water-bath. Following the incubation sample plates were transferred to ice where 250 μl of chilled Assay Fixative Buffer was added promptly to all wells.
  • Samples were incubated on ice for 7 minutes (no mixing). Following fixation 1.2 ml of 1× Lysis Solution was then added promptly to each well. Once added samples were mixed once and incubated on ice for 30 minutes to achieve uniform red blood cells lysis. After lysis, 200 μl of sample was transferred to a 96 well microplate on ice. Samples were acquired using the HTS on high throughput mode on a Becton Dickinson FACS Canto II. Granulocytes were identified based on differential side scatter (SSC) and forward scatter (FSC) characteristics. Neutrophils were distinguished from eosinophils using the phycoerythrin channel, as the latter have higher auto-fluorescence.
  • The mean FSC value for the neutrophil population was taken as measure of cell shape change (the greater the FSC value meant the greater the degree of shape change). Data was presented as % shape change over basal for the IL-8 dose response curve and assay window controls and presented as % inhibition of shape change for compound treated samples.
    • % Shape Change Above Basal
  • Subtract the un-stimulated control FSC reading from agonist FSC readings, divide results by the un-stimulated FSC value and multiply by 100 to give % shape change above basal.
  • % inhibition

  • % inhibition=(X−Y)/X*100(FIG. 2. for sample values)
  • X=IL-8 FSC response minus the un-stimulated control (basal) FSC.
      • (120,984−86,163=34821=X)
        Y=IL-8 FSC response in compound treated samples minus the un-stimulated control (basal) FSC.
      • (89,841−86,163=3678=Y)
      • (34821−3678)/34821*100=89% inhibition of shape change
  • The % inhibition values were plotted on the Y-axis against compound concentration on the x-axis, to give IC50 values.
    • Microsomal Clearance Assay (M)
  • The experiments were performed in 96-well glass plates at 37° C. on an automated Tecan EVO platform. Test compounds at a concentration of 10 mM in pure DMSO were diluted 1:1000 in water to 10 μM. This solution (30 μL) was added to 120 μL of rat liver microsomal protein (1.25 mg/mL) suspended in phosphate buffer (pH 7.4). Reactions were initiated by the addition of 150 μL of a cofactor solution containing 2 mM NADPH. At specific reaction time points (0, 5, 20, and 30 min), aliquots (50 μL) were removed and reactions were terminated by the addition to acetonitrile (100 μL) containing the analytical internal standards (1 μM alprenolol and 1.6 μM chlorzoxazone) and stored at −20° C. for at least 1 h to allow complete precipitation of proteins. The samples were then centrifuged at 5000 g at 4° C. for 35 min, and 20 μL of the supernatants were analyzed by LC-MS/MS for quantitation of the remaining test article. The percentage of test compound remaining, relative to time zero minute incubation, is used to estimate the in vitro elimination-rate constant (kmic), which is used to calculate the in vitro metabolic clearance rates.
  • The biochemical assay data for examples 1-143 is provided in the following Table 4:
  • TABLE 4
    Biochemical assay data
    Assay A Assay B Assay C Assay D Assay E Assay F Assay G
    PI3Kα PI3Kβ VPS34 PI4Kβ PI3Kγ PI3Kδ mTOR
    Example IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM)
     1 1.30 5.86 >9.1 >9.1 0.015 1.01
     2 0.82 7.60 >9.1 >9.1 0.003 0.39 >9.1
     3 0.60 5.88 >9.1 >9.1 0.046 0.14 >9.1
     4 0.51 3.24 >9.1 3.70 0.026 0.30 6.51
     5 0.68 0.69 >10 6.70 0.012 1.00 >10
     6 0.52 2.31 >9.4 7.12 0.039 0.95 9.01
     7 0.06 0.99 0.39 1.95 0.006 0.07 0.92
     8 0.04 1.52 0.41 1.96 <0.003 0.02 0.27
     9a 0.12 0.54 >10 9.60 0.015 0.20 8.10
     9b 0.21 1.20 >10 9.10 0.012 0.24 >10
     10 0.04 0.89 0.21 1.89 0.013 0.06 1.88
     11 0.14 2.62 >9.1 3.58 0.010 0.13 5.89
     12 0.14 2.65 >9.1 >9.1 0.041 0.24 >9.1
     13 0.20 1.09 >10 6.50 0.034 0.33 >10
     14 0.09 0.62 0.42 1.57 0.014 0.04 0.88
     15 0.16 1.93 >9.1 5.68 0.018 0.15 >9.1
     16 0.14 1.02 >10 6.40 0.009 0.25 5.30
     17 0.22 0.90 >10 8.30 0.010 0.59 6.10
     18 0.29 2.80 >10 8.60 0.031 0.62 5.55
     19 0.04 0.14 9.40 3.85 0.005 0.02 0.42
     20a 0.03 1.06 >9.1 5.28 0.007 0.05 1.88
     20b 0.05 0.88 0.40 4.98 0.011 0.05 3.31
     21 0.04 0.15 1.40 1.50 0.006 0.08 0.69
     22 0.76 5.71 >9.1 7.08 0.044 0.42 8.02
     23 0.39 >9.10 >9.1 >9.1 0.010 0.09 6.45
     24 0.20 6.06 >9.1 >9.1 0.007 0.06 7.91
     25 0.62 3.15 >10 >10 0.079 1.03 0.21
     26 0.31 6.38 >9.1 5.47 0.003 0.07 >9.1
     27 0.21 0.87 >10 6.65 0.047 0.07 7.40
     28 0.68 4.30 >9.1 8.90 0.026 0.56 >9.1
     29 1.30 6.80 >9.1 5.20 0.009 0.91 >9.1
     30 0.30 5.21 >9.1 7.89 0.024 0.05 6.99
     31 0.16 2.00 >9.55 4.40 0.027 0.12 3.80
     32 0.66 1.46 >10 4.05 0.094 1.50 >10
     33 0.21 0.38 >10 0.91 0.047 0.78 1.50
     34 0.70 2.50 >10 3.80 0.074 2.90 2.50
     35 0.63 1.90 >10 3.70 0.025 0.99 5.60
     36 0.16 0.85 >10 8.00 0.017 0.11 0.25
     37 1.00 3.50 >9.1 3.50 0.083 0.73 5.90
     38 0.92 3.50 >9.1 4.20 0.025 0.14 8.40
     39 0.79 3.95 >9.55 7.05 0.067 1.07 >9.55
     40 0.76 1.40 >10 >10 0.036 0.84 3.80
     41 0.11 0.25 7.70 9.40 0.010 0.02
     42 0.03 0.66 4.65 3.50 0.007 0.03
     43 0.05 0.20 0.90 1.40 0.006 0.22
     43a 0.1 0.69 2.5 2.3 0.026 0.67
     43b 0.23 1.5 5.5 4.8 0.042 2.2
     44 0.06 0.24 2.30 1.60 0.005 0.15
     45 0.06 0.53 1.10 1.60 0.014 0.23
     45.1 0.05 0.20 1.90 3.00 0.011 0.08
     45.2 0.04 0.37 6.00 5.80 0.018 0.05
     45.3 0.04 0.24 1.60 1.60 0.013 0.10
     45.4 0.11 0.88 3.00 1.80 0.009 0.10
     45.5 0.04 0.99 0.65 0.78 0.005 0.04
     45.6a 0.07 0.29 1.5 4.1 0.009 0.11
     45.6b 0.38 2.5 4.5 >10 0.042 1.1
     45.7a 0.28 0.68 1.1 3.4 0.027 0.42
     45.7b 0.16 0.31 1.1 1.3 0.010 0.16
     45.8 0.09 0.59 2.00 3.30 0.130 0.32
     45.9 0.03 0.32 9.40 4.90 0.039 0.10
     45.10 0.02 0.34 3.90 1.90 0.010 0.15
     45.11 0.04 0.29 1.60 1.20 0.005 0.13
     45.12 0.05 0.39 2.60 1.40 0.015 0.10
     46 0.22 0.82 >10 >10 0.026 0.45 >10
     46.1 1.40 >10 >10 >10 0.210 2.60 >10
     46.2 0.48 2.00 >10 6.20 0.054 0.73 9.70
     47 0.33 6.00 >10 8.70 0.049 0.53 >10
     48 2.60 7.30 >10 >10 0.081 0.92 >10
     49 0.62 5.30 >10 >10 0.049 1.70 >10
     50 2.50 2.80 >10 >10 0.850 >10 >10
     51 0.37 4.19 7.15 >9.1 0.042 0.49 >9.1
     52a 0.17 1.10 >10 5.50 0.016 0.15 2.00
     52b 0.23 2.10 >10 4.20 0.026 0.53 >10
     53 1.70 7.00 >10 >10 0.690 3.70
     54 0.19 0.77 >9.1 >9.1 0.017 0.11 4.81
     55 0.04 0.12 0.64 3.74 0.026 0.03 0.62
     56 0.29 1.75 3.52 7.27 0.019 0.08 2.38
     57 0.32 6.48 >9.1 >9.1 0.057 0.58 >9.1
     58 0.49 2.93 3.10 5.85 0.019 0.10 >9.1
     59 0.91 5.29 >9.1 >9.1 0.105 0.41 6.02
     60 0.11 4.57 >9.1 3.63 0.040 0.22 8.35
     61 5.47 >9.10 >9.1 >9.1 1.823 5.81 >9.1
     62 0.68 1.01 >9.1 3.68 0.056 0.21 >9.1
     63 0.33 3.93 >9.1 7.85 0.068 0.42 6.50
     64 0.37 3.85 8.49 6.61 0.046 0.25 >9.1
     65 0.44 4.03 >9.1 >9.1 0.022 0.24 >9.1
     66 0.19 >9.10 >9.1 7.94 0.006 0.08 5.98
     67 0.09 0.86 1.80 7.40 0.003 0.16 2.20
     68 0.64 2.55 >10 4.40 0.072 1.50 8.75
     69a 0.39 3.50 >10 >10 0.038 0.53 9.20
     69b 0.39 1.40 >10 >10 0.057 0.69 9.60
     70a 0.11 0.75 >10 4.60 0.025 0.29 2.00
     70b 0.84 2.50 >10 >10 0.004 1.10 5.90
     71a 0.33 1.10 >10 2.80 0.013 1.00 >10
     71b 0.76 1.90 >10 4.60 0.021 1.30 >10
     72 0.58 2.67 >9.1 >9.1 0.034 0.39 >9.1
     73 0.35 1.83 >9.1 >9.1 0.015 0.39 >9.1
     74 0.19 0.83 >10 6.20 0.041 0.38 3.50
     75 0.47 2.48 7.49 7.97 0.056 0.24 4.51
     76 0.18 3.71 >9.1 4.47 0.064 0.48 4.19
     77 0.23 4.20 >9.1 >9.1 0.034 0.30 5.47
     78 0.24 2.20 >9.55 1.55 0.013 0.18 2.35
     79 0.28 1.20 7.60 3.90 0.022 0.37 6.50
     80 0.25 1.70 >10 4.55 0.077 0.40 >10
     81 2.60 6.30 >10 9.00 0.077 2.50 >10
     82 0.18 5.50 >10 >10 0.041 0.54 >10
     83 1.90 5.20 >10 4.30 0.085 0.70 >10
     84 0.12 2.30 >10 7.05 0.042 0.21 >10
     85 0.09 1.20 >10 >10 0.021 0.12 7.90
     87 0.06 0.27 0.32 1.57 0.006 0.03 1.84
     88 0.52 2.20 9.10 6.10 0.014 1.10 9.10
     89 0.42 1.30 3.40 7.00 0.018 0.84 >10
     90 2.10 0.94 >10 >10 0.078 2.00 >10
     91 2.35 2.55 >9.55 >9.55 0.270 2.10 >9.55
     92 1.40 8.20 >9.1 >9.1 0.073 0.69 >9.1
     93 1.10 >9.10 >9.1 >9.1 0.081 0.33 >9.1
     94 1.70 >9.10 >9.1 >9.1 0.014 0.57 8.90
     95 0.90 4.10 >9.55 >9.55 0.036 0.73 7.40
     96 0.55 3.35 >9.55 >9.55 0.092 0.55 8.80
     97 1.20 >10.00 >10 >10 0.061 1.70 >10
     98 1.70 1.40 >9.1 2.50 0.038 0.31 >9.1
     99 0.74 1.65 2.95 2.70 0.014 0.14 4.95
    100 0.50 5.30 7.20 5.75 0.003 0.68 >9.55
    101 2.00 1.70 >10 2.40 0.210 3.00 >10
    102 0.55 1.80 >10 5.90 0.150 0.90 2.90
    103 0.39 1.88 >9.1 2.74 0.013 0.15 >9.1
    105 0.12 0.16 9.40 2.60 0.014 0.01
    106 0.10 0.75 >10 5.60 0.025 0.14
    107 0.08 2.09 3.10 0.94 0.006 0.06 1.39
    108 0.31 0.26 >10 0.64 0.038 0.33 >10
    109 0.44 3.00 >10 8.60 0.028 0.69
    110 0.09 0.52 >10 >10 0.010 0.32 >10
    111 0.18 1.98 >9.1 1.96 0.018 0.06 >9.1
    112 0.86 3.30 >10 3.15 0.019 0.50 6.30
    112.1 0.29 1.70 >10 1.80 0.033 0.21 6.00
    112.2 0.86 1.30 >10 5.40 0.104 1.20 >10
    112.3 0.36 1.10 >10 1.20 0.26 1.36
    112.4 0.08 0.56 >10 1.10 0.093 0.19 >10
    112.5 0.12 2.25 >10 3.00 0.53 1.83
    113 0.05 0.44 0.47 1.48 0.008 0.32 3.45
    114 0.29 3.70 7.83 5.90 0.044 1.19 >9.1
    115 0.32 2.35 8.99 5.64 0.039 0.48 8.64
    116 1.20 >9.10 >9.1 8.10 0.028 0.30 >9.1
    117 0.90 >10.00 >10 >10 0.036 >10
    118 0.03 0.47 1.46 4.72 0.011 0.13 0.46
    119 0.60 >9.10 >9.1 >9.1 0.118 0.71 4.31
    119.1 0.61 >9.10 >9.1 6.20 1.003 2.30 4.91
    119.2 0.45 >9.10 >9.1 >9.1 0.050 0.25 >9.1
    119.3 0.09 7.49 >9.1 7.46 0.044 0.13 3.70
    119.4 2.83 >9.10 >9.1 >9.1 3.117 5.70 >9.1
    119.5 0.75 >9.10 >9.1 8.00 0.082 0.55 >9.1
    119.6 0.82 >9.10 7.99 7.70 0.161 0.38 5.61
    119.7 2.98 >9.10 >9.1 7.96 0.278 0.72 4.32
    119.8 1.05 >9.10 >9.1 4.53 0.167 0.20 5.94
    119.9 0.33 7.78 >9.1 0.69 0.178 0.90 >9.1
    119.10 0.12 6.47 >9.1 >9.1 0.030 0.10 6.40
    119.11 0.45 >9.10 >9.1 >9.1 0.303 1.10 >9.1
    119.13 0.58 >9.10 >9.1 4.14 0.098 0.45 >9.1
    119.14 1.16 >9.10 >9.1 7.35 0.667 1.44 8.53
    119.15 1.66 8.81 >9.1 4.86 0.162 0.96 >9.1
    119.16 0.39 3.79 6.23 6.61 0.022 0.19 >9.1
    119.17 1.45 >9.10 >9.1 1.56 0.362 2.54 >9.1
    119.18 0.49 8.04 >9.1 8.19 0.248 0.58 >9.1
    119.19 >9.10 >9.10 >9.1 >9.1 3.468 >9.1 >9.1
    119.20 1.48 >9.10 >9.1 >9.1 0.508 2.08 4.82
    119.21 1.73 >9.10 >9.1 3.83 0.401 2.18 >9.1
    119.22 0.57 1.93 >9.1 2.19 0.157 0.53 2.34
    119.23 1.34 >9.10 >9.1 0.94 0.525 2.04 7.60
    119.24 1.09 >9.10 >9.1 3.40 0.761 1.67 9.02
    119.25 0.40 5.78 >9.1 4.05 0.031 0.29 8.74
    119.26 0.25 3.90 >9.1 1.79 0.037 0.04 5.87
    119.27 0.17 4.97 >9.1 5.75 0.035 0.12 4.78
    119.28 0.23 7.38 >9.1 4.41 0.049 0.19 6.00
    119.29 0.17 0.92 0.57 2.64 0.009 0.07 0.59
    119.30 0.17 1.50 >9.1 4.71 0.013 0.11 2.88
    119.31 0.16 7.85 >9.1 3.74 0.007 0.11 2.23
    119.32 0.26 3.22 >9.1 2.67 0.011 0.20 6.04
    119.33 0.16 0.69 >9.1 1.00 0.014 0.26 >9.1
    119.34 0.18 3.51 >9.1 4.25 0.013 0.22 6.59
    119.35 0.08 0.94 >9.1 0.74 0.013 0.07 3.90
    119.36 0.22 4.41 >9.1 >9.1 0.034 0.17 >9.1
    119.37 0.18 3.00 >9.1 5.30 0.024 0.04 >9.1
    119.38 0.09 3.50 >9.1 6.30 0.012 0.03 4.60
    119.39 0.10 2.80 >9.1 6.50 0.006 0.04 6.90
    119.40 0.15 3.50 >10 6.20 0.023 0.18 >10
    119.41 0.42 3.25 >10 6.00 0.025 0.03 >10
    119.42 0.71 2.34 >9.1 0.88 0.069 0.36 >9.1
    119.43 0.25 1.78 >9.1 >9.1 0.054 0.10 3.37
    119.44 0.12 1.37 >9.1 0.76 0.099 0.04 3.99
    119.45 0.15 3.60 >9.1 2.46 0.012 0.10 8.69
    119.46 0.25 >9.1 0.61 0.110 0.07 6.70
    120 0.02 1.00 1.30 2.50 0.004 0.06
    121 0.12 1.20 >10 0.51 0.092 0.96 5.20
    122 0.49 2.20 >10 1.90 0.085 1.60 6.60
    123 2.90 5.50 >10 2.50 2.100 4.70 9.00
    124 0.04 0.10 >10 0.42 0.022 0.16 0.71
    125 0.28 6.00 >10 7.60 0.100 0.13 >10
    126 0.28 3.1 >10 >10 0.057 1
    127 0.30 1.10 >10 4.40 0.024 0.88 2.60
    127.1 0.29 1.20 >10 1.50 0.011 0.56 1.10
    127.2 0.32 1.00 >10 1.70 0.073 0.85 9.40
    127.3 0.38 3.20 >10 3.40 0.160 >10 >10
    127.4 2.55 6.55 >9.55 4.20 0.260 2.50 >9.55
    127.5 0.40 3.10 >10 >10 0.100 3.90 1.80
    127.6 0.39 2.20 >10 >10 0.160 1.50 >10
    127.7 0.26 1.30 >10 6.30 0.040 1.10 1.50
    127.8 6.00 >10.00 >10 >10 1.000 >10 >10
    127.9 2.30 >10.00 >10 >10 1.600 3.00 >10
    127.10 1.70 9.20 >10 >10 0.320 5.50 >10
    127.11 0.98 1.30 >10 >10 0.270 0.76 >10
    127.12 3.50 1.50 >10 >10 0.091 0.57 >10
    127.13 0.28 0.53 >10 3.80 0.026 1.10 6.10
    127.14 0.92 2.60 >10 8.45 0.069 0.90 9.00
    127.16 0.33 0.81 >10 5.00 0.045 1.10 8.70
    127.17 0.89 1.20 >10 7.40 0.038 1.10 >10
    127.18 1.90 2.40 >10 >10 1.300 0.38 >10
    127.19 0.26 1.30 >10 3.90 0.061 0.62 >10
    127.20 0.97 5.10 >10 5.30 0.130 1.70 >10
    127.21 0.36 1.90 >10 >10 0.098 1.20 3.00
    127.22 0.27 0.97 >10 8.30 0.040 0.50 3.90
    127.23 0.18 0.58 >10 2.90 0.023 0.36 9.10
    127.24 0.20 0.79 >10 1.80 0.027 0.32 4.70
    127.25 0.13 0.65 >10 4.40 0.031 0.34 3.30
    127.26 0.57 2.00 >10 5.20 0.150 0.23 5.90
    127.27 0.20 1.80 >10 8.70 0.026 0.79 9.60
    127.28 0.45 5.10 >10 8.40 0.160 3.50 >10
    127.29 0.24 1.80 >10 3.90 0.124 0.64 >10
    127.30 1.90 5.30 >10 7.70 0.130 1.60 >10
    127.31 0.19 1.55 >10 4.87 0.067 0.45 7.95
    127.32 1.80 4.60 >10 >10 0.140 1.20 6.70
    127.33 0.74 >10.00 >10 >10 0.170 8.70 >10
    127.34 1.50 5.30 >10 3.00 0.180 3.20 >10
    127.35 0.33 1.10 >10 6.30 0.050 0.81 7.10
    127.36 0.19 1.90 >10 5.30 0.024 0.79 7.60
    127.37 0.65 1.40 >10 8.00 0.034 1.50 >10
    127.38 0.54 3.50 >10 6.70 0.100 2.80 >10
    127.39 1.40 2.30 >10 >10 0.100 2.10 9.30
    127.40 0.77 1.50 >10 7.60 0.140 1.40 >10
    127.41 1.70 3.50 >10 4.20 0.270 6.60 >10
    127.42 1.70 5.90 >10 7.10 0.800 >10 >10
    127.43 0.56 1.70 >10 2.90 0.095 3.40 8.80
    127.44 0.73 2.20 >10 6.10 0.120 1.40 3.70
    127.45 0.42 6.20 >9.1 3.40 0.060 1.50 >9.1
    127.46 1.30 >9.10 >9.1 6.90 0.073 0.72 >9.1
    127.47 1.10 2.20 >10 6.60 0.060 3.20 >10
    127.48 1.20 6.20 >10 5.90 0.060 3.20
    127.49 0.10 0.46 >10 4.00 0.013 0.32 7.00
    127.50 0.84 1.40 >10 >10 0.032 2.10 5.60
    127.51 0.60 1.90 >10 5.30 0.065 0.58 5.90
    127.52 0.14 0.34 >10 3.10 0.009 0.33 3.60
    127.53 0.43 1.40 >10 1.70 0.025 1.40 3.90
    127.54 0.18 1.10 >10 2.60 0.032 1.10 1.80
    127.56 0.42 1.20 >10 >10 0.073 1.40 7.40
    127.57 1.40 0.73 >10 5.90 0.050 0.76 5.00
    127.58 1.30 1.30 >10 >10 0.042 0.46 1.20
    127.60 0.96 0.73 >10 3.30 0.140 2.40 >10
    128 0.15 0.50 >10 6.80 0.014 0.10
    128.1 1.00 3.00 >10 >10 0.25
    128.2 0.27 2.90 >10 >10 0.049 0.45
    128.3a 0.23 1.90 >10 >10 0.027 0.57
    128.3b 0.37 2.50 >10 4.60 0.055 0.54
    128.4 0.10 1.70 >10 >10 0.045 0.50
    128.5 2.30 9.60 >10 >10 0.370 2.20
    128.6 0.19 7.70 >10 >10 0.190 0.30
    128.7 0.22 1.90 >10 >10 0.079 0.69
    128.8 0.59 1.80 >10 >10 0.021 0.10
    129 0.13 7.30 >9.1 >9.1 0.024 0.55 >9.1
    129.1 0.19 6.30 >9.1 6.50 0.023 0.25 6.30
    129.2 0.28 4.30 >9.1 7.00 0.022 1.20 6.10
    129.3 0.49 7.10 >9.1 >9.1 0.016 0.34 >9.1
    129.4 0.19 >9.10 >9.1 >9.1 0.069 0.43 5.00
    129.5 0.27 >9.10 >9.1 5.00 0.038 0.57 6.50
    129.6 0.74 >9.10 >9.1 >9.1 0.270 2.80 >9.1
    129.7 0.90 >9.10 >9.1 >9.1 0.270 3.30 7.80
    129.9 0.42 6.90 >9.1 >9.1 0.045 0.94 >9.1
    129.10 0.55 >9.10 >9.1 6.20 0.027 0.94 >9.1
    129.11 0.64 >9.10 >9.1 >9.1 0.173 0.79 >9.1
    129.12 1.20 >9.10 >9.1 >9.1 0.058 0.91 8.70
    129.13 0.30 >9.10 >9.1 >9.1 0.028 0.26 >9.1
    129.14 0.21 4.50 >9.1 >9.1 0.059 0.48 5.70
    129.15 1.90 >9.10 >9.1 >9.1 0.240 2.10 >9.1
    129.16 0.63 >9.10 >9.1 >9.1 0.066 2.00 >9.1
    129.17 0.35 5.50 >9.1 >9.1 0.056 0.42 >9.1
    129.18 0.69 8.11 >9.1 >9.1 0.064 0.40 >9.1
    129.19 0.33 5.11 >9.1 7.20 0.066 0.47 3.02
    129.20 0.32 8.50 >9.1 >9.1 0.110 0.29 >9.1
    129.21 2.90 >9.10 >9.1 >9.1 0.053 1.00 >9.1
    129.22 1.50 >9.10 >9.1 >9.1 0.280 7.50 >9.1
    129.23 2.80 3.30 >9.1 >9.1 0.380 1.90 >9.1
    129.24 >9.10 >9.10 >9.1 >9.1 0.200 6.60 >9.1
    129.25 0.54 2.30 >9.1 >9.1 0.042 0.38 >9.1
    129.26 1.60 1.70 >9.1 >9.1 0.590 1.60 >9.1
    129.27 9.00 >9.10 >9.1 >9.1 0.760 2.10 >9.1
    129.28 0.26 5.30 >9.1 >9.1 0.140 1.10 >9.1
    129.29 0.69 5.40 >9.1 >9.1 0.140 1.20 6.00
    129.30 5.40 >9.10 >9.1 >9.1 0.041 1.20 >9.1
    129.31 0.29 1.80 >9.1 6.70 0.120 0.80 >9.1
    129.32 2.00 7.00 >9.1 >9.1 0.039 1.80 >9.1
    129.33 2.30 >9.10 >9.1 >9.1 0.260 2.00 >9.1
    129.34 0.70 >9.10 >9.1 >9.1 0.110 1.20 >9.1
    129.35 2.10 >9.10 >9.1 >9.1 0.089 1.20 >9.1
    129.36 1.30 6.90 >9.1 >9.1 0.110 0.96 >9.1
    129.37 1.30 >9.10 >9.1 8.30 0.540 2.80 >9.1
    129.38 1.60 2.70 >9.1 >9.1 0.820 4.50 >9.1
    129.39 0.73 7.50 >9.1 >9.1 0.110 0.91 >9.1
    129.40 0.67 6.40 >9.1 >9.1 1.100 4.00 >9.1
    129.41 1.60 4.00 >9.1 >9.1 0.320 2.30 >9.1
    129.42 2.00 6.60 >9.1 >9.1 0.150 1.70 >9.1
    129.43 3.00 5.70 >9.1 >9.1 1.000 2.30 >9.1
    130 0.15 2.83 >9.1 7.01 0.012 0.18 5.11
    131 0.37 2.45 4.30 4.95 0.042 0.76 3.70
    132 0.18 >9.10 >9.1 2.26 0.017 0.05 >9.1
    133 1.02 7.80 >9.55 8.90 0.110 1.14 >9.55
    134 0.40 4.33 >9.1 7.17 0.055 0.35 >9.1
    135 0.18 5.22 >9.55 4.16 0.051 1.70 4.37
    136 0.44 >9.10 >9.1 >9.1 0.012 0.13 >9.1
    137 1.74 >9.10 >9.1 >9.1 0.058 0.33 0.95
    138 2.70 >9.10 >9.1 8.54 0.004 0.86 >9.1
    139 0.54 8.39 >9.1 >9.1 0.016 0.16 8.30
    140 0.24 7.16 >9.1 >9.1 0.016 0.09 8.82
    141 1.77 >9.10 >9.1 >9.1 0.054 0.34 >9.1
    142 1.00 6.00 >10 >10 0.270 1.00
    143 0.2 >9.10 >9.1 >9.1 0.012 0.292 2.19
  • Compound 3-(5-amino-6-(2-isopropoxypyridin-3-yl)pyrazin-2-yl)-N-(3-hydroxy-3-methylbutyl)-4-methylbenzenesulfonamide (Reference example 119.12) has not shown any activity in assay E.
  • The cellular assay data and whole blood shape change functional assay data for examples 1-143 is provided in the following table:
  • TABLE 5
    Cellular data in isoform-specific assays (Assays H, I, J, K1, K2),
    whole blood neutrophil shape change data (WBSC, Assay L) and intrinsic
    clearance data in rat liver microsomes (RLM, Assay M).
    Assay H Assay I Assay J Assay K1 Assay K2 Assay L Assay M
    PI3Kα PI3Kβ PI3Kδ PI3Kγ PI3Kγ WBSC RLM CI(int)
    Ex. IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) IC50 (μM) (μL · min−1 · mg−1)
     1 9.36 >10    7.42 0.504 0.803 <3.4
     2 3.18 >10    1.07 0.147 0.687 25
     3 1.04 8.33 1.17 0.394 1.107
     4 2.55 4.46 0.91 0.038 0.675 27
     5 >10    >10    3.45 0.078 0.261 0.696 26
     6 4.38 7.28 4.14 0.366 0.215 0.470 14
     7 0.84 3.46 0.38 0.029 0.188 48
     8 0.75 6.03 0.37 0.021 0.169 50
     9a >10    >10    3.53 0.040 0.327 34
     9b >10    >10    7.64 0.335 27
     10 0.73 6.31 0.60 0.025 0.045 44
     11 2.57 6.91 3.52 0.057 0.157 78
     12 4.70 >10    3.41 0.117 0.200
     13 >10    >10    1.57 0.062 0.211 9
     14 1.00 1.79 0.31 0.008 0.044 39
     15 1.93 2.01 1.45 0.061 0.166 24
     16 0.90 1.86 0.62 0.043 0.154 47
     17 2.80 8.25 1.92 0.051 0.166 34
     18 1.69 2.60 0.79 0.145 0.207 0.568 29
     19 0.09 0.28 0.07 0.009 0.076 0.210 65
     20a 0.72 1.43 0.42 0.011 0.023 0.232 55
     20b 0.66 1.73 0.61 0.014 0.024 0.106 30
     21 0.51 0.59 0.46 0.018 0.090 0.244 109
     22 6.67 >10    4.69 0.164 0.100 0.256 47
     23 3.01 6.46 1.01 0.106 0.447
     24 1.06 6.25 0.66 0.053 0.561 43
     25 2.19 1.70 1.39 0.153 2.335 0.742 71
     26 1.10 2.03 0.76 0.054 0.683 223
     27 >10    >10    1.02 0.058 0.562 60
     28 0.280 0.759 34
     29 4.63 8.08 6.61 0.206 0.314 0.956 62
     30 3.81 1.65 0.48 0.098 0.407 116
     31 1.04 2.51 1.03 0.040 0.917 37
     32 0.387 0.668 28
     33 1.976 0.622 0.742 12
     34 0.137 0.805 52
     35 >10    >10    >10 0.418 0.669 25
     36 0.051 0.478 710
     37 7.91 1.89 5.92 1.548 33
     38 3.02 2.11 2.36 3.375 89
     39 0.192 0.999 88
     40 0.040 92
     41 >3    0.98 <0.003 0.039 0.024 314
     42 0.13 0.79 0.16 0.014 0.018 160
     43 1.39 >10    1.19 0.015 55
     43a  2.14*  4.56* 0.97* 0.068 0.992 63
     43b  5.44*  2.95* 2.18* 0.180 45
     44 7.04 >10    >10 0.022 0.059 0.413 37
     45 0.089 83
     45.1 0.306 70
     45.2 194
     45.3 0.494 78
     45.4  1.23*  2.13* 0.58* 502
     45.5 147
     45.6a  0.82*  1.56* 0.27* 228
     45.6b  1.76* 1.2* 0.96* 237
     45.7a  1.05*  2.20* 0.55* 151
     45.7b  0.31*  1.32* 0.37* 0.001 135
     45.8 0.317 67
     45.9  0.35*  0.88* 0.28* 0.033 83
     45.10 0.030 0.662 32
     45.11 0.012 0.026 0.079 43
     46 0.145 0.331 0.730 24
     46.1 16
     46.2 0.597 49
     47 3.138 140
     48 0.487 1.526 59
     49 0.856 20
     50 28
     51 6.17 6.60 3.95 0.068 55
     52a 0.806 60
     52b 0.060 0.337 0.550 43
     53 >10    >10    >10 29
     54 1.69 7.41 2.03 0.140 2.011 141
     55 1.04 2.67 1.24 0.065 0.893 237
     56 4.40 5.88 3.12 0.129 0.211 24
     57 >10    >10    >10 0.329 1.269 17
     58 8.58 6.13 2.46 0.073 0.385 14
     59 8.47 >10    6.42 0.801
     60 1.54 3.08 1.30 0.093 24
     61 8.97 >10    8.18 0.479 56
     62 1.44 >10    0.97 0.110 7.906 155
     63 2.97 >10    3.25 0.163 0.626 44
     64 1.24 4.37 1.19 0.189 0.543 61
     65 1.45 >10    1.44 0.155 0.802 87
     66 0.99 5.92 0.73 0.109 311
     67 1.33 2.93 0.92 0.068 0.249 36
     68 2.84 6.25 3.11 0.430 1.791 54
     69a 3.30 4.42 2.66 0.103 1.153 49
     69b 6.68 8.47 5.18 0.135 1.952 227
     70a 1.92 2.64 1.41 0.185 58
     70b 4.06 >10    3.98 0.687 57
     71a 3.06 8.02 3.65 0.763 18
     71b 6.91 >10    5.86 1.622 26
     72 3.11 6.03 2.64 0.293 0.723 41
     73 2.26 5.38 2.00 0.177 0.803 64
     74 >10    >10    6.86 30
     75 >10    >10    7.80 0.091 0.830 13
     76 3.37 >10    3.52 0.203 48
     77 0.134 0.881 45
     78 0.066 152
     79 0.053 3.212 63
     80 0.098 2.879 106
     81 >10    >10    4.04 29
     82 0.86 2.98 0.61 0.825 25
     83 >10    8.75 4.05 45
     84 0.45 >3    0.44 1.010 64
     85 0.041 0.065 0.497 73
     86 62
     87 1.34 3.40 1.22 0.018 0.447 61
     88 0.152 1.641 27
     89 3.699 46
     90 19
     91 46
     92 1.158 64
     94 2.98 8.96 2.09 3.781
     95 0.262 1.589 53
     96 0.276 62
     97 2.146 60
     98 0.200 4.172 31
     99 0.059 3.518 74
    100 0.074 95
    101 39
    102 4.53 5.30 1.33 0.211 75
    103 2.25 3.25 0.85 0.028 0.515 29
    106 >10    >10    >10 2.276 29
    107 0.79 1.29 0.96 119
    108 5.78 3.01 0.41 0.058 0.163 5.563 112
    109 2.61 >10    1.90 0.935 <3.4
    110 0.48 1.73 0.69 254
    111 1.47 >10    0.46 0.020 0.637 74
    112 0.79 1.14 0.31 0.095 0.172 0.586 62
    112.1 0.80 1.47 0.38 0.091 0.063 1.326
    112.2 >10    >10 0.137
    112.3 0.40 >3    0.86 123
    112.4 0.07 >3    0.40
    112.5 0.13 >10    0.83 0.036 0.970 40
    113 1.08 3.57 1.08 0.055 0.024 0.143 39
    114 5.43 >3    7.99 0.177 0.499 17
    115 2.98 3.53 2.21 0.117 1.109 38
    116 2.31 4.75 2.12 0.197 35
    117 >10    >3    >10 0.577 0.945 0.727 85
    118 0.63 1.59 0.53 0.102 0.898 264
    119 1.64 3.06 1.76
    119.1 2.69 3.81 2.82
    119.2 2.74 4.07 2.38 0.333 2.184 101
    119.3 0.49 1.77 0.87 3.641 81
    119.4 >10    >10    >10
    119.5 4.90 1.66 4.85 0.575 118
    119.6 4.07 1.72 2.88 0.860
    119.7 6.97 4.05 5.93
    119.8 3.85 4.64 5.20
    119.9 1.92 3.07 4.23
    119.10 0.63 2.59 1.04 0.172
    119.11 2.54 3.56 6.94
    119.12 >10    >10    >10
    119.13 2.45 6.75 3.26 >10 98
    119.14 3.14 4.39 4.96
    119.15 1.48 7.33 1.65
    119.16 4.01 3.70 2.35 0.081 1.244 21
    119.17 2.81 6.17 7.16
    119.18 1.32 4.48 1.30
    119.19 >10    >10    >10
    119.20 4.95 4.86 7.03
    119.21 5.16 >10    7.48
    119.22 4.41 >10    >10
    119.23 1.97 8.49 3.53
    119.24 2.60 9.22 3.17
    119.25 1.28 4.10 1.20 0.065 2.092
    119.26 0.70 1.80 0.51 380
    119.27 0.47 9.24 0.91 0.128 0.726 87
    119.28 1.25 >10    2.15 0.179 0.963 44
    119.29 0.58 9.08 0.47 0.057 1.464 68
    119.30 0.69 6.99 0.63 0.042 1.145 77
    119.31 2.83 6.99 1.24 0.046 1.664 79
    119.32 1.68 6.04 0.79 191
    119.33 5.51 >10    3.59 0.730 0.601 50
    119.34 2.27 7.42 1.27 0.041 1.491 49
    119.35 0.018 1.017 78
    119.36 1.283 48
    119.37 3.02 2.87 1.14 0.093 0.581 78
    119.38 6.57 2.21 1.03 0.034 167
    119.39 5.04 2.15 1.61 0.034 203
    119.40 1.10 8.16 1.04 0.047 56
    119.41 >10    3.20 6.49 0.091 73
    119.42 0.200 2.238 41
    119.43 0.060 136
    119.44 0.042 7.078 137
    119.45 0.085 188
    119.46 0.081 9.194 122
    120 95
    121 31
    122 2.28 1.49 1.19 0.151 0.296 0.988 26
    123 >10    >10    3.63 85.090 62
    124 0.25 0.81 0.29 0.038 79
    125 2.81 3.47 0.23 0.051 0.879 8
    126 4*   >10*    4.24* 20
    127 1.496
    127.1 1.57 >10    1.14 2.471 907
    127.2 0.084 3.565 375
    127.3 0.371
    127.4 1.968 1.491 85
    127.5 0.419 9.682 72
    127.7 3.986
    127.12 6.56 1.54 0.80 0.359 1.210 233
    127.13 0.210
    127.14 0.645 1.793
    127.16 1.725
    127.17 0.392
    127.19 0.153 1.618
    127.20 0.850
    127.21 0.320
    127.22 0.156
    127.23 0.082
    127.24 0.168
    127.25 0.066 493
    127.26 1.790
    127.27 0.242 1.087
    127.28 0.290
    127.29 0.131
    127.31 0.85 1.71 1.05 0.103 192
    127.32 1.878
    127.33 560
    127.34 641
    127.35 >10    2.05 >10 0.085 0.391 0.847 202
    127.36 0.126 3.849
    127.37 0.230 0.408 6.223
    127.39 6.285
    127.40 0.411
    127.43 0.275 1.640
    127.45 6.11 9.05 7.27 0.323 2.645 26
    127.46 0.708 0.546 3.766 34
    127.47 0.266 2.185
    127.48 2.489
    127.50 0.179 1.074
    127.52 0.97 6.28 1.10 0.052 1.772 >924
    127.53 0.65 >3    6.51 0.172 0.198 1.865 129
    127.54 >100
    127.56 9.61 3.56 6.00 0.715 25
    127.57 >10    >10    >10 13.765 21
    127.58 23.590
    127.60 20
    128 >10    9.91 >10 0.209 0.201 2.987 22
    128.1 >10    >10    1.64 0.332
    128.2 1.91 >10    1.57 0.09 27
    128.3a 5.15 >10    2.10 0.241
    128.3b 4.97 >10    3.82
    128.4 1.51 1.55 0.78 0.104 0.280 134
    128.5 >10    >10    >10
    128.6 >10    >10    >10 0.193 2.175 20
    128.7 >10    >10    >10 0.249 0.117 0.826 20
    128.8 >3    >10    >10 0.751 0.421 1.671 <3.4
    129 28
    129.1 0.721
    129.2 2.418 130
    129.3 7.60 >10    6.84 139
    129.5 1.167 79
    129.9 20
    129.10 1.607 78
    129.11 2.73 8.38 3.33 5.682 105
    129.12 4.29 >10    4.97 0.804 1.602 99
    129.13 3.00 >10    5.86 0.144 170
    129.14 2.96 5.15 2.96 347
    129.17 2.50 3.72 1.94 0.354 104
    129.18 4.92 >10    5.63 0.528 97
    129.19 8.58 >10    4.37 0.251 3.428 21
    129.21 8.953
    129.24 755
    129.25 2.954
    129.28 159
    129.29 >924
    129.3 >10    >10    >10 >10
    129.32 >10    >10    >10 0.800 1.996 18
    129.35 >10
    129.36 >10    >3    6.208 >10 15
    129.39 >924
    129.41 13
    130 1.63 4.52 1.20 0.065 0.735 62
    131 0.493 42
    132 1.28 6.05 0.35 0.074 0.449
    133 19
    134 >10    >10    >10
    135 7.84 8.75 9.39 0.063 0.359 30
    136 0.99 >10    1.12 0.124 1.298
    137 >10    >10    8.58 28
    138 8.80 >10    3.55 0.260 4.830 31
    139 1.08 7.96 0.97 0.102 0.565
    140 1.11 6.38 0.84 0.051 0.817 82
    141 4.70 8.75 5.31 0.947
    142 >10    >10    >10 34
    143 2.35 6.03 1.01 0.129 1.701 134
  • For assays H, I and J, non-asterisked data denotes data generated in versions H1, I1, J1 (Surefire format) of these assays and asterisked data denotes data generated in versions H2, I2, J2 (HTRF format) of these assays. Two closely related assay formats were used to generate PI3K gamma isoform cellular activities (IC50s). The table includes all data from both formats (Assays K1 and K2).
  • The following tables 6 and 7 give data generated in the above assays for compounds disclosed in the prior art.
  • Compound
    Assay A Assay B Assay C Assay D Assay E Assay F Assay G
    PI3Kα PI3Kβ VPS34 PI4Kβ PI3Kγ PI3Kδ mTOR
    Figure US20180243297A1-20180830-C00454
         		0.25 1.24 >9.4 3.16 0.064 0.63 —
    Figure US20180243297A1-20180830-C00455
         		1.50 2.00 >10 3.00 2.00 >10 —
    Figure US20180243297A1-20180830-C00456
         		0.02 1.70 0.70 0.30 1.200 2.30 —
    Figure US20180243297A1-20180830-C00457
         		0.49 1.27 1.76 3.76 0.060 1.50 —
    Figure US20180243297A1-20180830-C00458
         		0.07 0.14 0.91 0.16 0.247 1.97 —
    Figure US20180243297A1-20180830-C00459
         		0.09 0.19 2.38 0.61 0.034 0.45 —
    Figure US20180243297A1-20180830-C00460
         		— — — — — — —
    Figure US20180243297A1-20180830-C00461
         		0.06 0.46 — 0.29 — — —
    Figure US20180243297A1-20180830-C00462
         		0.78 0.63 6.31 4.01 0.007 0.08 —
    Figure US20180243297A1-20180830-C00463
         		0.46 0.70 1.80 0.54 0.110 1.40 2.50
    Figure US20180243297A1-20180830-C00464
         		1.20 1.60 1.60 0.41 0.031 1.00 4.50
    Figure US20180243297A1-20180830-C00465
         		3.32 1.19 0.753 6.01 —
  • Compounds (i)-(ix) are disclosed in WO09/115517, compounds (x) and (xi) are disclosed in Leahy et al., J. Med. Chem., 2012, 55 (11), pp 5467-5482 and compound (xii) is disclosed in WO09/013348.
  • TABLE 7
    Assay H Assay I Assay J Assay K1 Assay K2 Assay L Assay M
    Compound PI3Kα PI3Kβ PI3Kδ PI3Kγ PI3Kγ WBSC RLM CI (int)
    (i) 0.97 3.77 1.10 0.526 0.838 2.39  47
    (ii) >10*    >10*     0.58* — 9.48  11.32 233
    (iii) — — — — — — 219
    (iv) 0.93 3.96 1.36 0.128 0.264 2.06 465
    (v) 0.18 0.23 0.15 — — 0.71 173
    (vi) 0.17 0.26 0.17 0.182 — — 630
    (vii) — — — — — — 283
    (viii) — — — — — — —
    (ix) 0.85 2.29 1.26 0.020 — 2.34 267
    (x) >10    >10     2.87 0.352 — >100 —
    (xi) 5.41 5.58 5.87 0.539 — >44 271
    (xii) >10*     4.37*  5.55* — — 15.12  9
  • The numbering (i)-(xii) refers to the compounds in Table 6. For assays H, 1 and J, non-asterisked data denotes data generated in versions H1, I1, J1 of these assays and asterisked data denotes data generated in versions H2, I2, J2 of these assays.

Claims (11)

1. A compound of formula (I)
Figure US20180243297A1-20180830-C00466
wherein
E is selected from N and CRE;
R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
R3 is selected from
(i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(iii) C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(vii) H;
R4 is selected from H and C1-4 alkyl; or
R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
Y is a 5-6-membered heteroaryl, which heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-NR′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—NR′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl;
R′ and R″ are independently selected from H and C1-4 alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 of formula (Ia)
Figure US20180243297A1-20180830-C00467
wherein
R1 is independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
R2 is selected from H, halogen, CF3 and methyl;
R3 is selected from
(i) C1-4 alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(ii) C1-4 alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkyl, oxo, CN, —(C0-3 alkyl)-NR3aR3b, C3-7 cycloalkyl and C3-7 heterocyclyl, and wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(iii) —C3-7 cycloalkyl or —O—C3-7 cycloalkyl wherein the C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(iv) a —(C0-3 alkyl)-C3-7 cycloalkyl or —O—(C0-3 alkyl)-C3-7 cycloalkyl wherein the C3-7 cycloalkyl is spiro fused to a second C3-7 cycloalkyl or C3-7 heterocyclyl by one single carbon atom, and wherein the C3-7 cycloalkyl or C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(v) a —(C0-3 alkyl)-C3-7 heterocyclyl or —O—(C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(vi) a —(C0-3 alkyl)-C3-7 heterocyclyl or —(O—C0-3 alkyl)-C3-7 heterocyclyl, and wherein said C3-7 heterocyclyl is spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and wherein the C3-7 heterocyclyl or C3-7 cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
(vii) H;
R4 is selected from H and C1-4 alkyl; or
R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl, which C3-7 heterocyclyl is optionally spiro fused to a second C3-7 heterocyclyl or a C3-7 cycloalkyl by one single carbon atom, and which C3-7 heterocyclyl and C3-7 cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C1-4 hydroxyalkyl, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, oxo and —(C0-3 alkyl)-NR3aR3b;
R3a and R3b are independently selected from H, C1-4 alkyl and C1-4 haloalkyl;
Y is selected from the group consisting of
thiazolyl,
thiadiazolyl,
isothiazolyl,
pyrazolyl,
pyridyl,
pyrimidinyl,
triazolyl,
imidazolyl,
oxadiazolyl,
isoxazolyl,
oxazolyl,
pyrrolyl,
thienyl, and
furanyl;
each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4alkoxyC1-4alkyl, C1-4hydroxyalkyl, C1-4 alkoxy, C1-4 haloalkoxy, halogen, C1-4 hydroxyalkyl, —(C0-3 alkyl)-NR′R″, —(C0-3 alkyl)-C3-7 cycloalkyl and —(C0-3 alkyl)-C3-7 heterocyclyl, —(C═O)—C3-7 heterocyclyl, —(C═O)—NR′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-5-6-membered heteroaryl;
R′ and R″ are independently selected from H and C1-4 alkyl;
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1, wherein
Y is selected from the group consisting of
oxazol-2-yl,
oxazol-5-yl,
oxazol-4-yl,
thiazol-5-yl,
thiazol-4-yl,
1,3,4-thiadiazol-2-yl,
isothiazol-5-yl,
pyrazol-4-yl,
pyrazol-3-yl,
pyrazol-1-yl,
pyrid-4-yl,
pyrid-3-yl,
pyrid-2-yl,
1,2,4-triazol-1-yl,
1,2,3-triazol-4-yl,
imidazol-1-yl,
1,2,4-oxadiazol-5-yl,
1,3,4-oxadiazol-2-yl,
1,2,4-oxadiazol-3-yl,
isoxazol-5-yl,
isoxazol-3-yl,
isoxazol-4-yl,
pyrrol-3-yl,
thien-2-yl,
thien-3-yl, and
furan-3-yl,
each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, C1-4hydroxyalkyl, —(C0-3 alkyl)-C3-7 cycloalkyl, —(C═O)—C3-7 heterocyclyl, —(C0-3 alkyl)-NR′R″, —(C═O)—N′R″, —(C0-3 alkyl)-phenyl and —(C0-3 alkyl)-pyridyl;
R′ and R″ are independently selected from H and C1-4 alkyl;
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1, wherein
Y is selected from the group consisting of
Figure US20180243297A1-20180830-C00468
Figure US20180243297A1-20180830-C00469
Figure US20180243297A1-20180830-C00470
Figure US20180243297A1-20180830-C00471
Figure US20180243297A1-20180830-C00472
or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1, wherein
R3 is selected from
Figure US20180243297A1-20180830-C00473
Figure US20180243297A1-20180830-C00474
Figure US20180243297A1-20180830-C00475
Figure US20180243297A1-20180830-C00476
or R3 and R4 together with the nitrogen atom to which they are attached form a ring selected from
Figure US20180243297A1-20180830-C00477
or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 of formula (I)
Figure US20180243297A1-20180830-C00478
wherein
E is selected from N and CRE;
R1, R2 and RE are independently selected from H, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 hydroxyalkyl and C3-7 cycloalkyl;
Y is selected from the group consisting of
Figure US20180243297A1-20180830-C00479
Figure US20180243297A1-20180830-C00480
Figure US20180243297A1-20180830-C00481
R4 is H and R3 is selected from the group consisting of
Figure US20180243297A1-20180830-C00482
Figure US20180243297A1-20180830-C00483
or R3 and R4 together with the nitrogen atom to which they are attached form a C3-7 heterocyclyl selected from the group consisting of
Figure US20180243297A1-20180830-C00484
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 selected from Examples 1 to 143; or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition, comprising:
a therapeutically effective amount of the compound or salt according to claim 1 and one or more pharmaceutically acceptable carriers.
9. A pharmaceutical combination, comprising:
a therapeutically effective amount of the compound or salt according to claim 1 and a second active agent.
10. A method of a disorder or disease mediated by the activation of PI 3-kinase gamma isoform, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt according to claim 1.
11. A method of treating respiratory diseases, allergies, rheumatoid arthritis, osteoarthritis, rheumatic disorders, psoriasis, ulcerative colitis, Crohn's disease, septic shock, proliferative disorders such as cancer, atherosclerosis, allograft rejection following transplantation, diabetes, stroke, obesity and restenosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt according to claim 1.
US15/963,535 2014-04-24 2018-04-26 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors Abandoned US20180243297A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/963,535 US20180243297A1 (en) 2014-04-24 2018-04-26 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2014/060988 WO2015162459A1 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US15/303,868 US10004732B2 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US15/963,535 US20180243297A1 (en) 2014-04-24 2018-04-26 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/303,868 Continuation US10004732B2 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
PCT/IB2014/060988 Continuation WO2015162459A1 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
US20180243297A1 true US20180243297A1 (en) 2018-08-30

Family

ID=50819760

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/303,868 Active US10004732B2 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US15/963,535 Abandoned US20180243297A1 (en) 2014-04-24 2018-04-26 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/303,868 Active US10004732B2 (en) 2014-04-24 2014-04-24 Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors

Country Status (11)

Country Link
US (2) US10004732B2 (en)
EP (1) EP3134397A1 (en)
JP (1) JP6433509B2 (en)
KR (1) KR20160141855A (en)
CN (1) CN106458979B (en)
AU (2) AU2014391608A1 (en)
BR (1) BR112016024533A8 (en)
CA (1) CA2945212A1 (en)
EA (1) EA032075B1 (en)
MX (1) MX2016013812A (en)
WO (1) WO2015162459A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210379A1 (en) * 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102243637B1 (en) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 Bicyclic analgesic compounds
CN108947867A (en) 2013-12-12 2018-12-07 卡利拉制药公司 Bicyclic alkyl compound and synthesis
EP3114107B1 (en) 2014-03-07 2020-07-22 Recurium IP Holdings, LLC Propellane derivates and synthesis
BR112016024484A2 (en) 2014-04-24 2017-08-15 Novartis Ag aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PL3134395T3 (en) 2014-04-24 2018-07-31 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2961605C (en) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
US20190321443A1 (en) * 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
EA036388B1 (en) 2016-03-10 2020-11-03 Астразенека Аб Inhibitors of phosphatidylinositol 3-kinase gamma
WO2017160926A1 (en) * 2016-03-16 2017-09-21 Kalyra Pharmaceuticals, Inc. Analgesic compounds
MX389668B (en) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Analgesic compounds
WO2019126505A1 (en) * 2017-12-21 2019-06-27 Incyte Corporation 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
CR20200464A (en) 2018-03-08 2021-04-14 Incyte Corp DIOLIC AMINOPYRAZINE COMPOUNDS AS PI3K-Y INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3980010A4 (en) 2019-06-04 2023-06-07 Arcus Biosciences, Inc. PYRAZOLO[1,5-A]PYRIMIDINE 2,3,5-TRISUBSTITUTE COMPOUNDS
CN112341437A (en) * 2020-12-21 2021-02-09 李寒 Substituted pyrazine derivative and application thereof
CN112409337A (en) * 2020-12-21 2021-02-26 李寒 Substituted pyrazine derivative and application thereof
CN114994215A (en) * 2022-08-03 2022-09-02 北京华大吉比爱生物技术有限公司 Application of chlorzoxazone, method for detecting concentration of enzyme inhibitor antibiotic drug, kit and application

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (en) 1974-03-18 1977-05-30 Isf Spa INHALER
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (en) 1991-05-02 1993-09-30 Smithkline Beecham Corp PIRROLIDINONES, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE
JPH0525045A (en) 1991-07-18 1993-02-02 Tanabe Seiyaku Co Ltd Transdermal formulation
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
EP0633776B1 (en) 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
DE69331265T2 (en) 1992-04-02 2002-08-08 Smithkline Beecham Corp., Philadelphia COMPOUNDS FOR TREATING INFLAMMABLE DISEASES AND INHIBITING THE PRODUCTION OF TUMORNESCROSE FACTOR
JP3192424B2 (en) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション Compounds for the treatment of allergic or inflammatory diseases
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
EP0995457B1 (en) 1995-12-07 2004-03-10 Jago Research Ag Mouthpiece for an inhalator designed to provide multiple doses of dry pharmacological powder
NZ331361A (en) 1996-02-21 2000-01-28 Schering Corp Powder inhaler including swirl means for changing the flow direction of the powder and chimney means for reversing the flow direction
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
WO2000000531A1 (en) 1998-06-30 2000-01-06 The Dow Chemical Company Polymer polyols and a process for the production thereof
DE19834047A1 (en) 1998-07-29 2000-02-03 Bayer Ag Substituted pyrazole derivatives
DE19834044A1 (en) 1998-07-29 2000-02-03 Bayer Ag New substituted pyrazole derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
EP1659111A3 (en) 1999-05-04 2007-05-09 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
CZ20013940A3 (en) 1999-05-04 2002-04-17 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
SK287231B6 (en) 1999-08-21 2010-04-07 Nycomed Gmbh Medicament comprising a PDE inhibitor and a beta2 adrenoreceptor agonist
DE19943639A1 (en) 1999-09-13 2001-03-15 Bayer Ag Dicarboxylic acid derivatives with novel pharmaceutical properties
DE19943635A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
DE19943636A1 (en) 1999-09-13 2001-03-15 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
DE19943634A1 (en) 1999-09-13 2001-04-12 Bayer Ag Novel dicarboxylic acid derivatives with pharmaceutical properties
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
NZ522677A (en) 2000-04-27 2004-10-29 Boehringer Ingelheim Pharma Novel, slow-acting betamimetics, a method for their production and their use as medicaments
DK1300407T4 (en) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (en) 2000-07-28 2002-02-21 Schering Ag New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism
ATE416184T1 (en) 2000-08-05 2008-12-15 Glaxo Group Ltd 17.BETA.-CARBOTHIOATE 17.ALPHA.- ARYLCARBONYLOXYLOXY ANDROSTANDE DERIVATIVES AS ANTIPHLOGISTIC MEDICATIONS
BRPI0115193B1 (en) 2000-11-07 2016-08-09 Novartis Ag indolylmaleimide derivatives, process for preparing them as well as pharmaceutical composition comprising them
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AR031176A1 (en) 2000-11-22 2003-09-10 Bayer Ag NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
SK287414B6 (en) 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Quinuclidine derivatives and compositions contain thereof
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE10110749A1 (en) 2001-03-07 2002-09-12 Bayer Ag Substituted aminodicarboxylic acid derivatives
DE10110750A1 (en) 2001-03-07 2002-09-12 Bayer Ag Novel aminodicarboxylic acid derivatives with pharmaceutical properties
ES2288543T3 (en) 2001-03-08 2008-01-16 Glaxo Group Limited BETA-ADRENORRECEPTORS AGONISTS.
JP4143413B2 (en) 2001-03-22 2008-09-03 グラクソ グループ リミテッド Formanilide derivatives as β2-adrenergic receptor agonists
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
EP1395604B1 (en) 2001-06-12 2008-06-25 Glaxo Group Limited Novel anti inflammatory 17.alpha.-heterocyclic-esters of 17.beta.-carbothioate androstane derivatives
EP2327766B1 (en) 2001-06-21 2015-12-02 BASF Enzymes LLC Nitrilases
PL393155A1 (en) 2001-09-14 2011-03-28 Glaxo Group Limited Phenethanolamine derivatives for treating of respiratory diseases
RU2004110717A (en) 2001-10-17 2005-10-20 Юсиби, С.А. (Be) Quinuclidine derivatives, methods for their preparation and their use as both M2- and / or M3-muscarinic receptors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (en) 2001-11-05 2004-11-17 Novartis Ag DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
EP1461336B1 (en) 2001-12-20 2013-05-22 CHIESI FARMACEUTICI S.p.A. 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
WO2003077918A1 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
JP2005521717A (en) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Glucocorticoid mimetics, process for producing the same, pharmaceutical composition thereof, and use thereof
KR101022977B1 (en) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 Glucocorticoid mimetics, preparation methods thereof, pharmaceutical compositions and uses thereof
PE20040079A1 (en) 2002-04-03 2004-04-19 Novartis Ag INDOLYLMALEIMIDE DERIVATIVES
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (en) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF PIRROLIDINIO.
JP2005523920A (en) 2002-04-25 2005-08-11 グラクソ　グループ　リミテッド Phenetanolamine derivative
JP4901102B2 (en) 2002-05-03 2012-03-21 エクセリクシス， インク． Protein kinase modulator and method of use thereof
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
ES2201907B1 (en) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF INDOLILPIPERIDINE AS POWERFUL ANTIHISTAMINIC AND ANTIALERGIC AGENTS.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (en) 2002-06-05 2003-12-24 Merck Patent Gmbh pyridazine
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (en) 2002-06-10 2003-12-18 Merck Patent Gmbh New 1-acyl-3-phenyl-5,6-dihydro-4H-pyridazine derivatives, are phosphodiesterase IV inhibitors useful e.g. for treating asthma, allergy, inflammation, autoimmune diseases or myocardial diseases
DE10227269A1 (en) 2002-06-19 2004-01-08 Merck Patent Gmbh thiazole
EP1517895B1 (en) 2002-06-25 2007-03-14 Merck Frosst Canada Ltd. 8-(biaryl) quinoline pde4 inhibitors
ES2204295B1 (en) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. NEW DERIVATIVES OF QUINUCLIDINE-AMIDE.
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (en) 2002-08-09 2005-03-29 Novartis Ag ORGANIC COMPOUNDS
EP1556049A1 (en) 2002-08-10 2005-07-27 ALTANA Pharma AG Piperidine-pyridazones and phthalazones as pde4 inhibitors
WO2004018450A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004018451A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
AU2003253408A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Novel phenanthridines
US20060113968A1 (en) 2002-08-17 2006-06-01 Altana Pharma Ag Novel benzonaphthyridines
SE0202483D0 (en) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
JP4587294B2 (en) 2002-08-29 2010-11-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 2-hydroxy-6-phenylphenanthridine as PDE4 inhibitor
CN1678306A (en) 2002-08-29 2005-10-05 贝林格尔·英格海姆药物公司 -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
AU2003273805B8 (en) 2002-08-29 2010-06-17 Takeda Gmbh 3-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
KR20050057408A (en) 2002-09-18 2005-06-16 오노 야꾸힝 고교 가부시키가이샤 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2006096662A (en) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd Novel 6-substituted uracil derivatives and therapeutic agents for allergic diseases
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
JP2004107299A (en) 2002-09-20 2004-04-08 Japan Energy Corp Novel 1-substituted uracil derivatives and therapeutic agents for allergic diseases
DE10246374A1 (en) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 4-(2-alkylamino-1-hydroxyethyl)-3-alkoxy-benzene-1,2-diol derivatives, are beta-mimetics having a long duration of action, useful e.g. for treating asthma, chronic obstructive pulmonary disease or arrhythmia
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
AP2005003283A0 (en) 2002-10-11 2005-06-30 Pfizer Indole derivatives useful for the treatment os diseases
EP1554264B1 (en) 2002-10-22 2007-08-08 Glaxo Group Limited Medicinal arylethanolamine compounds
AU2003269317B2 (en) 2002-10-23 2009-10-29 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
BR0315720A (en) 2002-10-28 2005-09-06 Glaxo Group Ltd Compound, method for the prophylaxis or treatment of a clinical condition in a mammal, pharmaceutical formulation, combination, use of a compound, process for the preparation of a compound, and, intermediate
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Treatment of chronic obstructive pulmonary disease, using new or known N-substituted 2-amino-1-(benz-(1,4)-oxazin-3-on-8-yl)-ethanol derivative beta-mimetic agents, suitable for once-daily administration
DE10253220A1 (en) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg New 2-(N-phenylalkyl-amino)-1-phenyl-ethanol derivatives, are beta-adrenergic agents especially useful for treating inflammatory and obstructive respiratory diseases such as asthma or COPD
DE10253426B4 (en) 2002-11-15 2005-09-22 Elbion Ag Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and methods for their preparation
EP1578411A4 (en) 2002-12-09 2007-05-02 Univ Texas PROCESS FOR SELECTIVE INHIBITION OF JANUS TYROSINE KINASE 3 (JAK3)
DE10261874A1 (en) 2002-12-20 2004-07-08 Schering Ag Nonsteroidal anti-inflammatories
EP1587818A4 (en) 2003-01-21 2010-10-13 Merck Sharp & Dohme 17-CARBAMOYLOXY CORTISOL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
AU2004245174A1 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular Aspergillus polypeptides
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
US20080207613A1 (en) 2004-01-12 2008-08-28 Cytopia Research Pty Ltd Selective Kinase Inhibitors
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
JP2008515955A (en) 2004-10-12 2008-05-15 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ PI3 kinase gamma inhibitor for the treatment of anemia
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
DE602007004092D1 (en) 2006-03-22 2010-02-11 Vertex Pharma C-MET PROTEIN KINASE INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE DISEASES
AU2007229552C1 (en) 2006-03-29 2013-06-13 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mGluR2 antagonists
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
WO2009013348A2 (en) * 2007-07-26 2009-01-29 Novartis Ag Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CN106518856B (en) * 2008-12-19 2020-04-28 沃泰克斯药物股份有限公司 Compounds useful as inhibitors of ATR kinase
PT2526090E (en) 2010-01-18 2015-11-30 Medicines For Malaria Venture Mmv New anti-malarial agents
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
DK2593452T3 (en) 2010-07-14 2017-04-24 Novartis Ag Heterocyclic compounds as IP receptor agonists
DE102010033690A1 (en) 2010-08-06 2012-02-09 Saltigo Gmbh Process for the preparation of aminoarylalkyl compounds
PL3134395T3 (en) 2014-04-24 2018-07-31 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
BR112016024484A2 (en) 2014-04-24 2017-08-15 Novartis Ag aminopyridine derivatives as phosphatidylinositol 3-kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210379A1 (en) * 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
US11542262B2 (en) 2019-04-10 2023-01-03 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
BR112016024533A8 (en) 2021-03-30
CN106458979B (en) 2020-03-27
MX2016013812A (en) 2017-03-09
AU2018200536A9 (en) 2019-05-30
AU2018200536A1 (en) 2018-02-15
BR112016024533A2 (en) 2017-08-15
CN106458979A (en) 2017-02-22
AU2014391608A1 (en) 2016-10-27
JP2017513889A (en) 2017-06-01
EA201692143A1 (en) 2017-03-31
CA2945212A1 (en) 2015-10-29
EA032075B1 (en) 2019-04-30
KR20160141855A (en) 2016-12-09
US10004732B2 (en) 2018-06-26
US20170042889A1 (en) 2017-02-16
WO2015162459A1 (en) 2015-10-29
JP6433509B2 (en) 2018-12-05
EP3134397A1 (en) 2017-03-01
AU2018200536B2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
US10004732B2 (en) Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US9556179B2 (en) Substituted imidazoles as casein kinase 1 D/E inhibitors
EP3423445B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
AU2019210602A1 (en) Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
US9862711B2 (en) Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US20240366598A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
US20240309005A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
US20240245673A1 (en) Papain-like protease (PLpro) inhibitors

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION